diarylmethane - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	diarylmethane	go back to main search page
Accession:	CHEBI:51614	browse the term
Definition:	Any compound containing two aryl groups connected by a single C atom.
Synonyms:	related_synonym:	diarylmethanes

show annotations for term's descendants Sort by:
Rat (8309 ) Mouse (8581 ) Human (8544 ) Chinchilla (0 ) Bonobo (0 ) Dog (4 ) Squirrel (0 ) Pig (17 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (8309)

1,1,1-Trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

ISO

ESR1 protein affects the susceptibility to [1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane affects the expression of AHR mRNA]

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

catalase

affects binding

ISO

1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane binds to CAT protein

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

ISO

1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane results in decreased expression of CYP11A1 mRNA

NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression

ISO

1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane results in decreased expression of CYP17A1 mRNA

NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases expression

ISO

1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane results in decreased expression of CYP19A1 mRNA

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases chemical synthesis
increases hydroxylation

ISO

CYP1A2 protein results in increased chemical synthesis of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane
CYP1A2 protein results in increased hydroxylation of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane

PMID:9047321 PMID:9733665

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 2, subfamily b, polypeptide 1

increases hydroxylation

EXP

CYP2B1 protein results in increased hydroxylation of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane

NCBI chr 1:90,646,098...90,669,762

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases chemical synthesis
increases hydroxylation

ISO

CYP2B6 protein results in increased chemical synthesis of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane
CYP2B6 protein results in increased hydroxylation of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane

PMID:9047321 PMID:9733665 PMID:12167570

NCBI chr 1:90,780,468...90,859,852

G

cytochrome P450, subfamily 2, polypeptide 11

increases chemical synthesis

ISO

CYP2C18 protein results in increased chemical synthesis of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane

NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:246,174,711...246,211,853

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases chemical synthesis
increases hydroxylation

ISO

CYP2C19 protein results in increased chemical synthesis of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane
CYP2C19 protein results in increased hydroxylation of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane

PMID:9714305 PMID:9733665

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases hydroxylation

ISO

CYP2D6 protein results in increased hydroxylation of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases hydroxylation

ISO

CYP2E1 protein results in increased hydroxylation of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases hydroxylation

ISO

CYP3A4 protein results in increased hydroxylation of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane

PMID:9047321 PMID:9714305 PMID:12167570

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases hydroxylation

ISO

CYP3A5 protein results in increased hydroxylation of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

estrogen receptor 1

multiple interactions
increases response to substance

ISO

ESR1 protein affects the susceptibility to [1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane affects the expression of AHR mRNA]
ESR1 protein results in increased susceptibility to 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

nuclear receptor subfamily 1, group I, member 3

increases activity

EXP

1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane results in increased activity of NR1I3 protein

NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370

1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alanyl-tRNA synthetase 1

increases expression

EXP
ISO

o,p'-DDT results in increased expression of AARS1 mRNA

NCBI chr19:55,906,694...55,930,499
Ensembl chr19:55,906,702...55,930,497

G

ATP binding cassette subfamily B member 1A

decreases activity
increases expression

ISO

o,p'-DDT results in decreased activity of ABCB1 protein
o,p'-DDT results in increased expression of ABCB1 mRNA

PMID:23169446 PMID:24464585

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily C member 2

increases expression

ISO

o,p'-DDT results in increased expression of ABCC2 mRNA

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily G member 2

increases expression
decreases activity

ISO

o,p'-DDT results in increased expression of ABCG2 mRNA
o,p'-DDT results in decreased activity of ABCG2 protein

PMID:23169446 PMID:24464585

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

ADAM metallopeptidase with thrombospondin type 1 motif, 9

increases expression

ISO

o,p'-DDT results in increased expression of ADAMTS9 mRNA

NCBI chr 4:126,847,726...127,019,924
Ensembl chr 4:126,847,729...127,019,876

G

aryl hydrocarbon receptor

affects expression
decreases methylation
increases expression
multiple interactions

ISO

o,p'-DDT affects the expression of AHR mRNA
o,p'-DDT results in decreased methylation of AHR gene
o,p'-DDT results in increased expression of AHR mRNA; o,p'-DDT results in increased expression of AHR protein
o,p'-DDT promotes the reaction [AHR protein binds to CYP1A1 promoter]

PMID:12176094 PMID:18925944 PMID:28263910

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

aldo-keto reductase family 1, member C2

increases expression

ISO

o,p'-DDT results in increased expression of AKR1C2 mRNA

NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686

G

aldo-keto reductase family 7, member A2

affects expression

EXP

o,p'-DDT affects the expression of AKR7A2 mRNA

NCBI chr 5:156,835,589...156,844,127
Ensembl chr 5:156,835,551...156,844,109

G

AKT serine/threonine kinase 1

increases phosphorylation

ISO

o,p'-DDT results in increased phosphorylation of AKT1 protein

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

aldehyde dehydrogenase 1 family, member A1

affects expression

EXP

o,p'-DDT affects the expression of ALDH1A1 mRNA

NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500

G

alpha-kinase 2

decreases expression

ISO

o,p'-DDT results in decreased expression of ALPK2 mRNA

NCBI chr18:61,045,717...61,161,703
Ensembl chr18:61,045,380...61,175,985

G

alkaline phosphatase, biomineralization associated

multiple interactions

ISO

o,p'-DDT inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]

NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167

G

anaphase promoting complex subunit 1

increases expression

ISO

o,p'-DDT results in increased expression of ANAPC1 mRNA

NCBI chr 3:136,303,350...136,383,464
Ensembl chr 3:136,303,413...136,383,464

G

anoctamin 1

increases expression

ISO

o,p'-DDT results in increased expression of ANO1 mRNA

NCBI chr 1:209,180,755...209,329,413
Ensembl chr 1:209,180,755...209,329,550

G

adaptor-related protein complex 1 associated regulatory protein

increases expression

ISO

o,p'-DDT results in increased expression of AP1AR mRNA

NCBI chr 2:218,951,104...218,983,495
Ensembl chr 2:218,927,373...218,983,752

G

apoptotic peptidase activating factor 1

decreases expression

EXP

o,p'-DDT analog results in decreased expression of APAF1 mRNA

NCBI chr 7:27,381,392...27,466,772
Ensembl chr 7:27,381,855...27,466,772

G

apoptosis inhibitor 5

decreases expression

EXP

o,p'-DDT analog results in decreased expression of API5 mRNA

NCBI chr 3:100,833,417...100,858,580
Ensembl chr 3:100,833,417...100,858,580

G

APAF1 interacting protein

decreases expression

EXP
ISO

o,p'-DDT results in decreased expression of APIP mRNA

NCBI chr 3:109,886,919...109,913,295
Ensembl chr 3:109,886,953...109,915,862

G

apolipoprotein A4

affects expression

ISO

o,p'-DDT affects the expression of APOA4 mRNA

NCBI chr 8:55,435,779...55,438,160
Ensembl chr 8:55,434,168...55,438,164

G

amyloid beta precursor protein

affects expression

EXP

o,p'-DDT affects the expression of APP mRNA

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

aquaporin 8

increases expression

ISO
EXP

o,p'-DDT results in increased expression of AQP8 mRNA

NCBI chr 1:187,424,314...187,430,243
Ensembl chr 1:187,424,417...187,430,242

G

androgen receptor

multiple interactions
increases expression
decreases activity
decreases expression
affects binding

ISO
EXP

Dihydrotestosterone inhibits the reaction [o,p'-DDT results in increased activity of AR protein]; o,p'-DDT binds to and results in decreased activity of AR protein; o,p'-DDT inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; o,p'-DDT inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; o,p'-DDT inhibits the reaction [Dihydrotestosterone binds to AR protein]; o,p'-DDT inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; o,p'-DDT inhibits the reaction [Metribolone results in increased activity of AR protein]
o,p'-DDT results in increased expression of AR mRNA
o,p'-DDT results in decreased activity of AR protein
o,p'-DDT results in decreased expression of AR mRNA
o,p'-DDT binds to AR protein

PMID:9705896 PMID:9846162 PMID:10822019 PMID:12676605 PMID:14565775 More...

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

arginase 1

multiple interactions

EXP

o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of ARG1 mRNA]

NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713

G

aryl hydrocarbon receptor nuclear translocator

decreases expression

ISO

o,p'-DDT results in decreased expression of ARNT mRNA; o,p'-DDT results in decreased expression of ARNT protein

NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:185,680,683...185,745,546

G

aryl hydrocarbon receptor nuclear translocator 2

decreases expression
multiple interactions

ISO

o,p'-DDT results in decreased expression of ARNT2 mRNA
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [o,p'-DDT results in decreased expression of ARNT2 mRNA]

NCBI chr 1:147,645,354...147,801,986
Ensembl chr 1:147,599,058...147,801,997

G

actin related protein 2/3 complex, subunit 1A

increases expression

ISO
EXP

o,p'-DDT results in increased expression of ARPC1A mRNA

NCBI chr12:14,616,245...14,639,052
Ensembl chr12:14,616,248...14,639,052

G

assembly factor for spindle microtubules

decreases expression

ISO

o,p'-DDT results in decreased expression of ASPM mRNA

NCBI chr13:53,625,584...53,674,489
Ensembl chr13:53,625,584...53,674,489

G

asparaginase and isoaspartyl peptidase 1

increases expression

ISO

o,p'-DDT results in increased expression of ASRGL1 mRNA

NCBI chr 1:215,436,180...215,456,188
Ensembl chr 1:215,435,218...215,456,198

G

ATPase family, AAA domain containing 3A

increases expression

ISO
EXP

o,p'-DDT results in increased expression of ATAD3A mRNA

NCBI chr 5:171,632,545...171,652,725
Ensembl chr 5:171,632,547...171,652,725

G

activating transcription factor 4

increases expression

EXP
ISO

o,p'-DDT results in increased expression of ATF4 mRNA

NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739

G

ATPase Na+/K+ transporting subunit alpha 1

multiple interactions

ISO

[o,p'-DDT co-treated with DDT] results in increased expression of ATP1A1 mRNA

NCBI chr 2:191,709,311...191,737,414
Ensembl chr 2:191,709,311...191,737,425

G

ATP synthase F1 subunit beta

increases expression

EXP
ISO

o,p'-DDT results in increased expression of ATP5F1B mRNA

NCBI chr 7:1,100,058...1,106,461
Ensembl chr 7:1,099,860...1,106,462

G

apoptosis and caspase activation inhibitor

increases expression

EXP
ISO

o,p'-DDT analog results in increased expression of AVEN mRNA; o,p'-DDT results in increased expression of AVEN mRNA

PMID:22937105 PMID:24096037

NCBI chr 3:119,753,395...119,886,009
Ensembl chr 3:119,872,661...119,886,008

G

BCL2-associated agonist of cell death

decreases expression

EXP

o,p'-DDT analog results in decreased expression of BAD mRNA; o,p'-DDT results in decreased expression of BAD mRNA

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034

G

BAG cochaperone 1

decreases expression
increases expression

EXP

o,p'-DDT analog results in decreased expression of BAG1 mRNA
o,p'-DDT results in increased expression of BAG1 mRNA

NCBI chr 5:60,864,476...60,877,059
Ensembl chr 5:60,864,476...60,878,161

G

BCL2 associated X, apoptosis regulator

increases expression
decreases expression

EXP
ISO

o,p'-DDT results in increased expression of BAX mRNA
o,p'-DDT results in increased expression of BAX protein
o,p'-DDT analog results in decreased expression of BAX mRNA

PMID:22937105 PMID:35122929

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL10, immune signaling adaptor

decreases expression

EXP

o,p'-DDT results in decreased expression of BCL10 mRNA

NCBI chr 2:237,501,181...237,510,821
Ensembl chr 2:237,501,134...237,511,829

G

BCL2, apoptosis regulator

increases expression
decreases expression
multiple interactions

ISO
EXP

o,p'-DDT results in increased expression of BCL2 mRNA; o,p'-DDT results in increased expression of BCL2 protein
o,p'-DDT results in decreased expression of BCL2 protein
fulvestrant inhibits the reaction [o,p'-DDT results in increased expression of BCL2 protein]

PMID:10545406 PMID:22609851 PMID:22937105 PMID:35122929

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

BCL2-related protein A1

increases expression
decreases expression

EXP

o,p'-DDT results in increased expression of BCL2A1 mRNA
o,p'-DDT analog results in decreased expression of BCL2A1 mRNA

NCBI chr 8:98,596,806...98,604,890
Ensembl chr 8:98,596,650...98,604,890

G

Bcl2-like 1

decreases expression

EXP

o,p'-DDT analog results in decreased expression of BCL2L1 mRNA

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

Bcl2-like 11

increases expression
decreases expression

EXP

o,p'-DDT analog results in increased expression of BCL2L11 mRNA; o,p'-DDT results in increased expression of BCL2L11 mRNA
o,p'-DDT analog results in decreased expression of BCL2L11 mRNA

NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695

G

Bcl2-like 2

increases expression
decreases expression

EXP

o,p'-DDT results in increased expression of BCL2L2 mRNA
o,p'-DDT analog results in decreased expression of BCL2L2 mRNA

NCBI chr15:32,326,686...32,337,834
Ensembl chr15:32,326,020...32,335,379

G

BCL2-associated transcription factor 1

decreases expression

EXP

o,p'-DDT analog results in decreased expression of BCLAF1 mRNA

NCBI chr 1:16,904,572...16,937,106
Ensembl chr 1:16,914,118...16,936,801

G

brain expressed X-linked 1

increases expression

ISO

o,p'-DDT results in increased expression of BEX2 mRNA

NCBI chr X:104,010,639...104,012,143
Ensembl chr X:104,010,371...104,011,236

G

BH3 interacting domain death agonist

decreases expression
increases expression

EXP

o,p'-DDT analog results in decreased expression of BID mRNA
o,p'-DDT results in increased expression of BID mRNA

NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275

G

BCL2-interacting killer

increases expression
decreases expression

EXP

o,p'-DDT results in increased expression of BIK mRNA
o,p'-DDT analog results in decreased expression of BIK mRNA

NCBI chr 7:116,552,303...116,571,317
Ensembl chr 7:116,552,303...116,571,317

G

baculoviral IAP repeat-containing 3

increases expression

EXP

o,p'-DDT analog results in increased expression of BIRC3 mRNA

NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590

G

baculoviral IAP repeat-containing 5

decreases expression

EXP

o,p'-DDT analog results in decreased expression of BIRC5 mRNA

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155

G

BCL2 interacting protein 1

increases expression
decreases expression

ISO
EXP

o,p'-DDT results in increased expression of BNIP1 mRNA
o,p'-DDT analog results in decreased expression of BNIP1 mRNA

PMID:19371625 PMID:22937105

NCBI chr10:16,891,317...16,903,561
Ensembl chr10:16,891,317...16,903,561

G

BCL2 interacting protein 2

decreases expression

EXP

o,p'-DDT analog results in decreased expression of BNIP2 mRNA

NCBI chr 8:79,521,375...79,539,148
Ensembl chr 8:79,521,363...79,547,368

G

BCL2 interacting protein 3

increases expression

EXP

o,p'-DDT analog results in increased expression of BNIP3 mRNA; o,p'-DDT results in increased expression of BNIP3 mRNA

NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962

G

BCL2 family apoptosis regulator BOK

decreases expression

EXP

o,p'-DDT analog results in decreased expression of BOK mRNA

NCBI chr 9:101,670,729...101,681,834
Ensembl chr 9:101,670,625...101,681,833

G

BRCA1, DNA repair associated

multiple interactions
increases expression

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in increased expression of BRCA1 mRNA]; fulvestrant inhibits the reaction [o,p'-DDT results in increased expression of BRCA1 mRNA]

NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,917,693...86,977,763

G

complement C3

increases expression

ISO
EXP

o,p'-DDT results in increased expression of C3 mRNA; o,p'-DDT results in increased expression of C3 protein

PMID:10822019 PMID:11086226 PMID:11390168 PMID:24096037

NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,174,412...2,201,339

G

carbonic anhydrase 3

affects expression

EXP

o,p'-DDT affects the expression of CA3 mRNA

NCBI chr 2:88,491,666...88,501,299
Ensembl chr 2:88,491,670...88,500,524

G

Cdk5 and Abl enzyme substrate 1

increases expression

ISO

o,p'-DDT results in increased expression of CABLES1 mRNA

NCBI chr18:3,349,681...3,455,956
Ensembl chr18:3,351,652...3,455,956

G

capping actin protein, gelsolin like

increases expression

ISO
EXP

o,p'-DDT results in increased expression of CAPG mRNA

NCBI chr 4:106,152,912...106,170,010
Ensembl chr 4:106,152,890...106,170,672

G

calpain 9

increases expression

ISO

o,p'-DDT results in increased expression of CAPN9 mRNA

NCBI chr19:69,446,847...69,483,810
Ensembl chr19:69,446,847...69,483,810

G

carbonic anhydrase 2

increases expression

ISO
EXP

o,p'-DDT results in increased expression of CAR2 mRNA

NCBI chr 2:88,462,883...88,478,012
Ensembl chr 2:88,462,872...88,478,064

G

caspase recruitment domain family, member 10

decreases expression

EXP

o,p'-DDT analog results in decreased expression of CARD10 mRNA

NCBI chr 7:112,210,944...112,252,044
Ensembl chr 7:112,210,776...112,239,806

G

caspase recruitment domain family, member 6

decreases expression

EXP

o,p'-DDT analog results in decreased expression of CARD6 mRNA

NCBI chr 2:55,921,832...55,934,388
Ensembl chr 2:55,921,832...55,934,363

G

cysteinyl-tRNA synthetase 1

increases expression

ISO

o,p'-DDT results in increased expression of CARS1 mRNA

NCBI chr 1:208,183,092...208,225,425
Ensembl chr 1:208,182,788...208,225,407

G

caspase 1

increases expression

EXP

o,p'-DDT analog results in increased expression of CASP1 mRNA

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275

G

caspase 12

increases expression

EXP

o,p'-DDT results in increased expression of CASP12 mRNA

NCBI chr 8:10,927,188...10,954,442
Ensembl chr 8:10,926,994...10,954,442

G

caspase 14

decreases expression

EXP

o,p'-DDT analog results in decreased expression of CASP14 mRNA

NCBI chr 7:11,577,315...11,583,987
Ensembl chr 7:11,580,339...11,583,171

G

caspase 2

increases expression

EXP

o,p'-DDT analog results in increased expression of CASP2 mRNA; o,p'-DDT results in increased expression of CASP2 mRNA

NCBI chr 4:72,116,265...72,134,023
Ensembl chr 4:72,116,246...72,134,022

G

caspase 3

increases expression
multiple interactions

EXP
ISO

o,p'-DDT analog results in increased expression of CASP3 protein; o,p'-DDT results in increased expression of CASP3 mRNA; o,p'-DDT results in increased expression of CASP3 protein
Quercetin inhibits the reaction [o,p'-DDT results in increased expression of CASP3 protein modified form]

PMID:22937105 PMID:35122929

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 4

increases expression

EXP

o,p'-DDT results in increased expression of CASP4 mRNA

NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:10,883,769...10,920,727

G

caspase 6

decreases expression

EXP

o,p'-DDT analog results in decreased expression of CASP6 mRNA

NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:221,140,256...221,152,726

G

caspase 7

decreases expression
increases expression

EXP

o,p'-DDT analog results in decreased expression of CASP7 mRNA
o,p'-DDT results in increased expression of CASP7 mRNA

NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512

G

caspase 8

decreases expression
increases expression

EXP

o,p'-DDT analog results in decreased expression of CASP8 mRNA
o,p'-DDT results in increased expression of CASP8 mRNA

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 8 associated protein 2

decreases expression
increases expression

EXP

o,p'-DDT analog results in decreased expression of CASP8AP2 mRNA; o,p'-DDT results in decreased expression of CASP8AP2 mRNA
o,p'-DDT analog results in increased expression of CASP8AP2 mRNA

NCBI chr 5:51,809,366...51,848,633
Ensembl chr 5:51,810,972...51,848,632

G

caspase 9

decreases expression
increases expression
multiple interactions
affects expression

EXP
ISO

o,p'-DDT analog results in decreased expression of CASP9 mRNA
o,p'-DDT results in increased expression of CASP9 protein modified form
Quercetin inhibits the reaction [o,p'-DDT results in increased expression of CASP9 protein modified form]
o,p'-DDT affects the expression of CASP9 mRNA
o,p'-DDT results in increased expression of CASP9 mRNA

PMID:18925944 PMID:22937105 PMID:35122929

Ensembl chr 5:159,391,188...159,409,648

G

catalase

multiple interactions
decreases activity

ISO

Quercetin inhibits the reaction [o,p'-DDT results in decreased activity of CAT protein]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

coiled-coil domain containing 85A

increases methylation

ISO

o,p'-DDT results in increased methylation of CCDC85A gene

NCBI chr14:106,327,580...106,560,205
Ensembl chr14:106,327,580...106,560,165

G

C-C motif chemokine ligand 2

decreases expression

ISO

o,p'-DDT results in decreased expression of CCL2 mRNA

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

cyclin A1

increases expression

ISO

o,p'-DDT results in increased expression of CCNA1 mRNA

NCBI chr 2:141,383,352...141,428,205
Ensembl chr 2:141,382,468...141,393,300

G

cyclin B1

affects expression

EXP

o,p'-DDT affects the expression of CCNB1 mRNA

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin B2

affects expression

ISO
EXP

o,p'-DDT affects the expression of CCNB2 mRNA

PMID:17984292 PMID:18925944

NCBI chr 8:79,968,459...79,981,717
Ensembl chr 8:79,968,465...79,981,682

G

cyclin D1

multiple interactions
affects expression
increases expression

ISO
EXP

fulvestrant inhibits the reaction [o,p'-DDT results in increased expression of CCND1 mRNA]
o,p'-DDT affects the expression of CCND1 mRNA

PMID:17984292 PMID:18925944 PMID:20206645 PMID:33728745

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin D2

decreases expression

EXP
ISO

o,p'-DDT results in decreased expression of CCND2 mRNA

NCBI chr 4:161,653,048...161,675,422
Ensembl chr 4:161,653,048...161,680,301
Ensembl chr 4:161,653,048...161,680,301

G

cyclin E2

decreases expression

ISO

o,p'-DDT results in decreased expression of CCNE2 mRNA

NCBI chr 5:29,082,169...29,094,879
Ensembl chr 5:29,082,703...29,094,882

G

cyclin G2

affects expression

ISO

o,p'-DDT affects the expression of CCNG2 mRNA

NCBI chr14:15,088,694...15,097,190
Ensembl chr14:15,088,695...15,096,206

G

chaperonin containing TCP1 subunit 2

increases expression

ISO
EXP

o,p'-DDT results in increased expression of CCT2 mRNA

NCBI chr 7:54,578,654...54,591,428
Ensembl chr 7:54,578,663...54,592,977

G

chaperonin containing TCP1 subunit 4

increases expression

ISO
EXP

o,p'-DDT results in increased expression of CCT4 mRNA

NCBI chr14:101,193,057...101,205,935
Ensembl chr14:101,192,772...101,205,770

G

chaperonin containing TCP1 subunit 5

increases expression

ISO
EXP

o,p'-DDT results in increased expression of CCT5 mRNA

NCBI chr 2:84,302,621...84,313,773
Ensembl chr 2:84,302,623...84,313,779

G

chaperonin containing TCP1 subunit 7

increases expression

ISO
EXP

o,p'-DDT results in increased expression of CCT7 mRNA

NCBI chr 4:119,546,730...119,563,973
Ensembl chr 4:119,546,730...119,563,973

G

CD24 molecule

increases expression

ISO
EXP

o,p'-DDT results in increased expression of CD24A mRNA

NCBI chr20:48,655,549...48,661,786
Ensembl chr20:48,655,805...48,661,785

G

CD34 molecule

decreases expression

ISO

o,p'-DDT results in decreased expression of CD34 mRNA

NCBI chr13:109,008,786...109,029,317
Ensembl chr13:109,008,623...109,029,315

G

CD40 molecule

decreases expression
increases expression

EXP

o,p'-DDT analog results in decreased expression of CD40 mRNA
o,p'-DDT results in increased expression of CD40 mRNA

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847

G

CD40 ligand

decreases expression
increases expression

EXP

o,p'-DDT analog results in decreased expression of CD40LG mRNA
o,p'-DDT results in increased expression of CD40LG mRNA

NCBI chr X:140,164,341...140,176,057
Ensembl chr X:140,164,302...140,176,475

G

CD55 molecule (Cromer blood group)

increases expression

ISO

o,p'-DDT results in increased expression of CD55 mRNA

NCBI chr13:44,409,574...44,438,913
Ensembl chr13:44,409,587...44,438,107

G

cell division cycle 25A

increases expression

ISO
EXP

o,p'-DDT results in increased expression of CDC25A mRNA

NCBI chr 8:118,742,824...118,761,190
Ensembl chr 8:118,742,426...118,761,188

G

cell division cycle associated 8

decreases expression

ISO

o,p'-DDT results in decreased expression of CDCA8 mRNA

NCBI chr 5:142,461,082...142,483,336
Ensembl chr 5:142,461,084...142,483,283

G

CUB domain containing protein 1

increases expression

ISO

o,p'-DDT results in increased expression of CDCP1 mRNA

NCBI chr 8:131,706,140...131,742,799
Ensembl chr 8:131,706,140...131,742,877

G

cadherin 1

decreases expression

ISO

o,p'-DDT results in decreased expression of CDH1 mRNA

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cyclin-dependent kinase 1

increases expression

ISO
EXP

o,p'-DDT results in increased expression of CDK1 mRNA

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

cyclin-dependent kinase 9

increases expression

EXP
ISO

o,p'-DDT results in increased expression of CDK9 mRNA

NCBI chr 3:36,394,168...36,399,016
Ensembl chr 3:36,394,169...36,399,528

G

cyclin-dependent kinase inhibitor 1A

affects expression
decreases expression

ISO
EXP

o,p'-DDT affects the expression of CDKN1A mRNA
o,p'-DDT results in decreased expression of CDKN1A mRNA

PMID:18925944 PMID:23209616

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

carboxylesterase 2A

affects expression

EXP

o,p'-DDT affects the expression of CES2A mRNA

NCBI chr19:135,885...142,935
Ensembl chr19:135,885...142,935

G

carboxylesterase 2H

affects expression

ISO

o,p'-DDT affects the expression of CES2 mRNA

NCBI chr19:49,884,164...49,898,764
Ensembl chr19:49,884,164...49,898,752

G

complement factor B

increases expression

ISO
EXP

o,p'-DDT results in increased expression of CFB mRNA

NCBI chr20:3,975,271...3,981,138
Ensembl chr20:3,955,776...3,981,740

G

CASP8 and FADD-like apoptosis regulator

decreases expression

EXP

o,p'-DDT analog results in decreased expression of CFLAR mRNA

NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434

G

ChaC glutathione specific gamma-glutamylcyclotransferase 2

increases expression

ISO

o,p'-DDT results in increased expression of CHAC2 mRNA

NCBI chr14:108,921,669...108,929,215
Ensembl chr14:108,921,341...108,929,469

G

cholinergic receptor, muscarinic 1

increases expression

ISO

o,p'-DDT results in increased expression of CHRM1 mRNA; o,p'-DDT results in increased expression of CHRM1 protein

NCBI chr 1:214,996,180...215,012,136
Ensembl chr 1:214,995,872...215,020,602

G

cholinergic receptor, muscarinic 3

increases expression

ISO

o,p'-DDT results in increased expression of CHRM3 mRNA; o,p'-DDT results in increased expression of CHRM3 protein

NCBI chr17:64,696,549...65,158,622
Ensembl chr17:64,696,066...65,173,304

G

cholinergic receptor nicotinic alpha 1 subunit

increases expression

ISO

o,p'-DDT results in increased expression of CHRNA1 mRNA; o,p'-DDT results in increased expression of CHRNA1 protein

NCBI chr 3:78,862,286...78,877,353
Ensembl chr 3:78,862,286...78,877,353

G

cytokine induced apoptosis inhibitor 1

increases expression

ISO
EXP

o,p'-DDT results in increased expression of CIAPIN1 mRNA

NCBI chr19:10,185,955...10,199,120
Ensembl chr19:10,182,088...10,201,495

G

cell death-inducing DFFA-like effector a

decreases expression

EXP

o,p'-DDT analog results in decreased expression of CIDEA mRNA

NCBI chr18:63,164,817...63,190,384
Ensembl chr18:63,164,099...63,190,382

G

cell death-inducing DFFA-like effector b

decreases expression
increases expression

EXP

o,p'-DDT analog results in decreased expression of CIDEB mRNA
o,p'-DDT results in increased expression of CIDEB mRNA

NCBI chr15:33,222,135...33,226,407
Ensembl chr15:33,221,824...33,226,688

G

cold inducible RNA binding protein

decreases expression

ISO

o,p'-DDT results in decreased expression of CIRBP mRNA

NCBI chr 7:10,184,515...10,189,623

G

clusterin

decreases expression

EXP

o,p'-DDT results in decreased expression of CLU mRNA

NCBI chr15:44,336,619...44,375,861
Ensembl chr15:44,359,914...44,375,860

G

cytochrome c oxidase subunit 5A

increases expression

EXP
ISO

o,p'-DDT results in increased expression of COX5A mRNA

NCBI chr 8:66,818,284...66,829,691
Ensembl chr 8:66,818,196...66,830,279

G

cytochrome c oxidase subunit 6B1

increases expression

ISO

o,p'-DDT results in increased expression of COX6B1 mRNA

NCBI chr 1:95,002,513...95,011,516
Ensembl chr 1:95,001,707...95,011,431
Ensembl chr 5:95,001,707...95,011,431

G

copine 7

increases expression

ISO

o,p'-DDT results in increased expression of CPNE7 mRNA

NCBI chr19:68,072,165...68,091,197
Ensembl chr19:68,074,545...68,091,197

G

carboxypeptidase X (M14 family), member 1

increases expression

ISO
EXP

o,p'-DDT results in increased expression of CPXM1 mRNA

NCBI chr 3:138,041,645...138,048,443
Ensembl chr 3:138,041,645...138,048,857

G

CASP2 and RIPK1 domain containing adaptor with death domain

decreases expression

EXP

o,p'-DDT analog results in decreased expression of CRADD mRNA

NCBI chr 7:31,827,131...31,839,796
Ensembl chr 7:31,685,622...31,874,512

G

cAMP responsive element binding protein 1

increases phosphorylation
affects localization
increases activity

ISO

o,p'-DDT results in increased phosphorylation of CREB1 protein
o,p'-DDT affects the localization of CREB1 protein
o,p'-DDT results in increased activity of CREB1 protein

PMID:18791200 PMID:20678559

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

CREB binding protein

multiple interactions
increases activity

ISO

o,p'-DDT promotes the reaction [MAP2K6 protein results in increased activity of CREBBP protein]; SB 203580 inhibits the reaction [o,p'-DDT results in increased activity of CREBBP protein]

NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266

G

crooked neck pre-mRNA splicing factor 1

increases expression

ISO
EXP

o,p'-DDT results in increased expression of CRNKL1 mRNA

NCBI chr 3:153,764,718...153,807,973
Ensembl chr 6:6,894,292...6,896,635
Ensembl chr 3:6,894,292...6,896,635

G

casein kinase 2 alpha 1

increases expression

ISO
EXP

o,p'-DDT results in increased expression of CSNK2A1 mRNA

NCBI chr 3:161,170,295...161,217,073
Ensembl chr 3:161,170,405...161,215,698

G

catenin beta 1

decreases expression

ISO

o,p'-DDT results in decreased expression of CTNNB1 mRNA

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

cathepsin D

increases expression

ISO

o,p'-DDT results in increased expression of CTSD mRNA

NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821

G

C-X3-C motif chemokine ligand 1

decreases expression

ISO

o,p'-DDT results in decreased expression of CX3CL1 mRNA

NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,233,329...10,242,999

G

cytochrome b-245 alpha chain

increases expression
multiple interactions

ISO
EXP

o,p'-DDT results in increased expression of CYBA mRNA
Quercetin inhibits the reaction [o,p'-DDT results in increased expression of CYBA mRNA]

PMID:24096037 PMID:35122929

NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214

G

cytochrome b-245 beta chain

increases expression
multiple interactions

ISO

o,p'-DDT results in increased expression of CYBB mRNA
Quercetin inhibits the reaction [o,p'-DDT results in increased expression of CYBB mRNA]

NCBI chr X:16,030,596...16,065,065
Ensembl chr X:16,030,596...16,065,065

G

cytochrome c, somatic

increases expression
multiple interactions

ISO
EXP

o,p'-DDT results in increased expression of CYCS mRNA
Quercetin inhibits the reaction [o,p'-DDT results in increased expression of CYCS protein]

PMID:24096037 PMID:35122929

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

EXP

o,p'-DDT results in decreased expression of CYP11A1 mRNA

NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196

G

cytochrome P450, family 17, subfamily a, polypeptide 1

affects expression

EXP
ISO

o,p'-DDT affects the expression of CYP17A1 mRNA

PMID:17984292 PMID:18925944

NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions
decreases expression
decreases activity
increases expression

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein]; 6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 mRNA]; 6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein]; [alpha-naphthoflavone results in decreased activity of CYP19A1 protein] which results in decreased susceptibility to o,p'-DDT; [Dichlorodiphenyl Dichloroethylene co-treated with o,p'-DDT] results in decreased activity of CYP19A1 protein; [o,p'-DDT co-treated with Atrazine] results in increased activity of CYP19A1 protein; [vinclozolin co-treated with o,p'-DDT] results in decreased activity of CYP19A1 protein; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 mRNA]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein]
o,p'-DDT results in decreased expression of CYP19A1 mRNA
o,p'-DDT results in decreased activity of CYP19A1 protein
o,p'-DDT results in increased expression of CYP19A1 mRNA; o,p'-DDT results in increased expression of CYP19A1 protein

PMID:17599374 PMID:20678559 PMID:28263910

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

cytochrome P450, family 1, subfamily a, polypeptide 1

affects expression
increases expression
multiple interactions

ISO

o,p'-DDT affects the expression of CYP1A1 mRNA
o,p'-DDT results in increased expression of CYP1A1 mRNA
o,p'-DDT inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; o,p'-DDT inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; o,p'-DDT promotes the reaction [AHR protein binds to CYP1A1 promoter]

PMID:12176094 PMID:18925944 PMID:28263910

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily a, polypeptide 2

affects expression
increases expression

ISO

o,p'-DDT affects the expression of CYP1A2 mRNA
o,p'-DDT results in increased expression of CYP1A2 mRNA

PMID:18925944 PMID:21924250

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 2, subfamily b, polypeptide 2

affects expression

ISO
EXP

o,p'-DDT affects the expression of CYP2B13 mRNA
o,p'-DDT affects the expression of CYP2B2 mRNA

PMID:17984292 PMID:18925944

NCBI chr 1:90,722,243...90,736,272

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression
affects expression
multiple interactions

ISO

o,p'-DDT results in increased expression of CYP2B6 mRNA; o,p'-DDT results in increased expression of CYP2B6 protein
o,p'-DDT affects the expression of CYP2B10 mRNA
o,p'-DDT inhibits the reaction [Androstenols inhibits the reaction [NR1I3 protein results in increased expression of CYP2B6 mRNA]]

PMID:10037683 PMID:15548381 PMID:18925944 PMID:21924250

NCBI chr 1:90,780,468...90,859,852

G

cytochrome P450, family 2, subfamily c, polypeptide 23

affects expression

EXP

o,p'-DDT affects the expression of CYP2C23 mRNA

NCBI chr 1:252,838,427...252,863,081
Ensembl chr 1:252,838,433...252,863,067

G

cytochrome P450, family 2, subfamily c, polypeptide 24

affects expression

ISO

o,p'-DDT affects the expression of CYP2C55 mRNA

NCBI chr 1:246,286,341...246,348,607
Ensembl chr 1:246,286,341...246,348,607

G

cytochrome P450, family 3, subfamily a, polypeptide 2

affects expression
increases activity
multiple interactions
increases expression

EXP
ISO

o,p'-DDT affects the expression of CYP3A2 mRNA
o,p'-DDT results in increased activity of CYP3A4 protein
Dactinomycin inhibits the reaction [o,p'-DDT results in increased expression of CYP3A4 mRNA]
o,p'-DDT results in increased expression of CYP3A4 mRNA; o,p'-DDT results in increased expression of CYP3A4 protein

PMID:15548381 PMID:15795092 PMID:17035600 PMID:17984292 PMID:21924250

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

affects expression

EXP

o,p'-DDT affects the expression of CYP3A23-3A1 mRNA

NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813

G

cytochrome P450, family 51

affects expression

ISO

o,p'-DDT affects the expression of CYP51 mRNA

NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,991,613...31,010,450

G

cytochrome P450 family 7 subfamily A member 1

affects expression

ISO

o,p'-DDT affects the expression of CYP7A1 mRNA

NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202

G

cytochrome P450 family 7 subfamily B member 1

affects expression

ISO

o,p'-DDT affects the expression of CYP7B1 mRNA

NCBI chr 2:102,419,011...102,586,047
Ensembl chr 2:102,419,011...102,451,804

G

death associated protein kinase 1

decreases expression
increases expression

EXP

o,p'-DDT analog results in decreased expression of DAPK1 mRNA
o,p'-DDT results in increased expression of DAPK1 mRNA

NCBI chr17:3,935,826...4,096,858
Ensembl chr17:3,935,625...4,096,581

G

decorin

decreases expression

ISO
EXP

o,p'-DDT results in decreased expression of DCN mRNA

NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926

G

DExD-box helicase 39A

increases expression

EXP
ISO

o,p'-DDT results in increased expression of DDX39A mRNA

NCBI chr19:41,323,465...41,331,413
Ensembl chr19:41,322,836...41,332,306

G

desmin

increases expression

EXP
ISO

o,p'-DDT results in increased expression of DES mRNA

NCBI chr 9:84,299,626...84,307,344
Ensembl chr 9:84,298,447...84,307,347

G

DNA fragmentation factor subunit alpha

increases expression

EXP

o,p'-DDT analog results in increased expression of DFFA mRNA; o,p'-DDT results in increased expression of DFFA mRNA

NCBI chr 5:164,823,807...164,836,729
Ensembl chr 5:164,823,807...164,836,728

G

DNA fragmentation factor subunit beta

decreases expression

EXP

o,p'-DDT analog results in decreased expression of DFFB mRNA

NCBI chr 5:169,804,873...169,817,157
Ensembl chr 5:169,804,889...169,817,225

G

7-dehydrocholesterol reductase

affects expression

EXP

o,p'-DDT affects the expression of DHCR7 mRNA

NCBI chr 1:208,444,434...208,460,408
Ensembl chr 1:208,444,434...208,461,382

G

dehydrogenase/reductase 3

increases expression

ISO

o,p'-DDT results in increased expression of DHRS3 mRNA

NCBI chr 5:162,031,853...162,065,655
Ensembl chr 5:162,031,386...162,065,653

G

DnaJ heat shock protein family (Hsp40) member C2

affects expression

EXP

o,p'-DDT affects the expression of DNAJC2 mRNA

NCBI chr 4:14,162,490...14,189,662
Ensembl chr 4:14,163,838...14,192,846

G

delta/notch-like EGF repeat containing

increases expression

ISO

o,p'-DDT results in increased expression of DNER mRNA

NCBI chr 9:93,035,108...93,350,568
Ensembl chr 9:93,035,108...93,350,568

G

DNA methyltransferase 3 alpha

increases expression

EXP
ISO

o,p'-DDT results in increased expression of DNMT3A mRNA

NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970

G

double C2-like domains, gamma

affects expression

EXP

o,p'-DDT affects the expression of DOC2G mRNA

NCBI chr 1:210,724,868...210,729,352
Ensembl chr 1:210,725,748...210,730,048

G

destrin, actin depolymerizing factor

increases expression

EXP
ISO

o,p'-DDT results in increased expression of DSTN mRNA

NCBI chr 3:151,737,711...151,764,752
Ensembl chr 3:151,737,849...151,764,769

G

dynein light chain LC8-type 1

increases expression

ISO
EXP

o,p'-DDT results in increased expression of DYNLL1 mRNA

NCBI chr12:46,945,291...46,976,867
Ensembl chr12:46,973,050...46,976,861

G

E2F transcription factor 7

increases expression

ISO

o,p'-DDT results in increased expression of E2F7 mRNA

NCBI chr 7:48,036,881...48,079,055
Ensembl chr 7:48,037,749...48,079,055

G

eukaryotic translation elongation factor 1 gamma

increases expression

ISO
EXP

o,p'-DDT results in increased expression of EEF1G mRNA

NCBI chr 1:215,289,815...215,300,421
Ensembl chr 1:215,277,860...215,301,479

G

eukaryotic translation initiation factor 2B subunit delta

increases expression

ISO

o,p'-DDT results in increased expression of EIF2B4 mRNA

NCBI chr 6:30,903,148...30,908,803
Ensembl chr 6:30,903,219...30,908,800

G

eukaryotic translation initiation factor 2 subunit beta

affects expression
increases expression

EXP
ISO

o,p'-DDT affects the expression of EIF2S2 mRNA
o,p'-DDT results in increased expression of EIF2S2 mRNA

PMID:17984292 PMID:24096037

NCBI chr 3:163,834,846...163,855,733
Ensembl chr 3:163,834,851...163,855,570

G

eukaryotic translation initiation factor 3, subunit C

affects expression

EXP

o,p'-DDT affects the expression of EIF3C mRNA

NCBI chr 1:190,565,183...190,583,067
Ensembl chr 1:190,565,184...190,583,067

G

eukaryotic translation initiation factor 3, subunit G

increases expression

ISO
EXP

o,p'-DDT results in increased expression of EIF3G mRNA

NCBI chr 8:27,705,914...27,709,946
Ensembl chr 8:27,705,915...27,709,987

G

eukaryotic translation initiation factor 4E binding protein 1

affects expression

EXP

o,p'-DDT affects the expression of EIF4EBP1 mRNA

NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874

G

eukaryotic translation initiation factor 5

increases expression

ISO
EXP

o,p'-DDT results in increased expression of EIF5 mRNA

NCBI chr 6:136,410,333...136,418,827
Ensembl chr 6:136,407,440...136,418,821

G

ETS transcription factor ELK1

increases activity

ISO

o,p'-DDT results in increased activity of ELK1 protein

NCBI chr X:3,692,367...3,709,252
Ensembl chr X:3,693,293...3,709,249

G

elongin B

increases expression

ISO
EXP

o,p'-DDT results in increased expression of ELOB mRNA

NCBI chr10:13,353,413...13,358,484
Ensembl chr10:13,353,417...13,358,563

G

epoxide hydrolase 1

affects expression

EXP

o,p'-DDT affects the expression of EPHX1 mRNA

NCBI chr13:95,246,079...95,275,852
Ensembl chr13:95,246,080...95,321,981

G

glutamyl-prolyl-tRNA synthetase 1

increases expression

ISO
EXP

o,p'-DDT results in increased expression of EPRS1 mRNA

NCBI chr13:99,431,955...99,503,510
Ensembl chr13:99,433,130...99,503,509

G

erb-b2 receptor tyrosine kinase 2

increases activity

ISO

o,p'-DDT results in increased activity of ERBB2 protein

PMID:9443065 PMID:11222871

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481

G

ERCC excision repair 3, TFIIH core complex helicase subunit

increases expression

ISO

o,p'-DDT results in increased expression of ERCC3 mRNA

NCBI chr18:24,157,831...24,188,543
Ensembl chr18:24,148,084...24,190,898

G

epiregulin

decreases expression

EXP

o,p'-DDT results in decreased expression of EREG mRNA

NCBI chr14:17,311,485...17,325,260
Ensembl chr14:17,311,485...17,325,260

G

estrogen receptor 1

affects binding
decreases expression
increases activity
multiple interactions
increases expression

ISO
EXP

o,p'-DDT binds to ESR1 protein
o,p'-DDT results in decreased expression of ESR1 mRNA
o,p'-DDT results in increased activity of ESR1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in decreased expression of ESR1 mRNA]; [Estradiol co-treated with Genistein co-treated with o,p'-DDT] affects the expression of ESR1 mRNA; [o,p'-DDT co-treated with Methoxychlor co-treated with Dieldrin] results in increased expression of ESR1 mRNA; Fulvestrant inhibits the reaction [o,p'-DDT results in decreased expression of ESR1 mRNA]; o,p'-DDT binds to and results in increased activity of ESR1 protein; o,p'-DDT inhibits the reaction [Estradiol binds to ESR1 protein]; o,p'-DDT promotes the reaction [Estradiol results in increased activity of ESR1 protein]
[o,p'-DDT co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Methoxychlor co-treated with Endosulfan co-treated with DDT] results in increased activity of ESR1 protein; o,p'-DDT inhibits the reaction [Estradiol results in increased activity of ESR1 protein]
o,p'-DDT results in increased expression of ESR1 mRNA
o,p'-DDT results in decreased expression of ESR1 mRNA; o,p'-DDT results in decreased expression of ESR1 protein

PMID:8930550 PMID:9751507 PMID:9860891 PMID:11086226 PMID:11162928 More...

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

estrogen receptor 2

multiple interactions
decreases expression
increases activity

ISO
EXP

o,p'-DDT binds to and results in increased activity of ESR2 protein
o,p'-DDT results in decreased expression of ESR2 mRNA; o,p'-DDT results in decreased expression of ESR2 protein
o,p'-DDT results in increased activity of ESR2 protein
[o,p'-DDT co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Methoxychlor co-treated with Endosulfan co-treated with DDT] results in increased activity of ESR2 protein

PMID:9751507 PMID:9860891 PMID:15064155 PMID:16626760 PMID:18700809 More...

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

G

ethanolamine kinase 2

increases expression

ISO

o,p'-DDT results in increased expression of ETNK2 mRNA

NCBI chr13:47,362,964...47,381,100
Ensembl chr13:47,363,060...47,381,100

G

Fas associated via death domain

decreases expression

EXP

o,p'-DDT analog results in decreased expression of FADD mRNA

NCBI chr 1:209,169,245...209,175,423
Ensembl chr 1:209,169,318...209,174,976

G

fatty acid desaturase 2

decreases expression

ISO

o,p'-DDT results in decreased expression of FADS2 mRNA

NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:216,133,676...216,172,066

G

Fas apoptotic inhibitory molecule

decreases expression

EXP

o,p'-DDT analog results in decreased expression of FAIM mRNA; o,p'-DDT results in decreased expression of FAIM mRNA

NCBI chr 8:108,423,259...108,445,365
Ensembl chr 8:108,423,221...108,440,151

G

family with sequence similarity 107, member A

decreases expression

ISO

o,p'-DDT results in decreased expression of FAM107A mRNA

NCBI chr15:19,038,726...19,060,644
Ensembl chr15:19,038,616...19,065,219

G

Fas cell surface death receptor

affects expression
increases expression
decreases expression

ISO
EXP

o,p'-DDT affects the expression of FAS mRNA
o,p'-DDT results in increased expression of FAS mRNA
o,p'-DDT analog results in decreased expression of FAS mRNA

PMID:18925944 PMID:22937105

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

Fas ligand

increases expression
decreases expression

ISO
EXP

o,p'-DDT results in increased expression of FASLG mRNA
o,p'-DDT analog results in decreased expression of FASLG mRNA

PMID:22609851 PMID:22937105

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

fibrillin 2

increases expression

ISO

o,p'-DDT results in increased expression of FBN2 mRNA

NCBI chr18:53,696,197...53,901,992
Ensembl chr18:53,697,708...53,902,191

G

folate receptor alpha

decreases expression

ISO

o,p'-DDT results in decreased expression of FOLR1 mRNA

NCBI chr 1:165,631,462...165,650,430
Ensembl chr 1:165,631,462...165,642,669

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression
affects localization
multiple interactions

ISO
EXP

o,p'-DDT results in increased expression of FOS mRNA
o,p'-DDT affects the localization of FOS protein
o,p'-DDT results in increased expression of and results in increased activity of FOS protein

PMID:18840457 PMID:24096037 PMID:34167450

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

FOS like 1, AP-1 transcription factor subunit

increases expression

ISO

o,p'-DDT results in increased expression of FOSL1 mRNA

NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:212,183,833...212,192,391

G

forkhead box D1

increases expression

ISO

o,p'-DDT results in increased expression of FOXD1 mRNA

NCBI chr 2:31,436,802...31,439,222
Ensembl chr 2:31,436,813...31,439,399

G

follicle stimulating hormone subunit beta

multiple interactions

ISO

o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]

NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072

G

follicle stimulating hormone receptor

multiple interactions

ISO

o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]

NCBI chr 6:10,952,329...11,160,288
Ensembl chr 6:10,952,329...11,160,288

G

ferritin light chain 1

affects expression

EXP

o,p'-DDT affects the expression of FTL1 mRNA

NCBI chr 1:105,072,858...105,074,705
Ensembl chr X:45,399,355...45,399,915
Ensembl chr 2:45,399,355...45,399,915
Ensembl chr 1:45,399,355...45,399,915

G

FXYD domain-containing ion transport regulator 4

decreases expression

EXP
ISO

o,p'-DDT results in decreased expression of FXYD4 mRNA

NCBI chr 4:152,782,181...152,786,118
Ensembl chr 4:152,782,181...152,786,039

G

G0/G1switch 2

increases expression

ISO
EXP

o,p'-DDT results in increased expression of G0S2 mRNA

PMID:19371625 PMID:24096037

NCBI chr13:107,335,036...107,335,948
Ensembl chr13:107,335,036...107,336,293

G

growth arrest and DNA-damage-inducible, alpha

affects expression
increases expression

ISO
EXP

o,p'-DDT affects the expression of GADD45A mRNA
o,p'-DDT analog results in increased expression of GADD45A mRNA; o,p'-DDT results in increased expression of GADD45A mRNA

PMID:18925944 PMID:22937105

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807

G

growth arrest and DNA-damage-inducible, beta

affects expression

ISO

o,p'-DDT affects the expression of GADD45B mRNA

NCBI chr 7:9,428,689...9,430,991
Ensembl chr 7:9,428,689...9,430,718

G

polypeptide N-acetylgalactosaminyltransferase 4

increases expression

ISO

o,p'-DDT results in increased expression of GALNT4 mRNA

NCBI chr 7:35,811,904...35,814,445

G

galanin receptor 2

decreases expression

ISO

o,p'-DDT results in decreased expression of GALR2 mRNA

NCBI chr10:102,012,086...102,016,057
Ensembl chr10:102,013,370...102,016,055

G

glutamate-cysteine ligase, catalytic subunit

affects expression

EXP

o,p'-DDT affects the expression of GCLC mRNA

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glutamate cysteine ligase, modifier subunit

affects expression

EXP
ISO

o,p'-DDT affects the expression of GCLM mRNA

PMID:17984292 PMID:18925944

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

glycerophosphodiester phosphodiesterase domain containing 5

increases expression

ISO

o,p'-DDT results in increased expression of GDPD5 mRNA

NCBI chr 1:163,091,844...163,173,559
Ensembl chr 1:163,091,833...163,173,559

G

gonadotropin releasing hormone 1

multiple interactions
affects secretion

EXP

o,p'-DDT affects the reaction [LHB protein results in increased susceptibility to GNRH1 protein]
o,p'-DDT affects the secretion of GNRH1 protein

NCBI chr15:46,147,878...46,152,086
Ensembl chr15:46,148,301...46,148,977
Ensembl chr15:46,148,301...46,148,977

G

G protein-coupled receptor 142

increases expression

ISO

o,p'-DDT results in increased expression of GPR142 mRNA

NCBI chr10:100,339,112...100,342,453
Ensembl chr10:100,339,112...100,342,453

G

glutathione peroxidase 2

affects expression

EXP

o,p'-DDT affects the expression of GPX2 mRNA

NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:101,226,745...101,230,862

G

GRAM domain containing 2B

decreases expression

ISO

o,p'-DDT results in decreased expression of GRAMD2B mRNA

NCBI chr18:52,082,128...52,180,056
Ensembl chr18:52,082,029...52,180,054

G

gremlin 1, DAN family BMP antagonist

increases expression

ISO

o,p'-DDT results in increased expression of GREM1 mRNA

NCBI chr 3:120,966,639...120,978,319
Ensembl chr 3:120,966,623...120,979,089

G

G1 to S phase transition 1

increases expression

ISO
EXP

o,p'-DDT results in increased expression of GSPT1 mRNA

NCBI chr10:4,867,687...4,904,186
Ensembl chr10:4,869,465...4,908,040

G

glutathione-disulfide reductase

affects expression

ISO

o,p'-DDT affects the expression of GSR mRNA

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

glutathione S-transferase alpha 2

affects expression

ISO

o,p'-DDT affects the expression of GSTA1 mRNA

NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092

G

glutathione S-transferase alpha 3

affects expression

EXP

o,p'-DDT affects the expression of GSTA3 mRNA

NCBI chr 9:31,154,989...31,180,653
Ensembl chr 9:31,154,989...31,180,654

G

glutathione S-transferase mu 2

affects expression

ISO

o,p'-DDT affects the expression of GSTM2 mRNA

NCBI chr 2:198,312,179...198,316,962

G

glutathione S-transferase theta 1

affects expression

EXP

o,p'-DDT affects the expression of GSTT1 mRNA

NCBI chr20:12,856,068...12,873,020
Ensembl chr20:12,856,083...12,873,019

G

granzyme A

increases expression

ISO
EXP

o,p'-DDT results in increased expression of GZMA mRNA

NCBI chr 2:46,473,763...46,485,696
Ensembl chr 2:46,473,763...46,485,696

G

H2B clustered histone 14

decreases expression

ISO

o,p'-DDT results in decreased expression of H2BC5 mRNA

NCBI chr17:47,488,627...47,489,008

G

hyaluronan and proteoglycan link protein 3

decreases expression

ISO

o,p'-DDT results in decreased expression of HAPLN3 mRNA

NCBI chr 1:142,455,828...142,473,877
Ensembl chr 1:142,454,629...142,471,832

G

hes family bHLH transcription factor 2

increases expression

ISO

o,p'-DDT results in increased expression of HES2 mRNA

NCBI chr 5:167,947,948...167,964,660
Ensembl chr 5:167,949,918...167,955,601

G

HIVEP zinc finger 1

increases expression

ISO

o,p'-DDT results in increased expression of HIVEP1 mRNA

NCBI chr17:22,790,855...22,920,359
Ensembl chr17:22,790,855...22,917,196

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

decreases expression

ISO

o,p'-DDT results in decreased expression of HMGCS1 mRNA

NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:53,382,643...53,399,802

G

high mobility group nucleosomal binding domain 2

decreases expression

ISO

o,p'-DDT results in decreased expression of HMGN2 mRNA

NCBI chr 5:151,475,907...151,479,361
Ensembl chr 5:151,475,909...151,479,397

G

heme oxygenase 1

affects expression

EXP

o,p'-DDT affects the expression of HMOX1 mRNA

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heme oxygenase 2

affects expression

ISO

o,p'-DDT affects the expression of HMOX2 mRNA

NCBI chr10:11,303,512...11,337,640
Ensembl chr10:11,303,512...11,318,800

G

heterogeneous nuclear ribonucleoprotein A/B

increases expression

ISO
EXP

o,p'-DDT results in increased expression of HNRNPAB mRNA

NCBI chr10:36,358,004...36,363,898
Ensembl chr10:36,358,006...36,364,307

G

heterogeneous nuclear ribonucleoprotein U

increases expression

ISO
EXP

o,p'-DDT results in increased expression of HNRNPU mRNA

NCBI chr13:92,609,791...92,618,580
Ensembl chr13:92,605,216...92,618,612

G

harakiri, BCL2 interacting protein

decreases expression
increases expression

EXP
ISO

o,p'-DDT analog results in decreased expression of HRK mRNA
o,p'-DDT results in increased expression of HRK mRNA

PMID:18204070 PMID:22937105

NCBI chr12:44,048,402...44,070,561
Ensembl chr12:44,048,402...44,070,561

G

heat shock protein 90 alpha family class A member 1

increases expression
affects expression

ISO
EXP

o,p'-DDT results in increased expression of HSP90AA1 mRNA
o,p'-DDT affects the expression of HSP90AA1 mRNA

PMID:17984292 PMID:24096037

NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499

G

heat shock protein 90 alpha family class B member 1

affects expression

EXP

o,p'-DDT affects the expression of HSP90AB1 mRNA

NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:22,931,070...22,935,926

G

heat shock protein family A (Hsp70) member 2

decreases expression

ISO

o,p'-DDT results in decreased expression of HSPA2 mRNA

NCBI chr 6:100,864,172...100,866,946
Ensembl chr 6:100,864,553...100,867,133

G

heat shock protein family A (Hsp70) member 4

increases expression

ISO
EXP

o,p'-DDT results in increased expression of HSPA4 mRNA
o,p'-DDT analog results in increased expression of HSPA4 mRNA; o,p'-DDT results in increased expression of HSPA4 mRNA

PMID:22937105 PMID:24096037

NCBI chr10:37,908,866...37,951,994
Ensembl chr10:37,908,866...37,949,835

G

heat shock protein family A (Hsp70) member 8

increases expression

ISO
EXP

o,p'-DDT results in increased expression of HSPA8 mRNA

NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:50,080,199...50,084,372

G

heat shock protein family D (Hsp60) member 1

increases expression
affects expression

ISO
EXP

o,p'-DDT results in increased expression of HSPD1 mRNA
o,p'-DDT affects the expression of HSPD1 mRNA

PMID:17984292 PMID:24096037

NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:64,073,611...64,084,037

G

heat shock protein family E (Hsp10) member 1

affects expression

EXP

o,p'-DDT affects the expression of HSPE1 mRNA

NCBI chr 9:64,084,327...64,087,415
Ensembl chr 9:64,085,068...64,087,502

G

heat shock protein family H (Hsp110) member 1

increases expression

EXP
ISO

o,p'-DDT results in increased expression of HSPH1 mRNA

NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891

G

isopentenyl-diphosphate delta isomerase 1

decreases expression

ISO

o,p'-DDT results in decreased expression of IDI1 mRNA

NCBI chr17:66,539,761...66,547,524
Ensembl chr17:66,539,763...66,547,524

G

insulin-like growth factor 1

affects expression
increases expression

EXP
ISO

o,p'-DDT affects the expression of IGF1 mRNA
o,p'-DDT results in increased expression of IGF1 mRNA

PMID:17984292 PMID:24096037

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor binding protein 3

affects expression

EXP

o,p'-DDT affects the expression of IGFBP3 mRNA

NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944

G

interleukin 10

decreases expression

EXP

o,p'-DDT analog results in decreased expression of IL10 mRNA

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 1 beta

multiple interactions
increases expression

ISO

[DDT co-treated with o,p'-DDT] results in decreased expression of IL1B mRNA
o,p'-DDT results in increased expression of IL1B

PMID:12007859 PMID:15104118

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 24

increases expression

ISO

o,p'-DDT results in increased expression of IL24 mRNA

NCBI chr13:44,905,362...44,910,760
Ensembl chr13:44,905,363...44,910,760

G

interleukin 6

increases expression

ISO

o,p'-DDT results in increased expression of IL6; o,p'-DDT results in increased expression of IL6 mRNA

PMID:15104118 PMID:17035600

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin 6 receptor

increases expression

ISO

o,p'-DDT results in increased expression of IL6R mRNA

NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221

G

inosine monophosphate dehydrogenase 2

increases expression

ISO

o,p'-DDT results in increased expression of IMPDH2 mRNA

NCBI chr 8:118,135,204...118,139,892
Ensembl chr 8:118,135,262...118,139,873

G

insulin induced gene 2

affects expression

ISO

o,p'-DDT affects the expression of INSIG2 mRNA

NCBI chr13:35,025,160...35,052,937
Ensembl chr13:35,025,164...35,047,658

G

interferon regulatory factor 1

affects expression

EXP

o,p'-DDT affects the expression of IRF1 mRNA

NCBI chr10:38,417,935...38,424,946
Ensembl chr10:38,417,148...38,424,947

G

integrin subunit alpha 6

increases expression

ISO

o,p'-DDT results in increased expression of ITGA6 mRNA

NCBI chr 3:77,012,168...77,097,076
Ensembl chr 3:77,017,766...77,097,076

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression
affects localization
multiple interactions

EXP
ISO

o,p'-DDT results in increased expression of JUN mRNA
o,p'-DDT affects the localization of JUN protein
o,p'-DDT results in increased expression of and results in increased activity of JUN protein

PMID:18840457 PMID:24096037 PMID:34167450

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

potassium voltage-gated channel subfamily A member 3

multiple interactions
decreases activity

ISO

[o,p'-DDT results in decreased activity of KCNA3 protein] which results in decreased import of Thallium

NCBI chr 2:197,320,324...197,322,277
Ensembl chr 2:197,318,134...197,350,739

G

potassium voltage-gated channel subfamily H member 2

multiple interactions
decreases activity

ISO

[o,p'-DDT results in decreased activity of KCNH2 protein] which results in decreased import of Thallium

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

potassium channel tetramerization domain containing 20

increases expression

ISO

o,p'-DDT results in increased expression of KCTD20 mRNA

NCBI chr20:7,017,480...7,034,440
Ensembl chr20:7,017,502...7,034,441

G

kinesin family member 20A

decreases expression

ISO

o,p'-DDT results in decreased expression of KIF20A mRNA

NCBI chr18:26,504,422...26,512,908
Ensembl chr18:26,504,072...26,512,909

G

KLF transcription factor 4

increases expression

ISO

o,p'-DDT results in increased expression of KLF4 mRNA

NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:75,074,236...75,078,592

G

keratin 13

increases expression

ISO
EXP

o,p'-DDT results in increased expression of KRT13 mRNA

NCBI chr10:85,552,287...85,556,499
Ensembl chr10:85,552,287...85,556,499

G

keratin 17

decreases expression

ISO

o,p'-DDT results in decreased expression of KRT17 mRNA

NCBI chr10:85,679,068...85,683,792
Ensembl chr10:85,679,070...85,683,787

G

keratin 8

increases expression

ISO
EXP

o,p'-DDT results in increased expression of KRT8 mRNA

NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:135,002,894...135,010,403

G

La ribonucleoprotein 6, translational regulator

increases expression

ISO

o,p'-DDT results in increased expression of LARP6 mRNA

NCBI chr 8:70,079,753...70,101,175
Ensembl chr 8:70,079,647...70,101,198

G

low density lipoprotein receptor

decreases expression

ISO

o,p'-DDT results in decreased expression of LDLR mRNA

NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675

G

luteinizing hormone subunit beta

multiple interactions

EXP

o,p'-DDT affects the reaction [LHB protein results in increased susceptibility to GNRH1 protein]

NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445

G

LIM homeobox 4

decreases expression

EXP

o,p'-DDT analog results in decreased expression of LHX4 mRNA

NCBI chr13:70,423,768...70,477,337
Ensembl chr13:70,427,399...70,467,505

G

lipase G, endothelial type

decreases expression

ISO

o,p'-DDT results in decreased expression of LIPG mRNA

NCBI chr18:70,790,077...70,811,259
Ensembl chr18:70,790,077...70,812,260

G

lamin A/C

increases expression

ISO
EXP

o,p'-DDT results in increased expression of LMNA mRNA

NCBI chr 2:176,237,564...176,265,301
Ensembl chr 2:176,237,564...176,288,072

G

leucine rich repeat containing 17

decreases expression

ISO

o,p'-DDT results in decreased expression of LRRC17 mRNA

NCBI chr 4:14,393,632...14,424,048
Ensembl chr 4:14,393,640...14,424,048

G

lymphotoxin alpha

decreases expression
increases expression

EXP

o,p'-DDT analog results in decreased expression of LTA mRNA
o,p'-DDT results in increased expression of LTA mRNA

NCBI chr20:3,622,291...3,625,852
Ensembl chr20:3,623,527...3,625,533

G

lymphotoxin beta receptor

increases expression
decreases expression

EXP

o,p'-DDT results in increased expression of LTBR mRNA
o,p'-DDT analog results in decreased expression of LTBR mRNA

NCBI chr 4:159,795,115...159,801,571
Ensembl chr 4:159,795,115...159,807,296

G

lactotransferrin

multiple interactions
increases expression

ISO

fulvestrant inhibits the reaction [o,p'-DDT results in increased expression of LTF mRNA]
o,p'-DDT results in increased expression of LTF mRNA; o,p'-DDT results in increased expression of LTF protein

PMID:9607801 PMID:11390168

NCBI chr 8:119,878,344...119,901,189
Ensembl chr 8:119,878,344...119,901,189

G

latexin

decreases expression

ISO

o,p'-DDT results in decreased expression of LXN mRNA

NCBI chr 2:154,037,604...154,043,473
Ensembl chr 2:154,037,292...154,043,488

G

LYL1, basic helix-loop-helix family member

increases expression

ISO
EXP

o,p'-DDT results in increased expression of LYL1 mRNA

NCBI chr19:40,356,967...40,359,834
Ensembl chr19:40,354,819...40,359,834

G

lysosomal trafficking regulator

increases expression

ISO

o,p'-DDT results in increased expression of LYST mRNA

NCBI chr17:93,225,509...93,427,650
Ensembl chr17:93,225,540...93,427,650

G

MAF bZIP transcription factor B

increases expression

ISO
EXP

o,p'-DDT results in increased expression of MAFB mRNA

NCBI chr 3:169,417,890...169,419,810
Ensembl chr 3:169,416,945...169,419,975

G

MAGE family member D1

increases expression

ISO
EXP

o,p'-DDT results in increased expression of MAGED1 mRNA

NCBI chr X:63,416,464...63,423,167
Ensembl chr X:63,416,466...63,423,112

G

MAK16 homolog

increases expression

ISO

o,p'-DDT results in increased expression of RBM13 mRNA

NCBI chr16:67,675,757...67,684,188
Ensembl chr16:67,675,735...67,684,836

G

MANSC domain containing 1

decreases expression

ISO

o,p'-DDT results in decreased expression of MANSC1 mRNA

NCBI chr 4:169,170,164...169,190,379
Ensembl chr 4:169,170,164...169,189,864

G

mitogen-activated protein kinase kinase 6

multiple interactions

ISO

o,p'-DDT promotes the reaction [MAP2K6 protein results in increased activity of CREBBP protein]

NCBI chr10:95,872,747...95,987,747
Ensembl chr10:95,872,546...95,987,721

G

mitogen activated protein kinase 1

increases phosphorylation
increases activity
multiple interactions

ISO
EXP

o,p'-DDT results in increased phosphorylation of MAPK1 protein
o,p'-DDT results in increased activity of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in increased phosphorylation of and results in increased activity of MAPK1 protein]; o,p'-DDT results in increased phosphorylation of and results in increased activity of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in increased phosphorylation of MAPK1 protein]; MAPK1 protein promotes the reaction [o,p'-DDT results in increased activity of NOTCH1 protein]

PMID:11222871 PMID:12523960 PMID:18791200 PMID:18840457 PMID:20678559 More...

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 13

decreases expression

ISO

o,p'-DDT results in decreased expression of MAPK13 mRNA

NCBI chr20:6,836,979...6,847,197
Ensembl chr20:6,837,013...6,847,191

G

mitogen activated protein kinase 14

multiple interactions

ISO

MAPK14 protein promotes the reaction [o,p'-DDT results in increased activity of NOTCH1 protein]

NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in increased phosphorylation of and results in increased activity of MAPK3 protein]; o,p'-DDT results in increased phosphorylation of and results in increased activity of MAPK3 protein
o,p'-DDT results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in increased phosphorylation of MAPK3 protein]

PMID:11222871 PMID:18840457 PMID:20678559 PMID:34167450

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 8

multiple interactions
increases phosphorylation

ISO

o,p'-DDT results in increased phosphorylation of and results in increased activity of MAPK8 protein; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased phosphorylation of and results in increased activity of MAPK8 protein]
pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased phosphorylation of MAPK8 protein]

PMID:18840457 PMID:20678559

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

mitogen-activated protein kinase 8 interacting protein 1

increases expression

EXP

o,p'-DDT analog results in increased expression of MAPK8IP1 mRNA; o,p'-DDT results in increased expression of MAPK8IP1 mRNA

NCBI chr 3:98,810,540...98,829,302
Ensembl chr 3:98,810,541...98,828,368

G

mitogen-activated protein kinase 9

multiple interactions
increases phosphorylation

ISO

pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased phosphorylation of MAPK9 protein]
o,p'-DDT results in increased phosphorylation of and results in increased activity of MAPK9 protein; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased phosphorylation of and results in increased activity of MAPK9 protein]

PMID:18840457 PMID:20678559

NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228

G

MCL1 apoptosis regulator, BCL2 family member

increases expression
decreases expression

EXP

o,p'-DDT results in increased expression of MCL1 mRNA
o,p'-DDT analog results in decreased expression of MCL1 mRNA

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782

G

MDM2 proto-oncogene

affects expression

ISO

o,p'-DDT affects the expression of MDM2 mRNA

NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791

G

mesenchyme homeobox 1

decreases expression

ISO

o,p'-DDT results in decreased expression of MEOX1 mRNA

NCBI chr10:87,318,668...87,338,169
Ensembl chr10:87,318,695...87,337,976

G

MET proto-oncogene, receptor tyrosine kinase

increases expression

ISO

o,p'-DDT results in increased expression of MET mRNA

NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821

G

milk fat globule EGF and factor V/VIII domain containing

decreases expression

ISO

o,p'-DDT results in decreased expression of MFGE8 mRNA

NCBI chr 1:142,474,027...142,489,431
Ensembl chr 1:142,474,028...142,489,431

G

mitofusin 2

increases expression

ISO

o,p'-DDT results in increased expression of MFN2 mRNA

NCBI chr 5:163,587,463...163,617,363
Ensembl chr 5:163,587,463...163,618,495

G

melanophilin

increases expression

ISO

o,p'-DDT results in increased expression of MLPH mRNA

NCBI chr 9:98,955,036...98,990,566
Ensembl chr 9:98,955,141...98,990,556

G

matrix metallopeptidase 2

increases expression

ISO

o,p'-DDT results in increased expression of MMP2 mRNA

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 23

increases expression

ISO
EXP

o,p'-DDT results in increased expression of MMP23 mRNA

NCBI chr 5:171,521,905...171,525,007
Ensembl chr 5:171,520,494...171,524,695

G

matrix metallopeptidase 9

increases expression

ISO

o,p'-DDT results in increased expression of MMP9 mRNA

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

mitochondrial ribosomal protein S7

increases expression

ISO

o,p'-DDT results in increased expression of MRPS7 mRNA

NCBI chr10:101,342,642...101,345,790
Ensembl chr10:101,342,421...101,346,082

G

mucin 5AC, oligomeric mucus/gel-forming

increases expression
multiple interactions

ISO

o,p'-DDT results in increased expression of MUC5AC mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in increased expression of MUC5AC mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in increased expression of MUC5AC mRNA]; 4-methyl-N1-(3-phenylpropyl)benzene-1,2-diamine inhibits the reaction [o,p'-DDT results in increased expression of MUC5AC mRNA]; Curcumin inhibits the reaction [o,p'-DDT results in increased expression of MUC5AC mRNA]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased expression of MUC5AC mRNA]; SB 203580 inhibits the reaction [o,p'-DDT results in increased expression of MUC5AC mRNA]

NCBI chr 1:206,293,717...206,326,006
Ensembl chr 1:206,293,869...206,326,006

G

myc target 1

increases expression

ISO

o,p'-DDT results in increased expression of MYCT1 mRNA

NCBI chr 1:44,423,478...44,434,751
Ensembl chr 1:44,423,544...44,436,992

G

myosin heavy chain 6

increases expression

ISO
EXP

o,p'-DDT results in increased expression of MYH6 mRNA

NCBI chr15:32,388,102...32,413,663
Ensembl chr15:32,387,487...32,411,333

G

myosin VA

increases expression

ISO
EXP

o,p'-DDT results in increased expression of MYO5A mRNA

NCBI chr 8:84,692,524...84,860,564
Ensembl chr 8:84,692,910...84,856,265

G

myosin Vb

increases expression

ISO
EXP

o,p'-DDT results in increased expression of MYO5B mRNA

NCBI chr18:70,313,717...70,613,918
Ensembl chr18:70,311,990...70,613,918

G

NLR family, apoptosis inhibitory protein 6

increases expression

EXP

o,p'-DDT analog results in increased expression of NAIP2 mRNA

NCBI chr 2:33,241,520...33,293,184
Ensembl chr 2:33,241,521...33,276,859

G

neutrophil cytosolic factor 1

increases expression
multiple interactions

ISO

o,p'-DDT results in increased expression of NCF1 mRNA
Quercetin inhibits the reaction [o,p'-DDT results in increased expression of NCF1 mRNA]

NCBI chr12:28,121,816...28,131,080
Ensembl chr12:28,121,366...28,131,079

G

neutrophil cytosolic factor 2

multiple interactions
increases expression

ISO

Quercetin inhibits the reaction [o,p'-DDT results in increased expression of NCF2 mRNA]

NCBI chr13:67,505,492...67,536,015
Ensembl chr13:67,505,375...67,536,149

G

neutrophil cytosolic factor 4

multiple interactions
increases expression

ISO

Quercetin inhibits the reaction [o,p'-DDT results in increased expression of NCF4 mRNA]

NCBI chr 7:111,705,926...111,723,893
Ensembl chr 7:111,706,520...111,723,898

G

nuclear receptor coactivator 1

multiple interactions

ISO

o,p'-DDT promotes the reaction [NR1I3 protein modified form binds to NCOA1 protein]

NCBI chr 6:32,952,090...33,229,829
Ensembl chr 6:32,952,090...33,195,924

G

NADH:ubiquinone oxidoreductase subunit A1

increases expression

ISO
EXP

o,p'-DDT results in increased expression of NDUFA1 mRNA

NCBI chr X:121,289,904...121,293,555
Ensembl chr X:121,289,925...121,293,555

G

NADH:ubiquinone oxidoreductase subunit S5

increases expression

ISO
EXP

o,p'-DDT results in increased expression of NDUFS5 mRNA

NCBI chr 5:141,258,828...141,264,552
Ensembl chr 2:184,849,197...185,028,909
Ensembl chr 5:184,849,197...185,028,909
Ensembl chr14:184,849,197...185,028,909

G

NADH:ubiquinone oxidoreductase core subunit V2

increases expression

ISO
EXP

o,p'-DDT results in increased expression of NDUFV2 mRNA

NCBI chr 9:113,137,305...113,157,571
Ensembl chr 9:113,137,306...113,157,520

G

nei-like DNA glycosylase 2

increases expression

ISO

o,p'-DDT results in increased expression of NEIL2 mRNA

NCBI chr15:41,620,650...41,631,551
Ensembl chr15:41,621,352...41,630,834

G

nuclear factor kappa B subunit 1

increases expression

EXP

o,p'-DDT analog results in increased expression of NFKB1 mRNA; o,p'-DDT results in increased expression of NFKB1 mRNA

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

niban apoptosis regulator 1

increases expression

ISO

o,p'-DDT results in increased expression of NIBAN1 mRNA

NCBI chr13:66,224,219...66,377,728
Ensembl chr13:66,224,021...66,377,724

G

NME/NM23 nucleoside diphosphate kinase 1

increases expression

ISO

o,p'-DDT results in increased expression of NME1 mRNA

NCBI chr10:79,403,939...79,426,620
Ensembl chr10:79,403,940...79,413,310

G

nucleolar protein 3

increases expression

EXP

o,p'-DDT analog results in increased expression of NOL3 mRNA; o,p'-DDT results in increased expression of NOL3 mRNA

NCBI chr19:50,066,493...50,068,175
Ensembl chr19:50,063,986...50,068,722

G

nitric oxide synthase 2

multiple interactions
increases expression

ISO

[DDT co-treated with o,p'-DDT] results in decreased expression of NOS2 mRNA
o,p'-DDT results in increased expression of NOS2

PMID:12007859 PMID:15104118

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

notch receptor 1

multiple interactions

ISO

MAPK1 protein promotes the reaction [o,p'-DDT results in increased activity of NOTCH1 protein]; MAPK14 protein promotes the reaction [o,p'-DDT results in increased activity of NOTCH1 protein]; o,p'-DDT results in increased phosphorylation of and results in increased activity of NOTCH1 protein; SB 203580 inhibits the reaction [o,p'-DDT results in increased activity of NOTCH1 protein]; U 0126 inhibits the reaction [o,p'-DDT results in increased activity of NOTCH1 protein]

NCBI chr 3:29,676,040...29,721,613
Ensembl chr 3:29,676,171...29,721,613

G

NADPH oxidase 1

multiple interactions
increases expression

ISO

Quercetin inhibits the reaction [o,p'-DDT results in increased expression of NOX1 mRNA]

NCBI chr X:101,572,338...101,625,571
Ensembl chr X:101,572,340...101,595,520

G

NPC intracellular cholesterol transporter 1

increases expression

ISO

o,p'-DDT results in increased expression of NPC1 mRNA

NCBI chr18:3,654,237...3,699,853
Ensembl chr18:3,654,237...3,699,800

G

NAD(P)H quinone dehydrogenase 1

affects expression

ISO

o,p'-DDT affects the expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions
affects expression
increases activity

ISO
EXP

o,p'-DDT binds to and results in increased activity of NR1I2 protein
o,p'-DDT affects the expression of NR1I2 mRNA
o,p'-DDT results in increased activity of NR1I2 protein

PMID:15548381 PMID:16054614 PMID:17984292 PMID:18925944 PMID:21115097 More...

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 1, group I, member 3

affects expression
increases activity
multiple interactions

ISO
EXP

o,p'-DDT affects the expression of NR1I3 mRNA
o,p'-DDT results in increased activity of NR1I3 protein
o,p'-DDT inhibits the reaction [Androstenols inhibits the reaction [NR1I3 protein results in increased expression of CYP2B6 mRNA]]; o,p'-DDT promotes the reaction [NR1I3 protein modified form binds to NCOA1 protein]

PMID:10037683 PMID:17984292 PMID:18925944 PMID:21924250 PMID:26187274 More...

NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

ISO

o,p'-DDT inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 3, group C, member 2

multiple interactions

ISO

o,p'-DDT inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; o,p'-DDT inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]

NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078

G

out at first homolog

increases expression

ISO

o,p'-DDT results in increased expression of OAF mRNA

NCBI chr 8:52,491,314...52,509,285
Ensembl chr 8:52,491,315...52,509,285

G

olfactomedin 1

increases expression

ISO

o,p'-DDT results in increased expression of OLFM1 mRNA

NCBI chr 3:31,918,512...31,956,261
Ensembl chr 3:31,918,573...31,956,260

G

olfactomedin-like 3

increases expression

ISO

o,p'-DDT results in increased expression of OLFML3 mRNA

NCBI chr 2:193,932,665...193,935,494
Ensembl chr 2:193,932,665...193,935,494

G

oxysterol binding protein-like 1A

affects expression

EXP

o,p'-DDT affects the expression of OSBPL1A mRNA

NCBI chr18:4,178,734...4,383,511
Ensembl chr18:4,179,631...4,369,421

G

osteoclast associated Ig-like receptor

increases expression

ISO

o,p'-DDT results in increased expression of OSCAR mRNA

NCBI chr 1:74,521,626...74,529,119
Ensembl chr 1:74,515,001...74,529,119

G

poly(A) binding protein, cytoplasmic 1

increases expression

ISO
EXP

o,p'-DDT results in increased expression of PABPC1 mRNA

NCBI chr 7:69,662,513...69,674,806
Ensembl chr 7:69,663,068...69,675,050

G

poly (ADP-ribose) polymerase 1

affects expression

EXP

o,p'-DDT affects the expression of PARP1 mRNA

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

phosphoenolpyruvate carboxykinase 1

multiple interactions

EXP

o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]

NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561

G

programmed cell death 2

increases expression

EXP
ISO

o,p'-DDT results in increased expression of PDCD2 mRNA

NCBI chr 1:65,158,034...65,163,524
Ensembl chr 1:65,158,034...65,163,524

G

programmed cell death 5

increases expression

ISO
EXP

o,p'-DDT results in increased expression of PDCD5 mRNA

NCBI chr 1:97,442,755...97,448,084
Ensembl chr 1:97,442,755...97,449,844

G

programmed cell death 7

increases expression

ISO

o,p'-DDT results in increased expression of PDCD7 mRNA

NCBI chr 8:74,757,768...74,772,495
Ensembl chr 8:74,757,768...74,781,634

G

pellino E3 ubiquitin protein ligase 1

decreases expression

ISO

o,p'-DDT results in decreased expression of PELI1 mRNA

NCBI chr14:99,455,970...99,510,474
Ensembl chr14:99,455,811...99,510,466

G

progesterone receptor

multiple interactions
decreases expression
increases expression
affects binding

ISO
EXP

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in increased expression of PGR mRNA]; fulvestrant inhibits the reaction [o,p'-DDT results in increased expression of PGR mRNA]; o,p'-DDT inhibits the reaction [16 alpha-ethyl-21-hydroxy-19-nor-4-pregnene-3,20-dione results in increased activity of PGR protein]; o,p'-DDT inhibits the reaction [Progesterone binds to PGR protein]; o,p'-DDT inhibits the reaction [Progesterone results in increased expression of PGR protein]
o,p'-DDT promotes the reaction [Progesterone binds to PGR protein]
o,p'-DDT results in decreased expression of PGR mRNA
o,p'-DDT binds to PGR protein

PMID:7414049 PMID:9607801 PMID:10822019 PMID:11867264 PMID:14579009 More...

NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271

G

phosphatidylinositol 4-kinase alpha

increases activity

ISO

o,p'-DDT results in increased activity of PI4KA protein

NCBI chr11:97,113,390...97,234,374
Ensembl chr11:97,113,245...97,228,315

G

protein inhibitor of activated STAT, 2

increases expression

ISO
EXP

o,p'-DDT results in increased expression of PIAS2 mRNA

NCBI chr18:72,883,008...72,989,486
Ensembl chr18:72,882,890...73,006,662

G

Pim-1 proto-oncogene, serine/threonine kinase

increases expression

ISO

o,p'-DDT results in increased expression of PIM1 mRNA

NCBI chr20:7,556,496...7,560,747
Ensembl chr20:7,556,113...7,561,764

G

pyruvate kinase M1/2

increases expression

ISO

o,p'-DDT results in increased expression of PKM mRNA

NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:68,948,815...68,975,396

G

phospholipase A2, group III

decreases expression

ISO

o,p'-DDT results in decreased expression of PLA2G3 mRNA

NCBI chr14:82,589,908...82,597,542
Ensembl chr14:82,591,862...82,597,542

G

phospholipid phosphatase related 2

increases expression

ISO

o,p'-DDT results in increased expression of PLPPR2 mRNA

NCBI chr 8:28,742,787...28,755,555
Ensembl chr 8:28,745,639...28,755,555

G

DNA polymerase beta

decreases expression
increases expression

EXP

o,p'-DDT analog results in decreased expression of POLB mRNA
o,p'-DDT results in increased expression of POLB mRNA

NCBI chr16:76,081,903...76,105,174
Ensembl chr16:76,081,864...76,108,180

G

cytochrome p450 oxidoreductase

affects expression

EXP

o,p'-DDT affects the expression of POR mRNA

NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809

G

peroxiredoxin 2

decreases expression

EXP

o,p'-DDT analog results in decreased expression of PRDX2 mRNA; o,p'-DDT results in decreased expression of PRDX2 mRNA

NCBI chr19:40,085,788...40,091,083
Ensembl chr19:40,084,430...40,091,006

G

protein kinase cAMP-activated catalytic subunit alpha

increases activity
decreases activity

ISO
EXP

o,p'-DDT results in increased activity of PRKACA protein
o,p'-DDT results in decreased activity of PRKACA protein

PMID:19526567 PMID:23209616

NCBI chr19:41,059,843...41,083,189
Ensembl chr19:41,059,843...41,086,494

G

protein kinase cAMP-dependent type II regulatory subunit alpha

increases expression

ISO

o,p'-DDT results in increased expression of PRKAR2A mRNA

NCBI chr 8:118,271,608...118,337,332
Ensembl chr 8:118,274,167...118,337,330

G

prolactin

multiple interactions
increases expression
increases secretion

EXP
ISO

Nifedipine inhibits the reaction [o,p'-DDT results in increased secretion of PRL protein]
o,p'-DDT results in increased expression of PRL mRNA
ICI 164384 inhibits the reaction [o,p'-DDT results in increased expression of PRL mRNA]

PMID:8968093 PMID:15811834

NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217

G

prolactin receptor

decreases expression
increases expression

EXP
ISO

o,p'-DDT analog results in decreased expression of PRLR mRNA
o,p'-DDT results in decreased expression of PRLR mRNA
o,p'-DDT results in increased expression of PRLR mRNA

PMID:22937105 PMID:33728745

NCBI chr 2:60,861,391...61,051,883
Ensembl chr 2:60,861,658...61,051,882

G

prokineticin 2

decreases expression

EXP

o,p'-DDT analog results in decreased expression of PROK2 mRNA

NCBI chr 4:133,903,210...133,918,126
Ensembl chr 4:133,903,210...133,917,933

G

pre-mRNA processing factor 8

increases expression

ISO
EXP

o,p'-DDT results in increased expression of PRPF8 mRNA

NCBI chr10:60,829,778...60,852,887
Ensembl chr10:60,829,778...60,852,887

G

proteasome 20S subunit alpha 4

increases expression
affects expression

ISO
EXP

o,p'-DDT results in increased expression of PSMA4 mRNA
o,p'-DDT affects the expression of PSMA4 mRNA

PMID:17984292 PMID:24096037

NCBI chr 8:64,236,520...64,243,980
Ensembl chr 8:64,236,783...64,243,979

G

proteasome 20S subunit alpha 5

affects expression

EXP

o,p'-DDT affects the expression of PSMA5 mRNA

NCBI chr 2:198,584,502...198,607,867
Ensembl chr 2:198,584,505...198,607,867

G

proteasome 20S subunit alpha 6

affects expression

EXP

o,p'-DDT affects the expression of PSMA6 mRNA

NCBI chr 6:78,500,676...78,531,693
Ensembl chr 6:78,500,736...78,531,717

G

proteasome 20S subunit beta 1

affects expression
increases expression

EXP
ISO

o,p'-DDT affects the expression of PSMB1 mRNA
o,p'-DDT results in increased expression of PSMB1 mRNA

PMID:17984292 PMID:24096037

NCBI chr 1:65,115,770...65,136,516
Ensembl chr 1:65,114,724...65,136,640

G

proteasome 20S subunit beta 4

affects expression

EXP

o,p'-DDT affects the expression of PSMB4 mRNA

NCBI chr 2:185,131,787...185,134,561
Ensembl chr 2:185,131,786...185,135,287

G

proteasome 20S subunit beta 5

increases expression
affects expression

ISO
EXP

o,p'-DDT results in increased expression of PSMB5 mRNA
o,p'-DDT affects the expression of PSMB5 mRNA

PMID:17984292 PMID:24096037

NCBI chr15:32,042,784...32,047,379
Ensembl chr15:32,042,787...32,047,379

G

proteasome 26S subunit, ATPase 3

affects expression

EXP

o,p'-DDT affects the expression of PSMC3 mRNA

NCBI chr 3:97,487,643...97,493,025
Ensembl chr 3:97,487,632...97,499,176

G

proteasome 26S subunit, ATPase 4

affects expression

EXP

o,p'-DDT affects the expression of PSMC4 mRNA

NCBI chr 1:92,476,690...92,485,268
Ensembl chr 1:92,476,690...92,485,060

G

proteasome 26S subunit, ATPase 5

increases expression

ISO
EXP

o,p'-DDT results in increased expression of PSMC5 mRNA

NCBI chr10:91,687,553...91,693,487
Ensembl chr10:91,686,295...91,695,921

G

proteasome 26S subunit, non-ATPase 1

affects expression

EXP

o,p'-DDT affects the expression of PSMD1 mRNA

NCBI chr 9:94,157,971...94,233,218
Ensembl chr 9:94,157,971...94,233,218

G

proteasome 26S subunit, non-ATPase 12

affects expression

EXP

o,p'-DDT affects the expression of PSMD12 mRNA

NCBI chr10:92,937,957...92,956,601
Ensembl chr10:92,901,133...92,988,964

G

proteasome 26S subunit ubiquitin receptor, non-ATPase 2

increases expression
affects expression

ISO
EXP

o,p'-DDT results in increased expression of PSMD2 mRNA
o,p'-DDT affects the expression of PSMD2 mRNA

PMID:17984292 PMID:24096037

NCBI chr11:93,752,761...93,763,388
Ensembl chr11:93,752,763...93,763,388

G

proteasome 26S subunit ubiquitin receptor, non-ATPase 4

affects expression

EXP

o,p'-DDT affects the expression of PSMD4 mRNA

NCBI chr 2:185,287,941...185,297,238
Ensembl chr 2:185,286,868...185,297,201

G

proteasome 26S subunit, non-ATPase 8

affects expression

EXP

o,p'-DDT affects the expression of PSMD8 mRNA

NCBI chr 1:93,601,857...93,608,689
Ensembl chr 1:93,601,853...93,608,689

G

prostaglandin-endoperoxide synthase 2

multiple interactions
decreases expression
increases expression

ISO
EXP

6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; 6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased susceptibility to o,p'-DDT; [o,p'-DDT results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; AH 23848 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein]
[o,p'-DDT results in decreased expression of PTGS2 mRNA] which results in decreased abundance of Dinoprostone
o,p'-DDT results in increased expression of PTGS2 mRNA; o,p'-DDT results in increased expression of PTGS2 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein]; [o,p'-DDT results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein]; wortmannin inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; wortmannin inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein]

PMID:18840457 PMID:20678559 PMID:23209616

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

protein tyrosine phosphatase, receptor type, C

increases expression

ISO
EXP

o,p'-DDT results in increased expression of PTPRC mRNA

NCBI chr13:52,147,717...52,259,810
Ensembl chr13:52,147,717...52,259,746

G

PYD and CARD domain containing

decreases expression

EXP

o,p'-DDT analog results in decreased expression of PYCARD mRNA

NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:192,032,124...192,033,419

G

RAB3A interacting protein-like 1

increases expression

ISO

o,p'-DDT results in increased expression of RAB3IL1 mRNA

NCBI chr 1:216,071,043...216,107,609
Ensembl chr 1:216,071,084...216,107,609

G

RAN, member RAS oncogene family

affects expression

EXP

o,p'-DDT affects the expression of RAN mRNA

NCBI chr12:33,311,155...33,314,339
Ensembl chr12:33,311,158...33,314,317

G

RNA binding protein, mRNA processing factor

decreases expression

ISO

o,p'-DDT results in decreased expression of RBPMS mRNA

NCBI chr16:64,942,159...65,098,504
Ensembl chr16:64,942,530...65,098,503

G

RecQ like helicase 4

increases methylation

ISO

o,p'-DDT results in increased methylation of RECQL4 gene

NCBI chr 7:110,304,092...110,311,426
Ensembl chr 7:110,304,094...110,311,258

G

RELA proto-oncogene, NF-kB subunit

affects localization

ISO

o,p'-DDT affects the localization of RELA protein

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

arginine-glutamic acid dipeptide repeats

decreases expression

ISO
EXP

o,p'-DDT results in decreased expression of RERE mRNA

NCBI chr 5:166,048,770...166,380,559
Ensembl chr 5:166,048,844...166,380,558

G

similar to RIKEN cDNA 3110043O21

increases expression

ISO

o,p'-DDT results in increased expression of C9ORF72 mRNA

NCBI chr 5:54,562,570...54,587,649
Ensembl chr 5:54,562,570...54,587,637

G

receptor-interacting serine-threonine kinase 2

increases expression
decreases expression

EXP

o,p'-DDT results in increased expression of RIPK2 mRNA
o,p'-DDT analog results in decreased expression of RIPK2 mRNA

NCBI chr 5:34,428,573...34,459,808
Ensembl chr 5:34,428,573...34,459,663

G

RecQ mediated genome instability 2

decreases expression

ISO

o,p'-DDT results in decreased expression of RMI2 mRNA

NCBI chr10:5,336,269...5,344,202
Ensembl chr10:5,338,060...5,344,235

G

ribosomal protein L13

affects expression

EXP

o,p'-DDT affects the expression of RPL13 mRNA

NCBI chr19:68,062,442...68,065,065
Ensembl chr19:68,062,493...68,065,059

G

ribosomal protein L18

affects expression

EXP

o,p'-DDT affects the expression of RPL18 mRNA

NCBI chr 1:105,325,269...105,327,911
Ensembl chr 1:105,325,250...105,327,910

G

ribosomal protein L23

affects expression

EXP

o,p'-DDT affects the expression of RPL23 mRNA

NCBI chr10:83,268,223...83,272,184
Ensembl chr10:83,262,592...83,272,214

G

ribosomal protein L3

affects expression

EXP

o,p'-DDT affects the expression of RPL3 mRNA

NCBI chr 7:113,491,943...113,508,115
Ensembl chr 7:113,501,960...113,507,990

G

ribosomal protein L37

affects expression

EXP

o,p'-DDT affects the expression of RPL37 mRNA

NCBI chr 2:55,942,827...55,944,905
Ensembl chr 2:55,942,945...55,944,900

G

ribosomal protein L6

affects expression

EXP

o,p'-DDT affects the expression of RPL6 mRNA

NCBI chr12:41,008,142...41,012,756
Ensembl chr12:41,008,142...41,025,733

G

ribosomal protein S15a

affects expression

EXP

o,p'-DDT affects the expression of RPS15A mRNA

NCBI chr 1:181,854,396...181,861,330
Ensembl chr 1:181,854,396...181,861,201

G

ribosomal protein S17

affects expression

EXP

o,p'-DDT affects the expression of RPS17 mRNA

NCBI chr 1:144,705,150...144,707,736
Ensembl chr 1:144,705,149...144,707,734
Ensembl chr 8:144,705,149...144,707,734

G

ribosomal protein S20

affects expression

EXP

o,p'-DDT affects the expression of RPS20 mRNA

NCBI chr 5:21,616,687...21,618,068
Ensembl chr 3:42,839,965...43,095,621
Ensembl chr 9:42,839,965...43,095,621
Ensembl chr 5:42,839,965...43,095,621

G

ribosomal protein S3

affects expression

EXP

o,p'-DDT affects the expression of RPS3 mRNA

NCBI chr 1:163,190,476...163,195,885
Ensembl chr 1:163,189,842...163,195,776

G

ribosomal protein S5

affects expression

EXP

o,p'-DDT affects the expression of RPS5 mRNA

NCBI chr 1:82,610,965...82,615,262
Ensembl chr 1:82,610,965...82,615,262

G

ribosomal protein S6

affects expression

EXP

o,p'-DDT affects the expression of RPS6 mRNA

NCBI chr 5:106,417,680...106,420,540
Ensembl chr 5:106,417,680...106,420,566

G

ribosomal protein S8

affects expression

EXP

o,p'-DDT affects the expression of RPS8 mRNA

NCBI chr 5:135,866,941...135,869,511
Ensembl chr 5:135,866,941...135,869,548

G

ribosomal protein SA

affects expression

EXP

o,p'-DDT affects the expression of RPSA mRNA

NCBI chr 8:128,728,761...128,732,736
Ensembl chr 8:128,728,862...128,732,737

G

ribonucleotide reductase regulatory subunit M2

decreases expression

ISO

o,p'-DDT results in decreased expression of RRM2 mRNA

NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370

G

RUNX family transcription factor 1

decreases expression

EXP

o,p'-DDT results in decreased expression of RUNX1 mRNA

NCBI chr11:45,325,778...45,560,300
Ensembl chr11:45,329,044...45,564,925

G

sphingosine-1-phosphate receptor 3

increases expression

ISO

o,p'-DDT results in increased expression of S1PR3 mRNA

NCBI chr17:13,932,773...13,946,213
Ensembl chr17:13,928,444...13,947,197

G

Sin3A associated protein 18

increases expression

EXP
ISO

o,p'-DDT results in increased expression of SAP18 mRNA

NCBI chr15:36,058,784...36,063,089
Ensembl chr10:87,156,914...87,158,257
Ensembl chr15:87,156,914...87,158,257

G

secretoglobin, family 1D, member 2

increases expression

ISO

o,p'-DDT results in increased expression of SCGB1D2 mRNA

NCBI chr 1:215,653,464...215,658,101
Ensembl chr 1:215,653,464...215,656,710

G

serpin family A member 3N

increases expression

ISO

o,p'-DDT results in increased expression of SERPINA3 mRNA

NCBI chr 6:129,088,392...129,095,950
Ensembl chr 6:129,088,398...129,097,415

G

serpin family B member 5

increases expression

ISO

o,p'-DDT results in increased expression of SERPINB5 mRNA

NCBI chr13:23,500,203...23,520,401
Ensembl chr13:23,500,198...23,520,400

G

SERTA domain containing 2

increases expression

ISO
EXP

o,p'-DDT results in increased expression of SERTAD2 mRNA

NCBI chr14:98,935,428...99,039,536
Ensembl chr14:98,934,769...99,041,468

G

sestrin 2

increases expression

ISO

o,p'-DDT results in increased expression of SESN2 mRNA

NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:149,986,317...150,005,255

G

splicing factor 1

increases expression

ISO
EXP

o,p'-DDT results in increased expression of SF1 mRNA

NCBI chr 1:213,090,256...213,112,688
Ensembl chr 1:213,099,260...213,113,590

G

splicing factor 3b, subunit 3

increases expression

ISO
EXP

o,p'-DDT results in increased expression of SF3B3 mRNA

NCBI chr19:55,692,124...55,729,640
Ensembl chr19:55,692,126...55,729,621

G

splicing factor 3b, subunit 5

increases expression

ISO

o,p'-DDT results in increased expression of SF3B5 mRNA

NCBI chr 1:9,177,189...9,177,901
Ensembl chr 1:9,177,098...9,177,900

G

splicing factor proline and glutamine rich

increases expression

ISO
EXP

o,p'-DDT results in increased expression of SFPQ mRNA

NCBI chr 5:144,621,678...144,637,930
Ensembl chr 5:144,622,476...144,637,926

G

shugoshin 2

decreases expression

ISO

o,p'-DDT results in decreased expression of SGO2 mRNA

NCBI chr 9:67,032,083...67,067,439
Ensembl chr 9:67,042,833...67,068,152

G

sex hormone binding globulin

multiple interactions
affects binding

EXP
ISO

o,p'-DDT inhibits the reaction [Dihydrotestosterone binds to SHBG protein]
o,p'-DDT binds to SHBG protein

PMID:9171990 PMID:25349334

NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,831,718...54,838,760

G

siah E3 ubiquitin protein ligase 2

increases expression

ISO

o,p'-DDT results in increased expression of SIAH2 mRNA

NCBI chr 2:145,063,847...145,081,675
Ensembl chr 2:145,063,857...145,081,873

G

SKI3 subunit of superkiller complex

increases expression
decreases expression

EXP

o,p'-DDT results in increased expression of TNFRSF10B mRNA
o,p'-DDT analog results in decreased expression of TNFRSF10B mRNA

NCBI chr 2:7,363,417...7,526,351
Ensembl chr 2:7,363,535...7,483,496

G

solute carrier family 10 member 1

decreases expression

ISO

o,p'-DDT results in decreased expression of SLC10A1 mRNA

NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944

G

solute carrier family 12 member 2

multiple interactions

ISO

[o,p'-DDT co-treated with DDT] results in increased expression of SLC12A2 mRNA

NCBI chr18:53,546,263...53,614,478
Ensembl chr18:53,546,333...53,614,470

G

solute carrier family 1 member 5

increases expression

ISO

o,p'-DDT results in increased expression of SLC1A5 mRNA

NCBI chr 1:86,584,949...86,599,052
Ensembl chr 1:86,584,949...86,599,054

G

solute carrier family 22 member 1

decreases expression

ISO

o,p'-DDT results in decreased expression of SLC22A1 mRNA

NCBI chr 1:50,624,339...50,651,437
Ensembl chr 1:50,624,377...50,651,436

G

solute carrier family 31 member 1

increases expression

ISO

o,p'-DDT results in increased expression of SLC31A1 mRNA

NCBI chr 5:80,830,574...80,859,810
Ensembl chr 5:80,830,389...80,859,809

G

solute carrier family 35, member F5

increases expression

ISO

o,p'-DDT results in increased expression of SLC35F5 mRNA

NCBI chr13:39,544,253...39,581,210
Ensembl chr13:39,544,757...39,581,223

G

solute carrier family 38, member 1

increases expression

ISO

o,p'-DDT results in increased expression of SLC38A1 mRNA

NCBI chr 7:129,612,414...129,681,727
Ensembl chr 7:129,617,387...129,681,778

G

solute carrier family 7 member 5

increases expression

ISO

o,p'-DDT results in increased expression of SLC7A5 mRNA

NCBI chr19:66,843,808...66,872,412
Ensembl chr19:66,843,808...66,872,412

G

solute carrier family 8 member A1

multiple interactions

ISO

[o,p'-DDT co-treated with DDT] results in increased expression of SLC8A1 mRNA

NCBI chr 6:18,975,498...19,299,704
Ensembl chr 6:18,946,798...19,287,964

G

solute carrier family 9 member A1

multiple interactions

ISO

[o,p'-DDT co-treated with DDT] results in increased expression of SLC9A1 mRNA

NCBI chr 5:150,859,412...150,913,525
Ensembl chr 5:150,860,228...150,913,517

G

solute carrier family 9 member A2

multiple interactions

ISO

[o,p'-DDT co-treated with DDT] results in increased expression of SLC9A2 mRNA

NCBI chr 9:50,427,612...50,510,043
Ensembl chr 9:50,426,798...50,510,040

G

solute carrier family 9 member A3

multiple interactions

ISO

[o,p'-DDT co-treated with DDT] results in increased expression of SLC9A3 mRNA

NCBI chr 1:30,953,215...30,996,209
Ensembl chr 1:30,953,216...30,996,002

G

solute carrier organic anion transporter family, member 2a1

increases expression

ISO

o,p'-DDT results in increased expression of SLCO2A1 mRNA

NCBI chr 8:112,467,739...112,551,923
Ensembl chr 8:112,467,160...112,551,921

G

survival of motor neuron 1, telomeric

increases expression

ISO
EXP

o,p'-DDT results in increased expression of SMN1 mRNA

NCBI chr 2:33,224,115...33,235,162
Ensembl chr 2:33,224,095...33,235,162

G

survival motor neuron domain containing 1

increases expression

ISO
EXP

o,p'-DDT results in increased expression of SMNDC1 mRNA

NCBI chr 1:262,395,034...262,406,104
Ensembl chr 1:262,386,590...262,405,707

G

superoxide dismutase 1

increases expression
decreases expression

EXP

o,p'-DDT analog results in increased expression of SOD1 mRNA
o,p'-DDT results in decreased expression of SOD1 mRNA

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399

G

superoxide dismutase 2

decreases expression

EXP

o,p'-DDT analog results in decreased expression of SOD2 mRNA

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

SPC25 component of NDC80 kinetochore complex

decreases expression

ISO

o,p'-DDT results in decreased expression of SPC25 mRNA

NCBI chr 3:74,337,872...74,396,825
Ensembl chr 3:74,383,548...74,396,718

G

sphingosine kinase 2

increases expression
decreases expression

ISO
EXP

o,p'-DDT results in increased expression of SPHK2 mRNA
o,p'-DDT analog results in decreased expression of SPHK2 mRNA; o,p'-DDT results in decreased expression of SPHK2 mRNA

PMID:22937105 PMID:24096037

NCBI chr 1:105,317,332...105,324,985
Ensembl chr 1:105,317,333...105,321,637

G

spectrin, beta, non-erythrocytic 1

decreases expression

ISO
EXP

o,p'-DDT results in decreased expression of SPTBN1 mRNA

NCBI chr14:108,042,629...108,217,884
Ensembl chr14:108,042,629...108,217,836

G

squalene epoxidase

decreases expression

ISO

o,p'-DDT results in decreased expression of SQLE mRNA

NCBI chr 7:92,758,175...92,773,049
Ensembl chr 7:92,757,409...92,773,050

G

sterol regulatory element binding transcription factor 1

affects expression

ISO
EXP

o,p'-DDT affects the expression of SREBF1 mRNA

PMID:17984292 PMID:18925944

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

ST14 transmembrane serine protease matriptase

increases expression

ISO
EXP

o,p'-DDT results in increased expression of ST14 mRNA

NCBI chr 8:37,798,994...37,839,881
Ensembl chr 8:37,798,995...37,855,652

G

steroidogenic acute regulatory protein

decreases expression

EXP

o,p'-DDT results in decreased expression of STAR mRNA

NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447

G

stanniocalcin 2

increases expression

ISO

o,p'-DDT results in increased expression of STC2 mRNA

NCBI chr10:16,755,508...16,765,275
Ensembl chr10:16,755,267...16,767,447

G

stathmin 1

affects expression

ISO
EXP

o,p'-DDT affects the expression of STMN1 mRNA

PMID:17984292 PMID:18925944

NCBI chr 5:151,964,308...151,970,843
Ensembl chr 5:151,964,351...151,970,842

G

sulfotransferase family 1E member 1

decreases expression

EXP

o,p'-DDT results in decreased expression of SULT1E1 mRNA

NCBI chr14:20,700,444...20,718,719
Ensembl chr14:20,700,292...20,718,716

G

TATA-box binding protein associated factor 9b

increases expression

EXP
ISO

o,p'-DDT results in increased expression of TAF9B mRNA

NCBI chr X:75,354,823...75,366,166
Ensembl chr X:75,354,825...75,366,414

G

tyrosine aminotransferase

multiple interactions

EXP

o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]

NCBI chr19:54,856,604...54,867,168
Ensembl chr19:54,856,563...54,867,482

G

t-complex 1

increases expression

EXP
ISO

o,p'-DDT results in increased expression of TCP1 mRNA

NCBI chr 1:50,376,848...50,384,527
Ensembl chr 1:50,376,848...50,384,527

G

telomerase reverse transcriptase

increases expression

ISO

o,p'-DDT results in increased expression of TERT mRNA

NCBI chr 1:31,465,766...31,488,650
Ensembl chr 1:31,466,056...31,488,111

G

transcription factor EC

increases expression

ISO

o,p'-DDT results in increased expression of TFEC mRNA

NCBI chr 4:46,072,093...46,146,200
Ensembl chr 4:46,073,605...46,146,200

G

trefoil factor 1

multiple interactions
increases expression

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [o,p'-DDT results in increased expression of TFF1 mRNA]; Fulvestrant inhibits the reaction [o,p'-DDT results in increased expression of TFF1 mRNA]; ICI 164384 inhibits the reaction [o,p'-DDT results in increased expression of TFF1 mRNA]

PMID:8968093 PMID:18700809 PMID:20206645 PMID:22609851 PMID:23478948

NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,237,095...9,240,956

G

trefoil factor 2

decreases expression

ISO

o,p'-DDT results in decreased expression of TFF2 mRNA

NCBI chr20:9,217,110...9,220,979
Ensembl chr20:9,217,121...9,220,979

G

transforming growth factor alpha

increases expression

ISO

o,p'-DDT results in increased expression of TGFA mRNA

NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:120,175,593...120,258,339

G

transforming growth factor, beta 2

decreases expression

ISO

o,p'-DDT results in decreased expression of TGFB2 mRNA

NCBI chr13:100,691,540...100,793,227
Ensembl chr13:100,692,953...100,792,856

G

thrombomodulin

increases expression

ISO

o,p'-DDT results in increased expression of THBD mRNA

NCBI chr 3:156,316,526...156,320,178
Ensembl chr 3:156,306,632...156,320,582

G

thrombospondin 1

increases expression

ISO

o,p'-DDT results in increased expression of THBS1 mRNA

NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:125,510,250...125,525,402

G

thyroid hormone receptor beta

multiple interactions

ISO

o,p'-DDT binds to and results in increased activity of THRB protein

NCBI chr15:10,115,954...10,465,231
Ensembl chr15:10,115,954...10,313,680

G

TIMP metallopeptidase inhibitor 1

decreases expression

ISO

o,p'-DDT results in decreased expression of TIMP1 mRNA

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

TIMP metallopeptidase inhibitor 2

decreases expression

ISO

o,p'-DDT results in decreased expression of TIMP2 mRNA

NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214

G

transmembrane p24 trafficking protein 4

decreases expression

ISO

o,p'-DDT results in decreased expression of TMED4 mRNA

NCBI chr14:85,338,980...85,343,577
Ensembl chr14:85,338,980...85,343,577

G

tumor necrosis factor

multiple interactions
increases expression
decreases expression

ISO
EXP

[DDT co-treated with o,p'-DDT] results in decreased expression of TNF mRNA
o,p'-DDT results in increased expression of TNF
o,p'-DDT results in increased expression of TNF mRNA
o,p'-DDT analog results in decreased expression of TNF mRNA

PMID:12007859 PMID:15104118 PMID:22937105

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF receptor superfamily member 11B

increases expression
decreases expression

EXP

o,p'-DDT results in increased expression of TNFRSF11B mRNA
o,p'-DDT analog results in decreased expression of TNFRSF11B mRNA

NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:87,456,319...87,485,075

G

TNF receptor superfamily member 14

increases expression

ISO

o,p'-DDT results in increased expression of TNFRSF14 mRNA

NCBI chr 5:170,768,413...170,776,749
Ensembl chr 5:170,768,416...170,776,046

G

TNF receptor superfamily member 19

affects expression

ISO

o,p'-DDT affects the expression of TNFRSF19 mRNA

NCBI chr15:39,268,305...39,334,566
Ensembl chr15:39,268,305...39,356,438

G

TNF receptor superfamily member 1A

increases expression

EXP

o,p'-DDT results in increased expression of TNFRSF1A mRNA

NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816

G

TNF receptor superfamily member 1B

decreases expression
increases expression

EXP

o,p'-DDT analog results in decreased expression of TNFRSF1B mRNA
o,p'-DDT analog results in increased expression of TNFRSF1B mRNA; o,p'-DDT results in increased expression of TNFRSF1B mRNA

NCBI chr 5:162,356,250...162,387,411
Ensembl chr 5:162,353,848...162,387,411

G

TNF superfamily member 10

increases expression
decreases expression

EXP

o,p'-DDT results in increased expression of TNFSF10 mRNA
o,p'-DDT analog results in decreased expression of TNFSF10 mRNA

NCBI chr 2:112,136,550...112,155,903

G

TNF superfamily member 12

increases expression
decreases expression

EXP

o,p'-DDT results in increased expression of TNFSF12 mRNA
o,p'-DDT analog results in decreased expression of TNFSF12 mRNA

NCBI chr10:54,902,616...54,912,628
Ensembl chr10:54,902,616...54,911,913

G

translocase of outer mitochondrial membrane 20

increases expression

EXP
ISO

o,p'-DDT results in increased expression of TOMM20 mRNA

NCBI chr19:71,822,429...71,832,420
Ensembl chr19:71,822,411...71,832,510

G

tumor protein p53

increases expression

EXP

o,p'-DDT analog results in increased expression of TP53 mRNA; o,p'-DDT analog results in increased expression of TP53 protein; o,p'-DDT results in increased expression of TP53 mRNA; o,p'-DDT results in increased expression of TP53 protein

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

tumor protein p53 binding protein, 2

increases expression
decreases expression

EXP

o,p'-DDT results in increased expression of TP53BP2 mRNA
o,p'-DDT analog results in decreased expression of TP53BP2 mRNA

NCBI chr13:96,620,429...96,677,090
Ensembl chr13:96,620,428...96,677,616

G

tumor protein p63

increases expression
decreases expression

EXP

o,p'-DDT results in increased expression of TP63 mRNA
o,p'-DDT analog results in decreased expression of TP63 mRNA

NCBI chr11:88,343,647...88,554,543
Ensembl chr11:88,343,651...88,554,177

G

tumor protein p73

increases expression
decreases expression

EXP

o,p'-DDT results in increased expression of TP73 mRNA
o,p'-DDT analog results in decreased expression of TP73 mRNA

NCBI chr 5:169,903,801...169,988,075
Ensembl chr 5:169,903,801...169,963,552

G

TNFRSF1A-associated via death domain

increases expression
decreases expression

EXP

o,p'-DDT results in increased expression of TRADD mRNA
o,p'-DDT analog results in decreased expression of TRADD mRNA

NCBI chr19:50,046,057...50,048,158
Ensembl chr19:50,046,061...50,052,550

G

Tnf receptor-associated factor 2

increases expression
decreases expression

EXP

o,p'-DDT results in increased expression of TRAF2 mRNA
o,p'-DDT analog results in decreased expression of TRAF2 mRNA

NCBI chr 3:28,740,098...28,764,752
Ensembl chr 3:28,740,098...28,764,691

G

Tnf receptor-associated factor 3

increases expression

EXP

o,p'-DDT results in increased expression of TRAF3 mRNA

NCBI chr 6:136,025,097...136,128,363
Ensembl chr 6:136,027,157...136,128,363

G

Tnf receptor associated factor 4

decreases expression
increases expression

EXP

o,p'-DDT analog results in decreased expression of TRAF4 mRNA
o,p'-DDT results in increased expression of TRAF4 mRNA

NCBI chr10:63,552,251...63,558,356
Ensembl chr10:63,552,253...63,558,356

G

TSC22 domain family, member 1

decreases expression

ISO

o,p'-DDT results in decreased expression of TSC22D1 mRNA

NCBI chr15:58,159,612...58,260,244
Ensembl chr15:58,159,952...58,183,322

G

TSC22 domain family, member 3

multiple interactions

ISO

o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]

NCBI chr X:109,006,410...109,066,389
Ensembl chr X:109,006,420...109,015,519

G

tsukushi, small leucine rich proteoglycan

increases expression

ISO

o,p'-DDT results in increased expression of TSKU mRNA

NCBI chr 1:162,071,459...162,082,972
Ensembl chr 1:162,064,126...162,089,272

G

tetraspanin 10

increases expression

ISO

o,p'-DDT results in increased expression of TSPAN10 mRNA

NCBI chr10:106,213,672...106,219,951
Ensembl chr10:106,214,208...106,219,085

G

tetraspanin 12

decreases expression

ISO

o,p'-DDT results in decreased expression of TSPAN12 mRNA

NCBI chr 4:51,279,562...51,355,030
Ensembl chr 4:51,279,563...51,355,030

G

tubulin, beta 2B class IIb

increases expression

ISO
EXP

o,p'-DDT results in increased expression of TUBB2B mRNA

NCBI chr17:30,953,086...30,956,133
Ensembl chr17:30,952,923...30,955,990

G

tubulin, beta 5 class I

increases expression

ISO
EXP

o,p'-DDT results in increased expression of TUBB5 mRNA

NCBI chr20:2,917,577...2,921,726
Ensembl chr20:2,917,539...2,921,726

G

thioredoxin 1

affects expression

EXP

o,p'-DDT affects the expression of TXN1 mRNA

NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307

G

thioredoxin interacting protein

decreases expression

ISO

o,p'-DDT results in decreased expression of TXNIP mRNA

NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:186,781,163...186,785,731

G

thioredoxin reductase 1

affects expression

EXP

o,p'-DDT affects the expression of TXNRD1 mRNA

NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817

G

ubiquitin-conjugating enzyme E2F (putative)

increases expression

EXP
ISO

o,p'-DDT results in increased expression of UBE2F mRNA

NCBI chr 9:99,293,506...99,328,690
Ensembl chr 9:99,293,515...99,330,479

G

ubiquitin-conjugating enzyme E2L 3

increases expression

EXP
ISO

o,p'-DDT results in increased expression of UBE2L3 mRNA

NCBI chr11:97,300,584...97,343,084
Ensembl chr11:97,301,945...97,343,084

G

ubiquitin specific peptidase 1

increases expression

ISO
EXP

o,p'-DDT results in increased expression of USP1 mRNA

NCBI chr 5:118,703,056...118,714,426
Ensembl chr 5:118,702,868...118,714,434

G

valosin containing protein lysine methyltransferase

decreases expression

ISO

o,p'-DDT results in decreased expression of VCPKMT mRNA

NCBI chr 6:93,772,558...93,778,400
Ensembl chr 6:93,772,575...93,777,975

G

vascular endothelial growth factor A

increases expression

ISO

o,p'-DDT results in increased expression of VEGFA mRNA

PMID:22609851 PMID:33728745

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

X-linked inhibitor of apoptosis

decreases expression

EXP

o,p'-DDT analog results in decreased expression of XIAP mRNA

NCBI chr X:125,756,107...125,803,979
Ensembl chr X:125,737,971...125,803,978

G

zinc finger protein, multitype 2

increases methylation

ISO

o,p'-DDT results in increased methylation of ZFPM2 gene

NCBI chr 7:73,563,732...74,001,041
Ensembl chr 7:73,563,732...74,001,041

G

zinc finger with KRAB and SCAN domains 2

increases expression

ISO

o,p'-DDT results in increased expression of ZKSCAN2 mRNA

NCBI chr 1:187,437,095...187,459,300
Ensembl chr 1:187,440,330...187,458,985

G

zinc finger MYM-type containing 3

increases expression

ISO

o,p'-DDT results in increased expression of ZMYM3 mRNA

NCBI chr X:70,568,573...70,584,221
Ensembl chr X:70,568,573...70,584,768

1-[(4-chlorophenyl)-phenylmethyl]-4-methyl-1,4-diazepane

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 2

multiple interactions

ISO

homochlorocyclizine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily G member 1

decreases expression

EXP

chlorcyclizine results in decreased expression of ABCG1 mRNA

NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,127,803...9,186,563

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

decreases expression

EXP

chlorcyclizine results in decreased expression of ADH1 mRNA

NCBI chr 2:229,470,703...229,482,291
Ensembl chr 2:229,470,703...229,482,291

G

argonaute RISC component 1

decreases expression

EXP

chlorcyclizine results in decreased expression of AGO1 mRNA

NCBI chr 5:144,006,618...144,064,740
Ensembl chr 5:144,006,618...144,041,624

G

A-kinase anchoring protein 9

decreases expression

EXP

chlorcyclizine results in decreased expression of AKAP9 mRNA

NCBI chr 4:31,011,475...31,147,338
Ensembl chr 4:31,011,475...31,147,338

G

aldehyde dehydrogenase 1 family, member A1

increases expression

EXP

chlorcyclizine results in increased expression of ALDH1A1 mRNA

NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500

G

N-acylsphingosine amidohydrolase 1

increases expression

ISO

chlorcyclizine results in increased expression of ASAH1 mRNA

NCBI chr16:57,669,927...57,701,349
Ensembl chr16:57,669,750...57,718,305

G

ATRX, chromatin remodeler

decreases expression

EXP

chlorcyclizine results in decreased expression of ATRX mRNA

NCBI chr X:74,916,548...75,062,880
Ensembl chr X:74,916,548...75,062,880

G

basal cell adhesion molecule (Lutheran blood group)

increases expression

EXP

chlorcyclizine results in increased expression of BCAM mRNA

NCBI chr 1:88,542,971...88,557,358
Ensembl chr 1:88,542,972...88,557,888

G

bone morphogenetic protein 2

increases expression

EXP

chlorcyclizine results in increased expression of BMP2 mRNA

NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760

G

bone morphogenetic protein 4

increases expression

EXP

chlorcyclizine results in increased expression of BMP4 mRNA

NCBI chr15:22,098,191...22,113,145
Ensembl chr15:22,098,470...22,105,172

G

biorientation of chromosomes in cell division 1-like 1

decreases expression

EXP

chlorcyclizine results in decreased expression of BOD1L1 mRNA

NCBI chr14:73,320,880...73,375,662
Ensembl chr14:73,320,832...73,375,658

G

calcium/calmodulin-dependent protein kinase II gamma

increases expression

EXP

chlorcyclizine results in increased expression of CAMK2G mRNA

NCBI chr15:3,553,238...3,612,310
Ensembl chr15:3,553,294...3,612,310

G

cadherin 22

decreases expression

EXP

chlorcyclizine results in decreased expression of CDH22 mRNA

NCBI chr 3:174,264,869...174,389,940
Ensembl chr 3:174,264,869...174,390,142

G

cytochrome c oxidase subunit 4i2

increases expression

EXP

chlorcyclizine results in increased expression of COX4I2 mRNA

NCBI chr 3:161,686,193...161,699,605
Ensembl chr 3:161,689,017...161,699,602

G

complexin 1

increases expression

EXP

chlorcyclizine results in increased expression of CPLX1 mRNA

NCBI chr14:1,329,073...1,360,781
Ensembl chr14:1,329,032...1,360,769

G

CREB binding protein

decreases expression

EXP

chlorcyclizine results in decreased expression of CREBBP mRNA

NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266

G

DEPP autophagy regulator 1

increases expression

ISO

chlorcyclizine results in increased expression of DEPP1 mRNA

NCBI chr 4:151,583,105...151,585,455
Ensembl chr 4:151,581,502...151,586,233

G

dihydropyrimidinase-like 3

decreases expression
increases expression

EXP

chlorcyclizine results in decreased expression of DPYSL3 mRNA
chlorcyclizine results in increased expression of DPYSL3 mRNA

NCBI chr18:35,625,357...35,731,152
Ensembl chr18:35,625,357...35,731,152

G

ephrin A5

increases expression

EXP

chlorcyclizine results in increased expression of EFNA5 mRNA

NCBI chr 9:109,763,786...110,042,396
Ensembl chr 9:109,767,252...110,042,348

G

elastin

increases expression

EXP

chlorcyclizine results in increased expression of ELN mRNA

NCBI chr12:27,604,983...27,648,413
Ensembl chr12:27,604,680...27,648,413

G

fatty acid binding protein 1

increases expression

ISO

chlorcyclizine results in increased expression of FABP1 mRNA

NCBI chr 4:104,744,302...104,753,119
Ensembl chr 4:104,744,309...104,753,113

G

fibroblast growth factor 10

increases expression

EXP

chlorcyclizine results in increased expression of FGF10 mRNA

NCBI chr 2:52,533,939...52,610,980
Ensembl chr 2:52,533,939...52,610,980

G

fibroblast growth factor receptor 2

increases expression

EXP

chlorcyclizine results in increased expression of FGFR2 mRNA

NCBI chr 1:194,175,703...194,280,914
Ensembl chr 1:194,175,705...194,280,914

G

fibromodulin

increases expression

EXP

chlorcyclizine results in increased expression of FMOD mRNA

NCBI chr13:48,045,567...48,056,184
Ensembl chr13:47,990,774...48,056,183

G

fibronectin type III domain containing 4

increases expression

ISO

chlorcyclizine results in increased expression of FNDC4 mRNA

NCBI chr 6:30,797,102...30,800,782
Ensembl chr 6:30,796,871...30,800,769

G

gamma-aminobutyric acid type A receptor subunit beta 3

increases expression

EXP

chlorcyclizine results in increased expression of GABRB3 mRNA

NCBI chr 1:117,602,772...117,838,230
Ensembl chr 1:117,431,842...117,836,725

G

glycerophosphodiester phosphodiesterase domain containing 3

increases expression

ISO

chlorcyclizine results in increased expression of GDPD3 mRNA

NCBI chr 1:190,804,053...190,813,609
Ensembl chr 1:190,803,993...190,813,606

G

gamma-glutamyl carboxylase

increases expression

EXP

chlorcyclizine results in increased expression of GGCX mRNA

NCBI chr 4:106,027,918...106,043,653
Ensembl chr 4:106,027,912...106,043,923

G

glycoprotein nmb

increases expression

EXP

chlorcyclizine results in increased expression of GPNMB mRNA

NCBI chr 4:79,341,128...79,362,366
Ensembl chr 4:79,341,021...79,380,240

G

glycogen synthase kinase 3 beta

decreases expression

EXP

chlorcyclizine results in decreased expression of GSK3B mRNA

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

glutathione S-transferase mu 2

increases expression

EXP

chlorcyclizine results in increased expression of GSTM2 mRNA

NCBI chr 2:198,312,179...198,316,962

G

hyaluronan and proteoglycan link protein 1

increases expression

EXP

chlorcyclizine results in increased expression of HAPLN1 mRNA

NCBI chr 2:22,366,967...22,431,709
Ensembl chr 2:22,366,967...22,429,098

G

hepsin

increases expression

ISO

chlorcyclizine results in increased expression of HPN mRNA

NCBI chr 1:95,464,468...95,480,169
Ensembl chr 1:95,464,470...95,480,199

G

hypoxia up-regulated 1

increases expression

EXP

chlorcyclizine results in increased expression of HYOU1 mRNA

NCBI chr 8:53,602,882...53,614,998
Ensembl chr 8:53,602,604...53,614,997

G

integrin-binding sialoprotein

increases expression

EXP

chlorcyclizine results in increased expression of IBSP mRNA

NCBI chr14:5,744,497...5,757,242
Ensembl chr14:5,744,501...5,775,299

G

isopentenyl-diphosphate delta isomerase 1

increases expression

EXP

chlorcyclizine results in increased expression of IDI1 mRNA

NCBI chr17:66,539,761...66,547,524
Ensembl chr17:66,539,763...66,547,524

G

interleukin 6 cytokine family signal transducer

decreases expression

EXP

chlorcyclizine results in decreased expression of IL6ST mRNA

NCBI chr 2:45,798,872...45,839,501
Ensembl chr 2:45,799,380...45,843,182

G

interleukin enhancer binding factor 3

decreases expression

EXP

chlorcyclizine results in decreased expression of ILF3 mRNA

NCBI chr 8:28,198,454...28,236,634
Ensembl chr 8:28,198,543...28,236,612

G

inhibin subunit beta E

increases expression

ISO

chlorcyclizine results in increased expression of INHBE mRNA

NCBI chr 7:65,061,531...65,064,519
Ensembl chr 7:65,061,531...65,064,519

G

insulin induced gene 1

increases expression

EXP

chlorcyclizine results in increased expression of INSIG1 mRNA

NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:8,049,556...8,057,778

G

KH RNA binding domain containing, signal transduction associated 2

increases expression

EXP

chlorcyclizine results in increased expression of KHDRBS2 mRNA

NCBI chr 9:41,943,029...42,449,687
Ensembl chr 9:41,943,050...42,412,905

G

low density lipoprotein receptor

increases expression

EXP

chlorcyclizine results in increased expression of LDLR mRNA

NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675

G

galectin 7

increases expression

EXP

chlorcyclizine results in increased expression of LGALS7 mRNA

NCBI chr 1:93,275,092...93,279,529
Ensembl chr 1:93,273,836...93,279,528

G

lamin A/C

increases expression

EXP

chlorcyclizine results in increased expression of LMNA mRNA

NCBI chr 2:176,237,564...176,265,301
Ensembl chr 2:176,237,564...176,288,072

G

lanosterol synthase

increases expression

ISO

chlorcyclizine results in increased expression of LSS mRNA

NCBI chr20:12,090,641...12,118,230
Ensembl chr20:12,073,543...12,118,253

G

microtubule-associated protein tau

increases expression

EXP

chlorcyclizine results in increased expression of MAPT mRNA

NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108

G

myelin basic protein

increases expression

EXP

chlorcyclizine results in increased expression of MBP mRNA

NCBI chr18:78,130,652...78,241,174
Ensembl chr18:78,130,325...78,241,174

G

methylsterol monooxygenase 1

increases expression

EXP

chlorcyclizine results in increased expression of MSMO1 mRNA

NCBI chr16:29,747,113...29,764,360
Ensembl chr16:29,747,137...29,764,445

G

msh homeobox 1

increases expression

EXP

chlorcyclizine results in increased expression of MSX1 mRNA

NCBI chr14:77,185,802...77,189,735
Ensembl chr14:77,185,802...77,189,735

G

msh homeobox 2

increases expression

EXP

chlorcyclizine results in increased expression of MSX2 mRNA

NCBI chr17:11,102,284...11,107,949
Ensembl chr17:11,102,247...11,107,945

G

mevalonate kinase

increases expression

EXP

chlorcyclizine results in increased expression of MVK mRNA

NCBI chr12:47,802,002...47,819,503
Ensembl chr12:47,802,002...47,819,503

G

myosin binding protein C1

increases expression

EXP

chlorcyclizine results in increased expression of MYBPC1 mRNA

NCBI chr 7:24,817,770...24,903,681
Ensembl chr 7:24,817,561...24,903,544

G

neural cell adhesion molecule 1

decreases expression

EXP

chlorcyclizine results in decreased expression of NCAM1 mRNA

NCBI chr 8:58,762,088...59,062,131
Ensembl chr 8:58,762,116...59,061,971

G

nuclear factor I X

decreases expression
increases expression

EXP

chlorcyclizine results in decreased expression of NFIX mRNA
chlorcyclizine results in increased expression of NFIX mRNA

NCBI chr19:40,259,873...40,356,966
Ensembl chr19:40,260,084...40,353,092

G

nuclear receptor subfamily 0, group B, member 2

increases expression

ISO

chlorcyclizine results in increased expression of NR0B2 mRNA

NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475

G

nuclear receptor subfamily 2, group F, member 1

increases expression

EXP

chlorcyclizine results in increased expression of NR2F1 mRNA

NCBI chr 2:9,776,179...9,785,924
Ensembl chr 2:9,776,179...9,785,924

G

neurotrophic receptor tyrosine kinase 1

increases expression

EXP

chlorcyclizine results in increased expression of NTRK1 mRNA

NCBI chr 2:175,534,844...175,551,664
Ensembl chr 2:175,534,844...175,551,787

G

nuclear casein kinase and cyclin-dependent kinase substrate 1

decreases expression

EXP

chlorcyclizine results in decreased expression of NUCKS1 mRNA

NCBI chr13:45,897,275...45,926,491
Ensembl chr13:45,897,248...45,923,101

G

nuclear protein 1, transcriptional regulator

increases expression

ISO

chlorcyclizine results in increased expression of NUPR1 mRNA

NCBI chr 1:190,643,866...190,645,901
Ensembl chr 1:190,643,867...190,645,901

G

osteomodulin

increases expression

EXP

chlorcyclizine results in increased expression of OMD mRNA

NCBI chr17:15,266,646...15,274,870
Ensembl chr17:15,266,646...15,274,870

G

prolyl 3-hydroxylase 1

increases expression

EXP

chlorcyclizine results in increased expression of P3H1 mRNA

NCBI chr 5:138,127,240...138,141,974
Ensembl chr 5:138,126,860...138,142,836

G

phosphoinositide-3-kinase regulatory subunit 1

increases expression

EXP

chlorcyclizine results in increased expression of PIK3R1 mRNA

NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347

G

POU class 3 homeobox 3

increases expression

EXP

chlorcyclizine results in increased expression of POU3F3 mRNA

NCBI chr 9:52,438,026...52,441,152
Ensembl chr 9:52,435,625...52,454,705

G

protein phosphatase 1, regulatory subunit 12A

decreases expression

EXP

chlorcyclizine results in decreased expression of PPP1R12A mRNA

NCBI chr 7:45,368,922...45,480,158
Ensembl chr 7:45,369,315...45,480,157

G

protein phosphatase 1, regulatory subunit 17

increases expression

EXP

chlorcyclizine results in increased expression of PPP1R17 mRNA

NCBI chr 4:86,544,024...86,560,839
Ensembl chr 4:86,544,121...86,560,835

G

RAB38, member RAS oncogene family

increases expression

EXP

chlorcyclizine results in increased expression of RAB38 mRNA

NCBI chr 1:151,595,153...151,675,492
Ensembl chr 1:151,595,078...151,675,493

G

Rho family GTPase 2

affects expression

EXP

chlorcyclizine affects the expression of RND2 mRNA

NCBI chr10:86,899,395...86,902,992
Ensembl chr10:86,899,395...86,902,992

G

ROS proto-oncogene 1 , receptor tyrosine kinase

decreases expression

EXP

chlorcyclizine results in decreased expression of H4C8 mRNA

NCBI chr20:31,975,328...32,126,675
Ensembl chr20:31,975,329...32,126,547

G

semaphorin 6C

increases expression

EXP

chlorcyclizine results in increased expression of SEMA6C mRNA

NCBI chr 2:185,422,636...185,436,237
Ensembl chr 2:185,422,639...185,448,689

G

serpin family A member 3N

increases expression

ISO

chlorcyclizine results in increased expression of SERPINA3 mRNA

NCBI chr 6:129,088,392...129,095,950
Ensembl chr 6:129,088,398...129,097,415

G

sonic hedgehog signaling molecule

decreases expression

EXP

chlorcyclizine results in decreased expression of SHH mRNA

NCBI chr 4:7,687,872...7,697,025
Ensembl chr 4:7,687,846...7,697,901

G

solute carrier family 2 member 3

decreases expression

ISO

chlorcyclizine results in decreased expression of SLC2A3 mRNA

NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:157,632,887...157,646,186

G

solute carrier family 6 member 4

increases expression

EXP

chlorcyclizine results in increased expression of SLC6A4 mRNA

NCBI chr10:62,322,688...62,357,060
Ensembl chr10:62,324,254...62,357,056

G

SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4

decreases expression

EXP

chlorcyclizine results in decreased expression of SMARCA4 mRNA

NCBI chr 8:28,438,370...28,535,071
Ensembl chr 8:28,443,810...28,535,070

G

sphingomyelin phosphodiesterase 3

increases expression

EXP

chlorcyclizine results in increased expression of SMPD3 mRNA

NCBI chr19:51,072,209...51,155,639
Ensembl chr19:51,072,209...51,085,936

G

secreted protein acidic and cysteine rich

increases expression

EXP

chlorcyclizine results in increased expression of SPARC mRNA

NCBI chr10:40,017,065...40,038,816
Ensembl chr10:40,017,075...40,039,268

G

sushi-repeat-containing protein, X-linked

increases expression

EXP

chlorcyclizine results in increased expression of SRPX mRNA

NCBI chr X:15,349,498...15,420,389
Ensembl chr X:15,349,440...15,420,392

G

transgelin

decreases expression

ISO

chlorcyclizine results in decreased expression of TAGLN mRNA

NCBI chr 8:55,121,647...55,127,121
Ensembl chr 8:55,121,301...55,127,563

G

tropomodulin 2

decreases expression

EXP

chlorcyclizine results in decreased expression of TMOD2 mRNA

NCBI chr 8:85,197,222...85,250,627
Ensembl chr 8:85,196,226...85,246,371

G

tenomodulin

increases expression

EXP

chlorcyclizine results in increased expression of TNMD mRNA

NCBI chr X:101,350,432...101,365,929
Ensembl chr X:101,350,269...101,365,929

G

tetraspanin 8

increases expression

EXP

chlorcyclizine results in increased expression of TSPAN8 mRNA

NCBI chr 7:53,331,019...53,365,402
Ensembl chr 7:53,330,963...53,365,401

G

thiosulfate sulfurtransferase

affects expression
decreases expression

EXP

chlorcyclizine affects the expression of TST mRNA
chlorcyclizine results in decreased expression of TST mRNA

NCBI chr 7:111,828,557...111,836,980
Ensembl chr 7:111,828,558...111,837,116

G

transthyretin

increases expression

EXP

chlorcyclizine results in increased expression of TTR mRNA

NCBI chr18:12,216,684...12,225,972
Ensembl chr18:12,216,732...12,225,969

G

ischemia related factor vof-16

decreases expression

EXP

chlorcyclizine results in decreased expression of VOF16 mRNA

NCBI chr 8:50,850,132...50,852,238

G

Wnt inhibitory factor 1

increases expression

EXP

chlorcyclizine results in increased expression of WIF1 mRNA

NCBI chr 7:58,433,326...58,503,853
Ensembl chr 7:58,384,643...58,503,852

G

WD repeat domain, phosphoinositide interacting 1

increases expression

ISO

chlorcyclizine results in increased expression of WIPI1 mRNA

NCBI chr10:95,042,451...95,079,679
Ensembl chr10:95,042,441...95,079,293

G

Wnt family member 4

increases expression

EXP

chlorcyclizine results in increased expression of WNT4 mRNA

NCBI chr 5:154,797,245...154,818,565
Ensembl chr 5:154,797,311...154,817,128

G

Wnt family member 5A

increases expression

EXP

chlorcyclizine results in increased expression of WNT5A mRNA

NCBI chr16:3,702,300...3,724,860
Ensembl chr16:3,703,665...3,724,860

1-[2-[(4-chlorophenyl)-phenylmethoxy]ethyl]piperidine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity

ISO

cloperastine results in decreased activity of KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Bcl2-like 11

increases expression
multiple interactions

ISO

Penfluridol results in increased expression of BCL2L11 mRNA; Penfluridol results in increased expression of BCL2L11 protein
dorsomorphin inhibits the reaction [Penfluridol results in increased expression of BCL2L11 mRNA]; Penfluridol promotes the reaction [FOXO3A protein binds to BCL2L11 promoter]; PFKL protein affects the reaction [Penfluridol results in increased expression of BCL2L11 mRNA]; PFKL protein affects the reaction [Penfluridol results in increased expression of BCL2L11 protein]

NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695

G

caspase 3

multiple interactions
increases cleavage

ISO

dorsomorphin inhibits the reaction [Penfluridol results in increased cleavage of CASP3 protein]; PFKL protein affects the reaction [Penfluridol results in increased cleavage of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

forkhead box O3

affects localization
multiple interactions

ISO

Penfluridol affects the localization of FOXO3A protein
dorsomorphin inhibits the reaction [Penfluridol affects the localization of FOXO3A protein]; Penfluridol promotes the reaction [FOXO3A protein binds to BCL2L11 promoter]; PFKL protein affects the reaction [Penfluridol affects the localization of FOXO3A protein]

NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845

G

phosphofructokinase, liver type

decreases activity
increases response to substance
multiple interactions

ISO

Penfluridol results in decreased activity of PFKL protein
PFKL protein results in increased susceptibility to Penfluridol
Penfluridol binds to and results in decreased activity of PFKL protein; PFKL protein affects the reaction [Penfluridol affects the localization of FOXO3A protein]; PFKL protein affects the reaction [Penfluridol results in increased cleavage of CASP3 protein]; PFKL protein affects the reaction [Penfluridol results in increased expression of BCL2L11 mRNA]; PFKL protein affects the reaction [Penfluridol results in increased expression of BCL2L11 protein]

NCBI chr20:10,663,907...10,685,967
Ensembl chr20:10,663,955...10,685,966

G

ribosomal protein S6 kinase B1

decreases phosphorylation

ISO

Penfluridol results in decreased phosphorylation of RPS6KB1 protein

NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238

2,2'-Bisphenol F

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

androgen receptor

multiple interactions

ISO

2,2'-bisphenol F inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

estrogen receptor 1

multiple interactions

ISO

2,2'-bisphenol F binds to and results in increased activity of ESR1 protein

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

estrogen receptor 2

multiple interactions

ISO

2,2'-bisphenol F binds to and results in increased activity of ESR2 protein

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

ISO

2,2'-bisphenol F binds to and results in increased activity of NR1I2 protein

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ISO

2,2'-bisphenol F binds to and results in increased activity of PPARG protein

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

2,2'-Methylenebis(4-methyl-6-tert-butylphenol)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ABCC1 mRNA

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

acid phosphatase 5, tartrate resistant

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ACP5 mRNA

NCBI chr 8:28,939,984...28,946,639
Ensembl chr 8:28,939,985...28,943,929

G

activin A receptor type 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ACVR1 mRNA

NCBI chr 3:63,387,378...63,506,980
Ensembl chr 3:63,387,381...63,477,884

G

adenylate cyclase 7

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ADCY7 mRNA

NCBI chr19:34,913,154...34,972,366
Ensembl chr19:34,914,322...34,936,743

G

adenosine A2B receptor

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ADORA2B mRNA

NCBI chr10:47,439,712...47,456,092
Ensembl chr10:47,439,701...47,456,091

G

Aly/REF export factor

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ALYREF mRNA

NCBI chr10:106,369,750...106,373,395
Ensembl chr10:106,369,750...106,373,395

G

apolipoprotein A2

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of APOA2 mRNA

NCBI chr13:86,176,767...86,178,819
Ensembl chr13:86,174,741...86,179,410

G

amyloid beta precursor protein

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of APP mRNA

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

argininosuccinate synthase 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ASS1 mRNA

NCBI chr 3:35,144,765...35,194,632
Ensembl chr 3:35,144,999...35,194,627

G

ATPase family, AAA domain containing 5

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ATAD5 mRNA

NCBI chr10:65,568,569...65,616,379
Ensembl chr10:65,568,591...65,616,376

G

ATRX, chromatin remodeler

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ATRX mRNA

NCBI chr X:74,916,548...75,062,880
Ensembl chr X:74,916,548...75,062,880

G

Axl receptor tyrosine kinase

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of AXL mRNA

NCBI chr 1:90,392,864...90,424,123
Ensembl chr 1:90,392,864...90,424,009

G

BLM RecQ like helicase

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of BLM mRNA

NCBI chr 1:143,819,072...143,905,300
Ensembl chr 1:143,819,090...143,905,210

G

bone morphogenetic protein 6

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of BMP6 mRNA

NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,523,704...26,675,261

G

bone morphogenetic protein 8b

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of BMP8B mRNA

NCBI chr 5:140,671,117...140,696,450
Ensembl chr 5:140,671,211...140,696,448

G

BRCA1, DNA repair associated

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of BRCA1 mRNA

NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,917,693...86,977,763

G

complement C4A (Rodgers blood group)

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of C4A mRNA

NCBI chr20:4,010,306...4,024,707

G

C-C motif chemokine ligand 20

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CCL20 mRNA

NCBI chr 9:91,837,139...91,839,736
Ensembl chr 9:91,836,946...91,839,736

G

C-C motif chemokine ligand 9

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CCL15 mRNA

NCBI chr10:68,863,994...68,868,928
Ensembl chr10:68,863,995...68,868,877

G

C-C motif chemokine receptor 6

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CCR6 mRNA

NCBI chr 1:55,022,037...55,055,857
Ensembl chr 1:55,021,833...55,046,059

G

Cd68 molecule

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CD68 mRNA

NCBI chr10:54,880,562...54,882,441
Ensembl chr10:54,880,563...54,882,540

G

cell division cycle 45

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CDC45 mRNA

NCBI chr11:95,689,702...95,714,980
Ensembl chr11:95,689,919...95,714,981

G

cell division cycle 6

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CDC6 mRNA

NCBI chr10:84,360,361...84,374,239
Ensembl chr10:84,360,381...84,374,241

G

chromatin licensing and DNA replication factor 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CDT1 mRNA

NCBI chr19:67,529,249...67,534,195
Ensembl chr19:67,529,201...67,534,194

G

CCAAT/enhancer binding protein beta

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CEBPB mRNA

NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072

G

colony stimulating factor 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CSF1 mRNA

NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:198,065,405...198,084,468

G

cytochrome b-245 alpha chain

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CYBA mRNA

NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
affects response to substance

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ABCC1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ACP5 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ACVR1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ADCY7 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ADORA2B mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ALYREF mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of APOA2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of APP mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ASS1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ATAD5 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ATRX mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of AXL mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of BLM mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of BMP6 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of BMP8B mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of BRCA1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of C4A mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CCL15 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CCL20 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CCR6 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CD68 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CDC45 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CDC6 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CDT1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CEBPB mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CSF1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of CYBA mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of DAGLA mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of DBF4 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of DBF4B mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of DDT mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of DDX23 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of DNA2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of DSCC1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of E2F7 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of E2F8 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of EME1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of EPHA2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of F2RL1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of FBXO5 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of FBXO6 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of FEN1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of FN1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of FNDC4 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of FURIN mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of GEN1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of GINS1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of GINS2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of GINS3 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of GINS4 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of GMNN mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of HAMP mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of HDAC1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of HDAC4 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of HK1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of HSPG2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of IFNGR1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of IGF1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of IKBKG mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of IL4R mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of IL6R mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of IRAK2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of IRF3 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ITGB1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of KDM6B mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of LGALS1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of LIG1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MAPK13 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MAPKAPK2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM10 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM3 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM4 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM5 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM6 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM7 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM8 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of METRNL mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MGME1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MGST2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MMS22L mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MRE11 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MTOR mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of NEAT1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of NFKBIB mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of NINJ1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of NLRP1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of NR1D1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of NUCKS1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of NUPR1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ORC1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ORC3 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ORC5 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ORC6 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of OSMR mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PARP1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PCNA mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PIK3CD mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLA1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLA2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLD2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLD3 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLE mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLE2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLE3 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLQ mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PPARD mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PRDX5 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PRIM1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PRIM2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PRKCZ mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RAD51 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RBBP8 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RECQL4 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RFC1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RFC2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RFC3 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RFC4 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RFC5 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RFWD3 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RHBDF2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RPA1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RPS6KA4 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RRM1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of SAMHD1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of SBNO2 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of SCYL1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of SERPINE1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of SETMAR mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of SPP1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of STK39 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TGFB1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of THBS1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of THOC1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TICAM1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TICRR mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TIMP1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TIPIN mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TNFRSF1A mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TOLLIP mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TOPBP1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TRAIP mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TWNK mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TYRO3 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of UNC13D mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of UPF1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of WDHD1 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of WNK4 mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of WRN mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of XIAP mRNA; [CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ZYX mRNA

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

diacylglycerol lipase, alpha

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of DAGLA mRNA

NCBI chr 1:216,315,515...216,372,219
Ensembl chr 1:216,315,516...216,372,111

G

DBF4-CDC7 kinase regulatory subunit

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of DBF4 mRNA

NCBI chr 4:26,631,491...26,656,080
Ensembl chr 4:26,631,514...26,656,562

G

DBF4B-CDC7 kinase regulatory subunit

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of DBF4B mRNA

NCBI chr10:88,209,913...88,219,336

G

D-dopachrome tautomerase

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of DDT mRNA

NCBI chr20:12,883,025...12,886,121

G

DEAD-box helicase 23

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of DDX23 mRNA

NCBI chr 7:131,676,636...131,693,917
Ensembl chr 7:131,676,636...131,689,074

G

DNA replication and sister chromatid cohesion 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of DSCC1 mRNA

NCBI chr 7:88,372,349...88,390,815
Ensembl chr 7:88,372,146...88,387,973

G

E2F transcription factor 7

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of E2F7 mRNA

NCBI chr 7:48,036,881...48,079,055
Ensembl chr 7:48,037,749...48,079,055

G

E2F transcription factor 8

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of E2F8 mRNA

NCBI chr 1:107,701,985...107,720,538
Ensembl chr 1:107,701,985...107,720,009

G

essential meiotic structure-specific endonuclease 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of EME1 mRNA

NCBI chr10:80,083,585...80,092,450
Ensembl chr10:80,083,585...80,092,301

G

Eph receptor A2

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of EPHA2 mRNA

NCBI chr 5:158,888,629...158,917,100
Ensembl chr 5:158,888,629...158,917,234

G

F2R like trypsin receptor 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of F2RL1 mRNA

NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:28,507,003...28,519,954

G

F-box protein 5

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of FBXO5 mRNA

NCBI chr 1:44,601,412...44,607,781
Ensembl chr 1:44,601,412...44,607,781

G

F-box protein 6

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of FBXO6 mRNA

NCBI chr 5:163,859,909...163,865,693
Ensembl chr 5:163,859,916...163,865,574

G

flap structure-specific endonuclease 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of FEN1 mRNA

NCBI chr 1:216,270,016...216,274,873
Ensembl chr 1:216,269,163...216,275,016

G

fibronectin 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of FN1 mRNA

NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137

G

fibronectin type III domain containing 4

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of FNDC4 mRNA

NCBI chr 6:30,797,102...30,800,782
Ensembl chr 6:30,796,871...30,800,769

G

furin (paired basic amino acid cleaving enzyme)

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of FURIN mRNA

NCBI chr 1:143,757,389...143,770,430
Ensembl chr 1:143,757,391...143,773,497

G

GEN1 Holliday junction 5' flap endonuclease

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of GEN1 mRNA

NCBI chr 6:39,666,675...39,697,480
Ensembl chr 6:39,667,286...39,697,480

G

GINS complex subunit 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of GINS1 mRNA

NCBI chr 3:160,184,920...160,206,334
Ensembl chr 3:160,180,151...160,206,332

G

GINS complex subunit 2

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of GINS2 mRNA

NCBI chr19:65,535,492...65,548,270
Ensembl chr19:65,535,492...65,548,052

G

GINS complex subunit 3

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of GINS3 mRNA

NCBI chr19:9,426,140...9,435,192
Ensembl chr19:9,399,759...9,434,679

G

GINS complex subunit 4

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of GINS4 mRNA

NCBI chr16:75,489,990...75,502,455
Ensembl chr16:75,490,126...75,505,000

G

geminin, DNA replication inhibitor

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of GMNN mRNA

NCBI chr17:40,729,760...40,738,077
Ensembl chr17:40,729,824...40,738,068

G

hepcidin antimicrobial peptide

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of HAMP mRNA

NCBI chr 1:95,298,332...95,300,271
Ensembl chr 1:95,298,307...95,300,297

G

histone deacetylase 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of HDAC1 mRNA

NCBI chr 5:147,138,328...147,165,387
Ensembl chr 5:147,138,156...147,165,387

G

histone deacetylase 4

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of HDAC4 mRNA

NCBI chr 9:99,950,972...100,200,994
Ensembl chr 9:99,955,116...100,197,637

G

hexokinase 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of HK1 mRNA

NCBI chr20:30,773,222...30,874,814
Ensembl chr20:30,773,220...30,874,814

G

heparan sulfate proteoglycan 2

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of HSPG2 mRNA

NCBI chr 5:154,960,818...155,061,971
Ensembl chr 5:154,960,846...155,061,971

G

interferon gamma receptor 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of IFNGR1 mRNA

NCBI chr 1:16,152,811...16,171,439
Ensembl chr 1:16,152,879...16,171,437

G

insulin-like growth factor 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of IGF1 mRNA

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

inhibitor of nuclear factor kappa B kinase regulatory subunit gamma

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of IKBKG mRNA

NCBI chr X:157,358,279...157,397,563
Ensembl chr X:157,367,639...157,392,757

G

interleukin 4 receptor

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of IL4R mRNA

NCBI chr 1:189,545,739...189,570,639
Ensembl chr 1:189,544,988...189,570,636

G

interleukin 6 receptor

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of IL6R mRNA

NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221

G

interleukin-1 receptor-associated kinase 2

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of IRAK2 mRNA

NCBI chr 4:148,341,704...148,398,211
Ensembl chr 4:148,341,719...148,398,210

G

interferon regulatory factor 3

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of IRF3 mRNA

NCBI chr 1:104,616,608...104,621,402
Ensembl chr 1:104,616,469...104,621,401

G

integrin subunit beta 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ITGB1 mRNA

NCBI chr19:73,602,277...73,650,271
Ensembl chr19:73,602,126...73,650,269

G

iodotyrosine deiodinase

multiple interactions

ISO

2,2'-methylenebis(4-methyl-6-tert-butylphenol) inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 1:42,410,099...42,425,414
Ensembl chr 1:42,410,130...42,426,386

G

lysine demethylase 6B

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of KDM6B mRNA

NCBI chr10:54,619,520...54,641,014
Ensembl chr10:54,619,544...54,629,610

G

galectin 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of LGALS1 mRNA

NCBI chr 7:112,365,695...112,368,801
Ensembl chr 7:112,361,850...112,368,800

G

DNA ligase 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of LIG1 mRNA

NCBI chr 1:83,243,043...83,281,707
Ensembl chr 1:83,219,545...83,281,708

G

mitogen activated protein kinase 13

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MAPK13 mRNA

NCBI chr20:6,836,979...6,847,197
Ensembl chr20:6,837,013...6,847,191

G

MAPK activated protein kinase 2

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MAPKAPK2 mRNA

NCBI chr13:45,066,027...45,112,326
Ensembl chr13:45,066,031...45,112,326

G

minichromosome maintenance 10 replication initiation factor

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM10 mRNA

NCBI chr17:78,172,049...78,197,644
Ensembl chr17:78,175,398...78,197,636

G

minichromosome maintenance complex component 2

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM2 mRNA

NCBI chr 4:122,903,679...122,918,205
Ensembl chr 4:122,903,682...122,918,094

G

minichromosome maintenance complex component 3

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM3 mRNA

NCBI chr 9:30,715,602...30,733,746
Ensembl chr 9:30,715,602...30,733,746

G

minichromosome maintenance complex component 4

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM4 mRNA

NCBI chr11:98,762,599...98,776,300
Ensembl chr11:98,762,634...98,776,536

G

minichromosome maintenance complex component 5

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM5 mRNA

NCBI chr19:13,488,813...13,510,131
Ensembl chr19:13,488,813...13,517,758

G

minichromosome maintenance complex component 6

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM6 mRNA

NCBI chr13:42,379,161...42,404,352
Ensembl chr13:42,379,162...42,465,467

G

minichromosome maintenance complex component 7

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM7 mRNA

NCBI chr12:22,155,921...22,163,320
Ensembl chr12:22,155,921...22,163,771

G

minichromosome maintenance 8 homologous recombination repair factor

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MCM8 mRNA

NCBI chr 3:140,539,590...140,569,891
Ensembl chr 3:140,539,647...140,569,891

G

meteorin-like, glial cell differentiation regulator

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of METRNL mRNA

NCBI chr10:107,462,148...107,476,143
Ensembl chr10:107,462,109...107,476,135

G

mitochondrial genome maintenance exonuclease 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MGME1 mRNA

NCBI chr 3:152,094,514...152,103,314
Ensembl chr 3:152,094,658...152,103,313

G

microsomal glutathione S-transferase 2

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MGST2 mRNA

NCBI chr 2:137,821,787...137,866,664
Ensembl chr 2:137,836,140...137,866,661

G

MMS22-like, DNA repair protein

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MMS22L mRNA

NCBI chr 5:42,994,382...43,110,371
Ensembl chr 5:42,994,359...43,110,369

G

MRE11 homolog, double strand break repair nuclease

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MRE11 mRNA

NCBI chr 8:19,900,211...19,961,906
Ensembl chr 8:19,913,772...19,961,904

G

mechanistic target of rapamycin kinase

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of MTOR mRNA

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

NFKB inhibitor beta

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of NFKBIB mRNA

NCBI chr 1:93,173,817...93,181,387
Ensembl chr 1:93,173,820...93,326,366

G

ninjurin 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of NINJ1 mRNA

NCBI chr17:15,659,208...15,668,115
Ensembl chr17:15,659,200...15,668,063

G

NLR family, pyrin domain containing 1A

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of NLRP1 mRNA

NCBI chr10:56,277,134...56,332,229
Ensembl chr10:56,277,134...56,323,880

G

nuclear receptor subfamily 1, group D, member 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of NR1D1 mRNA

NCBI chr10:84,224,599...84,231,812
Ensembl chr10:84,224,540...84,231,812

G

nuclear casein kinase and cyclin-dependent kinase substrate 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of NUCKS1 mRNA

NCBI chr13:45,897,275...45,926,491
Ensembl chr13:45,897,248...45,923,101

G

nuclear protein 1, transcriptional regulator

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of NUPR1 mRNA

NCBI chr 1:190,643,866...190,645,901
Ensembl chr 1:190,643,867...190,645,901

G

origin recognition complex, subunit 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ORC1 mRNA

NCBI chr 5:128,552,975...128,581,943
Ensembl chr 5:128,552,991...128,577,071

G

origin recognition complex, subunit 3

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ORC3 mRNA

NCBI chr 5:53,923,264...53,977,869
Ensembl chr 5:53,923,393...53,978,115

G

origin recognition complex, subunit 5

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ORC5 mRNA

NCBI chr 4:13,440,264...13,504,888
Ensembl chr 4:13,440,300...13,504,886

G

origin recognition complex, subunit 6

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ORC6 mRNA

NCBI chr19:37,931,085...37,938,856
Ensembl chr19:37,931,090...37,938,856

G

oncostatin M receptor

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of OSMR mRNA

NCBI chr 2:57,634,517...57,688,802
Ensembl chr 2:57,634,517...57,688,561

G

poly (ADP-ribose) polymerase 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PARP1 mRNA

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

proliferating cell nuclear antigen

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PCNA mRNA

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PIK3CD mRNA

NCBI chr 5:165,377,994...165,426,620
Ensembl chr 5:165,377,994...165,403,968

G

DNA polymerase alpha 1, catalytic subunit

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLA1 mRNA

NCBI chr X:62,028,475...62,342,455
Ensembl chr X:62,028,476...62,342,355

G

DNA polymerase alpha 2, accessory subunit

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLA2 mRNA

NCBI chr 1:212,656,500...212,680,667
Ensembl chr 1:212,656,501...212,680,542

G

DNA polymerase delta 2, accessory subunit

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLD2 mRNA

NCBI chr14:84,962,933...84,969,148
Ensembl chr14:84,962,022...84,967,874

G

DNA polymerase delta 3, accessory subunit

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLD3 mRNA

NCBI chr 1:163,830,217...163,870,015
Ensembl chr 1:163,830,437...163,869,202

G

DNA polymerase epsilon, catalytic subunit

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLE mRNA

NCBI chr12:52,005,155...52,053,761
Ensembl chr12:52,005,155...52,053,662

G

DNA polymerase epsilon 2, accessory subunit

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLE2 mRNA

NCBI chr 6:93,410,713...93,448,782
Ensembl chr 6:93,410,758...93,435,361

G

DNA polymerase epsilon 3, accessory subunit

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLE3 mRNA

NCBI chr 5:80,989,508...80,992,742
Ensembl chr 5:80,989,511...80,992,742
Ensembl chr 7:80,989,511...80,992,742

G

DNA polymerase theta

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of POLQ mRNA

NCBI chr11:77,179,190...77,281,270
Ensembl chr11:77,179,209...77,281,268

G

peroxisome proliferator-activated receptor delta

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PPARD mRNA

NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,352,183...6,365,707

G

peroxiredoxin 5

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PRDX5 mRNA

NCBI chr 1:213,529,042...213,532,787
Ensembl chr 1:213,529,035...213,533,020

G

DNA primase subunit 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PRIM1 mRNA

NCBI chr 7:1,031,436...1,047,134

G

DNA primase subunit 2

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PRIM2 mRNA

NCBI chr 9:43,188,350...43,400,482
Ensembl chr 9:43,188,350...43,398,990

G

protein kinase C, zeta

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of PRKCZ mRNA

NCBI chr 5:171,101,774...171,212,694
Ensembl chr 5:171,101,774...171,212,674

G

RAD51 recombinase

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RAD51 mRNA

NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469

G

RB binding protein 8, endonuclease

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RBBP8 mRNA

NCBI chr18:3,198,188...3,263,643
Ensembl chr18:3,197,310...3,263,985

G

RecQ like helicase 4

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RECQL4 mRNA

NCBI chr 7:110,304,092...110,311,426
Ensembl chr 7:110,304,094...110,311,258

G

replication factor C subunit 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RFC1 mRNA

NCBI chr14:43,319,768...43,395,028
Ensembl chr14:43,319,935...43,395,026

G

replication factor C subunit 2

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RFC2 mRNA

NCBI chr12:27,756,920...27,770,049
Ensembl chr12:27,756,922...27,770,025

G

replication factor C subunit 3

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RFC3 mRNA

NCBI chr12:5,836,546...5,847,331
Ensembl chr12:5,836,553...5,847,340

G

replication factor C subunit 4

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RFC4 mRNA

NCBI chr11:91,254,273...91,268,727
Ensembl chr11:91,254,243...91,268,730

G

replication factor C subunit 5

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RFC5 mRNA

NCBI chr12:44,868,322...44,877,879
Ensembl chr12:44,862,329...44,878,151

G

ring finger and WD repeat domain 3

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RFWD3 mRNA

NCBI chr19:56,145,221...56,177,871
Ensembl chr19:56,145,221...56,177,815

G

rhomboid 5 homolog 2

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RHBDF2 mRNA

NCBI chr10:102,331,991...102,359,117
Ensembl chr10:102,331,991...102,359,117

G

replication protein A1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RPA1 mRNA

NCBI chr10:60,647,185...60,698,279
Ensembl chr10:60,647,185...60,698,279

G

ribosomal protein S6 kinase A4

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RPS6KA4 mRNA

NCBI chr 1:213,451,026...213,461,982
Ensembl chr 1:213,451,027...213,461,982

G

ribonucleotide reductase catalytic subunit M1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of RRM1 mRNA

NCBI chr 1:166,235,904...166,260,206
Ensembl chr 1:166,235,900...166,260,944

G

SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of SAMHD1 mRNA

NCBI chr 3:166,179,742...166,214,448
Ensembl chr 3:166,181,588...166,214,410

G

strawberry notch homolog 2

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of SBNO2 mRNA

NCBI chr 7:10,256,221...10,300,175
Ensembl chr 7:10,253,248...10,300,176

G

SCY1 like pseudokinase 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of SCYL1 mRNA

NCBI chr 1:212,475,198...212,489,285
Ensembl chr 1:212,475,068...212,501,129

G

serpin family E member 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of SERPINE1 mRNA

NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357

G

SET domain and mariner transposase fusion gene

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of SETMAR mRNA

NCBI chr 4:142,602,066...142,614,208
Ensembl chr 4:142,602,088...142,614,206

G

secreted phosphoprotein 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of SPP1 mRNA

NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820

G

serine threonine kinase 39

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of STK39 mRNA

NCBI chr 3:73,321,522...73,588,397
Ensembl chr 3:73,321,522...73,586,740

G

transforming growth factor, beta 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TGFB1 mRNA

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

thrombospondin 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of THBS1 mRNA

NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:125,510,250...125,525,402

G

THO complex subunit 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of THOC1 mRNA

NCBI chr18:1,253,041...1,291,956
Ensembl chr18:1,256,637...1,292,630

G

TIR domain containing adaptor molecule 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TICAM1 mRNA

NCBI chr 9:1,189,717...1,197,730
Ensembl chr 9:1,172,963...1,196,892

G

TOPBP1-interacting checkpoint and replication regulator

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TICRR mRNA

NCBI chr 1:143,006,989...143,048,836
Ensembl chr 1:143,006,924...143,049,133

G

TIMP metallopeptidase inhibitor 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TIMP1 mRNA

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

timeless interacting protein

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TIPIN mRNA

NCBI chr 8:73,676,020...73,696,620
Ensembl chr 8:73,676,091...73,696,620

G

TNF receptor superfamily member 1A

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TNFRSF1A mRNA

NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816

G

toll interacting protein

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TOLLIP mRNA

NCBI chr 1:206,391,120...206,413,809
Ensembl chr 1:206,380,308...206,411,988

G

DNA topoisomerase II binding protein 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TOPBP1 mRNA

NCBI chr 8:112,766,791...112,815,203
Ensembl chr 8:112,766,508...112,810,540

G

TRAF-interacting protein

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TRAIP mRNA

NCBI chr 8:117,520,476...117,540,253
Ensembl chr 8:117,520,441...117,540,253

G

twinkle mtDNA helicase

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TWNK mRNA

NCBI chr 1:253,817,074...253,823,958
Ensembl chr 1:253,817,564...253,824,162

G

TYRO3 protein tyrosine kinase

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of TYRO3 mRNA

NCBI chr 3:127,231,468...127,254,806
Ensembl chr 3:127,231,903...127,250,943

G

unc-13 homolog D

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of UNC13D mRNA

NCBI chr10:101,795,652...101,810,409
Ensembl chr10:101,795,652...101,810,409

G

UPF1, RNA helicase and ATPase

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of UPF1 mRNA

NCBI chr16:19,110,531...19,131,327
Ensembl chr16:19,110,538...19,131,327

G

WD repeat and HMG-box DNA binding protein 1

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of WDHD1 mRNA

NCBI chr15:22,957,492...23,002,820
Ensembl chr15:22,958,069...23,002,820

G

WNK lysine deficient protein kinase 4

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of WNK4 mRNA

NCBI chr10:86,702,828...86,719,917
Ensembl chr10:86,702,865...86,720,198

G

WRN RecQ like helicase

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of WRN mRNA

NCBI chr16:65,466,552...65,602,951
Ensembl chr16:65,456,254...65,602,951

G

X-linked inhibitor of apoptosis

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of XIAP mRNA

NCBI chr X:125,756,107...125,803,979
Ensembl chr X:125,737,971...125,803,978

G

zyxin

multiple interactions

ISO

[CYP3A4 protein affects the susceptibility to 2,2'-methylenebis(4-methyl-6-tert-butylphenol)] which affects the expression of ZYX mRNA

NCBI chr 4:72,203,991...72,213,181
Ensembl chr 4:72,204,007...72,213,181

2,2-(2-Chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

activin A receptor type 1C

multiple interactions

ISO

[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ACVR1C mRNA

NCBI chr 3:63,224,322...63,301,252
Ensembl chr 3:63,227,559...63,301,205

G

activin A receptor like type 1

multiple interactions

ISO

[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ACVRL1 mRNA

NCBI chr 7:134,117,917...134,135,306
Ensembl chr 7:134,118,024...134,135,305

G

aryl hydrocarbon receptor

increases expression

ISO

2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased expression of AHR protein

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

ALK receptor tyrosine kinase

multiple interactions

ISO

[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ALK mRNA

NCBI chr 6:28,631,431...29,351,321
Ensembl chr 6:28,632,197...29,349,721

G

androgen receptor

multiple interactions
affects binding

ISO
EXP

2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene binds to and results in decreased activity of AR protein; 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene inhibits the reaction [Dihydrotestosterone binds to AR protein]; 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene inhibits the reaction [Metribolone results in increased activity of AR protein]
2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene binds to AR protein

PMID:9705896 PMID:14565775 PMID:14579009 PMID:18324785

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

autophagy related 7

multiple interactions

ISO

ATG7 protein affects the reaction [2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased activity of CASP3 protein]

NCBI chr 4:149,390,000...149,597,534
Ensembl chr 4:149,391,390...149,598,319

G

beclin 1

increases expression
multiple interactions

ISO

2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased expression of BECN1 mRNA
BECN1 protein affects the reaction [2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased activity of CASP3 protein]

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

caspase 3

increases activity
multiple interactions

ISO

2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased activity of CASP3 protein
ATG7 protein affects the reaction [2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased activity of CASP3 protein]; BECN1 protein affects the reaction [2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased activity of CASP3 protein]; diazepinylbenzoic acid inhibits the reaction [2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased activity of CASP3 protein]; ethyl (5-(diethylglycyl)-10,11-dihydro-5H-dibenzo(b,f)azepin-3-yl)carbamate inhibits the reaction [2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased activity of CASP3 protein]; RXRA mRNA promotes the reaction [2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased activity of CASP3 protein]; RXRB mRNA promotes the reaction [2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased activity of CASP3 protein]

PMID:26563996 PMID:32721735

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

CREB binding protein

increases activity

ISO

2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased activity of CREBBP protein

NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266

G

erb-b2 receptor tyrosine kinase 3

multiple interactions

ISO

[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ERBB3 mRNA

NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:1,579,816...1,601,120

G

estrogen receptor 1

affects binding
multiple interactions

ISO

2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene binds to ESR1 protein
2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene inhibits the reaction [Estradiol binds to ESR1 protein]

PMID:14579009 PMID:19913605 PMID:32278787

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

G protein-coupled estrogen receptor 1

affects binding

ISO

2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene binds to GPER1 protein

NCBI chr12:20,331,073...20,336,527
Ensembl chr12:20,327,679...20,337,144

G

KIT proto-oncogene receptor tyrosine kinase

multiple interactions

ISO

[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of KIT mRNA

NCBI chr14:32,901,615...32,978,895
Ensembl chr14:32,903,033...32,978,812

G

microtubule-associated protein 1 light chain 3 alpha

increases expression

ISO

2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased expression of MAP1LC3A mRNA; 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased expression of MAP1LC3A protein

NCBI chr 3:164,243,204...164,244,850
Ensembl chr 3:164,243,093...164,244,850

G

microtubule-associated protein 1 light chain 3 beta

affects expression

ISO

2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene affects the expression of MAP1LC3B mRNA

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

nuclear receptor subfamily 1, group I, member 3

increases activity
affects expression
increases expression

ISO

2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased activity of NR1I3 protein
2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene affects the expression of NR1I3 mRNA
2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased expression of NR1I3 protein

PMID:28927721 PMID:32721735

NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370

G

nucleoporin 62

increases expression
affects expression

ISO

2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased expression of NUP62 protein
2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene affects the expression of NUP62 mRNA

NCBI chr 1:104,435,532...104,451,392
Ensembl chr 1:104,432,093...104,452,710

G

platelet derived growth factor receptor alpha

multiple interactions

ISO

[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of PDGFRA mRNA

NCBI chr14:33,360,027...33,408,604
Ensembl chr14:33,360,028...33,408,516

G

platelet derived growth factor receptor beta

multiple interactions

ISO

[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of PDGFRB mRNA

NCBI chr18:56,770,348...56,809,228
Ensembl chr18:56,770,348...56,809,233

G

progesterone receptor

affects binding
multiple interactions

ISO

2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene binds to PGR protein
2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene inhibits the reaction [Progesterone binds to PGR protein]; 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene inhibits the reaction [Progesterone results in increased expression of PGR protein]

PMID:14579009 PMID:18262749

NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271

G

prostaglandin-endoperoxide synthase 2

increases expression

ISO

2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased expression of PTGS2 protein

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

retinoic acid receptor, beta

affects binding

ISO

2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene binds to RARB protein

NCBI chr15:10,837,252...11,482,037
Ensembl chr15:11,131,358...11,482,040

G

retinoid X receptor alpha

multiple interactions
increases expression

ISO

RXRA mRNA promotes the reaction [2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased activity of CASP3 protein]
2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased expression of RXRA mRNA; 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased expression of RXRA protein

NCBI chr 3:31,387,892...31,474,415
Ensembl chr 3:31,388,223...31,474,417

G

retinoid X receptor beta

increases expression
multiple interactions

ISO

2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased expression of RXRB mRNA; 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased expression of RXRB protein
RXRB mRNA promotes the reaction [2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in increased activity of CASP3 protein]

NCBI chr20:4,818,707...4,824,968
Ensembl chr20:4,818,709...4,825,359

2,2-diphenylacetic acid (1-ethyl-3-piperidinyl) ester

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity

ISO

piperidolate results in decreased activity of KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

2,2-diphenylacetic acid 2-(diethylamino)ethyl ester

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor subfamily 1, group I, member 2

increases activity

ISO

adiphenine results in increased activity of NR1I2 protein

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

2-[(2,4-dichlorophenyl)methyl]-4-(2,4,4-trimethylpentan-2-yl)phenol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

nuclear receptor coactivator 2

multiple interactions

EXP

clofoctol promotes the reaction [THRA protein binds to NCOA2 protein]; clofoctol promotes the reaction [THRB protein binds to NCOA2 protein]

NCBI chr 5:10,618,712...10,852,776
Ensembl chr 5:10,618,722...10,852,776

G

retinoid X receptor alpha

affects binding

EXP

clofoctol binds to RXRA protein

NCBI chr 3:31,387,892...31,474,415
Ensembl chr 3:31,388,223...31,474,417

G

thyroid hormone receptor alpha

multiple interactions

EXP

clofoctol promotes the reaction [THRA protein binds to NCOA2 protein]

NCBI chr10:84,198,141...84,225,659
Ensembl chr10:84,197,011...84,225,657

G

thyroid hormone receptor beta

multiple interactions

EXP

clofoctol promotes the reaction [THRB protein binds to NCOA2 protein]

NCBI chr15:10,115,954...10,465,231
Ensembl chr15:10,115,954...10,313,680

2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-N-(2,6-dimethylphenyl)acetamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity
multiple interactions

ISO

Lidoflazine results in decreased activity of KCNH2 protein
Lidoflazine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]

PMID:16278312 PMID:21158687 PMID:28551711

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

solute carrier family 29 member 1

multiple interactions

ISO

Lidoflazine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine]

NCBI chr 9:22,897,099...22,911,640
Ensembl chr 9:22,902,471...22,914,620

2-benzyl-4-chlorophenol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

androgen receptor

multiple interactions

ISO

clorophene inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; clorophene inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]

PMID:28728110 PMID:33049310

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

iodothyronine deiodinase 1

decreases activity

ISO

clorophene results in decreased activity of DIO1 protein

NCBI chr 5:127,303,089...127,319,784
Ensembl chr 5:127,303,083...127,319,771

G

estrogen receptor 1

multiple interactions
affects activity

ISO

clorophene binds to and results in increased activity of ESR1 protein
clorophene affects the activity of ESR1 protein

PMID:21251949 PMID:33049310

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

estrogen receptor 2

multiple interactions

ISO

clorophene binds to and results in increased activity of ESR2 protein

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

G

nuclear receptor subfamily 1, group I, member 2

increases activity
multiple interactions

ISO

clorophene results in increased activity of NR1I2 protein
clorophene binds to and results in increased activity of NR1I2 protein

PMID:28728110 PMID:33049310

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ISO

clorophene binds to and results in increased activity of PPARG protein

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

thyroid hormone receptor beta

multiple interactions

ISO

clorophene binds to and results in increased activity of THRB protein

NCBI chr15:10,115,954...10,465,231
Ensembl chr15:10,115,954...10,313,680

2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions
affects chemical synthesis

ISO

Aminoglutethimide inhibits the reaction [CYP19A1 protein affects the chemical synthesis of 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine]; formestane inhibits the reaction [CYP19A1 protein affects the chemical synthesis of 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine]

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

2-hydroxy-2,2-diphenylacetic acid (1,1-dimethyl-3-piperidin-1-iumyl) ester

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 2

multiple interactions

ISO

mepenzolic acid inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

2-hydroxy-2,2-diphenylacetic acid (1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl) ester

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 2

multiple interactions

ISO

clidinium inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

2-hydroxy-2,2-diphenylacetic acid 2-(diethylamino)ethyl ester

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity

ISO

Benactyzine results in decreased activity of KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

3,3-diphenyl-N-(1-phenylethyl)-1-propanamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

coagulation factor II, thrombin

multiple interactions

ISO

Fendiline affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]

NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246

G

gamma-aminobutyric acid type B receptor subunit 1

multiple interactions

ISO

Fendiline inhibits the reaction [2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol promotes the reaction [gamma-Aminobutyric Acid binds to and results in increased activity of [GABBR1 protein binds to GABBR2 protein]]]

NCBI chr20:1,469,779...1,499,352
Ensembl chr20:1,469,779...1,498,607

G

gamma-aminobutyric acid type B receptor subunit 2

multiple interactions

ISO

Fendiline inhibits the reaction [2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol promotes the reaction [gamma-Aminobutyric Acid binds to and results in increased activity of [GABBR1 protein binds to GABBR2 protein]]]

NCBI chr 5:65,743,073...66,083,695
Ensembl chr 5:65,743,073...66,083,695

G

potassium voltage-gated channel subfamily H member 2

decreases activity

ISO

Fendiline results in decreased activity of KCNH2 protein

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

nitric oxide synthase 3

decreases activity

EXP

Fendiline results in decreased activity of NOS3 protein

NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664

G

sphingomyelin phosphodiesterase 1

increases response to substance
decreases activity

ISO

SMPD1 protein results in increased susceptibility to Fendiline
Fendiline results in decreased activity of SMPD1 protein

NCBI chr 1:169,304,772...169,308,615
Ensembl chr 1:169,304,708...169,308,614

4,4'-methanol-bisbenzonitrile

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases chemical synthesis

ISO

CYP3A4 protein results in increased chemical synthesis of 4,4'-methanol-bisbenzonitrile

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

4-[2-(diphenylmethoxy)ethyl]-1-[(4-azidophenyl)-methyl]-piperidine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 6 member 3

affects binding

EXP

4-[2-(diphenylmethoxy)ethyl]-1-[(4-azidophenyl)-methyl]-piperidine binds to Slc6a3 protein

RGD

NCBI chr 1:31,537,990...31,578,962
Ensembl chr 1:31,537,990...31,578,962

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

multiple interactions

ISO

Methadyl Acetate inhibits the reaction [KCNH2 protein results in increased transport of Thallium]

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

opioid receptor, delta 1

multiple interactions
affects binding

EXP

[Methadyl Acetate binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Methadyl Acetate binds to OPRD1 protein] which results in decreased uptake of Serotonin

NCBI chr 5:149,590,244...149,624,999
Ensembl chr 5:149,590,244...149,624,999

G

opioid receptor, kappa 1

affects binding
multiple interactions

EXP

Methadyl Acetate binds to OPRK1 protein
[Methadyl Acetate binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Methadyl Acetate binds to OPRK1 protein] which results in decreased uptake of Serotonin

NCBI chr 5:18,657,866...18,675,671
Ensembl chr 5:18,657,871...18,675,671

G

opioid receptor, mu 1

multiple interactions
affects binding

EXP

[Methadyl Acetate binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Methadyl Acetate binds to OPRM1 protein] which results in decreased uptake of Serotonin

NCBI chr 1:45,565,371...45,818,722
Ensembl chr 1:45,565,371...45,638,756

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

ISO

ambrisentan inhibits the reaction [Cisplatin results in increased expression of BAX protein]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions

ISO

ambrisentan inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

caspase 3

multiple interactions

ISO

ambrisentan inhibits the reaction [Cisplatin results in increased expression of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

endothelin receptor type A

multiple interactions

ISO

ambrisentan binds to and results in decreased activity of EDNRA protein

NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284

G

mitogen-activated protein kinase 8

multiple interactions

ISO

ambrisentan inhibits the reaction [Cisplatin results in increased expression of MAPK8 protein]

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

nuclear factor kappa B subunit 1

multiple interactions

ISO

ambrisentan inhibits the reaction [Cisplatin results in increased expression of NFKB1 protein]

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

nerve growth factor receptor

multiple interactions

ISO

ambrisentan inhibits the reaction [Cisplatin results in increased expression of NGFR protein]

NCBI chr10:81,012,077...81,030,305
Ensembl chr10:81,012,089...81,030,305

G

nitric oxide synthase 3

multiple interactions

ISO

ambrisentan inhibits the reaction [Cisplatin results in decreased expression of NOS3 protein]

NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664

G

tumor protein p53

multiple interactions

ISO

ambrisentan inhibits the reaction [Cisplatin results in increased expression of TRP53 protein]

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

vascular endothelial growth factor A

multiple interactions

ISO

ambrisentan inhibits the reaction [Cisplatin results in decreased expression of VEGFA protein]

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

multiple interactions

ISO

amperozide inhibits the reaction [KCNH2 protein results in increased transport of Thallium]

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

decreases expression

ISO

aurin results in decreased expression of AHR protein

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

androgen receptor

affects binding

EXP

aurin binds to AR protein

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

cyclin-dependent kinase inhibitor 1A

increases expression

ISO

aurin results in increased expression of CDKN1A mRNA

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

crystallin, alpha B

increases expression

ISO

aurin results in increased expression of CRYAB mRNA

NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528

G

C-X-C motif chemokine ligand 10

decreases expression

ISO

aurin results in decreased expression of CXCL10 mRNA

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases expression

ISO

aurin results in decreased expression of CYP1A1 mRNA

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

DNA-damage inducible transcript 3

increases expression

ISO

aurin results in increased expression of DDIT3 mRNA; aurin results in increased expression of DDIT3 protein

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

DnaJ heat shock protein family (Hsp40) member A1

increases expression

ISO

aurin results in increased expression of DNAJA1 mRNA

NCBI chr 5:60,638,404...60,649,315
Ensembl chr 5:60,638,410...60,650,160

G

DnaJ heat shock protein family (Hsp40) member B4

increases expression

ISO

aurin results in increased expression of DNAJB4 mRNA

NCBI chr 2:243,790,296...243,819,042
Ensembl chr 2:243,790,297...243,819,042

G

early growth response 1

increases expression

ISO

aurin results in increased expression of EGR1 mRNA

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

eukaryotic translation initiation factor 2 alpha kinase 3

increases phosphorylation

ISO

aurin results in increased phosphorylation of EIF2AK3 protein

NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation

ISO

aurin results in increased phosphorylation of EIF2S1 protein

NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649

G

FKBP prolyl isomerase 5

multiple interactions

ISO

aurin inhibits the reaction [Dexamethasone results in increased expression of FKBP5 mRNA]; aurin inhibits the reaction [NR3C1 protein results in increased expression of FKBP5 mRNA]

NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,458,940...6,543,118

G

growth arrest and DNA-damage-inducible, alpha

increases expression

ISO

aurin results in increased expression of GADD45A mRNA

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807

G

growth differentiation factor 15

increases expression

ISO

aurin results in increased expression of GDF15 mRNA

NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022

G

heme oxygenase 1

increases expression

ISO

aurin results in increased expression of HMOX1 mRNA; aurin results in increased expression of HMOX1 protein

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heat shock transcription factor 1

affects localization

ISO

aurin affects the localization of HSF1 protein

NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665

G

heat shock protein family A (Hsp70) member 1A

increases expression

ISO

aurin results in increased expression of HSPA1A mRNA; aurin results in increased expression of HSPA1A protein

NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979

G

heat shock protein family A (Hsp70) member 1 like

increases expression

ISO

aurin results in increased expression of HSPA1L mRNA

NCBI chr20:3,853,496...3,860,223
Ensembl chr20:3,853,331...3,876,877

G

heat shock protein family A (Hsp70) member 6 like, pseudogene 1

increases expression

ISO

aurin results in increased expression of HSPA6 mRNA

NCBI chr13:85,805,911...85,807,052

G

heat shock protein family B (small) member 1

increases expression

ISO

aurin results in increased expression of HSPB1 mRNA

NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301

G

heat shock protein family H (Hsp110) member 1

increases expression

ISO

aurin results in increased expression of HSPH1 mRNA

NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891

G

interleukin 1 beta

decreases expression

ISO

aurin results in decreased expression of IL1B mRNA

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

decreases expression

ISO

aurin results in decreased expression of IL6 mRNA

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

nuclear receptor subfamily 3, group C, member 1

decreases activity
multiple interactions

ISO

aurin results in decreased activity of NR3C1 protein
aurin inhibits the reaction [NR3C1 protein results in increased expression of FKBP5 mRNA]

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

phorbol-12-myristate-13-acetate-induced protein 1

increases expression
increases response to substance

ISO

aurin results in increased expression of PMAIP1 mRNA; aurin results in increased expression of PMAIP1 protein
PMAIP1 protein results in increased susceptibility to aurin

NCBI chr18:62,255,970...62,262,384
Ensembl chr18:62,255,598...62,262,382

G

serpin family E member 1

increases expression

ISO

aurin results in increased expression of SERPINE1 mRNA

NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357

G

sex hormone binding globulin

affects binding

ISO

aurin binds to SHBG protein

NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,831,718...54,838,760

Bisphenol A diglycidyl ether

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ABL proto-oncogene 1, non-receptor tyrosine kinase

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of ABL1 mRNA

NCBI chr 3:35,377,587...35,480,843
Ensembl chr 3:35,377,391...35,480,846

G

acetylcholinesterase

multiple interactions

ISO
EXP

bisphenol A diglycidyl ether inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; bisphenol A diglycidyl ether inhibits the reaction [Plant Extracts inhibits the reaction [Aluminum Chloride results in increased expression of ACHE]]; bisphenol A diglycidyl ether inhibits the reaction [Telmisartan inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]
[bergenin co-treated with bisphenol A diglycidyl ether] inhibits the reaction [Sodium Azide results in increased activity of ACHE protein]; [bisphenol A diglycidyl ether co-treated with Hesperidin] inhibits the reaction [[Sodium Fluoride results in increased abundance of Fluorides] which results in increased activity of ACHE protein]

PMID:23060470 PMID:25940660 PMID:32627286 PMID:36249784

NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410

G

acyl-CoA oxidase 1

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [TRIB3 protein affects the expression of ACOX1 protein]

NCBI chr10:101,905,083...101,930,136
Ensembl chr10:101,905,083...101,930,136

G

adiponectin, C1Q and collagen domain containing

multiple interactions
increases expression

ISO

[bisphenol A diglycidyl ether co-treated with Cytarabine] results in decreased expression of ADIPOQ mRNA; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phloretin] results in increased expression of ADIPOQ mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phloretin] affects the expression of ADIPOQ mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of ADIPOQ mRNA]; bisphenol A diglycidyl ether affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phloretin] affects the expression of ADIPOQ mRNA]; bisphenol A diglycidyl ether affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of ADIPOQ mRNA]; bisphenol A diglycidyl ether inhibits the reaction [butylparaben results in increased expression of ADIPOQ mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Docosahexaenoic Acids results in increased secretion of ADIPOQ protein]; bisphenol A diglycidyl ether inhibits the reaction [Fish Oils results in increased secretion of ADIPOQ protein]; bisphenol A diglycidyl ether inhibits the reaction [Palmitates results in increased secretion of ADIPOQ protein]; bisphenol A diglycidyl ether inhibits the reaction [Phloretin inhibits the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in decreased secretion of ADIPOQ protein]]
bisphenol A diglycidyl ether results in increased expression of ADIPOQ mRNA

PMID:16567512 PMID:18303122 PMID:21164549 PMID:22763116 PMID:22956630 More...

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169

G

advanced glycosylation end product-specific receptor

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of AGER protein]]

NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685

G

argonaute RISC component 4

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of AGO4 mRNA

NCBI chr 5:144,064,949...144,110,422
Ensembl chr 5:144,064,949...144,110,402

G

angiotensinogen

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxyprostaglandin J2 inhibits the reaction [AGT protein results in increased expression of KLF5 mRNA]]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxyprostaglandin J2 inhibits the reaction [AGT protein results in increased expression of KLF5 protein]]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [AGT protein results in increased expression of KLF5 mRNA]]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [AGT protein results in increased expression of KLF5 protein]]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]

PMID:18278065 PMID:25874449

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944

G

alkB homolog 1, histone H2A dioxygenase

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of ALKBH1 mRNA

NCBI chr 6:112,799,234...112,819,708
Ensembl chr 6:112,799,234...112,819,708

G

anaphase promoting complex subunit 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of ANAPC1 mRNA

NCBI chr 3:136,303,350...136,383,464
Ensembl chr 3:136,303,413...136,383,464

G

angiopoietin-like 4

multiple interactions

ISO

bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phloretin] results in increased expression of ANGPTL4 mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phloretin] affects the expression of ANGPTL4 mRNA]

NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:15,252,473...15,258,681

G

amyloid beta precursor protein

multiple interactions

EXP

bisphenol A diglycidyl ether affects the reaction [bergenin affects the reaction [Sodium Azide results in increased expression of APP protein]]

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

androgen receptor

multiple interactions

ISO

bisphenol A diglycidyl ether analog binds to and results in decreased activity of AR protein

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

assembly factor for spindle microtubules

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of ASPM mRNA

NCBI chr13:53,625,584...53,674,489
Ensembl chr13:53,625,584...53,674,489

G

activating transcription factor 3

increases expression

ISO

bisphenol A diglycidyl ether results in increased expression of ATF3 mRNA

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750

G

ATM serine/threonine kinase

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of ATM mRNA

NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:62,727,291...62,828,629

G

ATR serine/threonine kinase

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of ATR mRNA

NCBI chr 8:105,306,299...105,403,742
Ensembl chr 8:105,306,305...105,403,718

G

BCL2-associated agonist of cell death

multiple interactions

ISO

[bisphenol A diglycidyl ether co-treated with Phlorhizin] promotes the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of BAD protein]; bisphenol A diglycidyl ether inhibits the reaction [Phloretin inhibits the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of BAD protein]]; bisphenol A diglycidyl ether promotes the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of BAD protein]

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034

G

BCL2 associated X, apoptosis regulator

affects localization
multiple interactions

ISO
EXP

bisphenol A diglycidyl ether affects the localization of BAX protein
bisphenol A diglycidyl ether inhibits the reaction [7-hydroxycoumarin inhibits the reaction [Glycerol results in increased expression of BAX protein]]; bisphenol A diglycidyl ether inhibits the reaction [Calcitriol inhibits the reaction [Streptozocin results in increased expression of BAX protein]]
bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester inhibits the reaction [VEGFA protein results in decreased expression of BAX protein]]

PMID:12788809 PMID:21769449 PMID:29953732 PMID:34409680

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions

ISO
EXP

bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester inhibits the reaction [VEGFA protein results in increased expression of BCL2 protein]]
bisphenol A diglycidyl ether inhibits the reaction [7-hydroxycoumarin inhibits the reaction [Glycerol results in decreased expression of BCL2 protein]]; bisphenol A diglycidyl ether inhibits the reaction [Calcitriol inhibits the reaction [Streptozocin results in decreased expression of BCL2 protein]]

PMID:21769449 PMID:29953732 PMID:34409680

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

multiple interactions

ISO

[bisphenol A diglycidyl ether co-treated with Phlorhizin] promotes the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of BCL2L1 protein]; bisphenol A diglycidyl ether inhibits the reaction [Phloretin inhibits the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of BCL2L1 protein]]; bisphenol A diglycidyl ether promotes the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of BCL2L1 protein]

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

beclin 1

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [eicosapentaenoic acid ethyl ester inhibits the reaction [Methotrexate results in increased expression of BECN1 protein]]

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

bone gamma-carboxyglutamate protein

decreases expression
increases expression
multiple interactions

ISO
EXP

bisphenol A diglycidyl ether results in decreased expression of BGLAP mRNA
bisphenol A diglycidyl ether results in increased expression of BGLAP protein
bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in decreased expression of BGLAP mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in decreased expression of BGLAP protein]; Methylprednisolone inhibits the reaction [bisphenol A diglycidyl ether results in increased expression of BGLAP mRNA]; Methylprednisolone inhibits the reaction [bisphenol A diglycidyl ether results in increased expression of BGLAP protein]
bisphenol A diglycidyl ether inhibits the reaction [Dexamethasone results in decreased expression of BGLAP mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Dexamethasone results in decreased expression of BGLAP protein]

PMID:16972249 PMID:31709877 PMID:37659742

NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318

G

BH3 interacting domain death agonist

increases cleavage

ISO

bisphenol A diglycidyl ether results in increased cleavage of BID protein

NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275

G

BUB1 mitotic checkpoint serine/threonine kinase

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of BUB1 mRNA

NCBI chr 3:135,473,525...135,504,921
Ensembl chr 3:135,472,582...135,504,921

G

BUB1 mitotic checkpoint serine/threonine kinase B

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of BUB1B mRNA

NCBI chr 3:126,017,019...126,069,470
Ensembl chr 3:126,017,045...126,069,796

G

caspase 3

multiple interactions

ISO
EXP

bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester results in increased activity of CASP3 protein]; bisphenol A diglycidyl ether inhibits the reaction [PPARG protein promotes the reaction [mono-(2-ethylhexyl)phthalate results in increased activity of CASP3 protein]]
bisphenol A diglycidyl ether inhibits the reaction [eicosapentaenoic acid ethyl ester inhibits the reaction [Methotrexate results in increased expression of CASP3 protein]]

PMID:12927354 PMID:21769449 PMID:37450014

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

catalase

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [Pioglitazone inhibits the reaction [Quinolinic Acid results in decreased activity of CAT protein]]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

caveolin 1

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone results in increased expression of CAV1 protein]

NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740

G

caveolin 2

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone results in increased expression of CAV2 protein]

NCBI chr 4:46,582,681...46,590,058
Ensembl chr 4:46,582,096...46,591,425

G

C-C motif chemokine ligand 2

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [Eicosapentaenoic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]]
bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phloretin] results in increased expression of CCL2 mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phloretin] affects the expression of CCL2 mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of CCL2 mRNA]; bisphenol A diglycidyl ether affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phloretin] affects the expression of CCL2 mRNA]; bisphenol A diglycidyl ether affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of CCL2 mRNA]

PMID:15698426 PMID:32408695

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

cyclin E1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of CCNE1 mRNA

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822

G

CD36 molecule

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [TRIB3 protein affects the expression of CD36 protein]

NCBI chr 4:18,209,088...18,302,142

G

cell division cycle 20

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of CDC20 mRNA

NCBI chr 5:137,251,596...137,255,799
Ensembl chr 5:137,251,596...137,255,799

G

cell division cycle 45

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of CDC45 mRNA

NCBI chr11:95,689,702...95,714,980
Ensembl chr11:95,689,919...95,714,981

G

cell division cycle 5-like

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of CDC5L mRNA

NCBI chr 9:23,062,397...23,100,901
Ensembl chr 9:23,062,205...23,100,899

G

cell division cycle 7

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of CDC7 mRNA

NCBI chr14:2,949,538...2,969,656
Ensembl chr14:2,949,539...2,969,656

G

CCAAT/enhancer binding protein alpha

multiple interactions

ISO
EXP

bisphenol A diglycidyl ether inhibits the reaction [butylparaben results in increased expression of CEBPA mRNA]
bisphenol A diglycidyl ether inhibits the reaction [TRIB3 protein affects the expression of CEBPA protein]

PMID:21190014 PMID:22956630

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

centromere protein H

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of CENPH mRNA

NCBI chr 2:33,630,738...33,644,258
Ensembl chr 2:33,630,738...33,644,242

G

centrosomal protein 164

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of CEP164 mRNA

NCBI chr 8:54,967,621...55,031,264
Ensembl chr 8:54,967,621...55,031,206

G

centrosomal protein 63

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of CEP63 mRNA

NCBI chr 8:112,041,586...112,093,061
Ensembl chr 8:112,041,594...112,084,646

G

citron rho-interacting serine/threonine kinase

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of CIT mRNA

NCBI chr12:46,263,881...46,425,642
Ensembl chr12:46,266,369...46,424,656

G

cyclin N-terminal domain containing 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of CNTD1 mRNA

NCBI chr10:86,721,692...86,732,074

G

casein kinase 2 alpha 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of CSNK2A1 mRNA

NCBI chr 3:161,170,295...161,217,073
Ensembl chr 3:161,170,405...161,215,698

G

DNA cross-link repair 1A

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of DCLRE1A mRNA

NCBI chr 1:265,575,087...265,594,987
Ensembl chr 1:265,575,087...265,593,899

G

DEAD/H-box helicase 11

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of DDX11 mRNA

NCBI chr 9:113,204,886...113,309,692
Ensembl chr 9:113,276,985...113,316,152

G

diablo, IAP-binding mitochondrial protein

affects localization

ISO

bisphenol A diglycidyl ether affects the localization of DIABLO protein

NCBI chr12:38,716,668...38,731,285
Ensembl chr12:38,716,668...38,731,265

G

iodothyronine deiodinase 1

decreases activity

ISO

bisphenol A diglycidyl ether results in decreased activity of DIO1 protein

NCBI chr 5:127,303,089...127,319,784
Ensembl chr 5:127,303,083...127,319,771

G

iodothyronine deiodinase 2

decreases activity

ISO

bisphenol A diglycidyl ether results in decreased activity of DIO2 protein

NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594

G

iodothyronine deiodinase 3

decreases activity

ISO

bisphenol A diglycidyl ether results in decreased activity of DIO3 protein

NCBI chr 6:135,107,072...135,108,933
Ensembl chr 6:135,107,074...135,107,985

G

delta like non-canonical Notch ligand 1

decreases expression

ISO

bisphenol A diglycidyl ether results in decreased expression of DLK1 mRNA

NCBI chr 6:134,192,491...134,199,779
Ensembl chr 6:134,192,518...134,200,529

G

DNA meiotic recombinase 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of DMC1 mRNA

NCBI chr 7:113,005,278...113,047,854
Ensembl chr 7:113,005,281...113,047,854

G

DnaJ heat shock protein family (Hsp40) member B4

increases expression

ISO

bisphenol A diglycidyl ether results in increased expression of DNAJB4 mRNA

NCBI chr 2:243,790,296...243,819,042
Ensembl chr 2:243,790,297...243,819,042

G

euchromatic histone lysine methyltransferase 2

affects expression

ISO

bisphenol A diglycidyl ether affects the expression of EHMT2 mRNA

NCBI chr20:3,924,263...3,941,238
Ensembl chr20:3,924,263...3,941,384

G

ERCC excision repair 6 like 2

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of ERCC6L2 mRNA

NCBI chr17:1,055,881...1,323,207
Ensembl chr17:1,222,139...1,316,056

G

extra spindle pole bodies like 1, separase

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of ESPL1 mRNA

NCBI chr 7:135,302,460...135,329,570
Ensembl chr 7:135,302,716...135,329,570

G

estrogen receptor 1

multiple interactions

ISO

bisphenol A diglycidyl ether analog inhibits the reaction [Coumestrol binds to ESR1 protein]; bisphenol A diglycidyl ether inhibits the reaction [Coumestrol binds to ESR1 protein]

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

EYA transcriptional coactivator and phosphatase 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of EYA1 mRNA

NCBI chr 5:9,646,599...9,884,609
Ensembl chr 5:9,646,591...9,884,614

G

fatty acid binding protein 4

increases expression
decreases expression
multiple interactions

ISO
EXP

bisphenol A diglycidyl ether results in increased expression of FABP4 mRNA
bisphenol A diglycidyl ether results in decreased expression of FABP4 mRNA
bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in increased expression of FABP4 mRNA]
bisphenol A diglycidyl ether inhibits the reaction [Dexamethasone results in increased expression of FABP4 mRNA]

PMID:22763116 PMID:31709877 PMID:37659742

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972

G

FA complementation group D2

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of FANCD2 mRNA

NCBI chr 4:148,234,633...148,299,035
Ensembl chr 4:148,234,708...148,299,035

G

FA complementation group I

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of FANCI mRNA

NCBI chr 1:142,736,636...142,792,999
Ensembl chr 1:142,736,653...142,792,999

G

frizzled class receptor 1

affects expression

ISO

bisphenol A diglycidyl ether affects the expression of FZD1 mRNA

NCBI chr 4:30,265,074...30,269,472
Ensembl chr 4:30,247,228...30,833,176

G

glutamate cysteine ligase, modifier subunit

increases expression

ISO

bisphenol A diglycidyl ether results in increased expression of GCLM mRNA

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

GINS complex subunit 4

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of GINS4 mRNA

NCBI chr16:75,489,990...75,502,455
Ensembl chr16:75,490,126...75,505,000

G

general transcription factor IIH subunit 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of GTF2H1 mRNA

NCBI chr 1:106,457,692...106,485,729
Ensembl chr 1:106,457,394...106,485,727

G

histone deacetylase 9

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of HDAC9 mRNA

NCBI chr 6:56,489,472...57,351,654
Ensembl chr 6:56,490,988...57,351,835

G

HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of HECW2 mRNA

NCBI chr 9:62,853,904...63,247,472
Ensembl chr 9:62,859,645...63,074,758

G

helicase, POLQ-like

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of HELQ mRNA

NCBI chr14:9,122,978...9,167,310
Ensembl chr14:9,122,978...9,167,310

G

helicase for meiosis 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of HFM1 mRNA

NCBI chr14:3,002,103...3,108,567
Ensembl chr14:3,001,906...3,084,401

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

ISO

bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phloretin] results in increased expression of HIF1A mRNA]

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

histone cell cycle regulator

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of HIRA mRNA

NCBI chr11:95,528,831...95,637,565
Ensembl chr11:95,528,831...95,638,549

G

high mobility group box 1

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of HMGB1 protein]]

NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327

G

heme oxygenase 1

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [Curcumin inhibits the reaction [Lipopolysaccharides results in decreased expression of HMOX1 protein]]; bisphenol A diglycidyl ether inhibits the reaction [mangiferin inhibits the reaction [Methotrexate results in decreased expression of HMOX1 mRNA]]

PMID:29480285 PMID:36249937

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

HORMA domain containing 1

affects expression

ISO

bisphenol A diglycidyl ether affects the expression of HORMAD1 mRNA

NCBI chr 2:185,803,572...185,841,449
Ensembl chr 2:185,805,669...185,841,249

G

HORMA domain containing 2

affects expression

ISO

bisphenol A diglycidyl ether affects the expression of HORMAD2 mRNA

NCBI chr14:83,438,555...83,524,015
Ensembl chr14:83,438,563...83,523,450

G

hydroxysteroid (17-beta) dehydrogenase 4

affects response to substance

ISO

HSD17B4 gene SNP affects the susceptibility to bisphenol A diglycidyl ether

NCBI chr18:45,515,427...45,604,467
Ensembl chr18:45,515,373...45,604,467

G

HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of HUWE1 mRNA

NCBI chr X:24,350,708...24,480,798
Ensembl chr X:24,353,217...24,480,798

G

intercellular adhesion molecule 1

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [NTN1 protein results in decreased expression of ICAM1 protein]

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

interferon gamma

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein]; bisphenol A diglycidyl ether inhibits the reaction [ciglitazone results in decreased secretion of IFNG protein]; bisphenol A diglycidyl ether results in decreased expression of and results in decreased secretion of IFNG protein

PMID:16091293 PMID:16844232

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interleukin 10

increases expression

EXP

bisphenol A diglycidyl ether results in increased expression of IL10 protein

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 1 beta

increases expression
multiple interactions

EXP
ISO

bisphenol A diglycidyl ether results in increased expression of IL1B protein
[bergenin co-treated with bisphenol A diglycidyl ether] inhibits the reaction [Sodium Azide results in increased expression of IL1B protein]; bisphenol A diglycidyl ether inhibits the reaction [eicosapentaenoic acid ethyl ester inhibits the reaction [Methotrexate results in increased expression of IL1B protein]]; bisphenol A diglycidyl ether inhibits the reaction [sinapinic acid inhibits the reaction [Cisplatin results in increased expression of IL1B protein]]
bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phloretin] results in increased expression of IL1B mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phloretin] affects the expression of IL1B mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of IL1B mRNA]; bisphenol A diglycidyl ether affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phloretin] affects the expression of IL1B mRNA]

PMID:21893696 PMID:32408695 PMID:32742113 PMID:36249784 PMID:37450014

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

increases expression
multiple interactions

EXP
ISO

bisphenol A diglycidyl ether results in increased expression of IL6 protein
bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phloretin] results in increased expression of IL6 mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phloretin] affects the expression of IL6 mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of IL6 mRNA]; bisphenol A diglycidyl ether affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phloretin] affects the expression of IL6 mRNA]; bisphenol A diglycidyl ether affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of IL6 mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Phloretin inhibits the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]]
bisphenol A diglycidyl ether inhibits the reaction [Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]
bisphenol A diglycidyl ether inhibits the reaction [NTN1 protein results in decreased expression of IL6 protein]

PMID:21893696 PMID:29162556 PMID:29480285 PMID:32408695

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

INO80 complex ATPase subunit

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of INO80 mRNA

NCBI chr 3:126,822,280...126,919,532
Ensembl chr 3:126,822,280...126,919,532

G

insulin 1

increases secretion
multiple interactions

EXP

bisphenol A diglycidyl ether results in increased secretion of INS1 protein
bisphenol A diglycidyl ether inhibits the reaction [chrysin inhibits the reaction [Fructose results in increased expression of INS1 protein]]

PMID:21190014 PMID:25169908

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

insulin-like 3

increases expression

ISO

bisphenol A diglycidyl ether results in increased expression of INSL3 protein

NCBI chr16:18,432,668...18,434,539

G

iodotyrosine deiodinase

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 1:42,410,099...42,425,414
Ensembl chr 1:42,410,130...42,426,386

G

lysine demethylase 2A

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of KDM2A mRNA

NCBI chr 1:211,041,859...211,125,749
Ensembl chr 1:211,041,885...211,084,479

G

kinase insert domain receptor

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester inhibits the reaction [VEGFA protein results in increased phosphorylation of KDR protein]]

NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192

G

kinesin family member 4A

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of KIF4 mRNA

NCBI chr X:69,761,803...69,864,335
Ensembl chr X:69,761,883...69,864,335

G

KLF transcription factor 4

affects expression

ISO

bisphenol A diglycidyl ether affects the expression of KLF4 mRNA

NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:75,074,236...75,078,592

G

KLF transcription factor 5

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [15-deoxyprostaglandin J2 inhibits the reaction [AGT protein results in increased expression of KLF5 mRNA]]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxyprostaglandin J2 inhibits the reaction [AGT protein results in increased expression of KLF5 protein]]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [AGT protein results in increased expression of KLF5 mRNA]]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [AGT protein results in increased expression of KLF5 protein]]

NCBI chr15:82,472,081...82,487,267
Ensembl chr15:82,472,065...82,487,262

G

leptin

increases expression
multiple interactions

ISO

bisphenol A diglycidyl ether results in increased expression of LEP mRNA
[bisphenol A diglycidyl ether co-treated with cobaltous chloride] affects the expression of LEP mRNA; [bisphenol A diglycidyl ether co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] affects the expression of LEP mRNA; [bisphenol A diglycidyl ether co-treated with lipopolysaccharide, E coli O55-B5] affects the expression of LEP mRNA; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phloretin] results in increased expression of LEP mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phloretin] affects the expression of LEP mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of LEP mRNA]; bisphenol A diglycidyl ether affects the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Phloretin] affects the expression of LEP mRNA]

PMID:22763116 PMID:32408695

NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661

G

LIF, interleukin 6 family cytokine

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; bisphenol A diglycidyl ether inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; bisphenol A diglycidyl ether inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]

NCBI chr14:83,354,602...83,364,053
Ensembl chr14:83,358,164...83,364,053

G

lipoprotein lipase

increases expression

ISO

bisphenol A diglycidyl ether results in increased expression of LPL mRNA

NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107

G

leucine-rich repeat kinase 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of LRRK1 mRNA

NCBI chr 1:129,254,815...129,390,217
Ensembl chr 1:129,254,515...129,389,941

G

mitogen activated protein kinase 1

multiple interactions

ISO
EXP

bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK1 protein]]
bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK1 protein]]

PMID:21769449 PMID:27274199

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions

ISO
EXP

bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK3 protein]]
bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK3 protein]]

PMID:21769449 PMID:27274199

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 8

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK8 protein]]

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

mitogen-activated protein kinase 9

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased phosphorylation of MAPK9 protein]]

NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228

G

meiosis regulator and mRNA stability factor 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of MARF1 mRNA

NCBI chr10:1,395,271...1,439,974
Ensembl chr10:1,395,282...1,439,974

G

MAU2 sister chromatid cohesion factor

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of MAU2 mRNA

NCBI chr16:19,417,812...19,448,922
Ensembl chr16:19,417,613...19,445,841

G

minichromosome maintenance domain containing 2

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of MCMDC2 mRNA

NCBI chr 5:14,071,609...14,120,435
Ensembl chr 5:14,080,968...14,120,351

G

meiosis specific with OB-fold

affects expression

ISO

bisphenol A diglycidyl ether affects the expression of MEIOB mRNA

NCBI chr10:14,336,869...14,369,566
Ensembl chr10:14,338,288...14,369,565

G

mutL homolog 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of MLH1 mRNA

NCBI chr 8:120,074,871...120,112,109
Ensembl chr 8:120,065,900...120,112,011

G

matrix metallopeptidase 2

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP2 protein]]

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 9

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MMP9 protein]]

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

MMS19 homolog, cytosolic iron-sulfur assembly component

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of MMS19 mRNA

NCBI chr 1:250,706,595...250,743,604
Ensembl chr 1:250,706,595...250,743,582

G

myeloperoxidase

multiple interactions

ISO
EXP

bisphenol A diglycidyl ether inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; bisphenol A diglycidyl ether inhibits the reaction [Telmisartan inhibits the reaction [Streptozocin results in increased activity of MPO protein]]
bisphenol A diglycidyl ether inhibits the reaction [NTN1 protein results in decreased expression of MPO protein]
[bergenin co-treated with bisphenol A diglycidyl ether] inhibits the reaction [Sodium Azide results in increased activity of MPO protein]; bisphenol A diglycidyl ether inhibits the reaction [estradiol 3-benzoate inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MPO protein]]

PMID:23060470 PMID:27363640 PMID:29162556 PMID:36249784

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

misato mitochondrial distribution and morphology regulator 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of MSTO1 mRNA

NCBI chr 2:176,603,755...176,608,037
Ensembl chr 2:176,599,671...176,608,026

G

metal-regulatory transcription factor 1

increases activity

ISO

bisphenol A diglycidyl ether results in increased activity of MTF1 protein

NCBI chr 5:142,347,024...142,391,810
Ensembl chr 5:142,347,054...142,391,810

G

nucleic acid binding protein 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of NABP1 mRNA

NCBI chr 9:57,570,326...57,625,926
Ensembl chr 9:57,618,505...57,626,052

G

non-SMC condensin II complex, subunit D3

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of NCAPD3 mRNA

NCBI chr 8:33,696,214...33,765,520
Ensembl chr 8:33,696,270...33,765,518

G

NDC1 transmembrane nucleoporin

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of NDC1 mRNA

NCBI chr 5:127,384,172...127,431,093
Ensembl chr 5:127,384,665...127,431,090

G

nei-like DNA glycosylase 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of NEIL1 mRNA

NCBI chr 8:66,446,106...66,452,844
Ensembl chr 8:66,445,953...66,452,378

G

NFE2 like bZIP transcription factor 2

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [mangiferin inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 mRNA]]

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear factor kappa B subunit 1

multiple interactions

ISO
EXP

[bisphenol A diglycidyl ether co-treated with cobaltous chloride] affects the expression of NFKB1 mRNA; [Phlorhizin co-treated with bisphenol A diglycidyl ether co-treated with cobaltous chloride] affects the expression of NFKB1 mRNA; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phloretin] results in increased expression of NFKB1 mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phloretin] affects the expression of NFKB1 mRNA]
bisphenol A diglycidyl ether inhibits the reaction [mangiferin inhibits the reaction [Methotrexate results in increased expression of NFKB1 mRNA]]

PMID:32408695 PMID:36249937

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

NFKB inhibitor alpha

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [Calcitriol inhibits the reaction [Streptozocin results in decreased expression of NFKBIA protein]]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [Tobacco Smoke Pollution results in increased degradation of NFKBIA protein]]

PMID:24612634 PMID:29953732

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

nonhomologous end-joining factor 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of NHEJ1 mRNA

NCBI chr 9:83,974,995...84,071,161
Ensembl chr 9:83,974,997...84,070,594

G

NIPBL, cohesin loading factor

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of NIPBL mRNA

NCBI chr 2:59,126,676...59,314,841
Ensembl chr 2:59,126,676...59,293,277

G

nitric oxide synthase 2

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [caryophyllene inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of NOS2 protein]]; bisphenol A diglycidyl ether inhibits the reaction [mangiferin inhibits the reaction [Methotrexate results in increased expression of NOS2 mRNA]]

PMID:30343038 PMID:36249937

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

nitric oxide synthase 3

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [caryophyllene inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of NOS3 protein]]

NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664

G

neuronal PAS domain protein 2

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of NPAS2 mRNA

NCBI chr 9:48,959,225...49,138,036
Ensembl chr 9:48,959,148...49,138,037

G

nucleophosmin 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of NPM1 mRNA

NCBI chr10:18,245,739...18,255,913
Ensembl chr10:18,245,740...18,256,024
Ensembl chr X:18,245,740...18,256,024

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

ISO

bisphenol A diglycidyl ether binds to and results in increased activity of NR1I2 protein

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions

ISO

bisphenol A diglycidyl ether binds to and results in decreased activity of NR1I3 protein alternative form

NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

ISO

bisphenol A diglycidyl ether promotes the reaction [Dexamethasone binds to NR3C1 protein]

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 4, group A, member 1

increases expression
multiple interactions

ISO

bisphenol A diglycidyl ether results in increased expression of NR4A1 mRNA; bisphenol A diglycidyl ether results in increased expression of NR4A1 protein
NR4A1 protein promotes the reaction [bisphenol A diglycidyl ether affects the abundance of Progesterone]

NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041

G

neuropilin 1

multiple interactions

ISO

[bisphenol A diglycidyl ether co-treated with Cytarabine] results in decreased expression of NRP1 mRNA

NCBI chr19:73,256,557...73,411,705
Ensembl chr19:73,256,557...73,411,702

G

NOP2/Sun RNA methyltransferase 2

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of NSUN2 mRNA

NCBI chr 1:35,490,583...35,514,839
Ensembl chr 1:35,490,583...35,514,306

G

netrin 1

decreases response to substance
multiple interactions

ISO

bisphenol A diglycidyl ether results in decreased susceptibility to NTN1 protein
bisphenol A diglycidyl ether inhibits the reaction [NTN1 protein results in decreased expression of ICAM1 protein]; bisphenol A diglycidyl ether inhibits the reaction [NTN1 protein results in decreased expression of IL6 protein]; bisphenol A diglycidyl ether inhibits the reaction [NTN1 protein results in decreased expression of MPO protein]; bisphenol A diglycidyl ether inhibits the reaction [NTN1 protein results in decreased expression of RELA protein]; bisphenol A diglycidyl ether inhibits the reaction [NTN1 protein results in decreased expression of TNF protein]

NCBI chr10:53,398,852...53,597,595
Ensembl chr10:53,398,852...53,584,060

G

O-GlcNAcase

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [mangiferin inhibits the reaction [Methotrexate results in increased expression of OGA protein]]

NCBI chr 1:254,547,311...254,589,596
Ensembl chr 1:254,547,311...254,582,855

G

OTU deubiquitinase, ubiquitin aldehyde binding 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of OTUB1 mRNA

NCBI chr 1:213,816,400...213,824,679
Ensembl chr 1:213,816,400...213,824,679

G

poly (ADP-ribose) polymerase family, member 9

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of PARP9 mRNA

NCBI chr11:78,286,282...78,320,409
Ensembl chr11:78,286,287...78,320,608

G

phosphoenolpyruvate carboxykinase 1

decreases expression

EXP

bisphenol A diglycidyl ether results in decreased expression of PCK1 mRNA

NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561

G

progesterone immunomodulatory binding factor 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of PIBF1 mRNA

NCBI chr15:82,258,243...82,427,546
Ensembl chr15:82,258,468...82,427,548

G

PIF1 5'-to-3' DNA helicase

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of PIF1 mRNA

NCBI chr 8:75,005,820...75,015,331
Ensembl chr 8:75,006,815...75,015,331

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester inhibits the reaction [VEGFA protein results in increased phosphorylation of PIK3R1 protein]]; bisphenol A diglycidyl ether inhibits the reaction [Vincristine results in decreased phosphorylation of PIK3R1 protein]

PMID:21769449 PMID:36181250

NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347

G

paired-like homeodomain 2

affects expression

ISO

bisphenol A diglycidyl ether affects the expression of PITX2 mRNA

NCBI chr 2:220,391,417...220,411,588
Ensembl chr 2:220,391,888...220,411,591

G

phospholipase C beta 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of PLCB1 mRNA

NCBI chr 3:142,512,765...143,224,042
Ensembl chr 3:142,513,033...143,225,646

G

PMS1 homolog 2, mismatch repair system component

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of PMS2 mRNA

NCBI chr12:15,790,478...15,814,790
Ensembl chr12:15,790,478...15,815,248

G

patatin-like phospholipase domain containing 2

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone results in increased expression of PNPLA2 mRNA]

NCBI chr 1:205,982,279...205,987,361
Ensembl chr 1:205,982,258...205,987,359

G

pogo transposable element derived with ZNF domain

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of POGZ mRNA

NCBI chr 2:185,069,492...185,129,741
Ensembl chr 2:185,084,826...185,129,739

G

DNA polymerase delta 2, accessory subunit

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of POLD2 mRNA

NCBI chr14:84,962,933...84,969,148
Ensembl chr14:84,962,022...84,967,874

G

DNA polymerase iota

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of POLI mRNA

NCBI chr18:66,389,214...66,409,734
Ensembl chr18:66,364,236...66,409,819

G

peroxisome proliferator activated receptor alpha

affects binding

ISO

bisphenol A diglycidyl ether binds to PPARA protein modified form

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

peroxisome proliferator-activated receptor gamma

multiple interactions
decreases activity
decreases expression
increases expression

ISO
EXP

bisphenol A diglycidyl ether binds to and results in decreased activity of PPARG protein; bisphenol A diglycidyl ether binds to and results in increased localization of and results in increased activity of PPARG protein; bisphenol A diglycidyl ether inhibits the reaction [[cis-9, trans-11-conjugated linoleic acid co-treated with trans-10,cis-12-conjugated linoleic acid] results in increased expression of PPARG protein]; bisphenol A diglycidyl ether inhibits the reaction [Capsaicin results in increased activity of PPARG protein]; bisphenol A diglycidyl ether inhibits the reaction [Docosahexaenoic Acids results in increased activity of PPARG protein]; bisphenol A diglycidyl ether inhibits the reaction [Eicosapentaenoic Acid results in increased activity of PPARG protein]; bisphenol A diglycidyl ether inhibits the reaction [Indomethacin results in increased activity of PPARG protein]; bisphenol A diglycidyl ether inhibits the reaction [PPARG protein promotes the reaction [mono-(2-ethylhexyl)phthalate results in increased activity of CASP3 protein]]; bisphenol A diglycidyl ether inhibits the reaction [PPARG protein results in increased susceptibility to Troglitazone]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone results in increased activity of PPARG protein]
bisphenol A diglycidyl ether results in decreased activity of PPARG protein
bisphenol A diglycidyl ether results in decreased expression of PPARG mRNA; bisphenol A diglycidyl ether results in decreased expression of PPARG protein
bisphenol A diglycidyl ether binds to and results in decreased activity of PPARG protein; bisphenol A diglycidyl ether inhibits the reaction [Calcitriol inhibits the reaction [Streptozocin results in decreased expression of PPARG mRNA]]; bisphenol A diglycidyl ether inhibits the reaction [Calcitriol inhibits the reaction [Streptozocin results in decreased expression of PPARG protein]]; bisphenol A diglycidyl ether inhibits the reaction [Cisplatin results in decreased expression of PPARG mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Curcumin inhibits the reaction [Lipopolysaccharides results in decreased activity of PPARG protein]]; bisphenol A diglycidyl ether inhibits the reaction [Genistein results in increased activity of PPARG protein]; bisphenol A diglycidyl ether inhibits the reaction [mangiferin inhibits the reaction [Methotrexate results in decreased expression of PPARG mRNA]]; bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in increased expression of PPARG mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in increased expression of PPARG protein]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of PPARG mRNA]]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of PPARG protein]]; bisphenol A diglycidyl ether inhibits the reaction [TRIB3 protein affects the expression of PPARG protein]; bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of PPARG protein]]; Methylprednisolone inhibits the reaction [bisphenol A diglycidyl ether results in decreased expression of PPARG mRNA]; Methylprednisolone inhibits the reaction [bisphenol A diglycidyl ether results in decreased expression of PPARG protein]
bisphenol A diglycidyl ether results in increased expression of PPARG mRNA
bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phloretin] affects the expression of PPARG mRNA]; bisphenol A diglycidyl ether binds to and results in decreased activity of PPARG protein; bisphenol A diglycidyl ether binds to and results in increased activity of PPARG protein; bisphenol A diglycidyl ether inhibits the reaction [butylparaben results in increased expression of PPARG mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Cytarabine results in increased expression of PPARG mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Dexamethasone results in increased expression of PPARG mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Dexamethasone results in increased expression of PPARG protein]; bisphenol A diglycidyl ether inhibits the reaction [Eugenol analog binds to and results in increased activity of PPARG protein]; bisphenol A diglycidyl ether inhibits the reaction [magnolol binds to and results in increased activity of PPARG protein]

PMID:11030710 PMID:11991651 PMID:12485869 PMID:12824901 PMID:12927354 More...

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

protein kinase, DNA-activated, catalytic subunit

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of PRKDC mRNA

NCBI chr11:98,544,952...98,762,499
Ensembl chr11:98,544,954...98,762,108

G

proline dehydrogenase 1

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester results in increased expression of PRODH mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone results in increased expression of PRODH mRNA]

NCBI chr11:96,414,275...96,431,604
Ensembl chr11:96,414,224...96,433,418

G

PSMC3 interacting protein

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of PSMC3IP mRNA

NCBI chr10:86,524,546...86,527,764
Ensembl chr10:86,524,571...86,527,666

G

proline and serine rich coiled-coil 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of PSRC1 mRNA

NCBI chr 2:198,710,427...198,715,001
Ensembl chr 2:198,705,839...198,714,997

G

phosphatase and tensin homolog

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester inhibits the reaction [VEGFA protein results in increased expression of PTEN protein]]; bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester results in increased expression of PTEN protein]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone results in increased expression of PTEN protein]

PMID:16806087 PMID:21769449

NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [VEGFA protein results in increased expression of PTGS2 protein]]

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

PTTG1 regulator of sister chromatid separation, securin

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of PTTG1 mRNA

NCBI chr10:28,394,940...28,406,410
Ensembl chr10:28,394,814...28,406,309

G

pumilio RNA-binding family member 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of PUM1 mRNA

NCBI chr 5:148,120,712...148,238,468
Ensembl chr 5:148,121,254...148,238,466

G

RAD51 recombinase

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of RAD51 mRNA

NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469

G

RAD52 homolog, DNA repair protein

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of RAD52 mRNA

NCBI chr 4:154,778,320...154,802,002
Ensembl chr 4:154,778,320...154,800,021

G

recombination activating 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of RAG1 mRNA

NCBI chr 3:108,372,087...108,383,184
Ensembl chr 3:108,371,978...108,383,261

G

retinoic acid receptor, beta

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]

NCBI chr15:10,837,252...11,482,037
Ensembl chr15:11,131,358...11,482,040

G

RB binding protein 8, endonuclease

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of RBBP8 mRNA

NCBI chr18:3,198,188...3,263,643
Ensembl chr18:3,197,310...3,263,985

G

RNA binding motif protein 17

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of RBM17 mRNA

NCBI chr17:71,846,941...71,863,834
Ensembl chr17:71,846,916...71,864,431

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO
EXP

bisphenol A diglycidyl ether inhibits the reaction [Docosahexaenoic Acids inhibits the reaction [Lipopolysaccharides results in increased activity of RELA protein]]; bisphenol A diglycidyl ether inhibits the reaction [Eicosapentaenoic Acid inhibits the reaction [Lipopolysaccharides results in increased activity of RELA protein]]; bisphenol A diglycidyl ether inhibits the reaction [NTN1 protein results in decreased expression of RELA protein]
bisphenol A diglycidyl ether inhibits the reaction [Phloretin inhibits the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of RELA protein]]
bisphenol A diglycidyl ether inhibits the reaction [15-deoxyprostaglandin J2 inhibits the reaction [Tobacco Smoke Pollution results in increased expression of RELA protein]]; bisphenol A diglycidyl ether inhibits the reaction [Calcitriol inhibits the reaction [Streptozocin results in increased expression of and results in decreased phosphorylation of RELA protein]]; bisphenol A diglycidyl ether inhibits the reaction [mangiferin inhibits the reaction [Methotrexate results in increased expression of and results in increased phosphorylation of RELA protein]]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [Tobacco Smoke Pollution results in increased expression of RELA protein]]

PMID:15698426 PMID:24612634 PMID:29162556 PMID:29953732 PMID:32408695 More...

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

REV1, DNA directed polymerase

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of REV1 mRNA

NCBI chr 9:47,773,907...47,847,554
Ensembl chr 9:47,773,907...47,847,332

G

replication timing regulatory factor 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of RIF1 mRNA

NCBI chr 3:56,963,840...57,017,106
Ensembl chr 3:56,963,854...57,017,106

G

regulator of telomere elongation helicase 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of RTEL1 mRNA

NCBI chr 3:188,778,329...188,842,877
Ensembl chr 3:188,807,951...188,843,709

G

RUNX family transcription factor 2

multiple interactions
increases expression

ISO
EXP

bisphenol A diglycidyl ether inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein]
bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in decreased expression of RUNX2 mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in decreased expression of RUNX2 protein]; Methylprednisolone inhibits the reaction [bisphenol A diglycidyl ether results in increased expression of RUNX2 protein]
bisphenol A diglycidyl ether results in increased expression of RUNX2 mRNA; bisphenol A diglycidyl ether results in increased expression of RUNX2 protein

PMID:31709877 PMID:37659742

NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027

G

serpin family E member 1

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]

NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357

G

SET domain bifurcated histone lysine methyltransferase 2

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of SETDB2 mRNA

NCBI chr15:37,731,029...37,782,790
Ensembl chr15:37,664,556...37,780,138

G

senataxin

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of SETX mRNA

NCBI chr 3:32,825,771...32,878,740
Ensembl chr 3:32,828,412...32,878,740

G

SNF2 histone linker PHD RING helicase

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of SHPRH mRNA

NCBI chr 1:7,349,073...7,422,804
Ensembl chr 1:7,320,395...7,422,794

G

structural maintenance of chromosomes 1B

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of SMC1B mRNA

NCBI chr 7:118,060,898...118,122,683
Ensembl chr 7:118,060,156...118,122,648

G

structural maintenance of chromosomes 4

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of SMC4 mRNA

NCBI chr 2:155,550,262...155,578,695
Ensembl chr 2:155,550,262...155,581,937

G

SRY-box transcription factor 2

affects expression

ISO

bisphenol A diglycidyl ether affects the expression of SOX2 mRNA

NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350

G

sperm associated antigen 5

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of SPAG5 mRNA

NCBI chr10:63,693,300...63,714,813
Ensembl chr10:63,696,466...63,714,811

G

SprT-like N-terminal domain

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of SPRTN mRNA

NCBI chr19:69,754,989...69,762,240
Ensembl chr19:69,754,980...69,762,237

G

sterol regulatory element binding transcription factor 1

decreases expression

EXP

bisphenol A diglycidyl ether results in decreased expression of SREBF1 protein

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

SRSF protein kinase 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of SRPK1 mRNA

NCBI chr20:6,647,539...6,684,129
Ensembl chr20:6,649,450...6,683,835

G

steroidogenic acute regulatory protein

increases expression

ISO

bisphenol A diglycidyl ether results in increased expression of STAR mRNA

NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447

G

signal transducer and activator of transcription 3

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; bisphenol A diglycidyl ether inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; bisphenol A diglycidyl ether inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; bisphenol A diglycidyl ether inhibits the reaction [ciglitazone inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

stimulated by retinoic acid 8

affects expression

ISO

bisphenol A diglycidyl ether affects the expression of STRA8 mRNA

NCBI chr 4:64,568,580...64,591,914
Ensembl chr 4:64,568,706...64,591,911

G

Sad1 and UNC84 domain containing 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of SUN1 mRNA

NCBI chr12:20,510,230...20,555,123
Ensembl chr12:20,490,861...20,555,240

G

SPT16 homolog, facilitates chromatin remodeling subunit

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of SUPT16 mRNA

NCBI chr15:27,341,196...27,378,314
Ensembl chr15:27,341,196...27,378,314

G

synaptonemal complex protein 1

affects expression

ISO

bisphenol A diglycidyl ether affects the expression of SYCP1 mRNA

NCBI chr 2:192,985,164...193,145,234
Ensembl chr 2:192,984,621...193,145,421

G

synaptonemal complex protein 2

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of SYCP2 mRNA

NCBI chr 3:185,814,033...185,876,516
Ensembl chr 3:185,814,035...185,876,492

G

TAO kinase 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of TAOK1 mRNA

NCBI chr10:62,871,198...62,989,049
Ensembl chr10:62,871,198...62,957,595

G

TAO kinase 3

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of TAOK3 mRNA

NCBI chr12:44,973,180...45,134,439
Ensembl chr12:44,973,180...45,134,439

G

tudor domain containing 9

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of TDRD9 mRNA

NCBI chr 6:136,850,797...136,966,225
Ensembl chr 6:136,850,812...136,966,225

G

tet methylcytosine dioxygenase 1

affects expression

ISO

bisphenol A diglycidyl ether affects the expression of TET1 mRNA

NCBI chr20:25,766,806...25,839,598
Ensembl chr20:25,760,057...25,832,730

G

transcription factor AP-2 alpha

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [Cytarabine results in increased expression of TFAP2A mRNA]

NCBI chr17:24,230,064...24,253,219
Ensembl chr17:24,229,910...24,253,219

G

transforming growth factor, beta 1

multiple interactions

ISO
EXP

bisphenol A diglycidyl ether inhibits the reaction [[Alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]
bisphenol A diglycidyl ether inhibits the reaction [Calcitriol inhibits the reaction [Streptozocin results in increased expression of TGFB1 mRNA]]; bisphenol A diglycidyl ether inhibits the reaction [Calcitriol inhibits the reaction [Streptozocin results in increased expression of TGFB1 protein]]; bisphenol A diglycidyl ether inhibits the reaction [Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of TGFB1 protein]]

PMID:16611854 PMID:29480285 PMID:29953732

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

THO complex subunit 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of THOC1 mRNA

NCBI chr18:1,253,041...1,291,956
Ensembl chr18:1,256,637...1,292,630

G

TOPBP1-interacting checkpoint and replication regulator

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of TICRR mRNA

NCBI chr 1:143,006,989...143,048,836
Ensembl chr 1:143,006,924...143,049,133

G

TIMP metallopeptidase inhibitor 1

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [Ursolic Acid inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of TIMP1 protein]]

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

toll-like receptor 2

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TLR2 protein]]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone promotes the reaction [Tobacco Smoke Pollution results in increased expression of TLR2 mRNA]]

NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:171,497,060...171,520,194

G

toll-like receptor 4

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TLR4 mRNA]]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TLR4 protein]]

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007

G

tumor necrosis factor

multiple interactions

ISO
EXP

bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phloretin] results in increased expression of TNF mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
bisphenol A diglycidyl ether inhibits the reaction [NTN1 protein results in decreased expression of TNF protein]
[bergenin co-treated with bisphenol A diglycidyl ether] inhibits the reaction [Sodium Azide results in increased expression of TNF protein]; [bisphenol A diglycidyl ether co-treated with Dextran Sulfate co-treated with Rosiglitazone] results in increased expression of TNF protein; [bisphenol A diglycidyl ether co-treated with Dextran Sulfate] results in increased expression of TNF protein; bisphenol A diglycidyl ether inhibits the reaction [caryophyllene inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of TNF protein]]; bisphenol A diglycidyl ether inhibits the reaction [Cisplatin results in increased expression of TNF mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; bisphenol A diglycidyl ether inhibits the reaction [eicosapentaenoic acid ethyl ester inhibits the reaction [Methotrexate results in increased expression of TNF protein]]; bisphenol A diglycidyl ether inhibits the reaction [Pioglitazone inhibits the reaction [Quinolinic Acid results in increased expression of TNF protein]]; bisphenol A diglycidyl ether inhibits the reaction [sinapinic acid inhibits the reaction [Cisplatin results in increased expression of TNF protein]]

PMID:11991651 PMID:20450929 PMID:21893696 PMID:22989705 PMID:29162556 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

DNA topoisomerase II beta

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of TOP2B mRNA

NCBI chr15:11,482,089...11,542,464
Ensembl chr15:11,482,089...11,542,464

G

DNA topoisomerase III beta

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of TOP3B mRNA

NCBI chr11:97,601,223...97,629,678
Ensembl chr11:97,601,231...97,629,597

G

TOP6B like initiator of meiotic double strand breaks

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of TOP6BL mRNA

NCBI chr 1:211,331,973...211,419,015
Ensembl chr 1:211,331,827...211,419,015

G

testis and ovary specific TOPAZ 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of TOPAZ1 mRNA

NCBI chr 8:131,235,714...131,290,359
Ensembl chr 8:131,236,522...131,290,342

G

translocated promoter region, nuclear basket protein

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of TPR mRNA

NCBI chr13:64,974,419...65,037,604
Ensembl chr13:64,974,419...65,037,602

G

tribbles pseudokinase 3

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [TRIB3 protein affects the expression of ACOX1 protein]; bisphenol A diglycidyl ether inhibits the reaction [TRIB3 protein affects the expression of CD36 protein]; bisphenol A diglycidyl ether inhibits the reaction [TRIB3 protein affects the expression of CEBPA protein]; bisphenol A diglycidyl ether inhibits the reaction [TRIB3 protein affects the expression of PPARG protein]

NCBI chr 3:161,269,939...161,275,533
Ensembl chr 3:161,269,955...161,274,802

G

ubiquitin-conjugating enzyme E2T

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of UBE2T mRNA

NCBI chr13:48,955,166...48,965,668
Ensembl chr13:48,955,183...48,966,646

G

ubiquitin protein ligase E3 component n-recognin 2

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of UBR2 mRNA

NCBI chr 9:21,480,058...21,559,936
Ensembl chr 9:21,480,037...21,559,936

G

ubiquitin C-terminal hydrolase L5

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of UCHL5 mRNA

NCBI chr13:58,070,947...58,106,825
Ensembl chr13:58,042,029...58,107,441

G

ubiquitin interaction motif containing 1

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of UIMC1 mRNA

NCBI chr17:9,528,923...9,597,967
Ensembl chr17:9,528,950...9,597,963

G

UPF1, RNA helicase and ATPase

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of UPF1 mRNA

NCBI chr16:19,110,531...19,131,327
Ensembl chr16:19,110,538...19,131,327

G

ubiquitin specific peptidase 28

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of USP28 mRNA

NCBI chr 8:58,222,258...58,282,711
Ensembl chr 8:58,222,220...58,282,750

G

ubiquitin specific peptidase 3

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of USP3 mRNA

NCBI chr 8:75,973,278...76,049,151
Ensembl chr 8:75,974,615...76,049,153

G

ubiquitin specific peptidase 47

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of USP47 mRNA

NCBI chr 1:175,586,758...175,669,904
Ensembl chr 1:175,586,723...175,669,904

G

ubiquitin specific peptidase 9, X-linked

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of USP9X mRNA

NCBI chr X:12,261,633...12,399,780
Ensembl chr X:12,261,633...12,369,491

G

vascular cell adhesion molecule 1

multiple interactions

EXP

bisphenol A diglycidyl ether inhibits the reaction [caryophyllene inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of VCAM1 protein]]

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

vascular endothelial growth factor A

multiple interactions

ISO

bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester inhibits the reaction [VEGFA protein results in decreased expression of BAX protein]]; bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester inhibits the reaction [VEGFA protein results in increased expression of BCL2 protein]]; bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester inhibits the reaction [VEGFA protein results in increased expression of PTEN protein]]; bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester inhibits the reaction [VEGFA protein results in increased phosphorylation of KDR protein]]; bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK1 protein]]; bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK3 protein]]; bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester inhibits the reaction [VEGFA protein results in increased phosphorylation of PIK3R1 protein]]; bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester results in decreased susceptibility to VEGFA protein]; bisphenol A diglycidyl ether inhibits the reaction [Rosiglitazone inhibits the reaction [VEGFA protein results in increased expression of PTGS2 protein]]
bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phloretin] results in increased expression of VEGFA mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5 co-treated with Phlorhizin] results in increased expression of VEGFA mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phloretin] affects the expression of VEGFA mRNA]; bisphenol A diglycidyl ether affects the reaction [[cobaltous chloride co-treated with Phlorhizin] affects the expression of VEGFA mRNA]; bisphenol A diglycidyl ether inhibits the reaction [1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester results in decreased susceptibility to VEGFA protein]; bisphenol A diglycidyl ether inhibits the reaction [Phloretin promotes the reaction [[cobaltous chloride co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of VEGFA protein]]

PMID:20032081 PMID:21769449 PMID:32408695

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

WRN RecQ like helicase

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of WRN mRNA

NCBI chr16:65,466,552...65,602,951
Ensembl chr16:65,456,254...65,602,951

G

XPC complex subunit, DNA damage recognition and repair factor

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of XPC mRNA

NCBI chr 4:125,550,833...125,578,084
Ensembl chr 4:125,550,833...125,578,305

G

zw10 kinetochore protein

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of ZW10 mRNA

NCBI chr 8:58,292,959...58,317,881
Ensembl chr 8:58,293,018...58,318,279

G

ZW10 interacting kinetochore protein

affects splicing

ISO

bisphenol A diglycidyl ether affects the splicing of ZWINT mRNA

NCBI chr20:15,502,559...15,953,701
Ensembl chr20:15,937,396...15,953,203

Bisphenol A glycidylmethacrylate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

increases activity
multiple interactions

ISO

Bisphenol A-Glycidyl Methacrylate results in increased activity of CASP3 protein
wogonin inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in increased activity of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

increases activity
multiple interactions

ISO

Bisphenol A-Glycidyl Methacrylate results in increased activity of CASP8 protein
wogonin inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in increased activity of CASP8 protein]

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

catalase

multiple interactions

ISO

CAT protein inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in decreased expression of CCNB1 mRNA]; CAT protein inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in decreased expression of CDC25C mRNA]; CAT protein inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in decreased expression of CDK1 mRNA]; CAT protein inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in increased expression of CES1 mRNA]; CAT protein inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in increased expression of CES2 mRNA]; CAT protein inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in increased expression of CES3 mRNA]; CAT protein inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in increased expression of HMOX1 mRNA]

PMID:20673999 PMID:21951919

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

cyclin B1

decreases expression
multiple interactions

ISO

Bisphenol A-Glycidyl Methacrylate results in decreased expression of CCNB1 mRNA; Bisphenol A-Glycidyl Methacrylate results in decreased expression of CCNB1 protein
CAT protein inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in decreased expression of CCNB1 mRNA]

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cell division cycle 25C

decreases expression
multiple interactions

ISO

Bisphenol A-Glycidyl Methacrylate results in decreased expression of CDC25C mRNA; Bisphenol A-Glycidyl Methacrylate results in decreased expression of CDC25C protein
CAT protein inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in decreased expression of CDC25C mRNA]

NCBI chr18:26,608,483...26,630,292
Ensembl chr18:26,609,959...26,630,292

G

cyclin-dependent kinase 1

decreases expression
multiple interactions

ISO

Bisphenol A-Glycidyl Methacrylate results in decreased expression of CDK1 mRNA; Bisphenol A-Glycidyl Methacrylate results in decreased expression of CDK1 protein
CAT protein inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in decreased expression of CDK1 mRNA]

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

carboxylesterase 1D

multiple interactions
increases expression

ISO

CAT protein inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in increased expression of CES1 mRNA]

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449

G

carboxylesterase 2H

increases expression
multiple interactions

ISO

Bisphenol A-Glycidyl Methacrylate results in increased expression of CES2 mRNA
[Loperamide results in decreased activity of CES2 protein] which results in increased susceptibility to Bisphenol A-Glycidyl Methacrylate; CAT protein inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in increased expression of CES2 mRNA]

NCBI chr19:49,884,164...49,898,764
Ensembl chr19:49,884,164...49,898,752

G

carboxylesterase 3a

increases expression
multiple interactions

ISO

Bisphenol A-Glycidyl Methacrylate results in increased expression of CES3 mRNA
CAT protein inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in increased expression of CES3 mRNA]

NCBI chr19:49,902,312...49,910,484

G

estrogen receptor 1

increases activity
multiple interactions

ISO

Bisphenol A-Glycidyl Methacrylate results in increased activity of ESR1 protein
[Bisphenol A-Glycidyl Methacrylate co-treated with 4,4'-isopropylidenediphenol dimethacrylate co-treated with triethylene glycol dimethacrylate] results in increased activity of ESR1 protein; Bisphenol A-Glycidyl Methacrylate promotes the reaction [ESR1 protein binds to ESR1 protein]

PMID:11145352 PMID:37696476

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

glutamate cysteine ligase, modifier subunit

increases expression

ISO

Bisphenol A-Glycidyl Methacrylate results in increased expression of GCLM mRNA

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

heme oxygenase 1

increases expression
multiple interactions

ISO

Bisphenol A-Glycidyl Methacrylate results in increased expression of HMOX1 mRNA
CAT protein inhibits the reaction [Bisphenol A-Glycidyl Methacrylate results in increased expression of HMOX1 mRNA]

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

[4,4'-isopropylidenediphenol dimethacrylate co-treated with triethylene glycol dimethacrylate co-treated with Bisphenol A-Glycidyl Methacrylate co-treated with Benzoyl Peroxide] results in increased expression of PTGS2 mRNA; [4,4'-isopropylidenediphenol dimethacrylate co-treated with triethylene glycol dimethacrylate co-treated with Bisphenol A-Glycidyl Methacrylate co-treated with Benzoyl Peroxide] results in increased expression of PTGS2 protein

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

tumor necrosis factor

multiple interactions

EXP

[Bisphenol A-Glycidyl Methacrylate co-treated with triethylene glycol dimethacrylate] results in increased expression of TNF mRNA

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

RIKEN cDNA 1700001K19 gene like

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of 1700001K19RIKL mRNA

NCBI chr 6:135,502,831...135,523,451
Ensembl chr 6:135,502,832...135,514,813

G

alpha-2-macroglobulin-like 1

decreases expression

ISO

bisphenol F results in decreased expression of A2ML1 mRNA

NCBI chr 4:163,501,210...163,543,419
Ensembl chr 4:163,501,585...163,543,506

G

aladin WD repeat nucleoporin

decreases expression

ISO

bisphenol F results in decreased expression of AAAS mRNA

NCBI chr 7:135,342,901...135,362,545
Ensembl chr 7:135,342,901...135,362,545

G

acetoacetyl-CoA synthetase

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of AACS gene
bisphenol F results in increased expression of AACS protein

PMID:31601247 PMID:34186270

NCBI chr12:36,774,471...36,817,835
Ensembl chr12:36,774,471...36,822,543

G

AADACL4 family member 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AADACL4FM2 mRNA

NCBI chr 5:161,707,170...161,718,664
Ensembl chr 5:161,709,985...161,718,598

G

aminoadipate aminotransferase

affects expression
increases expression

ISO

bisphenol F affects the expression of AADAT protein
bisphenol F results in increased expression of AADAT mRNA

NCBI chr16:34,520,236...34,566,388
Ensembl chr16:34,520,238...34,566,540

G

adipogenesis associated, Mth938 domain containing

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AAMDC mRNA

NCBI chr 1:161,273,205...161,303,253
Ensembl chr 1:161,262,347...161,299,340

G

AAR2 splicing factor

increases expression

ISO

bisphenol F results in increased expression of AAR2 mRNA

NCBI chr 3:165,517,467...165,540,260
Ensembl chr 3:165,517,556...165,548,519

G

alanine and arginine rich domain containing protein

increases expression

ISO

bisphenol F results in increased expression of AARD mRNA

NCBI chr 7:85,254,322...85,259,163
Ensembl chr 7:85,253,992...85,259,163

G

alanyl-tRNA synthetase 1

increases expression

ISO

bisphenol F results in increased expression of AARS1 protein

NCBI chr19:55,906,694...55,930,499
Ensembl chr19:55,906,702...55,930,497

G

alanyl-tRNA synthetase domain containing 1

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AARSD1 mRNA
bisphenol F results in decreased expression of AARSD1 mRNA

PMID:36041667 PMID:38685157

NCBI chr10:86,840,874...86,854,077
Ensembl chr10:86,840,874...86,849,734

G

aminoadipate-semialdehyde dehydrogenase

decreases expression

ISO

bisphenol F results in decreased expression of AASDH mRNA

NCBI chr14:31,609,488...31,636,066
Ensembl chr14:31,609,528...31,636,500

G

apoptosis-associated tyrosine kinase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AATK mRNA

NCBI chr10:105,789,171...105,825,634
Ensembl chr10:105,785,469...105,825,618

G

4-aminobutyrate aminotransferase

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ABAT gene
bisphenol F results in increased expression of ABAT mRNA
bisphenol F results in increased expression of ABAT protein

PMID:31601247 PMID:34186270 PMID:38685157

NCBI chr10:7,503,351...7,599,474
Ensembl chr10:7,492,022...7,599,474

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of ABCA1 mRNA
bisphenol F results in increased expression of ABCA1 mRNA

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473

G

ATP binding cassette subfamily A member 4

multiple interactions
decreases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of ABCA4 gene
bisphenol F results in decreased expression of ABCA4 mRNA

PMID:31601247 PMID:36706583

NCBI chr 2:212,849,470...212,986,730
Ensembl chr 2:212,755,803...212,986,729

G

ATP binding cassette subfamily A member 6

increases expression

ISO

bisphenol F results in increased expression of ABCA6 protein
bisphenol F results in increased expression of ABCA6 mRNA

PMID:34186270 PMID:38685157

NCBI chr10:95,642,026...95,711,535
Ensembl chr10:95,641,900...95,710,899

G

ATP binding cassette subfamily A member 7

decreases expression

ISO

bisphenol F results in decreased expression of ABCA7 mRNA

NCBI chr 7:10,342,092...10,362,094
Ensembl chr 7:10,342,092...10,361,989

G

ATP binding cassette subfamily A member 9

increases expression

ISO

bisphenol F results in increased expression of ABCA9 mRNA

NCBI chr10:95,577,079...95,638,706
Ensembl chr10:95,578,350...95,636,405

G

ATP-binding cassette, sub-family B member 1B

multiple interactions

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of ABCB1B mRNA

NCBI chr 4:26,197,706...26,280,156
Ensembl chr 4:26,106,903...26,279,567

G

ATP binding cassette subfamily B member 4

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ABCB4 gene

NCBI chr 4:26,106,895...26,164,440

G

ATP binding cassette subfamily B member 8

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ABCB8 mRNA

NCBI chr 4:11,660,716...11,676,030
Ensembl chr 4:11,660,716...11,676,002

G

ATP binding cassette subfamily B member 9

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ABCB9 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ABCB9 mRNA

PMID:28628672 PMID:36041667

NCBI chr12:38,146,659...38,192,862
Ensembl chr12:38,159,904...38,192,860

G

ATP binding cassette subfamily C member 10

decreases expression

ISO

bisphenol F results in decreased expression of ABCC10 mRNA

NCBI chr 9:22,154,811...22,174,743
Ensembl chr 9:22,154,804...22,174,743

G

ATP binding cassette subfamily C member 2

affects expression

ISO

bisphenol F affects the expression of ABCC2 mRNA

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily C member 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ABCC3 mRNA

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

ATP binding cassette subfamily C member 5

decreases expression

ISO

bisphenol F results in decreased expression of ABCC5 mRNA

NCBI chr11:93,975,579...94,071,659
Ensembl chr11:93,978,274...94,071,655

G

ATP binding cassette subfamily D member 1

increases expression

ISO

bisphenol F results in increased expression of ABCD1 protein

NCBI chr X:156,579,669...156,601,448
Ensembl chr X:156,579,785...156,601,446

G

ATP binding cassette subfamily D member 2

decreases expression
increases expression

ISO

bisphenol F results in decreased expression of ABCD2 mRNA
bisphenol F results in increased expression of ABCD2 mRNA

PMID:30951980 PMID:38685157

NCBI chr 7:124,142,597...124,191,202
Ensembl chr 7:124,142,595...124,191,202

G

ATP binding cassette subfamily D member 3

increases expression

ISO

bisphenol F results in increased expression of ABCD3 mRNA

NCBI chr 2:212,536,791...212,590,379
Ensembl chr 2:212,536,791...212,590,504

G

ATP binding cassette subfamily E member 1

increases methylation
increases expression

ISO

bisphenol F results in increased methylation of ABCE1 gene
bisphenol F results in increased expression of ABCE1 protein

PMID:31601247 PMID:34186270

NCBI chr19:45,109,880...45,134,819
Ensembl chr19:45,109,906...45,134,819

G

ATP binding cassette subfamily F member 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ABCF1 mRNA
bisphenol F results in increased expression of ABCF1 protein

PMID:28628672 PMID:34186270

NCBI chr20:2,807,315...2,820,240
Ensembl chr20:2,807,106...2,820,240

G

ATP binding cassette subfamily F member 2

increases expression

ISO

bisphenol F results in increased expression of ABCF2 protein

NCBI chr 4:11,485,865...11,500,067
Ensembl chr 4:11,487,395...11,500,053

G

ATP binding cassette subfamily G member 1

increases expression

ISO

bisphenol F results in increased expression of ABCG1 mRNA

NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,127,803...9,186,563

G

ATP binding cassette subfamily G member 5

decreases expression

ISO

bisphenol F results in decreased expression of ABCG5 mRNA

NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:15,717,936...15,743,376

G

abhydrolase domain containing 1

decreases expression

ISO

bisphenol F results in decreased expression of ABHD1 mRNA

NCBI chr 6:31,142,476...31,147,464
Ensembl chr 6:31,142,476...31,147,464

G

abhydrolase domain containing 10, depalmitoylase

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ABHD10 protein
bisphenol F results in decreased expression of ABHD10 mRNA

PMID:34186270 PMID:38685157

NCBI chr11:68,543,860...68,556,059
Ensembl chr11:68,543,606...68,557,640

G

abhydrolase domain containing 11

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ABHD11 mRNA
bisphenol F results in decreased expression of ABHD11 mRNA

PMID:36041667 PMID:38685157

NCBI chr12:27,318,739...27,322,016
Ensembl chr12:27,318,749...27,321,970

G

ABHD11 antisense RNA 1

decreases expression

ISO

bisphenol F results in decreased expression of ABHD11OS mRNA

NCBI chr12:27,317,656...27,318,643

G

abhydrolase domain containing 14A

decreases expression

ISO

bisphenol F results in decreased expression of ABHD14A mRNA

NCBI chr 8:115,957,853...115,965,697
Ensembl chr 8:115,957,858...115,965,697

G

abhydrolase domain containing 15

increases expression

ISO

bisphenol F results in increased expression of ABHD15 mRNA

NCBI chr10:62,861,335...62,866,726
Ensembl chr10:62,861,317...62,868,540

G

abhydrolase domain containing 16A, phospholipase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ABHD16A mRNA

NCBI chr20:3,723,756...3,738,617
Ensembl chr20:3,723,757...3,738,736

G

abhydrolase domain containing 17A, depalmitoylase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ABHD17A mRNA

NCBI chr 7:9,775,016...9,781,447

G

abhydrolase domain containing 17B, depalmitoylase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ABHD17B mRNA

NCBI chr 1:228,624,821...228,659,254
Ensembl chr 1:228,624,499...228,658,948

G

abhydrolase domain containing 18

increases expression

ISO

bisphenol F results in increased expression of ABHD18 mRNA

NCBI chr 2:125,800,488...125,850,167
Ensembl chr 2:125,800,392...125,850,166

G

abhydrolase domain containing 2, acylglycerol lipase

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ABHD2 mRNA
bisphenol F results in increased expression of ABHD2 mRNA

PMID:28628672 PMID:38685157

NCBI chr 1:142,626,748...142,707,892
Ensembl chr 1:142,626,732...142,712,674

G

abhydrolase domain containing 3, phospholipase

increases expression

ISO

bisphenol F results in increased expression of ABHD3 mRNA

NCBI chr18:1,996,010...2,051,311
Ensembl chr18:1,993,525...2,075,492

G

abl-interactor 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ABI1 mRNA

NCBI chr17:90,006,917...90,088,002
Ensembl chr17:90,006,925...90,087,827

G

ABI family, member 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ABI3 mRNA

NCBI chr10:81,266,571...81,277,561
Ensembl chr10:81,266,571...81,277,561

G

ABI family member 3 binding protein

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ABI3BP mRNA
bisphenol F results in decreased expression of ABI3BP mRNA

PMID:30951980 PMID:38685157

NCBI chr11:57,381,282...57,597,989
Ensembl chr11:57,381,422...57,598,120

G

ABL proto-oncogene 2, non-receptor tyrosine kinase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ABL2 mRNA

NCBI chr13:71,223,902...71,319,770
Ensembl chr13:71,224,019...71,389,775

G

actin-binding LIM protein 1

increases expression

ISO

bisphenol F results in increased expression of ABLIM1 mRNA

NCBI chr 1:266,088,868...266,377,169
Ensembl chr 1:266,088,870...266,377,098

G

actin binding LIM protein family, member 2

decreases expression

ISO

bisphenol F results in decreased expression of ABLIM2 mRNA

NCBI chr14:79,090,046...79,214,986
Ensembl chr14:79,090,923...79,214,972

G

actin binding LIM protein family, member 3

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ABLIM3 gene

NCBI chr18:57,527,917...57,646,936
Ensembl chr18:57,527,917...57,646,710

G

abraxas 1, BRCA1 A complex subunit

decreases expression

ISO

bisphenol F results in decreased expression of ABRAXAS1 mRNA

NCBI chr14:9,100,650...9,115,012
Ensembl chr14:9,100,671...9,115,011

G

acetyl-CoA acyltransferase 1A

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ACAA1A mRNA
bisphenol F results in increased expression of ACAA1 protein

PMID:34186270 PMID:36041667

NCBI chr 8:127,956,126...127,966,348
Ensembl chr 8:127,956,129...127,966,241

G

acetyl-CoA acyltransferase 2

increases expression

ISO

bisphenol F results in increased expression of ACAA2 protein
bisphenol F results in increased expression of ACAA2 mRNA

PMID:34186270 PMID:38685157

NCBI chr18:70,620,310...70,648,417
Ensembl chr18:70,620,110...70,648,420

G

acetyl-CoA carboxylase alpha

increases expression

ISO

bisphenol F results in increased expression of ACACA protein

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

acetyl-CoA carboxylase beta

increases expression

ISO

bisphenol F results in increased expression of ACACB protein

NCBI chr12:48,026,394...48,138,214
Ensembl chr12:48,026,394...48,138,214

G

acyl-CoA dehydrogenase family, member 10

increases expression

ISO

bisphenol F results in increased expression of ACAD10 protein

NCBI chr12:40,561,900...40,604,378
Ensembl chr12:40,566,701...40,604,378

G

acyl-CoA dehydrogenase family, member 11

increases expression

ISO

bisphenol F results in increased expression of ACAD11 mRNA

NCBI chr 8:113,560,142...113,625,346
Ensembl chr 8:113,560,196...113,625,352

G

acyl-CoA dehydrogenase family, member 9

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACAD9 mRNA
bisphenol F results in increased expression of ACAD9 protein

PMID:28628672 PMID:34186270

NCBI chr 2:120,871,329...120,894,306
Ensembl chr 2:120,871,227...120,894,709

G

acyl-CoA dehydrogenase, long chain

increases expression

ISO

4,4'-bisphenol F results in increased expression of ACADL mRNA

NCBI chr 9:75,783,689...75,822,077
Ensembl chr 9:75,783,689...75,822,164

G

acyl-CoA dehydrogenase medium chain

increases expression

ISO

4,4'-bisphenol F results in increased expression of ACADM mRNA; bisphenol F results in increased expression of ACADM protein

PMID:32763284 PMID:34186270

NCBI chr 2:245,518,693...245,542,864
Ensembl chr 2:245,518,693...245,542,864

G

acyl-CoA dehydrogenase short chain

increases expression

ISO

bisphenol F results in increased expression of ACADS protein
bisphenol F results in increased expression of ACADS mRNA

PMID:34186270 PMID:38685157

NCBI chr12:47,154,259...47,163,580
Ensembl chr12:47,154,276...47,164,103

G

acyl-CoA dehydrogenase, very long chain

increases expression

ISO

bisphenol F results in increased expression of ACADVL protein

NCBI chr10:55,231,558...55,236,786
Ensembl chr10:55,231,440...55,236,750

G

aggrecan

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACAN mRNA

NCBI chr 1:142,390,951...142,453,779
Ensembl chr 1:142,390,951...142,453,779

G

ArfGAP with coiled-coil, ankyrin repeat and PH domains 1

decreases expression

ISO

bisphenol F results in decreased expression of ACAP1 mRNA

NCBI chr10:55,104,040...55,119,280
Ensembl chr10:55,104,040...55,118,185

G

ArfGAP with coiled-coil, ankyrin repeat and PH domains 3

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ACAP3 mRNA
bisphenol F results in decreased expression of ACAP3 mRNA

PMID:36041667 PMID:38685157

NCBI chr 5:171,783,382...171,797,709
Ensembl chr 5:171,783,382...171,798,191

G

acetyl-CoA acetyltransferase 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACAT1 mRNA
bisphenol F results in increased expression of ACAT1 protein
bisphenol F results in increased expression of ACAT1 mRNA

PMID:28628672 PMID:34186270 PMID:38685157

NCBI chr 8:62,876,003...62,905,080
Ensembl chr 8:62,876,003...62,905,042

G

acetyl-CoA acetyltransferase 2

increases expression

ISO

bisphenol F results in increased expression of ACAT2 protein

NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:50,100,817...50,135,095

G

acyl-CoA binding domain containing 4

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ACBD4 mRNA

NCBI chr10:88,548,146...88,558,588
Ensembl chr10:88,548,158...88,558,587

G

acyl-CoA binding domain containing 5

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACBD5 mRNA
bisphenol F results in increased expression of ACBD5 protein

PMID:28628672 PMID:34186270

NCBI chr17:90,114,250...90,156,286
Ensembl chr17:90,114,375...90,156,286

G

acyl-CoA binding domain containing 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ACBD7 mRNA

NCBI chr17:79,813,106...79,821,254
Ensembl chr17:79,813,106...79,818,448

G

1-aminocyclopropane-1-carboxylate synthase

decreases expression

ISO

bisphenol F results in decreased expression of ACCS mRNA

NCBI chr 3:100,261,940...100,276,400
Ensembl chr 3:100,261,941...100,296,514

G

ACD, shelterin complex subunit and telomerase recruitment factor

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ACD mRNA

NCBI chr19:50,496,634...50,499,397
Ensembl chr19:50,496,635...50,499,326

G

angiotensin converting enzyme 2

increases expression

ISO

bisphenol F results in increased expression of ACE2 mRNA

NCBI chr X:33,925,458...33,972,851
Ensembl chr X:33,925,458...33,971,596

G

acetylcholinesterase

increases activity
multiple interactions

ISO
EXP

bisphenol F results in increased activity of ACHE protein
[bisphenol F co-treated with bisphenol S co-treated with bisphenol B] promotes the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ACHE protein]; [bisphenol F co-treated with bisphenol S co-treated with bisphenol B] results in increased activity of ACHE protein; NG-Nitroarginine Methyl Ester promotes the reaction [[bisphenol F co-treated with bisphenol S co-treated with bisphenol B] results in increased activity of ACHE protein]; thymoquinone inhibits the reaction [[bisphenol F co-treated with bisphenol S co-treated with bisphenol B] promotes the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ACHE protein]]; thymoquinone inhibits the reaction [[bisphenol F co-treated with bisphenol S co-treated with bisphenol B] results in increased activity of ACHE protein]; thymoquinone inhibits the reaction [NG-Nitroarginine Methyl Ester promotes the reaction [[bisphenol F co-treated with bisphenol S co-treated with bisphenol B] results in increased activity of ACHE protein]]

PMID:29079494 PMID:39577800

NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410

G

apoptotic chromatin condensation inducer 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACIN1 mRNA

NCBI chr15:32,072,121...32,117,004
Ensembl chr15:32,072,123...32,117,166

G

atypical chemokine receptor 3

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of ACKR3 gene

NCBI chr 9:98,247,300...98,258,877
Ensembl chr 9:98,246,605...98,260,214

G

atypical chemokine receptor 4

increases expression

ISO

bisphenol F results in increased expression of ACKR4 mRNA

NCBI chr 8:113,595,325...113,599,762
Ensembl chr 8:113,595,293...113,602,372

G

ATP citrate lyase

increases expression

ISO

bisphenol F results in increased expression of ACLY protein
bisphenol F results in increased expression of ACLY mRNA

PMID:34186270 PMID:38685157

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631

G

aminocarboxymuconate semialdehyde decarboxylase

increases expression

ISO

bisphenol F results in increased expression of ACMSD mRNA

NCBI chr13:41,752,894...41,798,427
Ensembl chr13:41,752,875...41,798,427

G

aconitase 1

increases expression

ISO

bisphenol F results in increased expression of ACO1 protein

NCBI chr 5:60,055,895...60,111,920
Ensembl chr 5:60,055,866...60,112,600

G

aconitase 2

increases expression

ISO

bisphenol F results in increased expression of ACO2 protein

NCBI chr 7:115,265,816...115,308,931
Ensembl chr 7:115,265,791...115,308,892

G

acyl-CoA thioesterase 1

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ACOT1 mRNA
bisphenol F results in increased expression of ACOT1 mRNA
bisphenol F results in increased expression of ACOT1 protein

PMID:34186270 PMID:36041667 PMID:38685157

NCBI chr 6:109,367,274...109,375,268
Ensembl chr 6:109,367,268...109,380,749

G

acyl-CoA thioesterase 11

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ACOT11 mRNA
bisphenol F results in increased expression of ACOT11 mRNA

PMID:28628672 PMID:30951980

NCBI chr 5:126,756,255...126,804,526
Ensembl chr 5:126,756,255...126,804,507

G

acyl-CoA thioesterase 13

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ACOT13 protein
bisphenol F results in increased expression of ACOT13 mRNA
bisphenol F results in decreased expression of ACOT13 mRNA

PMID:34186270 PMID:38685157

NCBI chr17:40,668,404...40,680,876
Ensembl chr17:40,668,316...40,680,876

G

acyl-CoA thioesterase 4

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ACOT4 mRNA
bisphenol F results in increased expression of ACOT4 mRNA

PMID:36041667 PMID:38685157

NCBI chr 6:109,399,032...109,405,138
Ensembl chr 6:109,399,578...109,405,138

G

acyl-CoA thioesterase 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACOT7 mRNA

NCBI chr 5:167,969,284...168,062,033
Ensembl chr 5:167,968,895...168,062,033

G

acyl-CoA thioesterase 9

increases expression

ISO

bisphenol F results in increased expression of ACOT9 mRNA

NCBI chr X:43,922,943...43,973,311
Ensembl chr X:43,914,923...43,973,205

G

acyl-CoA oxidase 1

increases expression

ISO

bisphenol F results in increased expression of ACOX1 protein
bisphenol F results in increased expression of ACOX1 mRNA

PMID:34186270 PMID:38685157

NCBI chr10:101,905,083...101,930,136
Ensembl chr10:101,905,083...101,930,136

G

acyl-CoA oxidase 2

increases expression

ISO

bisphenol F results in increased expression of ACOX2 protein
bisphenol F results in increased expression of ACOX2 mRNA

PMID:34186270 PMID:38685157

NCBI chr15:19,090,820...19,122,392
Ensembl chr15:19,090,926...19,122,392

G

acyl-CoA oxidase 3, pristanoyl

increases expression

ISO

bisphenol F results in increased expression of ACOX3 protein

NCBI chr14:79,358,604...79,405,160
Ensembl chr14:79,302,042...79,400,881

G

acrosin binding protein

decreases expression

ISO

bisphenol F results in decreased expression of ACRBP mRNA

NCBI chr 4:159,537,395...159,550,454
Ensembl chr 4:159,537,391...159,550,454

G

acyl-CoA synthetase family member 2

increases expression

ISO

bisphenol F results in increased expression of ACSF2 protein

NCBI chr10:80,001,389...80,043,796
Ensembl chr10:80,001,389...80,045,050

G

acyl-CoA synthetase family member 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ACSF3 mRNA

NCBI chr19:67,743,660...67,784,109
Ensembl chr19:67,743,490...67,784,084

G

acyl-CoA synthetase long-chain family member 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ACSL1 mRNA

NCBI chr16:52,487,870...52,554,110
Ensembl chr16:52,487,870...52,554,023

G

acyl-CoA synthetase long-chain family member 3

increases expression

ISO

bisphenol F results in increased expression of ACSL3 protein

NCBI chr 9:87,563,601...87,613,078
Ensembl chr 9:87,563,601...87,613,097

G

acyl-CoA synthetase long-chain family member 4

increases expression

ISO

bisphenol F results in increased expression of ACSL4 protein
bisphenol F results in increased expression of ACSL4 mRNA

PMID:34186270 PMID:38685157

NCBI chr X:110,739,633...110,803,416
Ensembl chr X:110,739,648...110,803,261

G

acyl-CoA synthetase long-chain family member 5

increases expression

ISO

bisphenol F results in increased expression of ACSL5 protein
bisphenol F results in increased expression of ACSL5 mRNA

PMID:34186270 PMID:38685157

NCBI chr 1:264,294,851...264,341,943
Ensembl chr 1:264,294,864...264,341,943

G

acyl-CoA synthetase long-chain family member 6

decreases expression
multiple interactions

ISO

bisphenol F results in decreased expression of ACSL6 mRNA
[bisphenol F co-treated with Fulvestrant] results in decreased methylation of ACSL6 gene

PMID:30951980 PMID:31601247

NCBI chr10:38,940,668...38,999,515
Ensembl chr10:38,940,747...39,002,873

G

acyl-CoA synthetase medium-chain family member 5

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ACSM5 mRNA

NCBI chr 1:183,302,241...183,328,175
Ensembl chr 1:183,294,105...183,329,925

G

acyl-CoA synthetase short-chain family member 2

increases expression

ISO

bisphenol F results in increased expression of ACSS2 protein

NCBI chr 3:164,464,124...164,507,607
Ensembl chr 3:164,464,055...164,519,830

G

actin, alpha 1, skeletal muscle

increases expression

ISO

bisphenol F results in increased expression of ACTA1 mRNA

PMID:30951980 PMID:38685157

NCBI chr19:68,781,168...68,784,194
Ensembl chr19:68,781,168...68,786,178

G

actin alpha 2, smooth muscle

increases expression
decreases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of ACTA2 mRNA
bisphenol F results in decreased expression of ACTA2 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ACTA2 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of ACTA2 mRNA

PMID:30951980 PMID:36041667 PMID:38685157

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

actin, beta

increases expression

ISO

bisphenol F results in increased expression of ACTB protein

NCBI chr12:16,776,664...16,779,634
Ensembl chr12:16,776,661...16,780,242

G

actin, alpha, cardiac muscle 1

increases expression

ISO

bisphenol F results in increased expression of ACTC1 mRNA

NCBI chr 3:121,266,291...121,271,827
Ensembl chr 3:121,266,291...121,271,827

G

actin, gamma 1

increases expression

ISO

bisphenol F results in increased expression of ACTG1 mRNA

NCBI chr10:106,118,106...106,120,951
Ensembl chr10:106,118,108...106,120,951

G

actin gamma 2, smooth muscle

increases expression
decreases expression
multiple interactions

ISO

bisphenol F results in increased expression of ACTG2 mRNA
bisphenol F results in decreased expression of ACTG2 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of ACTG2 mRNA

PMID:30951980 PMID:38685157

NCBI chr 4:117,579,513...117,604,379
Ensembl chr 4:117,579,514...117,604,295

G

actinin, alpha 1

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of ACTN1 mRNA
bisphenol F results in increased expression of ACTN1 protein

PMID:30951980 PMID:34186270

NCBI chr 6:104,731,485...104,826,312
Ensembl chr 6:104,731,485...104,826,172

G

actinin alpha 2

increases expression

ISO

bisphenol F results in increased expression of ACTN2 mRNA

NCBI chr17:62,835,055...62,902,331
Ensembl chr17:62,812,988...62,903,552

G

actinin alpha 4

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ACTN4 mRNA

NCBI chr 1:93,310,294...93,379,369
Ensembl chr 1:93,310,278...93,379,320

G

actin related protein 1A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ACTR1A mRNA

NCBI chr 1:255,179,241...255,199,009
Ensembl chr 1:255,179,242...255,199,459

G

actin related protein 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ACTR2 mRNA
bisphenol F results in increased expression of ACTR2 protein

PMID:28628672 PMID:34186270

NCBI chr14:98,500,119...98,535,092
Ensembl chr14:98,500,138...98,541,998

G

actin related protein 3

increases expression

ISO

bisphenol F results in increased expression of ACTR3 protein

NCBI chr13:39,353,413...39,396,509
Ensembl chr13:39,353,079...39,396,711

G

actin related protein 3B

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ACTR3B mRNA

NCBI chr 4:9,995,553...10,089,422
Ensembl chr 4:9,996,155...10,089,553

G

actin related protein 6

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ACTR6 mRNA
bisphenol F results in increased expression of ACTR6 mRNA

PMID:28628672 PMID:38685157

NCBI chr 7:26,037,574...26,058,362
Ensembl chr 7:26,037,574...26,060,604

G

activin A receptor type 2B

decreases expression

ISO

bisphenol F results in decreased expression of ACVR2B mRNA

NCBI chr 8:128,016,589...128,056,193
Ensembl chr 8:128,016,526...128,048,171

G

activin A receptor like type 1

increases expression

ISO

bisphenol F results in increased expression of ACVRL1 mRNA

NCBI chr 7:134,117,917...134,135,306
Ensembl chr 7:134,118,024...134,135,305

G

aminoacylase 1

increases expression

ISO

bisphenol F results in increased expression of ACY1 protein

NCBI chr 8:115,951,068...115,956,471
Ensembl chr 8:115,951,068...115,956,405

G

aminoacylase 3

increases expression

ISO

bisphenol F results in increased expression of ACY3 mRNA

NCBI chr 1:210,709,238...210,715,258
Ensembl chr 1:210,709,294...210,715,633

G

adenosine deaminase

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADA mRNA
[bisphenol F co-treated with bisphenol S co-treated with bisphenol B co-treated with NG-Nitroarginine Methyl Ester] results in increased activity of ADA protein; [bisphenol F co-treated with bisphenol S co-treated with bisphenol B] promotes the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ADA protein]; [bisphenol F co-treated with bisphenol S co-treated with bisphenol B] results in increased activity of ADA protein; thymoquinone inhibits the reaction [[bisphenol F co-treated with bisphenol S co-treated with bisphenol B co-treated with NG-Nitroarginine Methyl Ester] results in increased activity of ADA protein]; thymoquinone inhibits the reaction [[bisphenol F co-treated with bisphenol S co-treated with bisphenol B] promotes the reaction [NG-Nitroarginine Methyl Ester results in increased activity of ADA protein]]; thymoquinone inhibits the reaction [[bisphenol F co-treated with bisphenol S co-treated with bisphenol B] results in increased activity of ADA protein]

PMID:28628672 PMID:39577800

NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:172,818,176...172,842,293

G

ADAM metallopeptidase domain 11

decreases expression
multiple interactions

ISO
EXP

bisphenol F results in decreased expression of ADAM11 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ADAM11 mRNA

PMID:30951980 PMID:36041667 PMID:38685157

NCBI chr10:88,224,185...88,242,865
Ensembl chr10:88,224,347...88,242,864

G

ADAM metallopeptidase domain 12

increases expression

ISO

bisphenol F results in increased expression of ADAM12 mRNA

NCBI chr 1:198,116,968...198,443,680
Ensembl chr 1:198,116,975...198,447,552

G

ADAM metallopeptidase domain 15

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ADAM15 mRNA

NCBI chr 2:177,052,363...177,062,879
Ensembl chr 2:177,052,363...177,062,849

G

ADAM metallopeptidase domain 17

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADAM17 mRNA

NCBI chr 6:46,601,583...46,663,690
Ensembl chr 6:46,601,583...46,649,344

G

ADAM metallopeptidase domain 19

increases expression

ISO

bisphenol F results in increased expression of ADAM19 mRNA

NCBI chr10:30,992,713...31,084,455
Ensembl chr10:30,992,754...31,084,455

G

ADAM metallopeptidase domain 1a

decreases expression

ISO

bisphenol F results in decreased expression of ADAM1A mRNA

NCBI chr12:40,674,460...40,680,988
Ensembl chr12:40,676,918...40,684,619

G

ADAM metallopeptidase domain 33

decreases expression

ISO

bisphenol F results in decreased expression of ADAM33 mRNA

NCBI chr 3:138,715,428...138,736,392
Ensembl chr 3:138,724,046...138,736,347

G

ADAM metallopeptidase domain 8

increases expression

ISO

bisphenol F results in increased expression of ADAM8 mRNA

NCBI chr 1:204,206,206...204,218,988
Ensembl chr 1:204,206,199...204,218,485

G

ADAM metallopeptidase domain 9

increases expression

ISO

bisphenol F results in increased expression of ADAM9 mRNA

NCBI chr16:73,725,186...73,804,284
Ensembl chr16:73,725,114...73,804,646

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of ADAMTS1 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of ADAMTS1 mRNA

NCBI chr11:38,418,565...38,427,384
Ensembl chr11:38,418,101...38,427,390

G

ADAM metallopeptidase with thrombospondin type 1 motif, 10

decreases expression

ISO

bisphenol F results in decreased expression of ADAMTS10 mRNA

NCBI chr 7:15,033,859...15,063,800
Ensembl chr 7:15,033,934...15,063,800

G

ADAM metallopeptidase with thrombospondin type 1 motif, 12

increases expression

ISO

bisphenol F results in increased expression of ADAMTS12 mRNA

NCBI chr 2:61,759,975...62,054,716
Ensembl chr 2:61,759,987...62,054,716

G

ADAM metallopeptidase with thrombospondin type 1 motif, 14

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ADAMTS14 mRNA
bisphenol F results in decreased expression of ADAMTS14 mRNA

PMID:30951980 PMID:38685157

NCBI chr20:29,685,876...29,762,685
Ensembl chr20:29,685,876...29,762,682

G

ADAM metallopeptidase with thrombospondin type 1 motif, 15

increases expression

ISO

bisphenol F results in increased expression of ADAMTS15 mRNA

NCBI chr 8:37,566,064...37,589,446
Ensembl chr 8:37,566,065...37,589,446

G

ADAM metallopeptidase with thrombospondin type 1 motif, 16

increases expression

ISO

bisphenol F results in increased expression of ADAMTS16 mRNA

NCBI chr 1:34,258,899...34,388,952
Ensembl chr 1:34,258,899...34,388,952

G

ADAM metallopeptidase with thrombospondin type 1 motif, 17

increases expression

ISO

bisphenol F results in increased expression of ADAMTS17 mRNA

NCBI chr 1:129,856,062...130,178,430
Ensembl chr 1:129,856,074...130,176,844

G

ADAM metallopeptidase with thrombospondin type 1 motif, 18

increases expression

ISO

bisphenol F results in increased expression of ADAMTS18 mRNA

NCBI chr19:58,596,095...58,749,239
Ensembl chr19:58,597,761...58,749,138

G

ADAM metallopeptidase with thrombospondin type 1 motif, 2

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of ADAMTS2 mRNA
bisphenol F results in increased expression of ADAMTS2 mRNA

NCBI chr10:35,422,030...35,627,483
Ensembl chr10:35,422,030...35,627,483

G

ADAM metallopeptidase with thrombospondin type 1 motif, 20

decreases methylation

ISO

bisphenol F results in decreased methylation of ADAMTS20 gene

NCBI chr 7:127,275,538...127,407,325
Ensembl chr 7:127,275,538...127,407,296

G

ADAM metallopeptidase with thrombospondin type 1, motif 3

decreases expression
multiple interactions

ISO

bisphenol F results in decreased expression of ADAMTS3 mRNA
[bisphenol F co-treated with Fulvestrant] results in decreased methylation of ADAMTS3 gene

PMID:30951980 PMID:31601247

NCBI chr14:18,515,249...18,721,887
Ensembl chr14:18,515,249...18,721,887

G

ADAM metallopeptidase with thrombospondin type 1 motif, 5

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of ADAMTS5 mRNA
[bisphenol F co-treated with Fulvestrant] results in decreased methylation of ADAMTS5 gene
[bisphenol F co-treated with Tretinoin] results in decreased expression of ADAMTS5 mRNA

PMID:30951980 PMID:31601247

NCBI chr11:38,486,945...38,533,516
Ensembl chr11:38,486,955...38,533,516

G

ADAM metallopeptidase with thrombospondin type 1 motif, 6

increases methylation
decreases expression

ISO

bisphenol F results in increased methylation of ADAMTS6 gene
bisphenol F results in decreased expression of ADAMTS6 mRNA

PMID:31601247 PMID:38685157

NCBI chr 2:37,155,260...37,367,077
Ensembl chr 2:37,155,288...37,367,070

G

ADAM metallopeptidase with thrombospondin type 1 motif, 7

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ADAMTS7 mRNA
bisphenol F results in decreased expression of ADAMTS7 mRNA

PMID:30951980 PMID:38685157

NCBI chr 8:99,584,529...99,624,132
Ensembl chr 8:99,584,529...99,624,132

G

ADAM metallopeptidase with thrombospondin type 1 motif, 9

increases expression

ISO

bisphenol F results in increased expression of ADAMTS9 mRNA

NCBI chr 4:126,847,726...127,019,924
Ensembl chr 4:126,847,729...127,019,876

G

ADAMTS-like 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ADAMTSL1 mRNA
bisphenol F results in increased expression of ADAMTSL1 mRNA

PMID:28628672 PMID:30951980

NCBI chr 5:105,010,471...105,965,792
Ensembl chr 5:105,010,464...105,964,394

G

ADAMTS-like 2

increases expression

ISO

bisphenol F results in increased expression of ADAMTSL2 mRNA

NCBI chr 3:30,795,882...30,832,635
Ensembl chr 3:30,802,700...30,832,635

G

ADAMTS-like 3

increases expression

ISO

bisphenol F results in increased expression of ADAMTSL3 mRNA

NCBI chr 1:145,698,004...146,006,195
Ensembl chr 1:145,698,004...146,006,195

G

ADAMTS-like 4

decreases expression

ISO

bisphenol F results in decreased expression of ADAMTSL4 mRNA

NCBI chr 2:185,924,582...185,936,039
Ensembl chr 2:185,924,594...185,935,796

G

ADAMTS-like 5

decreases expression

ISO

bisphenol F results in decreased expression of ADAMTSL5 mRNA

NCBI chr 7:10,013,306...10,021,924
Ensembl chr 7:10,013,929...10,021,924

G

ArfGAP with dual PH domains 1

multiple interactions

ISO
EXP

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ADAP1 gene
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ADAP1 mRNA

PMID:31601247 PMID:36041667

NCBI chr12:20,438,091...20,489,961
Ensembl chr12:20,438,063...20,495,020

G

ArfGAP with dual PH domains 2

increases expression

ISO

bisphenol F results in increased expression of ADAP2 mRNA

NCBI chr10:65,635,891...65,665,019
Ensembl chr10:65,622,434...65,664,022

G

adenosine deaminase, RNA-specific, B1

increases expression

ISO

bisphenol F results in increased expression of ADARB1 mRNA

NCBI chr20:11,222,171...11,350,416
Ensembl chr20:11,222,164...11,350,415

G

adenosine deaminase RNA specific B2

multiple interactions
increases methylation

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ADARB2 gene
bisphenol F results in increased methylation of ADARB2 gene

NCBI chr17:66,660,586...67,211,104
Ensembl chr17:66,665,506...67,210,749

G

adenosine deaminase, tRNA-specific 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ADAT1 mRNA

NCBI chr19:56,825,153...56,866,136
Ensembl chr19:56,826,849...56,866,117

G

adenosine deaminase, tRNA-specific 2

increases expression

ISO

bisphenol F results in increased expression of ADAT2 mRNA

NCBI chr 1:9,774,680...9,795,376
Ensembl chr 1:9,774,680...9,795,376

G

aarF domain containing kinase 5

decreases expression

ISO

bisphenol F results in decreased expression of ADCK5 mRNA

NCBI chr 7:110,182,275...110,200,088
Ensembl chr 7:110,181,981...110,200,088

G

adenylate cyclase 1

decreases expression

EXP

4,4'-bisphenol F results in decreased expression of ADCY1 mRNA

NCBI chr14:86,125,119...86,234,459
Ensembl chr14:86,124,850...86,261,075

G

adenylate cyclase 2

decreases expression

EXP

4,4'-bisphenol F results in decreased expression of ADCY2 mRNA

NCBI chr 1:36,204,054...36,650,645
Ensembl chr 1:36,204,054...36,650,645

G

adenylate cyclase 3

decreases expression

EXP

4,4'-bisphenol F results in decreased expression of ADCY3 mRNA

NCBI chr 6:32,819,602...32,923,174
Ensembl chr 6:32,843,961...32,923,173

G

adenylate cyclase 4

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ADCY4 mRNA
bisphenol F results in decreased expression of ADCY4 mRNA

PMID:28628672 PMID:38685157

NCBI chr15:33,236,201...33,252,070
Ensembl chr15:33,236,208...33,252,026

G

adenylate cyclase 5

decreases expression
increases expression

EXP
ISO

4,4'-bisphenol F results in decreased expression of ADCY5 mRNA
bisphenol F results in increased expression of ADCY5 mRNA

PMID:26186136 PMID:30951980 PMID:38685157

NCBI chr11:78,976,861...79,123,343
Ensembl chr11:78,976,861...79,123,343

G

adenylate cyclase 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ADCY6 mRNA

NCBI chr 7:131,621,860...131,642,923
Ensembl chr 7:131,621,860...131,642,770

G

adenylate cyclase 7

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ADCY7 mRNA
bisphenol F results in decreased expression of ADCY7 mRNA

PMID:30951980 PMID:38685157

NCBI chr19:34,913,154...34,972,366
Ensembl chr19:34,914,322...34,936,743

G

adenylate cyclase 9

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ADCY9 mRNA

NCBI chr10:11,645,373...11,768,462
Ensembl chr10:11,645,282...11,765,792

G

adducin 1

increases expression

ISO

bisphenol F results in increased expression of ADD1 protein

NCBI chr14:80,333,242...80,401,641
Ensembl chr14:80,333,244...80,391,732

G

adducin 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ADD2 mRNA

NCBI chr 4:120,001,977...120,101,090
Ensembl chr 4:120,002,054...120,101,091

G

androglobin

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ADGB mRNA
bisphenol F results in decreased expression of ADGB mRNA

PMID:30951980 PMID:38685157

NCBI chr 1:6,573,863...6,717,632
Ensembl chr 1:6,573,225...6,739,715

G

adhesion G protein-coupled receptor A2

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of ADGRA2 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of ADGRA2 mRNA

NCBI chr16:71,635,814...71,674,275
Ensembl chr16:71,636,164...71,674,154

G

adhesion G protein-coupled receptor A3

increases expression

ISO

bisphenol F results in increased expression of ADGRA3 mRNA

NCBI chr14:65,085,418...65,188,949
Ensembl chr14:65,087,380...65,188,959

G

adhesion G protein-coupled receptor B2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ADGRB2 mRNA

NCBI chr 5:147,581,573...147,646,726
Ensembl chr 5:147,611,580...147,646,726

G

adhesion G protein-coupled receptor B3

decreases expression

ISO

bisphenol F results in decreased expression of ADGRB3 mRNA

NCBI chr 9:34,917,474...35,645,350
Ensembl chr 9:34,917,474...35,644,811

G

adhesion G protein-coupled receptor D1

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ADGRD1 mRNA
bisphenol F results in decreased expression of ADGRD1 mRNA

PMID:30951980 PMID:38685157

NCBI chr12:33,124,981...33,239,778
Ensembl chr12:33,125,915...33,272,509

G

adhesion G protein-coupled receptor E1

increases expression

ISO

bisphenol F results in increased expression of ADGRE1 mRNA

NCBI chr 9:2,329,398...2,484,959
Ensembl chr 9:2,329,438...2,484,959

G

adhesion G protein-coupled receptor E4

increases expression

ISO

bisphenol F results in increased expression of ADGRE4 mRNA

NCBI chr 9:10,085,258...10,240,346
Ensembl chr 9:10,085,352...10,240,229

G

adhesion G protein-coupled receptor E5

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of ADGRE5 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of ADGRE5 mRNA

NCBI chr19:41,302,687...41,332,183
Ensembl chr19:41,303,213...41,324,641

G

adhesion G protein-coupled receptor F5

increases expression

ISO

bisphenol F results in increased expression of ADGRF5 mRNA

NCBI chr 9:25,014,861...25,128,045
Ensembl chr 9:25,018,277...25,121,237

G

adhesion G protein-coupled receptor G2

decreases expression

ISO

bisphenol F results in decreased expression of ADGRG2 mRNA

NCBI chr X:38,106,067...38,231,286
Ensembl chr X:38,106,067...38,231,331

G

adhesion G protein-coupled receptor G3

decreases expression

ISO

bisphenol F results in decreased expression of ADGRG3 mRNA

NCBI chr19:9,978,450...10,007,145
Ensembl chr19:9,978,514...10,007,238

G

adhesion G protein-coupled receptor G6

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of ADGRG6 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of ADGRG6 mRNA

NCBI chr 1:10,633,004...10,774,685
Ensembl chr 1:10,631,829...10,774,023

G

adhesion G protein-coupled receptor L1

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ADGRL1 mRNA
bisphenol F results in decreased expression of ADGRL1 mRNA

PMID:36041667 PMID:38685157

NCBI chr19:41,107,162...41,148,752
Ensembl chr19:41,109,117...41,148,896

G

adhesion G protein-coupled receptor L3

decreases methylation
multiple interactions

ISO
EXP

bisphenol F results in decreased methylation of ADGRL3 gene
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ADGRL3 mRNA

PMID:31601247 PMID:36041667

NCBI chr14:26,690,891...27,458,132
Ensembl chr14:26,722,194...27,280,418

G

adhesion G protein-coupled receptor L4

increases expression

ISO

bisphenol F results in increased expression of ADGRL4 mRNA

PMID:30951980 PMID:38685157

NCBI chr 2:243,014,927...243,117,226
Ensembl chr 2:243,014,796...243,117,222

G

adhesion G protein-coupled receptor V1

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of ADGRV1 mRNA
[bisphenol F co-treated with Fulvestrant] results in decreased methylation of ADGRV1 gene

PMID:30951980 PMID:31601247

NCBI chr 2:13,067,149...13,647,407
Ensembl chr 2:13,067,150...13,647,372

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

increases expression

ISO

bisphenol F results in increased expression of ADH1 mRNA

NCBI chr 2:229,470,703...229,482,291
Ensembl chr 2:229,470,703...229,482,291

G

alcohol dehydrogenase 5 (class III), chi polypeptide

increases expression

ISO

bisphenol F results in increased expression of ADH5 protein

NCBI chr 2:229,648,557...229,660,964
Ensembl chr 2:229,648,501...229,665,232

G

alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide

decreases expression

ISO

bisphenol F results in decreased expression of ADH7 mRNA

NCBI chr 2:229,422,125...229,436,584
Ensembl chr 2:229,421,252...229,436,691

G

acireductone dioxygenase 1

increases expression

ISO

bisphenol F results in increased expression of ADI1 protein

NCBI chr 6:51,035,267...51,042,229
Ensembl chr 6:51,034,931...51,042,855

G

adiponectin, C1Q and collagen domain containing

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of ADIPOQ protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ADIPOQ mRNA

PMID:34186270 PMID:36041667

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169

G

adrenomedullin

increases expression

ISO

bisphenol F results in increased expression of ADM mRNA

NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371

G

activity-dependent neuroprotector homeobox

increases expression

ISO

bisphenol F results in increased expression of ADNP mRNA

NCBI chr 3:177,310,258...177,340,379
Ensembl chr 3:177,310,258...177,336,188

G

ADNP homeobox 2

increases expression

ISO

bisphenol F results in increased expression of ADNP2 mRNA

NCBI chr18:75,846,860...75,871,638
Ensembl chr18:75,847,165...75,903,317

G

2-aminoethanethiol dioxygenase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADO mRNA

NCBI chr20:21,043,694...21,044,862
Ensembl chr20:21,043,317...21,048,483

G

adenosine A1 receptor

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ADORA1 gene
bisphenol F results in increased expression of ADORA1 mRNA

PMID:31601247 PMID:38685157

NCBI chr13:48,210,922...48,247,826
Ensembl chr13:48,213,273...48,247,190

G

adenosine A2a receptor

increases expression

ISO

bisphenol F results in increased expression of ADORA2A mRNA

NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,270...13,332,802

G

ADP-dependent glucokinase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ADPGK mRNA

NCBI chr 8:68,595,194...68,623,179
Ensembl chr 8:68,595,248...68,623,178

G

ADP-ribosylarginine hydrolase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ADPRH mRNA

NCBI chr11:75,805,347...75,811,686
Ensembl chr11:75,805,310...75,812,452

G

adrenoceptor alpha 1A

increases expression

ISO

bisphenol F results in increased expression of ADRA1A mRNA

NCBI chr15:45,005,648...45,111,416
Ensembl chr15:45,005,799...45,102,534

G

adrenoceptor alpha 1B

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ADRA1B mRNA

NCBI chr10:28,756,461...28,874,831
Ensembl chr10:28,756,461...28,814,347

G

adrenoceptor alpha 1D

increases expression

ISO

bisphenol F results in increased expression of ADRA1D mRNA

NCBI chr 3:139,246,333...139,262,331
Ensembl chr 3:139,246,323...139,262,331

G

adrenoceptor alpha 2A

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ADRA2A mRNA
bisphenol F results in increased expression of ADRA2A mRNA

PMID:28628672 PMID:30951980

NCBI chr 1:263,066,780...263,069,580
Ensembl chr 1:263,065,278...263,069,871

G

adrenoceptor alpha 2C

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ADRA2C mRNA

NCBI chr14:79,695,514...79,697,476
Ensembl chr14:79,694,995...79,706,656

G

adrenoceptor beta 2

decreases expression

EXP
ISO

4,4'-bisphenol F results in decreased expression of ADRB2 mRNA

PMID:26186136 PMID:38685157

NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803

G

adrenoceptor beta 3

decreases expression

ISO

bisphenol F results in decreased expression of ADRB3 mRNA

NCBI chr16:71,544,603...71,547,410
Ensembl chr16:71,542,567...71,547,420

G

androgen-dependent TFPI-regulating protein

decreases expression

ISO

bisphenol F results in decreased expression of ADTRP mRNA

NCBI chr17:23,113,578...23,199,616
Ensembl chr17:23,135,809...23,216,622

G

AE binding protein 1

increases expression

ISO

bisphenol F results in increased expression of AEBP1 mRNA

NCBI chr14:84,951,577...84,962,840
Ensembl chr14:84,952,822...84,962,843

G

actin filament associated protein 1-like 1

increases expression

ISO

bisphenol F results in increased expression of AFAP1L1 mRNA

NCBI chr18:57,454,120...57,514,584
Ensembl chr18:57,454,121...57,514,480

G

actin filament associated protein 1-like 2

increases expression

ISO

bisphenol F results in increased expression of AFAP1L2 mRNA

NCBI chr 1:265,969,368...266,065,951
Ensembl chr 1:265,969,368...266,065,943

G

ALF transcription elongation factor 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AFF1 mRNA

NCBI chr14:6,165,864...6,328,848
Ensembl chr14:6,169,562...6,328,879

G

ALF transcription elongation factor 4

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AFF4 mRNA
bisphenol F results in increased expression of AFF4 mRNA

PMID:28628672 PMID:38685157

NCBI chr10:37,998,319...38,080,580
Ensembl chr10:37,999,579...38,080,580

G

AFG2 AAA ATPase homolog B

decreases expression
increases expression

ISO

bisphenol F results in decreased expression of AFG2B mRNA
bisphenol F results in increased expression of AFG2B mRNA

PMID:30951980 PMID:38685157

NCBI chr 3:130,148,061...130,162,458
Ensembl chr 3:130,148,301...130,162,112

G

AFG3 like matrix AAA peptidase subunit 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AFG3L2 mRNA

NCBI chr18:63,224,163...63,269,000
Ensembl chr18:63,224,163...63,269,000

G

arylformamidase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AFMID mRNA

NCBI chr10:103,544,822...103,560,408
Ensembl chr10:103,544,841...103,560,408

G

alpha-fetoprotein

affects expression

ISO

bisphenol F affects the expression of AFP mRNA

NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649

G

aftiphilin

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of AFTPH gene; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AFTPH mRNA

PMID:28628672 PMID:31601247

NCBI chr14:99,072,761...99,127,006
Ensembl chr14:99,072,761...99,126,727

G

ArfGAP with GTPase domain, ankyrin repeat and PH domain 1

increases expression

ISO

bisphenol F results in increased expression of AGAP1 mRNA

NCBI chr 9:97,487,382...97,922,870
Ensembl chr 9:97,487,406...97,922,870

G

AGBL carboxypeptidase 2

increases expression

ISO

bisphenol F results in increased expression of AGBL2 mRNA

NCBI chr 3:97,220,654...97,255,905
Ensembl chr 3:97,220,781...97,255,904

G

AGBL carboxypeptidase 3

increases expression

ISO

bisphenol F results in increased expression of AGBL3 mRNA

NCBI chr 4:64,416,139...64,498,987
Ensembl chr 4:64,421,397...64,498,985

G

advanced glycosylation end product-specific receptor

decreases expression

ISO

bisphenol F results in decreased expression of AGER mRNA

NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685

G

ArfGAP with FG repeats 1

increases expression

ISO

bisphenol F results in increased expression of AGFG1 protein

NCBI chr 9:91,572,962...91,630,688
Ensembl chr 9:91,573,157...91,626,910

G

ArfGAP with FG repeats 2

increases expression

ISO

bisphenol F results in increased expression of AGFG2 mRNA

NCBI chr12:24,649,008...24,692,069
Ensembl chr12:24,649,038...24,685,197

G

amylo-alpha-1,6-glucosidase and 4-alpha-glucanotransferase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AGL mRNA

NCBI chr 2:207,389,949...207,445,959
Ensembl chr 2:207,389,949...207,445,724

G

alkylglycerol monooxygenase

increases expression

ISO

bisphenol F results in increased expression of AGMO mRNA

NCBI chr 6:59,713,495...60,044,851
Ensembl chr 6:59,713,467...60,044,854

G

argonaute RISC component 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of AGO1 mRNA

NCBI chr 5:144,006,618...144,064,740
Ensembl chr 5:144,006,618...144,041,624

G

argonaute RISC catalytic component 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AGO2 mRNA
bisphenol F results in increased expression of AGO2 mRNA

PMID:28628672 PMID:38685157

NCBI chr 7:106,907,209...106,994,124
Ensembl chr 7:106,918,125...106,993,980

G

argonaute RISC catalytic component 3

increases expression

ISO

bisphenol F results in increased expression of AGO3 mRNA

NCBI chr 5:143,913,957...143,998,746
Ensembl chr 5:143,926,501...143,998,737

G

1-acylglycerol-3-phosphate O-acyltransferase 1

multiple interactions
decreases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AGPAT1 mRNA
bisphenol F results in decreased expression of AGPAT1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AGPAT1 mRNA

PMID:28628672 PMID:36041667 PMID:38685157

NCBI chr20:4,140,565...4,149,531
Ensembl chr20:4,140,565...4,150,445

G

1-acylglycerol-3-phosphate O-acyltransferase 3

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of AGPAT3 gene

NCBI chr20:10,330,650...10,415,026
Ensembl chr20:10,394,465...10,410,632

G

1-acylglycerol-3-phosphate O-acyltransferase 4

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AGPAT4 mRNA

NCBI chr 1:51,075,081...51,181,548
Ensembl chr 1:51,075,081...51,180,976

G

alkylglycerone phosphate synthase

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AGPS mRNA
bisphenol F results in increased expression of AGPS protein

PMID:28628672 PMID:34186270

NCBI chr 3:81,154,599...81,253,099
Ensembl chr 3:81,154,604...81,258,277

G

agrin

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AGRN mRNA

NCBI chr 5:172,031,528...172,064,429
Ensembl chr 5:172,031,528...172,064,539

G

angiotensinogen

increases expression

ISO

bisphenol F results in increased expression of AGT mRNA

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944

G

angiotensin II receptor, type 2

increases expression

ISO

bisphenol F results in increased expression of AGTR2 mRNA

NCBI chr X:116,914,320...116,918,504
Ensembl chr X:116,913,656...116,918,745

G

adenosylhomocysteinase

decreases expression

ISO

bisphenol F results in decreased expression of AHCY mRNA

NCBI chr 3:164,029,338...164,044,562
Ensembl chr 3:164,029,338...164,044,587

G

adenosylhomocysteinase-like 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AHCYL1 mRNA

NCBI chr 2:197,982,335...198,016,770
Ensembl chr 2:197,982,344...198,033,930

G

Abelson helper integration site 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AHI1 mRNA

NCBI chr 1:17,580,859...17,711,775
Ensembl chr 1:17,582,006...17,711,774

G

AHNAK nucleoprotein

multiple interactions
increases expression
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AHNAK mRNA
bisphenol F results in increased expression of AHNAK protein
bisphenol F results in decreased expression of AHNAK mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of AHNAK mRNA
bisphenol F results in increased expression of AHNAK mRNA

PMID:28628672 PMID:30951980 PMID:33476716 PMID:34186270

NCBI chr 1:215,311,289...215,400,010
Ensembl chr 1:215,321,931...215,400,675

G

AHNAK nucleoprotein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AHNAK2 mRNA

NCBI chr 6:137,648,867...137,697,580
Ensembl chr 6:137,652,537...137,675,546

G

aryl hydrocarbon receptor

increases activity
increases expression

ISO

4,4'-bisphenol F results in increased activity of AHR protein
bisphenol F results in increased expression of AHR mRNA

PMID:24563381 PMID:30951980 PMID:38685157

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

activator of HSP90 ATPase homolog 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AHSA2 mRNA

NCBI chr14:101,677,447...101,688,706
Ensembl chr14:101,677,447...101,686,923

G

alpha-2-HS-glycoprotein

increases expression

ISO

bisphenol F results in increased expression of AHSG protein

NCBI chr11:91,625,975...91,632,583
Ensembl chr11:91,625,975...91,634,039

G

axin interactor, dorsalization associated

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AIDA mRNA

NCBI chr13:97,471,931...97,499,531
Ensembl chr13:97,471,604...97,499,535

G

allograft inflammatory factor 1

increases expression

ISO

bisphenol F results in increased expression of AIF1 protein

NCBI chr20:3,651,435...3,657,341
Ensembl chr20:3,652,243...3,657,339

G

apoptosis inducing factor, mitochondria associated 1

increases expression
decreases expression

ISO

bisphenol F results in increased expression of AIFM1 protein
bisphenol F results in increased expression of AIFM1 mRNA
bisphenol F results in decreased expression of AIFM1 mRNA

PMID:33312107 PMID:34186270 PMID:38685157

NCBI chr X:132,528,107...132,567,237
Ensembl chr X:132,528,107...132,567,237

G

AIF family member 2

increases expression

ISO

bisphenol F results in increased expression of AIFM2 protein

NCBI chr20:30,195,781...30,222,014
Ensembl chr20:30,193,829...30,220,957

G

androgen-induced 1

increases expression

ISO

bisphenol F results in increased expression of AIG1 mRNA

NCBI chr 1:9,866,546...10,089,454
Ensembl chr 1:9,866,548...10,089,155

G

aminoacyl tRNA synthetase complex-interacting multifunctional protein 2

increases expression

ISO

bisphenol F results in increased expression of AIMP2 protein

NCBI chr12:15,814,854...15,824,432
Ensembl chr12:15,814,878...15,824,431

G

aryl-hydrocarbon receptor-interacting protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AIP mRNA

NCBI chr 1:210,837,473...210,848,691
Ensembl chr 1:210,836,755...210,848,634

G

adenylate kinase 2

increases expression

ISO

bisphenol F results in increased expression of AK2 protein

NCBI chr 5:146,609,469...146,649,008
Ensembl chr 5:146,630,445...146,650,610

G

adenylate kinase 3

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AK3 mRNA
bisphenol F results in increased expression of AK3 protein

PMID:28628672 PMID:34186270

NCBI chr 1:236,151,012...236,178,689
Ensembl chr 1:236,151,012...236,178,183

G

adenylate kinase 4

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AK4 mRNA
bisphenol F results in increased expression of AK4 mRNA
bisphenol F results in increased expression of AK4 protein

PMID:28628672 PMID:34186270 PMID:38685157

NCBI chr 5:121,154,565...121,214,403
Ensembl chr 5:121,154,572...121,214,401

G

adenylate kinase 5

increases expression

ISO

bisphenol F results in increased expression of AK5 mRNA

NCBI chr 2:244,057,240...244,241,372
Ensembl chr 2:244,057,240...244,241,366

G

adenylate kinase 7

increases expression

ISO

bisphenol F results in increased expression of AK7 mRNA

NCBI chr 6:130,376,499...130,444,674
Ensembl chr 6:130,376,550...130,444,677

G

adenylate kinase 8

increases expression

ISO

bisphenol F results in increased expression of AK8 mRNA

NCBI chr 3:32,426,892...32,542,432
Ensembl chr 3:32,426,421...32,542,431

G

A-kinase anchoring protein 10

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AKAP10 mRNA

NCBI chr10:47,044,819...47,108,153
Ensembl chr10:47,044,819...47,108,203

G

A-kinase anchoring protein 12

multiple interactions
increases expression
increases methylation

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of AKAP12 gene; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AKAP12 mRNA
bisphenol F results in increased expression of AKAP12 protein
bisphenol F results in increased methylation of AKAP12 gene

PMID:28628672 PMID:31601247 PMID:34186270

NCBI chr 1:43,135,515...43,225,245
Ensembl chr 1:43,199,008...43,225,557

G

A-kinase anchoring protein 13

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of AKAP13 gene

NCBI chr 1:138,722,445...139,029,401
Ensembl chr 1:138,724,150...139,029,401

G

A-kinase anchoring protein 14

increases expression

ISO

bisphenol F results in increased expression of AKAP14 mRNA

NCBI chr X:121,261,195...121,276,376
Ensembl chr X:121,259,899...121,276,376

G

A-kinase anchoring protein 17A

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AKAP17A mRNA

NCBI chr12:21,424,202...21,428,308
Ensembl chr12:21,424,202...21,428,247

G

A-kinase anchoring protein 5

increases expression

ISO

bisphenol F results in increased expression of AKAP5 mRNA

NCBI chr 6:100,787,169...100,796,712
Ensembl chr 6:100,790,148...100,796,620

G

A-kinase anchoring protein 8

decreases expression

ISO

bisphenol F results in decreased expression of AKAP8 mRNA

NCBI chr 7:11,966,769...11,983,056
Ensembl chr 7:11,966,772...11,982,900

G

A-kinase anchoring protein 8 like

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AKAP8L mRNA
bisphenol F results in decreased expression of AKAP8L mRNA

PMID:36041667 PMID:38685157

NCBI chr 7:11,983,215...12,012,843
Ensembl chr 7:11,982,721...12,012,811

G

A-kinase anchoring protein 9

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of AKAP9 gene

NCBI chr 4:31,011,475...31,147,338
Ensembl chr 4:31,011,475...31,147,338

G

akirin 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AKIRIN1 mRNA
bisphenol F results in increased expression of AKIRIN1 mRNA

PMID:28628672 PMID:38685157

NCBI chr 5:141,274,174...141,289,617
Ensembl chr 5:141,274,175...141,289,575

G

AT-hook transcription factor

decreases expression

ISO

bisphenol F results in decreased expression of AKNA mRNA

NCBI chr 5:81,792,928...81,839,936
Ensembl chr 5:81,792,929...81,831,528

G

aldo-keto reductase family 1 member A1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AKR1A1 mRNA
bisphenol F results in increased expression of AKR1A1 protein

PMID:28628672 PMID:34186270

NCBI chr 5:135,329,605...135,367,037
Ensembl chr 5:135,329,606...135,367,035

G

aldo-keto reductase family 1 member B1

increases expression

ISO

bisphenol F results in increased expression of AKR1B1 protein

NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:63,899,222...63,913,315

G

aldo-keto reductase family 1, member C1

increases expression

ISO

bisphenol F results in increased expression of AKR1C1 protein
bisphenol F results in increased expression of AKR1C6 mRNA

PMID:34186270 PMID:38685157

NCBI chr17:70,720,397...70,747,285
Ensembl chr17:70,720,398...70,747,247

G

aldo-keto reductase family 1, member C2

increases expression
decreases expression

ISO

bisphenol F results in increased expression of AKR1C2 protein
bisphenol F results in decreased expression of AKR1C2 mRNA

PMID:34186270 PMID:38568856

NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686

G

aldo-keto reductase family 1, member C3

increases expression

ISO

bisphenol F results in increased expression of AKR1C3 protein

NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438

G

aldo-keto reductase family 1, member D1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of AKR1D1 mRNA

NCBI chr 4:67,121,288...67,154,543
Ensembl chr 4:67,120,024...67,154,540

G

aldo-keto reductase family 7, member A2

increases expression

ISO

bisphenol F results in increased expression of AKR7A2 protein

NCBI chr 5:156,835,589...156,844,127
Ensembl chr 5:156,835,551...156,844,109

G

AKT serine/threonine kinase 1

decreases expression
increases expression
multiple interactions
increases phosphorylation
increases acetylation

EXP
ISO

4,4'-bisphenol F results in decreased expression of AKT1 mRNA
bisphenol F results in increased expression of AKT1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of AKT1 mRNA
bisphenol F results in increased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [bisphenol F results in increased phosphorylation of AKT1 protein]; Fulvestrant inhibits the reaction [bisphenol F results in increased phosphorylation of AKT1 protein]
bisphenol F results in decreased expression of AKT1 protein modified form
bisphenol F results in increased acetylation of AKT1 protein

PMID:26186136 PMID:31332466 PMID:32750123 PMID:34147605 PMID:36041667 More...

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

AKT1 substrate 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AKT1S1 mRNA

NCBI chr 1:104,469,823...104,476,168
Ensembl chr 1:104,469,803...104,476,167

G

AKT serine/threonine kinase 2

increases expression

ISO

bisphenol F results in increased expression of AKT2 mRNA

NCBI chr 1:92,004,705...92,061,420
Ensembl chr 1:92,014,859...92,061,420

G

AKT serine/threonine kinase 3

decreases expression

EXP

4,4'-bisphenol F results in decreased expression of AKT3 mRNA

NCBI chr13:91,475,839...91,758,060
Ensembl chr13:91,475,839...91,748,020

G

aminolevulinate dehydratase

decreases expression

ISO

bisphenol F results in decreased expression of ALAD mRNA

NCBI chr 5:80,977,562...80,987,901
Ensembl chr 5:80,977,562...80,988,041

G

5'-aminolevulinate synthase 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ALAS1 mRNA

NCBI chr 8:115,755,238...115,768,642
Ensembl chr 8:115,755,238...115,768,642

G

5'-aminolevulinate synthase 2

decreases expression

ISO

bisphenol F results in decreased expression of ALAS2 mRNA

NCBI chr X:22,890,650...22,914,046
Ensembl chr X:22,890,689...22,914,043

G

albumin superfamily member 1

decreases expression

ISO

bisphenol F results in decreased expression of ALBFM1 mRNA

NCBI chr14:17,762,615...17,814,075
Ensembl chr14:17,762,617...17,809,221

G

activated leukocyte cell adhesion molecule

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of ALCAM mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ALCAM mRNA

PMID:30951980 PMID:36041667

NCBI chr11:61,804,932...62,005,250
Ensembl chr11:61,805,049...62,006,876

G

aldehyde dehydrogenase 16 family, member A1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ALDH16A1 gene

NCBI chr 1:104,763,200...104,776,270
Ensembl chr 1:104,763,055...104,776,270

G

aldehyde dehydrogenase 18 family, member A1

increases expression

ISO

bisphenol F results in increased expression of ALDH18A1 protein

NCBI chr 1:249,325,082...249,357,383
Ensembl chr 1:249,325,082...249,357,383

G

aldehyde dehydrogenase 1 family, member A1

increases expression

ISO

bisphenol F results in increased expression of ALDH1A1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500

G

aldehyde dehydrogenase 1 family, member A2

increases expression

ISO

bisphenol F results in increased expression of ALDH1A2 mRNA
bisphenol F results in increased expression of ALDH1A2 protein

PMID:30951980 PMID:34186270

NCBI chr 8:80,758,641...80,837,891
Ensembl chr 8:80,758,142...80,837,883

G

aldehyde dehydrogenase 1 family, member A3

decreases expression
increases expression
multiple interactions

ISO

bisphenol F results in decreased expression of ALDH1A3 mRNA
bisphenol F results in increased expression of ALDH1A3 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ALDH1A3 mRNA

PMID:28591870 PMID:28628672 PMID:30951980

NCBI chr 1:129,392,516...129,436,552
Ensembl chr 1:129,392,516...129,427,777

G

aldehyde dehydrogenase 1 family, member B1

increases expression

ISO

bisphenol F results in increased expression of ALDH1B1 protein

NCBI chr 5:64,859,000...64,864,008
Ensembl chr 5:64,858,934...64,864,365

G

aldehyde dehydrogenase 1 family, member L1

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ALDH1L1 mRNA
bisphenol F results in increased expression of ALDH1L1 protein

PMID:34186270 PMID:36041667

NCBI chr 4:124,617,182...124,663,674
Ensembl chr 4:124,617,217...124,664,704

G

aldehyde dehydrogenase 1 family, member L2

increases expression

ISO

bisphenol F results in increased expression of ALDH1L2 protein

NCBI chr 7:22,141,872...22,193,403
Ensembl chr 7:22,141,842...22,193,398

G

aldehyde dehydrogenase 2 family member

increases expression

ISO

bisphenol F results in increased expression of ALDH2 protein

NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219

G

aldehyde dehydrogenase 3 family, member A2

increases expression

ISO

bisphenol F results in increased expression of ALDH3A2 protein
bisphenol F results in increased expression of ALDH3A2 mRNA

PMID:34186270 PMID:38685157

NCBI chr10:46,427,789...46,448,449
Ensembl chr10:46,407,993...46,448,648

G

aldehyde dehydrogenase 3 family, member B1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ALDH3B1 gene

NCBI chr 1:210,574,545...210,605,188
Ensembl chr 1:210,573,661...210,610,538

G

aldehyde dehydrogenase 4 family, member A1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ALDH4A1 mRNA
bisphenol F results in increased expression of ALDH4A1 mRNA
bisphenol F results in increased expression of ALDH4A1 protein

PMID:28628672 PMID:34186270 PMID:38685157

NCBI chr 5:157,163,189...157,188,673
Ensembl chr 5:157,162,945...157,188,673

G

aldehyde dehydrogenase 5 family, member A1

increases expression

ISO

bisphenol F results in increased expression of ALDH5A1 protein
bisphenol F results in increased expression of ALDH5A1 mRNA

PMID:34186270 PMID:38685157

NCBI chr17:40,560,373...40,586,711
Ensembl chr17:40,558,347...40,586,714

G

aldehyde dehydrogenase 6 family, member A1

increases expression

ISO

bisphenol F results in increased expression of ALDH6A1 protein

NCBI chr 6:109,809,092...109,829,725
Ensembl chr 6:109,809,122...109,829,743

G

aldehyde dehydrogenase 7 family, member A1

increases expression

ISO

bisphenol F results in increased expression of ALDH7A1 protein

NCBI chr18:52,208,035...52,240,293
Ensembl chr18:52,204,161...52,240,467

G

aldehyde dehydrogenase 9 family, member A1

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ALDH9A1 gene
bisphenol F results in increased expression of ALDH9A1 protein

PMID:31601247 PMID:34186270

NCBI chr13:82,038,679...82,055,478
Ensembl chr13:82,038,533...82,055,481

G

aldolase, fructose-bisphosphate A

increases expression

ISO

bisphenol F results in increased expression of ALDOA protein

NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:190,832,820...190,838,211

G

aldolase, fructose-bisphosphate C

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ALDOC protein
bisphenol F results in decreased expression of ALDOC mRNA

PMID:34186270 PMID:38685157

NCBI chr10:63,715,544...63,719,133
Ensembl chr10:63,715,489...63,719,133

G

ALG10, alpha-1,2-glucosyltransferase

increases expression

ISO

bisphenol F results in increased expression of ALG10B mRNA

NCBI chr 7:123,214,636...123,225,104
Ensembl chr 7:123,214,636...123,225,104

G

ALG12, alpha-1,6-mannosyltransferase

multiple interactions
decreases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ALG12 gene
bisphenol F results in decreased expression of ALG12 mRNA

PMID:31601247 PMID:38685157

NCBI chr 7:121,774,796...121,789,175
Ensembl chr 7:121,768,234...121,788,983

G

ALG2, alpha-1,3/1,6-mannosyltransferase

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ALG2 mRNA
bisphenol F results in increased expression of ALG2 protein

PMID:34186270 PMID:36041667

NCBI chr 5:66,564,328...66,568,887
Ensembl chr 5:66,564,330...66,568,887

G

ALG3, alpha-1,3- mannosyltransferase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ALG3 mRNA

NCBI chr11:93,804,859...93,810,403
Ensembl chr11:93,804,891...93,812,060

G

ALG5, dolichyl-phosphate beta-glucosyltransferase

increases expression

ISO

bisphenol F results in increased expression of ALG5 protein

NCBI chr 2:141,087,126...141,101,397
Ensembl chr 2:141,087,147...141,102,951

G

ALG8, alpha-1,3-glucosyltransferase

multiple interactions

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of ALG8 mRNA

NCBI chr 1:161,095,570...161,115,533
Ensembl chr 1:161,095,412...161,115,527

G

alkB homolog 1, histone H2A dioxygenase

decreases expression

ISO

bisphenol F results in decreased expression of ALKBH1 mRNA

NCBI chr 6:112,799,234...112,819,708
Ensembl chr 6:112,799,234...112,819,708

G

alkB homolog 2, alpha-ketoglutarate-dependent dioxygenase

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ALKBH2 mRNA
bisphenol F results in decreased expression of ALKBH2 mRNA

PMID:36041667 PMID:38685157

NCBI chr12:48,156,825...48,161,489
Ensembl chr12:48,156,827...48,161,483

G

alkB homolog 3, alpha-ketoglutarate-dependent dioxygenase

decreases expression

ISO

bisphenol F results in decreased expression of ALKBH3 mRNA

NCBI chr 3:100,394,942...100,429,466
Ensembl chr 3:100,380,273...100,427,294

G

alkB homolog 4, lysine demethylase

decreases expression

ISO

bisphenol F results in decreased expression of ALKBH4 mRNA

NCBI chr12:26,160,643...26,166,560
Ensembl chr12:26,160,643...26,166,560

G

alkB homolog 5, RNA demethylase

increases expression

ISO

bisphenol F results in increased expression of ALKBH5 mRNA

NCBI chr10:45,844,411...45,865,853
Ensembl chr10:45,843,656...45,869,658

G

alkB homolog 6

decreases expression

ISO

bisphenol F results in decreased expression of ALKBH6 mRNA

NCBI chr 1:94,690,979...94,696,429
Ensembl chr 1:94,691,822...94,696,427

G

alkB homolog 7

decreases methylation
multiple interactions

ISO
EXP

bisphenol F results in decreased methylation of ALKBH7 gene
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ALKBH7 mRNA

PMID:31601247 PMID:36041667

NCBI chr 9:1,925,896...1,928,048
Ensembl chr 9:1,925,743...1,928,048

G

alkB homolog 8, tRNA methyltransferase

increases expression

ISO

bisphenol F results in increased expression of ALKBH8 mRNA

NCBI chr 6:6,121,402...6,198,226
Ensembl chr 6:6,124,253...6,198,080

G

arachidonate 12-lipoxygenase, 12S type

decreases expression
increases expression

EXP
ISO

4,4'-bisphenol F results in decreased expression of ALOX12 mRNA
bisphenol F results in increased expression of ALOX12 mRNA

PMID:26186136 PMID:30951980

NCBI chr10:55,456,923...55,469,239
Ensembl chr10:55,456,928...55,469,199

G

arachidonate 15-lipoxygenase

increases expression

ISO

bisphenol F results in increased expression of ALOX15 mRNA

NCBI chr10:55,559,060...55,567,535
Ensembl chr10:55,559,061...55,567,723

G

alpha-kinase 1

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ALPK1 mRNA
bisphenol F results in decreased expression of ALPK1 mRNA

PMID:28628672 PMID:38685157

NCBI chr 2:218,801,425...218,924,013
Ensembl chr 2:218,780,189...218,921,646

G

alpha-kinase 2

increases expression
decreases methylation
multiple interactions

ISO

bisphenol F results in increased expression of ALPK2 mRNA
bisphenol F results in decreased methylation of ALPK2 gene
[bisphenol F co-treated with Fulvestrant] results in decreased methylation of ALPK2 gene

PMID:30951980 PMID:31601247

NCBI chr18:61,045,717...61,161,703
Ensembl chr18:61,045,380...61,175,985

G

alsin Rho guanine nucleotide exchange factor ALS2

increases expression

ISO

bisphenol F results in increased expression of ALS2 mRNA

NCBI chr 9:68,107,310...68,180,192
Ensembl chr 9:68,107,528...68,179,660

G

ALS2 C-terminal like

decreases expression

ISO

bisphenol F results in decreased expression of ALS2CL mRNA

NCBI chr 8:119,746,498...119,762,824
Ensembl chr 8:119,743,248...119,762,843

G

ALX homeobox 1

increases expression

ISO

bisphenol F results in increased expression of ALX1 mRNA

NCBI chr 7:40,044,185...40,063,778
Ensembl chr 7:40,033,676...40,063,778

G

ALX homeobox 4

affects expression

ISO

bisphenol F affects the expression of ALX4 mRNA

NCBI chr 3:100,067,052...100,103,624
Ensembl chr 3:100,067,052...100,103,624

G

Aly/REF export factor

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ALYREF mRNA
bisphenol F results in increased expression of ALYREF mRNA
bisphenol F results in increased expression of ALYREF mRNA; bisphenol F results in increased expression of ALYREF protein

PMID:28628672 PMID:34186270 PMID:38568856 PMID:38685157

NCBI chr10:106,369,750...106,373,395
Ensembl chr10:106,369,750...106,373,395

G

alpha-methylacyl-CoA racemase

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of AMACR gene

NCBI chr 2:61,673,291...61,685,381
Ensembl chr 2:61,670,475...61,685,379

G

amidohydrolase domain containing 2

increases expression

ISO

bisphenol F results in increased expression of AMDHD2 protein

NCBI chr10:13,692,136...13,700,632
Ensembl chr10:13,692,146...13,700,632

G

APC membrane recruitment protein 3

increases expression

ISO

bisphenol F results in increased expression of AMER3 mRNA

NCBI chr 9:44,286,274...44,298,246
Ensembl chr 9:44,268,722...44,351,398

G

adhesion molecule with Ig like domain 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AMIGO3 mRNA

NCBI chr 8:117,620,499...117,622,025
Ensembl chr 8:117,616,629...117,626,577

G

amnion associated transmembrane protein

affects expression

ISO

bisphenol F affects the expression of AMN mRNA

NCBI chr 6:136,132,567...136,140,008
Ensembl chr 6:136,132,567...136,140,008

G

antagonist of mitotic exit network 1 homolog

decreases expression

ISO

bisphenol F results in decreased expression of AMN1 mRNA

NCBI chr 4:183,886,469...183,913,411
Ensembl chr 4:183,886,474...183,913,411

G

angiomotin

increases expression

ISO

bisphenol F results in increased expression of AMOT mRNA

NCBI chr X:113,778,990...113,837,846
Ensembl chr X:113,781,526...113,837,482

G

angiomotin like 2

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of AMOTL2 gene

NCBI chr 8:112,182,060...112,198,032
Ensembl chr 8:112,181,863...112,198,030

G

adenosine monophosphate deaminase 2

multiple interactions
increases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AMPD2 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AMPD2 mRNA
bisphenol F results in increased expression of AMPD2 protein

PMID:28628672 PMID:34186270 PMID:36041667

NCBI chr 2:198,395,767...198,408,514
Ensembl chr 2:198,395,768...198,408,796

G

adenosine monophosphate deaminase 3

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of AMPD3 gene

NCBI chr 1:174,319,526...174,364,605
Ensembl chr 1:174,294,867...174,364,608

G

aminomethyltransferase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AMT mRNA

NCBI chr 8:117,859,700...117,866,692
Ensembl chr 8:117,860,345...117,866,803

G

anaphase promoting complex subunit 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] affects the expression of ANAPC1 mRNA

NCBI chr 3:136,303,350...136,383,464
Ensembl chr 3:136,303,413...136,383,464

G

anaphase promoting complex subunit 13

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ANAPC13 mRNA
bisphenol F results in decreased expression of ANAPC13 mRNA

PMID:36041667 PMID:38685157

NCBI chr 8:112,084,405...112,092,821
Ensembl chr 8:112,084,405...112,092,821

G

anaphase promoting complex subunit 15

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ANAPC15 mRNA
bisphenol F results in decreased expression of ANAPC15 mRNA

PMID:36041667 PMID:38685157

NCBI chr 1:165,650,478...165,678,004
Ensembl chr 1:165,675,754...165,679,501

G

anaphase promoting complex subunit 2

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ANAPC2 gene

NCBI chr 3:28,484,590...28,496,338
Ensembl chr 3:28,484,614...28,496,337

G

anaphase promoting complex subunit 7

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ANAPC7 mRNA

NCBI chr12:39,793,518...39,821,614
Ensembl chr12:39,794,349...39,821,066

G

angiogenin

decreases expression

ISO

bisphenol F results in decreased expression of ANG mRNA

NCBI chr15:26,786,233...26,796,883
Ensembl chr15:26,786,065...26,801,106

G

angel homolog 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ANGEL2 mRNA

NCBI chr13:105,041,727...105,060,640
Ensembl chr13:105,041,728...105,060,640

G

angiopoietin 1

increases expression

ISO

bisphenol F results in increased expression of ANGPT1 mRNA

PMID:30951980 PMID:33476716

NCBI chr 7:75,415,959...75,668,696
Ensembl chr 7:75,418,218...75,668,696

G

angiopoietin 2

increases expression
decreases methylation
decreases expression

ISO

bisphenol F results in increased expression of ANGPT2 mRNA
bisphenol F results in decreased methylation of ANGPT2 gene
bisphenol F results in decreased expression of ANGPT2 mRNA

PMID:30951980 PMID:38338858 PMID:38685157

NCBI chr16:77,790,760...77,841,241
Ensembl chr16:77,790,563...77,841,239

G

angiopoietin-like 1

increases expression

ISO

bisphenol F results in increased expression of ANGPTL1 mRNA

NCBI chr13:71,463,913...71,531,810
Ensembl chr13:71,511,727...71,531,818

G

angiopoietin-like 2

increases expression

ISO

bisphenol F results in increased expression of ANGPTL2 mRNA

PMID:30951980 PMID:38685157

NCBI chr 3:36,914,876...36,944,715
Ensembl chr 3:36,914,745...36,945,876

G

angiopoietin-like 4

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of ANGPTL4 mRNA
bisphenol F results in increased expression of ANGPTL4 mRNA

PMID:30951980 PMID:34627044

NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:15,252,473...15,258,681

G

angiopoietin-like 6

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ANGPTL6 mRNA
bisphenol F results in decreased expression of ANGPTL6 mRNA

PMID:36041667 PMID:38685157

NCBI chr 8:27,689,804...27,696,172
Ensembl chr 8:27,689,806...27,696,111

G

angiopoietin like 7

increases expression

ISO

bisphenol F results in increased expression of ANGPTL7 mRNA

NCBI chr 5:164,215,223...164,220,408
Ensembl chr 5:164,215,223...164,220,584

G

angiopoietin-like 8

multiple interactions
decreases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ANGPTL8 gene
bisphenol F results in decreased expression of ANGPTL8 mRNA

PMID:31601247 PMID:38685157

NCBI chr 8:28,652,555...28,654,581
Ensembl chr 8:28,652,555...28,654,581

G

ankyrin 2

increases expression

ISO

bisphenol F results in increased expression of ANK2 protein

NCBI chr 2:218,052,555...218,628,414
Ensembl chr 2:218,052,555...218,537,259

G

ankyrin repeat and FYVE domain containing 1

increases expression

ISO

bisphenol F results in increased expression of ANKFY1 mRNA

NCBI chr10:57,810,781...57,882,495
Ensembl chr10:57,810,781...57,882,495

G

ANKH inorganic pyrophosphate transport regulator

increases expression

ISO

bisphenol F results in increased expression of ANK mRNA

NCBI chr 2:79,883,350...80,011,222
Ensembl chr 2:79,883,544...80,011,699

G

ankyrin repeat and KH domain containing 1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of ANKHD1 gene

NCBI chr18:28,436,296...28,534,954
Ensembl chr18:28,436,394...28,534,954

G

ankyrin repeat and MYND domain containing 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ANKMY2 mRNA

NCBI chr 6:58,616,251...58,657,634
Ensembl chr 6:58,615,243...58,657,685

G

ankyrin repeat domain 1

increases expression

ISO

bisphenol F results in increased expression of ANKRD1 mRNA

NCBI chr 1:243,228,460...243,237,014
Ensembl chr 1:243,228,448...243,263,751

G

ankyrin repeat domain 10

decreases expression

ISO

bisphenol F results in decreased expression of ANKRD10 mRNA

NCBI chr16:84,566,021...84,591,849
Ensembl chr16:84,568,506...84,591,846

G

ankyrin repeat domain containing 11

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ANKRD11 mRNA

NCBI chr19:67,848,836...68,007,491
Ensembl chr19:67,848,844...68,007,491

G

ankyrin repeat domain 12

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ANKRD12 mRNA

NCBI chr 9:113,030,127...113,134,816
Ensembl chr 9:113,030,919...113,134,762

G

ankyrin repeat domain 13a

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ANKRD13A mRNA

NCBI chr12:47,458,828...47,488,959
Ensembl chr12:47,458,831...47,489,312

G

ankyrin repeat domain 13B

decreases expression

ISO

bisphenol F results in decreased expression of ANKRD13B mRNA

NCBI chr10:62,817,791...62,836,456
Ensembl chr10:62,817,778...62,836,635

G

ankyrin repeat domain 16

decreases expression

ISO

bisphenol F results in decreased expression of ANKRD16 mRNA

NCBI chr17:71,645,171...71,658,377
Ensembl chr17:71,647,107...71,658,377

G

ankyrin repeat domain 22

decreases methylation

ISO

bisphenol F results in decreased methylation of ANKRD22 gene

NCBI chr 1:241,052,235...241,083,737
Ensembl chr 1:241,052,237...241,105,559

G

ankyrin repeat domain 23

decreases expression

ISO

bisphenol F results in decreased expression of ANKRD23 mRNA

NCBI chr 9:46,269,107...46,274,578
Ensembl chr 9:46,269,107...46,274,510

G

ankyrin repeat domain 24

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ANKRD24 mRNA
bisphenol F results in decreased expression of ANKRD24 mRNA

PMID:28628672 PMID:38685157

NCBI chr 7:8,712,720...8,731,910
Ensembl chr 7:8,712,722...8,731,910

G

ankyrin repeat domain 28

increases expression

ISO

bisphenol F results in increased expression of ANKRD28 mRNA

NCBI chr16:6,924,868...7,056,593
Ensembl chr16:6,924,882...7,056,593

G

ankyrin repeat domain 33B

increases expression

ISO

bisphenol F results in increased expression of ANKRD33B mRNA

NCBI chr 2:83,988,505...84,070,311
Ensembl chr 2:83,993,974...84,070,936

G

ankyrin repeat domain 37

decreases expression

ISO

bisphenol F results in decreased expression of ANKRD37 mRNA

NCBI chr16:53,001,487...53,004,545
Ensembl chr16:52,994,740...53,004,545

G

ANKRD40 C-terminal like

decreases methylation

ISO

bisphenol F results in decreased methylation of ANKRD40CL gene

NCBI chr10:79,717,798...79,732,358
Ensembl chr10:79,728,105...79,732,218

G

ankyrin repeat domain 46

increases expression

ISO

bisphenol F results in increased expression of ANKRD46 mRNA

NCBI chr 7:69,532,303...69,553,311
Ensembl chr 7:69,532,304...69,545,421

G

ankyrin repeat domain containing 50

increases expression

ISO

bisphenol F results in increased expression of ANKRD50 mRNA

NCBI chr 2:123,394,311...123,428,788
Ensembl chr 2:123,396,606...123,427,340

G

ankyrin repeat domain 52

increases expression

ISO

bisphenol F results in increased expression of ANKRD52 mRNA

NCBI chr 7:1,390,730...1,410,139
Ensembl chr 7:1,391,325...1,407,410

G

ankyrin repeat domain 6

decreases methylation
multiple interactions

ISO

bisphenol F results in decreased methylation of ANKRD6 gene
[bisphenol F co-treated with Fulvestrant] results in decreased methylation of ANKRD6 gene

NCBI chr 5:51,999,225...52,139,623
Ensembl chr 5:51,999,221...52,139,594

G

ankyrin repeat and sterile alpha motif domain containing 1B

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ANKS1B gene

NCBI chr 7:26,200,649...27,366,552
Ensembl chr 7:26,201,240...27,364,943

G

ankyrin repeat and sterile alpha motif domain containing 3

decreases expression

ISO

bisphenol F results in decreased expression of ANKS3 mRNA

NCBI chr10:11,121,504...11,142,261
Ensembl chr10:11,121,553...11,142,491

G

ankyrin repeat and sterile alpha motif domain containing 4B

increases expression

ISO

bisphenol F results in increased expression of ANKS4B mRNA

NCBI chr 1:183,934,528...183,989,127
Ensembl chr 1:183,978,769...183,989,122

G

ankyrin repeat and zinc finger peptidyl tRNA hydrolase 1

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ANKZF1 mRNA
bisphenol F results in decreased expression of ANKZF1 mRNA

PMID:28628672 PMID:38685157

NCBI chr 9:84,136,862...84,143,830
Ensembl chr 9:84,136,862...84,145,091

G

anoctamin 1

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of ANO1 mRNA
Fulvestrant inhibits the reaction [bisphenol F results in increased expression of ANO1 mRNA]

PMID:30951980 PMID:34831106

NCBI chr 1:209,180,755...209,329,413
Ensembl chr 1:209,180,755...209,329,550

G

anoctamin 10

increases expression

ISO

bisphenol F results in increased expression of ANO10 protein

NCBI chr 8:130,719,177...130,838,243
Ensembl chr 8:130,718,755...130,877,636

G

anoctamin 3

decreases expression
multiple interactions

ISO

bisphenol F results in decreased expression of ANO3 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of ANO3 mRNA

NCBI chr 3:117,690,242...118,004,695
Ensembl chr 3:117,692,103...118,004,675

G

anoctamin 8

decreases expression

ISO

bisphenol F results in decreased expression of ANO8 mRNA

NCBI chr16:18,197,829...18,207,205
Ensembl chr16:18,197,001...18,207,234

G

acidic nuclear phosphoprotein 32 family member A

increases expression

ISO

bisphenol F results in increased expression of ANP32A protein

NCBI chr 8:71,724,578...71,760,922
Ensembl chr 8:71,724,531...71,760,922

G

acidic nuclear phosphoprotein 32 family member B

increases expression

ISO

bisphenol F results in increased expression of ANP32B mRNA

NCBI chr 5:65,538,872...65,561,305
Ensembl chr 5:65,538,535...65,561,437

G

acidic nuclear phosphoprotein 32 family member E

increases expression

ISO

bisphenol F results in increased expression of ANP32E mRNA

NCBI chr 2:186,161,520...186,177,984
Ensembl chr 2:186,161,532...186,177,986

G

alanyl aminopeptidase, membrane

increases expression

ISO

bisphenol F results in increased expression of ANPEP mRNA

NCBI chr 1:143,176,645...143,219,447
Ensembl chr 1:143,176,645...143,195,101

G

adenine nucleotide translocase lysine methyltransferase

decreases expression

ISO

bisphenol F results in decreased expression of ANTKMT mRNA

NCBI chr10:15,316,797...15,320,950
Ensembl chr10:15,316,772...15,318,656

G

ANTXR cell adhesion molecule 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ANTXR2 mRNA
bisphenol F results in increased expression of ANTXR2 mRNA

PMID:28628672 PMID:30951980 PMID:38685157

NCBI chr14:11,845,774...11,986,166
Ensembl chr14:11,845,700...11,986,168

G

annexin A1

increases expression
decreases expression
multiple interactions

ISO

bisphenol F results in increased expression of ANXA1 mRNA
bisphenol F results in increased expression of ANXA1 protein
bisphenol F results in decreased expression of ANXA1 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of ANXA1 mRNA

PMID:30951980 PMID:33476716 PMID:34186270

NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:227,287,717...227,306,831

G

annexin A10

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ANXA10 mRNA

NCBI chr16:32,505,025...32,571,961
Ensembl chr16:32,467,126...32,571,961

G

annexin A11

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ANXA11 mRNA
bisphenol F results in increased expression of ANXA11 mRNA
bisphenol F results in increased expression of ANXA11 protein

PMID:28628672 PMID:34186270 PMID:38685157

NCBI chr16:1,419,627...1,464,590
Ensembl chr16:1,418,351...1,464,839

G

annexin A13

decreases expression

ISO

bisphenol F results in decreased expression of ANXA13 mRNA

NCBI chr 7:91,773,844...91,826,386
Ensembl chr 7:91,770,861...91,826,386

G

annexin A2

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of ANXA2 mRNA
bisphenol F results in increased expression of ANXA2 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of ANXA2 mRNA

PMID:30951980 PMID:34186270

NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:78,986,242...79,022,631

G

annexin A3

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of ANXA3 mRNA
bisphenol F results in increased expression of ANXA3 mRNA

NCBI chr14:13,031,675...13,085,678
Ensembl chr14:13,023,762...13,085,849

G

annexin A5

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of ANXA5 mRNA
bisphenol F results in increased expression of ANXA5 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of ANXA5 mRNA

PMID:30951980 PMID:34186270

NCBI chr 2:121,242,133...121,272,935
Ensembl chr 2:121,242,136...121,281,400

G

annexin A6

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of ANXA6 mRNA
bisphenol F results in increased expression of ANXA6 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of ANXA6 mRNA

PMID:30951980 PMID:34186270

NCBI chr10:39,602,106...39,657,183
Ensembl chr10:39,602,106...39,657,359

G

annexin A7

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of ANXA7 mRNA
bisphenol F results in increased expression of ANXA7 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of ANXA7 mRNA

PMID:30951980 PMID:34186270

NCBI chr15:3,869,180...3,897,827
Ensembl chr15:3,870,974...3,898,891

G

annexin A8

increases expression

ISO

bisphenol F results in increased expression of ANXA8 mRNA

NCBI chr16:9,403,267...9,418,317
Ensembl chr16:9,403,353...9,418,310

G

annexin A9

decreases expression

ISO

bisphenol F results in decreased expression of ANXA9 mRNA

NCBI chr 2:185,562,174...185,572,560
Ensembl chr 2:185,562,174...185,572,560

G

amine oxidase, copper containing 2, pseudogene 1

decreases expression

ISO

bisphenol F results in decreased expression of AOC2 mRNA

NCBI chr10:86,767,268...86,768,734

G

amine oxidase, copper containing 3

increases expression

ISO

bisphenol F results in increased expression of AOC3 protein

NCBI chr10:86,773,018...86,780,961

G

aminopeptidase O

increases expression
decreases expression

ISO

bisphenol F results in increased expression of AOPEP mRNA
bisphenol F results in decreased expression of AOPEP mRNA

PMID:30951980 PMID:38685157

NCBI chr17:1,817,001...2,133,008
Ensembl chr17:1,817,001...2,133,104

G

aldehyde oxidase 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AOX1 mRNA

NCBI chr 9:67,073,831...67,152,980
Ensembl chr 9:67,073,821...67,152,980

G

adaptor related protein complex 1 subunit beta 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AP1B1 mRNA
bisphenol F results in increased expression of AP1B1 protein

PMID:28628672 PMID:34186270

NCBI chr14:84,093,529...84,144,835
Ensembl chr14:84,093,559...84,144,892

G

adaptor related protein complex 1 subunit gamma 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AP1G1 mRNA
bisphenol F results in increased expression of AP1G1 mRNA
bisphenol F results in increased expression of AP1G1 protein

PMID:28628672 PMID:34186270 PMID:38685157

NCBI chr19:54,654,101...54,740,586
Ensembl chr19:54,620,807...54,740,586

G

adaptor related protein complex 1 subunit gamma 2

decreases expression

ISO

bisphenol F results in decreased expression of AP1G2 mRNA

NCBI chr15:32,541,528...32,549,392
Ensembl chr15:32,541,528...32,549,280

G

adaptor related protein complex 1 subunit mu 1

increases expression

ISO

bisphenol F results in increased expression of AP1M1 protein

NCBI chr16:17,620,910...17,636,431
Ensembl chr16:17,616,187...17,636,462

G

adaptor related protein complex 1 subunit sigma 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AP1S1 mRNA

NCBI chr12:25,261,958...25,272,483
Ensembl chr12:25,262,036...25,272,483

G

adaptor related protein complex 1 subunit sigma 2

increases expression

ISO

bisphenol F results in increased expression of AP1S2 mRNA

NCBI chr X:34,204,601...34,230,819
Ensembl chr X:34,204,603...34,228,529

G

adaptor related protein complex 2 subunit alpha 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AP2A1 mRNA

NCBI chr 1:104,520,789...104,550,655
Ensembl chr 1:104,520,792...104,550,655

G

adaptor related protein complex 2 subunit beta 1

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AP2B1 mRNA
bisphenol F results in increased expression of AP2B1 mRNA

PMID:36041667 PMID:38685157

NCBI chr10:68,596,925...68,702,547
Ensembl chr10:68,597,093...68,702,539

G

adaptor related protein complex 2 subunit sigma 1

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AP2S1 mRNA
bisphenol F results in decreased expression of AP2S1 mRNA

PMID:36041667 PMID:38685157

NCBI chr 1:86,545,601...86,557,007
Ensembl chr 1:86,545,350...86,557,009

G

adaptor related protein complex 3 subunit beta 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of AP3B2 mRNA

NCBI chr 1:144,821,819...144,854,533
Ensembl chr 1:144,821,819...144,854,432

G

adaptor related protein complex 3 subunit mu 1

increases expression

ISO

bisphenol F results in increased expression of AP3M1 protein

NCBI chr15:3,285,591...3,314,139
Ensembl chr15:3,295,444...3,313,104

G

adaptor related protein complex 3 subunit sigma 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AP3S1 mRNA

NCBI chr18:41,649,321...41,718,221
Ensembl chr18:41,648,796...41,767,641

G

adaptor related protein complex 3 subunit sigma 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of AP3S2 mRNA

NCBI chr 1:143,228,131...143,268,573
Ensembl chr 1:143,228,135...143,268,573

G

adaptor related protein complex 4 subunit mu 1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of AP4M1 gene

NCBI chr12:22,163,474...22,171,734
Ensembl chr12:22,163,466...22,171,731

G

adaptor related protein complex 5 subunit beta 1

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AP5B1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AP5B1 mRNA

PMID:28628672 PMID:36041667

NCBI chr 1:212,305,612...212,309,643
Ensembl chr 1:212,305,604...212,309,629

G

adaptor related protein complex 5 subunit sigma 1

multiple interactions

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of AP5S1 mRNA

NCBI chr 3:138,882,634...138,885,940
Ensembl chr 3:138,882,634...138,888,899

G

adaptor related protein complex 5 subunit zeta 1

decreases expression

ISO

bisphenol F results in decreased expression of AP5Z1 mRNA

NCBI chr12:17,207,315...17,222,975
Ensembl chr12:17,207,315...17,222,467

G

amyloid beta precursor protein binding family B member 1 interacting protein

increases expression

ISO

bisphenol F results in increased expression of APBB1IP protein

NCBI chr17:89,849,474...89,941,099
Ensembl chr17:89,671,716...89,941,089

G

amyloid beta precursor protein binding family B member 2

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of APBB2 gene

NCBI chr14:41,849,638...42,232,930
Ensembl chr14:41,911,785...42,232,280

G

amyloid beta precursor protein binding family B member 3

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of APBB3 mRNA
bisphenol F results in decreased expression of APBB3 mRNA

PMID:36041667 PMID:38685157

NCBI chr18:28,547,205...28,554,383
Ensembl chr18:28,547,205...28,554,383

G

APC regulator of WNT signaling pathway 2

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of APC2 mRNA
bisphenol F results in decreased expression of APC2 mRNA

PMID:36041667 PMID:38685157

NCBI chr 7:10,043,010...10,065,037
Ensembl chr 7:10,043,010...10,065,210

G

acylaminoacyl-peptide hydrolase

increases expression

ISO

bisphenol F results in increased expression of APEH protein

NCBI chr 8:117,652,390...117,661,502
Ensembl chr 8:117,652,393...117,661,711

G

apelin receptor early endogenous ligand

increases expression

ISO

bisphenol F results in increased expression of APELA mRNA

NCBI chr16:29,460,855...29,469,962
Ensembl chr16:29,460,812...29,469,955

G

aph-1 homolog A, gamma secretase subunit

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of APH1A mRNA

NCBI chr 2:186,123,023...186,130,886
Ensembl chr 2:186,127,323...186,132,045

G

aph-1 homolog B, gamma secretase subunit

increases expression

ISO

bisphenol F results in increased expression of APH1B mRNA

NCBI chr 8:76,310,380...76,334,146
Ensembl chr 8:76,310,380...76,331,428

G

apoptosis inhibitor 5

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of API5 mRNA

NCBI chr 3:100,833,417...100,858,580
Ensembl chr 3:100,833,417...100,858,580

G

apelin receptor

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of APLNR mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of APLNR mRNA

PMID:30951980 PMID:36041667

NCBI chr 3:90,624,055...90,627,700
Ensembl chr 3:90,624,012...90,627,908

G

amyloid beta precursor like protein 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of APLP1 mRNA

NCBI chr 1:94,824,330...94,834,705
Ensembl chr 1:94,824,072...94,834,610

G

amyloid beta precursor like protein 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of APLP2 mRNA

NCBI chr 8:37,857,407...37,920,487
Ensembl chr 8:37,857,407...37,920,031

G

adipocyte plasma membrane associated protein

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of APMAP mRNA
bisphenol F results in increased expression of APMAP mRNA
bisphenol F results in increased expression of APMAP protein

PMID:28628672 PMID:34186270 PMID:38685157

NCBI chr 3:159,869,451...159,897,727
Ensembl chr 3:159,869,451...159,897,726

G

apolipoprotein A1

increases expression
decreases expression

ISO

bisphenol F results in increased expression of APOA1 mRNA
bisphenol F results in decreased expression of APOA1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:55,423,825...55,425,729

G

apolipoprotein A2

increases expression
decreases expression

ISO

bisphenol F results in increased expression of APOA2 mRNA
bisphenol F results in decreased expression of APOA2 mRNA

PMID:30951980 PMID:38685157

NCBI chr13:86,176,767...86,178,819
Ensembl chr13:86,174,741...86,179,410

G

apolipoprotein A4

increases expression

ISO

bisphenol F results in increased expression of APOA4 mRNA

NCBI chr 8:55,435,779...55,438,160
Ensembl chr 8:55,434,168...55,438,164

G

apolipoprotein B

affects expression
increases expression
multiple interactions

ISO

bisphenol F affects the expression of APOB mRNA
bisphenol F results in increased expression of APOB mRNA
[bisphenol F co-treated with LIF protein] results in decreased expression of APOB mRNA

PMID:30951980 PMID:38685157

NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:36,563,704...36,611,814

G

apolipoprotein C1

increases expression
decreases expression

ISO

bisphenol F results in increased expression of APOC1 protein
bisphenol F results in decreased expression of APOC1 mRNA

PMID:34186270 PMID:38685157

NCBI chr 1:88,475,018...88,479,052
Ensembl chr 1:88,474,663...88,478,155

G

apolipoprotein C2

increases expression
decreases expression

ISO

bisphenol F results in increased expression of APOC2 mRNA
bisphenol F results in decreased expression of APOC2 mRNA

PMID:30951980 PMID:38685157

NCBI chr 1:88,457,397...88,462,365
Ensembl chr 1:88,457,396...88,463,438

G

apolipoprotein C3

decreases expression

ISO

bisphenol F results in decreased expression of APOC3 mRNA

NCBI chr 8:55,428,172...55,430,352
Ensembl chr 8:55,428,024...55,458,679

G

apolipoprotein C4

decreases expression

ISO

bisphenol F results in decreased expression of APOC4 mRNA

NCBI chr 1:88,463,713...88,467,909
Ensembl chr 1:88,463,713...88,468,044

G

apolipoprotein D

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of APOD mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of APOD mRNA

PMID:30951980 PMID:36041667

NCBI chr11:82,936,216...82,957,264
Ensembl chr11:82,936,038...82,957,263

G

apolipoprotein E

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of APOE mRNA
bisphenol F results in increased expression of APOE protein

PMID:34186270 PMID:36041667

NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:88,481,385...88,485,855

G

apolipoprotein L domain containing 1

increases expression

ISO

bisphenol F results in increased expression of APOLD1 mRNA

NCBI chr 4:169,499,728...169,557,075
Ensembl chr 4:169,549,679...169,559,176

G

apolipoprotein M

increases expression

ISO

bisphenol F results in increased expression of APOM mRNA

PMID:30951980 PMID:38685157

NCBI chr20:3,695,618...3,698,218
Ensembl chr20:3,692,737...3,698,218

G

apolipoprotein O

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of APOO mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of APOO mRNA

PMID:28628672 PMID:36041667

NCBI chr X:63,151,736...63,256,696
Ensembl chr X:63,151,814...63,256,690

G

amyloid beta precursor protein

decreases expression
multiple interactions

EXP
ISO

4,4'-bisphenol F results in decreased expression of APP mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of APP mRNA
[bisphenol F co-treated with Fulvestrant] results in decreased methylation of APP gene

PMID:26186136 PMID:31601247 PMID:36041667

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

amyloid beta precursor protein binding protein 2

increases expression

ISO

bisphenol F results in increased expression of APPBP2 mRNA

NCBI chr10:70,555,212...70,597,267
Ensembl chr10:70,555,212...70,597,193

G

adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of APPL1 mRNA

NCBI chr16:2,125,234...2,173,457
Ensembl chr16:2,125,234...2,173,421

G

adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2

decreases expression

ISO

bisphenol F results in decreased expression of APPL2 mRNA

NCBI chr 7:22,019,480...22,072,386
Ensembl chr 7:22,022,963...22,072,385

G

adenine phosphoribosyl transferase

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of APRT protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of APRT mRNA

PMID:34186270 PMID:36041667

NCBI chr19:67,534,737...67,537,027

G

aquaporin 1

increases expression
decreases expression

ISO

bisphenol F results in increased expression of AQP1 mRNA
bisphenol F results in decreased expression of AQP1 mRNA

PMID:30951980 PMID:36706583 PMID:38685157

NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:85,812,784...85,830,504

G

aquaporin 3 (Gill blood group)

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of AQP3 mRNA
[bisphenol F co-treated with LIF protein] results in decreased expression of AQP3 mRNA

NCBI chr 5:61,035,165...61,040,683
Ensembl chr 5:61,035,166...61,040,685

G

aquaporin 4

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of AQP4 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of AQP4 mRNA

PMID:30951980 PMID:36041667

NCBI chr18:6,782,389...6,799,034
Ensembl chr18:6,782,389...6,799,098

G

aquarius intron-binding spliceosomal factor

increases expression

ISO

bisphenol F results in increased expression of AQR mRNA

NCBI chr 3:121,329,287...121,399,375
Ensembl chr 3:121,329,289...121,399,321

G

androgen receptor

decreases activity
decreases expression
affects binding
multiple interactions

ISO
EXP

4,4'-bisphenol F results in decreased activity of AR protein
bisphenol F results in decreased expression of AR mRNA; bisphenol F results in decreased expression of AR protein
bisphenol F binds to AR protein
4,4'-bisphenol F inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; 4,4'-bisphenol F inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; 4,4'-bisphenol F inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; 4,4'-bisphenol F inhibits the reaction [Testosterone binds to and results in increased activity of AR protein]; 4,4'-bisphenol F inhibits the reaction [Testosterone results in increased activity of AR protein]

PMID:15110108 PMID:18973785 PMID:24563381 PMID:25576683 PMID:27561732 More...

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1

increases expression

ISO

bisphenol F results in increased expression of ARAP1 mRNA

NCBI chr 1:165,160,701...165,226,219
Ensembl chr 1:165,160,678...165,226,218

G

ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ARAP3 mRNA
bisphenol F results in decreased expression of ARAP3 mRNA

PMID:30951980 PMID:38685157

NCBI chr18:30,058,739...30,085,415
Ensembl chr18:30,058,275...30,084,865

G

activity-regulated cytoskeleton-associated protein

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ARC mRNA

NCBI chr 7:108,444,959...108,448,413
Ensembl chr 7:108,444,692...108,451,220

G

amphiregulin

increases expression

ISO

bisphenol F results in increased expression of AREG mRNA

NCBI chr14:17,256,384...17,265,641
Ensembl chr14:17,256,384...17,265,641

G

ARF GTPase 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARF1 mRNA
bisphenol F results in increased expression of ARF1 mRNA

PMID:28628672 PMID:38685157

NCBI chr10:44,497,543...44,513,994

G

ADP-ribosylation factor 2

increases expression

ISO

bisphenol F results in increased expression of ARF2 mRNA

NCBI chr10:89,367,843...89,389,644
Ensembl chr10:89,368,044...89,389,651

G

ARF GTPase 3

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ARF3 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ARF3 mRNA

PMID:28628672 PMID:36041667

NCBI chr 7:131,765,039...131,792,075
Ensembl chr 7:131,750,672...131,770,123

G

ARF GTPase 4

increases expression

ISO

bisphenol F results in increased expression of ARF4 protein

NCBI chr16:1,903,238...1,920,012
Ensembl chr16:1,903,371...1,920,011

G

ARF GTPase 5

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ARF5 mRNA
bisphenol F results in decreased expression of ARF5 mRNA

PMID:36041667 PMID:38685157

NCBI chr 4:58,003,919...58,006,898
Ensembl chr 4:58,003,932...58,006,835

G

ARF GTPase activating protein 1

increases expression

ISO

bisphenol F results in increased expression of ARFGAP1 protein

NCBI chr 3:188,462,125...188,477,515
Ensembl chr 3:188,465,648...188,511,078

G

ARF guanine nucleotide exchange factor 1

increases expression

ISO

bisphenol F results in increased expression of ARFGEF1 mRNA

NCBI chr 5:13,764,507...13,859,237
Ensembl chr 5:13,764,975...13,859,237

G

ARF guanine nucleotide exchange factor 2

increases expression

ISO

bisphenol F results in increased expression of ARFGEF2 protein

NCBI chr 3:175,966,575...176,052,715
Ensembl chr 3:175,966,579...176,052,713

G

ARF interacting protein 1

increases expression

ISO

bisphenol F results in increased expression of ARFIP1 protein
bisphenol F results in increased expression of ARFIP1 mRNA

PMID:34186270 PMID:38685157

NCBI chr 2:172,141,862...172,224,464
Ensembl chr 2:172,141,859...172,221,280

G

ARF interacting protein 2

decreases expression

ISO

bisphenol F results in decreased expression of ARFIP2 mRNA

NCBI chr 1:169,387,484...169,392,290
Ensembl chr 1:169,387,485...169,392,166

G

arginase 1

increases expression
decreases expression
multiple interactions

ISO

bisphenol F results in increased expression of ARG1 mRNA
4,4'-bisphenol F results in decreased expression of ARG1 mRNA; 4,4'-bisphenol F results in decreased expression of ARG1 protein
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [4,4'-bisphenol F results in decreased expression of ARG1 mRNA]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [4,4'-bisphenol F results in decreased expression of ARG1 protein]; Fulvestrant inhibits the reaction [4,4'-bisphenol F results in decreased expression of ARG1 mRNA]; Fulvestrant inhibits the reaction [4,4'-bisphenol F results in decreased expression of ARG1 protein]

PMID:30951980 PMID:32044397

NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713

G

arginase 2

decreases expression
multiple interactions

ISO
EXP

bisphenol F results in decreased expression of ARG2 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ARG2 mRNA

PMID:30951980 PMID:36041667

NCBI chr 6:103,669,001...103,694,375
Ensembl chr 6:103,668,988...103,694,375

G

arginine and glutamate rich 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ARGLU1 mRNA

NCBI chr16:87,455,097...87,479,148
Ensembl chr16:87,455,113...87,479,148

G

Rho GTPase activating protein 1

increases expression

ISO

bisphenol F results in increased expression of ARHGAP1 protein

NCBI chr 3:98,077,064...98,099,163
Ensembl chr 3:98,077,150...98,099,154

G

Rho GTPase activating protein 17

increases expression

ISO

bisphenol F results in increased expression of ARHGAP17 protein

NCBI chr 1:187,238,675...187,328,093
Ensembl chr 1:187,238,380...187,327,936

G

Rho GTPase activating protein 19

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ARHGAP19 mRNA

NCBI chr 1:250,519,703...250,566,705
Ensembl chr 1:250,530,214...250,580,190

G

Rho GTPase activating protein 20

increases expression

ISO

bisphenol F results in increased expression of ARHGAP20 mRNA

NCBI chr 8:60,970,480...61,055,199
Ensembl chr 8:60,970,475...61,055,198

G

Rho GTPase activating protein 22

decreases expression
multiple interactions

ISO

bisphenol F results in decreased expression of ARHGAP22 mRNA
[bisphenol F co-treated with Fulvestrant] results in increased methylation of ARHGAP22 gene

PMID:30951980 PMID:31601247

NCBI chr16:8,480,222...8,637,823
Ensembl chr16:8,479,956...8,637,822

G

Rho GTPase activating protein 24

increases expression

ISO

bisphenol F results in increased expression of ARHGAP24 mRNA

PMID:30951980 PMID:38685157

NCBI chr14:7,105,200...7,488,437
Ensembl chr14:7,105,200...7,528,950

G

Rho GTPase activating protein 25

increases expression

ISO

bisphenol F results in increased expression of ARHGAP25 mRNA

NCBI chr 4:121,454,151...121,532,293
Ensembl chr 4:121,454,151...121,552,913

G

Rho GTPase activating protein 27

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ARHGAP27 mRNA
bisphenol F results in decreased expression of ARHGAP27 mRNA

PMID:30951980 PMID:38685157

NCBI chr10:88,780,527...88,813,275
Ensembl chr10:88,780,527...88,814,616

G

Rho GTPase activating protein 28

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of ARHGAP28 mRNA
[bisphenol F co-treated with Fulvestrant] results in decreased methylation of ARHGAP28 gene

PMID:30951980 PMID:31601247

NCBI chr 9:115,277,849...115,444,789
Ensembl chr 9:115,279,734...115,445,008

G

Rho GTPase activating protein 29

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARHGAP29 mRNA
bisphenol F results in increased expression of ARHGAP29 mRNA

PMID:28628672 PMID:30951980

NCBI chr 2:212,744,626...212,816,710
Ensembl chr 2:212,755,803...212,986,729

G

Rho GTPase activating protein 31

increases expression

ISO

bisphenol F results in increased expression of ARHGAP31 mRNA

NCBI chr11:75,544,176...75,657,087
Ensembl chr11:75,544,040...75,661,076

G

Rho GTPase activating protein 35

increases expression

ISO

bisphenol F results in increased expression of ARHGAP35 mRNA

NCBI chr 1:86,330,566...86,447,414
Ensembl chr 1:86,330,566...86,447,414

G

Rho GTPase activating protein 4

decreases expression

ISO

bisphenol F results in decreased expression of ARHGAP4 mRNA

NCBI chr X:156,787,566...156,802,841
Ensembl chr X:156,783,776...156,802,450

G

Rho GTPase activating protein 40

decreases expression

ISO

bisphenol F results in decreased expression of ARHGAP40 mRNA

NCBI chr 3:167,585,665...167,626,433
Ensembl chr 3:167,585,665...167,626,532

G

Rho GTPase activating protein 45

decreases expression

ISO

bisphenol F results in decreased expression of ARHGAP45 mRNA

NCBI chr 7:10,325,515...10,340,955
Ensembl chr 7:10,325,539...10,341,890

G

Rho GTPase activating protein 5

increases expression

ISO

bisphenol F results in increased expression of ARHGAP5 mRNA

NCBI chr 6:75,711,199...75,774,636
Ensembl chr 6:75,711,515...75,774,636

G

Rho GTPase activating protein 8

increases expression

ISO

bisphenol F results in increased expression of ARHGAP8 mRNA

NCBI chr 7:117,723,512...117,782,031
Ensembl chr 7:117,730,578...117,782,030

G

Rho GTPase activating protein 9

decreases expression

ISO

bisphenol F results in decreased expression of ARHGAP9 mRNA

NCBI chr 7:65,034,023...65,042,336
Ensembl chr 7:65,034,144...65,042,336

G

Rho GDP dissociation inhibitor alpha

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ARHGDIA mRNA

NCBI chr10:106,352,858...106,356,347
Ensembl chr10:106,353,491...106,356,347

G

Rho GDP dissociation inhibitor beta

increases expression

ISO

bisphenol F results in increased expression of ARHGDIB mRNA

NCBI chr 4:171,554,139...171,573,057
Ensembl chr 4:171,554,140...171,573,068

G

Rho guanine nucleotide exchange factor 1

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ARHGEF1 mRNA
bisphenol F results in decreased expression of ARHGEF1 mRNA

PMID:28628672 PMID:38685157

NCBI chr 1:89,626,884...89,648,823
Ensembl chr 1:89,628,266...89,649,067

G

Rho guanine nucleotide exchange factor 12

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ARHGEF12 gene
bisphenol F results in increased expression of ARHGEF12 mRNA

PMID:31601247 PMID:38685157

NCBI chr 8:52,247,047...52,373,158
Ensembl chr 8:52,247,047...52,372,376

G

Rho guanine nucleotide exchange factor 15

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ARHGEF15 mRNA
bisphenol F results in decreased expression of ARHGEF15 mRNA

PMID:30951980 PMID:38685157

NCBI chr10:54,149,372...54,162,128
Ensembl chr10:54,149,372...54,162,128

G

Rho guanine nucleotide exchange factor 16

increases expression

ISO

bisphenol F results in increased expression of ARHGEF16 mRNA

NCBI chr 5:170,126,573...170,148,624
Ensembl chr 5:170,126,575...170,148,624

G

Rho guanine nucleotide exchange factor 17

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ARHGEF17 gene

NCBI chr 1:164,642,690...164,702,241
Ensembl chr 1:164,642,690...164,702,241

G

Rho guanine nucleotide exchange factor 19

increases expression

ISO

bisphenol F results in increased expression of ARHGEF19 mRNA

NCBI chr 5:158,818,840...158,837,196
Ensembl chr 5:158,818,932...158,837,196

G

Rho guanine nucleotide exchange factor 25

decreases expression

ISO

bisphenol F results in decreased expression of ARHGEF25 mRNA

NCBI chr 7:64,891,260...64,898,382
Ensembl chr 7:64,890,879...64,898,697

G

Rho guanine nucleotide exchange factor 26

increases expression

ISO

bisphenol F results in increased expression of ARHGEF26 mRNA

NCBI chr 2:148,889,405...149,000,538
Ensembl chr 2:148,889,423...149,000,538

G

Rho guanine nucleotide exchange factor 28

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARHGEF28 mRNA

NCBI chr 2:30,998,292...31,294,757
Ensembl chr 2:30,998,295...31,294,853

G

Rho guanine nucleotide exchange factor 3

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of ARHGEF3 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ARHGEF3 mRNA

PMID:30951980 PMID:36041667 PMID:38685157

NCBI chr16:2,308,311...2,588,634
Ensembl chr16:2,308,400...2,588,819

G

Rho guanine nucleotide exchange factor 37

increases expression

ISO

bisphenol F results in increased expression of ARHGEF37 mRNA

NCBI chr18:57,205,621...57,271,284
Ensembl chr18:57,230,117...57,271,031

G

Rho guanine nucleotide exchange factor 38

multiple interactions
increases methylation

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ARHGEF38 gene
bisphenol F results in increased methylation of ARHGEF38 gene

NCBI chr 2:224,284,238...224,413,974
Ensembl chr 2:224,284,238...224,413,974

G

Rho guanine nucleotide exchange factor 5

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of ARHGEF5 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of ARHGEF5 mRNA

NCBI chr 4:73,087,240...73,112,311
Ensembl chr 4:73,087,240...73,112,311

G

Rac/Cdc42 guanine nucleotide exchange factor 6

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ARHGEF6 mRNA
bisphenol F results in decreased expression of ARHGEF6 mRNA

PMID:30951980 PMID:38685157

NCBI chr X:140,182,734...140,302,812
Ensembl chr X:140,182,734...140,344,458

G

AT-rich interaction domain 1A

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ARID1A mRNA

NCBI chr 5:151,192,014...151,269,291
Ensembl chr 5:151,192,014...151,265,386

G

AT-rich interaction domain 1B

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ARID1B mRNA

NCBI chr 1:47,973,199...48,328,793
Ensembl chr 1:47,973,997...48,328,793

G

AT-rich interaction domain 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARID2 mRNA

NCBI chr 7:129,326,371...129,443,813
Ensembl chr 7:129,324,137...129,443,187

G

AT-rich interaction domain 5B

increases expression

ISO

bisphenol F results in increased expression of ARID5B mRNA

NCBI chr20:20,305,693...20,489,689
Ensembl chr20:20,306,712...20,489,686

G

ariadne RBR E3 ubiquitin protein ligase 1

increases expression

ISO

bisphenol F results in increased expression of ARIH1 mRNA

NCBI chr 8:68,673,199...68,775,648
Ensembl chr 8:68,673,200...68,775,572

G

ariadne RBR E3 ubiquitin protein ligase 2

multiple interactions

ISO
EXP

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of ARIH2 gene
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ARIH2 mRNA

PMID:31601247 PMID:36041667

NCBI chr 8:118,175,267...118,234,425
Ensembl chr 8:118,175,267...118,234,284

G

ARF like GTPase 1

increases expression

ISO

bisphenol F results in increased expression of ARL1 protein
bisphenol F results in increased expression of ARL1 mRNA

PMID:34186270 PMID:38685157

NCBI chr 7:25,007,401...25,018,572
Ensembl chr 7:25,006,981...25,019,319

G

ARF like GTPase 10

increases expression

ISO

bisphenol F results in increased expression of ARL10 mRNA

NCBI chr17:10,035,320...10,043,732
Ensembl chr17:10,035,320...10,043,981

G

ARF like GTPase 15

increases expression

ISO

bisphenol F results in increased expression of ARL15 mRNA

NCBI chr 2:47,171,377...47,555,666
Ensembl chr 2:47,094,900...47,555,666

G

ARF like GTPase 2

decreases expression

ISO

bisphenol F results in decreased expression of ARL2 mRNA

NCBI chr 1:212,863,422...212,875,425
Ensembl chr 1:212,863,423...212,875,373

G

ARF like GTPase 2 binding protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ARL2BP mRNA

NCBI chr19:10,342,895...10,352,529
Ensembl chr19:10,342,895...10,352,514

G

ARF like GTPase 4D

increases expression

ISO

bisphenol F results in increased expression of ARL4D mRNA

NCBI chr10:87,092,276...87,103,079
Ensembl chr10:87,077,523...87,106,199

G

ARF like GTPase 5A

increases expression

ISO

bisphenol F results in increased expression of ARL5A mRNA

NCBI chr 3:57,287,599...57,312,488
Ensembl chr 3:57,289,846...57,312,488

G

ARF like GTPase 6 interacting protein 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ARL6IP4 mRNA

NCBI chr12:38,140,566...38,142,711
Ensembl chr12:38,140,550...38,142,724

G

ARF like GTPase 6 interacting protein 5

increases expression

ISO

bisphenol F results in increased expression of ARL6IP5 protein

NCBI chr 4:131,365,320...131,395,311
Ensembl chr 4:131,367,289...131,400,130

G

ARF like GTPase 8A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ARL8A mRNA

NCBI chr13:49,137,632...49,146,633
Ensembl chr13:49,137,632...49,146,633

G

ARF like GTPase 8B

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ARL8B mRNA
bisphenol F results in increased expression of ARL8B protein

PMID:34186270 PMID:36041667

NCBI chr 4:143,304,597...143,348,580
Ensembl chr 4:143,304,621...143,349,068

G

armadillo repeat containing 1

increases expression

ISO

bisphenol F results in increased expression of ARMC1 mRNA

NCBI chr 2:103,524,333...103,568,355
Ensembl chr 2:103,524,333...103,568,355

G

armadillo repeat containing 3

increases expression

ISO

bisphenol F results in increased expression of ARMC3 mRNA

NCBI chr17:86,722,436...86,825,899
Ensembl chr17:86,722,441...86,825,899

G

armadillo repeat containing 8

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ARMC8 mRNA

NCBI chr 8:108,916,274...109,010,877
Ensembl chr 8:108,916,274...109,010,717

G

armadillo repeat containing 9

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ARMC9 mRNA

NCBI chr 9:94,250,492...94,376,589
Ensembl chr 9:94,250,859...94,376,589

G

armadillo-like helical domain containing 3

increases expression

ISO

bisphenol F results in increased expression of ARMH3 mRNA

NCBI chr 1:254,615,274...254,797,673
Ensembl chr 1:254,615,274...254,781,315

G

armadillo-like helical domain containing 4

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of ARMH4 gene

NCBI chr15:25,455,478...25,556,569
Ensembl chr15:25,455,297...25,556,534

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ARNT mRNA

NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:185,680,683...185,745,546

G

actin related protein 2/3 complex, subunit 1B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARPC1B mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of ARPC1B mRNA

PMID:28628672 PMID:30951980

NCBI chr12:14,595,939...14,609,501
Ensembl chr12:14,595,678...14,609,504

G

actin related protein 2/3 complex, subunit 2

increases expression

ISO

bisphenol F results in increased expression of ARPC2 protein

NCBI chr 9:83,269,884...83,300,610
Ensembl chr 9:83,269,932...83,305,409

G

actin related protein 2/3 complex, subunit 3

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARPC3 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ARPC3 mRNA

PMID:28628672 PMID:36041667

NCBI chr12:39,833,569...39,847,436
Ensembl chr12:39,833,569...39,847,436

G

actin related protein 2/3 complex, subunit 4

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ARPC4 mRNA
bisphenol F results in increased expression of ARPC4 mRNA

PMID:36041667 PMID:38685157

NCBI chr 4:148,077,799...148,088,427
Ensembl chr 4:148,077,240...148,088,428

G

actin related protein 2/3 complex, subunit 5-like

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ARPC5L mRNA
bisphenol F results in increased expression of ARPC5L protein

PMID:28628672 PMID:34186270

NCBI chr 3:43,169,518...43,177,224
Ensembl chr 3:43,169,462...43,177,240
Ensembl chr 9:43,169,462...43,177,240

G

arrestin, beta 1

decreases expression
increases expression

EXP
ISO

4,4'-bisphenol F results in decreased expression of ARRB1 mRNA
bisphenol F results in increased expression of ARRB1 protein

PMID:26186136 PMID:34186270

NCBI chr 1:163,249,654...163,321,711
Ensembl chr 1:163,250,157...163,340,859

G

arrestin, beta 2

decreases expression

EXP
ISO

4,4'-bisphenol F results in decreased expression of ARRB2 mRNA

PMID:26186136 PMID:38685157

NCBI chr10:55,645,539...55,653,485
Ensembl chr10:55,645,357...55,653,487

G

arrestin domain containing 1

decreases expression

ISO

bisphenol F results in decreased expression of ARRDC1 mRNA

NCBI chr 3:28,133,190...28,140,378
Ensembl chr 3:28,133,191...28,140,687

G

arrestin domain containing 2

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ARRDC2 mRNA
bisphenol F results in decreased expression of ARRDC2 mRNA

PMID:28628672 PMID:38685157

NCBI chr16:18,635,883...18,640,019
Ensembl chr16:18,635,883...18,640,158

G

arrestin domain containing 3

increases expression

ISO

bisphenol F results in increased expression of ARRDC3 mRNA

NCBI chr 2:12,873,202...12,885,716
Ensembl chr 2:12,873,202...12,885,875

G

arylsulfatase B

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ARSB gene
bisphenol F results in increased expression of ARSB mRNA

PMID:31601247 PMID:38685157

NCBI chr 2:26,736,395...26,895,682
Ensembl chr 2:26,736,957...26,897,611

G

arylsulfatase G

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ARSG mRNA

NCBI chr10:94,912,094...95,063,021
Ensembl chr10:94,913,152...95,042,447

G

arylsulfatase family, member I

increases expression

ISO

bisphenol F results in increased expression of ARSI mRNA

NCBI chr18:56,634,556...56,642,168
Ensembl chr18:56,625,487...56,642,168

G

ARV1 homolog, fatty acid homeostasis modulator

decreases expression

ISO

bisphenol F results in decreased expression of ARV1 mRNA

NCBI chr19:69,589,728...69,601,547
Ensembl chr19:69,589,328...69,601,537

G

ARVCF, delta catenin family member

decreases expression

ISO

bisphenol F results in decreased expression of ARVCF mRNA

NCBI chr11:96,092,451...96,150,144
Ensembl chr11:96,092,451...96,150,163

G

aristaless related homeobox

decreases expression

ISO

bisphenol F results in decreased expression of ARX mRNA

NCBI chr X:62,010,097...62,022,009
Ensembl chr X:62,010,097...62,022,002

G

N-acylsphingosine amidohydrolase 1

increases expression

ISO

bisphenol F results in increased expression of ASAH1 protein

NCBI chr16:57,669,927...57,701,349
Ensembl chr16:57,669,750...57,718,305

G

N-acylsphingosine amidohydrolase 2

increases expression

ISO

bisphenol F results in increased expression of ASAH2 mRNA

PMID:30951980 PMID:38685157

NCBI chr 1:239,278,994...239,386,598
Ensembl chr 1:239,278,994...239,382,024

G

ArfGAP with SH3 domain, ankyrin repeat and PH domain 1

increases expression

ISO

bisphenol F results in increased expression of ASAP1 protein
bisphenol F results in increased expression of ASAP1 mRNA

PMID:34186270 PMID:38685157

NCBI chr 7:97,675,354...97,982,523
Ensembl chr 7:97,675,354...97,982,024

G

ArfGAP with SH3 domain, ankyrin repeat and PH domain 3

increases expression

ISO

bisphenol F results in increased expression of ASAP3 mRNA

NCBI chr 5:153,716,988...153,757,787
Ensembl chr 5:153,716,988...153,757,787

G

ankyrin repeat and SOCS box-containing 16

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ASB16 mRNA

NCBI chr10:87,726,128...87,733,228
Ensembl chr10:87,726,056...87,735,059

G

ankyrin repeat and SOCS box-containing 2

increases expression

ISO

bisphenol F results in increased expression of ASB2 mRNA

NCBI chr 6:128,239,550...128,275,833
Ensembl chr 6:128,239,552...128,266,321

G

ankyrin repeat and SOCS box-containing 4

increases expression

ISO

bisphenol F results in increased expression of ASB4 mRNA

NCBI chr 4:34,473,527...34,511,163
Ensembl chr 4:34,473,408...34,512,888

G

ankyrin repeat and SOCS box-containing 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ASB7 mRNA

NCBI chr 1:129,621,462...129,677,788
Ensembl chr 1:129,635,330...129,677,505

G

activating signal cointegrator 1 complex subunit 3

increases expression

ISO

bisphenol F results in increased expression of ASCC3 mRNA

NCBI chr20:55,089,430...55,372,374
Ensembl chr20:55,255,503...55,372,374

G

achaete-scute family bHLH transcription factor 1

decreases expression

ISO

bisphenol F results in decreased expression of ASCL1 mRNA

NCBI chr 7:23,790,642...23,793,509
Ensembl chr 7:23,790,360...23,798,231

G

anti-silencing function 1B histone chaperone

increases expression

ISO

bisphenol F results in increased expression of ASF1B mRNA

NCBI chr19:41,085,786...41,100,352
Ensembl chr19:41,086,114...41,100,352

G

ASH1 like histone lysine methyltransferase

increases expression

ISO

bisphenol F results in increased expression of ASH1L mRNA

NCBI chr 2:176,644,393...176,780,848
Ensembl chr 2:176,644,924...176,780,847

G

acid sensing ion channel subunit 3

decreases expression

ISO

bisphenol F results in decreased expression of ASIC3 mRNA

NCBI chr 4:11,652,946...11,657,415
Ensembl chr 4:11,652,946...11,657,367

G

acid sensing ion channel subunit family member 4

decreases expression

ISO

bisphenol F results in decreased expression of ASIC4 mRNA

NCBI chr 9:84,389,610...84,411,545
Ensembl chr 9:84,390,104...84,411,538

G

argininosuccinate lyase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ASL mRNA

NCBI chr12:32,295,779...32,313,257
Ensembl chr12:32,295,633...32,317,261

G

acetylserotonin O-methyltransferase-like

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ASMTL mRNA

NCBI chr12:21,429,119...21,431,847
Ensembl chr12:21,429,171...21,431,847

G

aspartoacylase

increases expression

ISO

bisphenol F results in increased expression of ASPA protein
bisphenol F results in increased expression of ASPA mRNA

PMID:34186270 PMID:36706583 PMID:38685157

NCBI chr10:58,390,204...58,443,790
Ensembl chr10:58,379,410...58,443,769

G

aspartate dehydrogenase domain containing

decreases expression

ISO

bisphenol F results in decreased expression of ASPDH mRNA

NCBI chr 1:104,094,983...104,097,244
Ensembl chr 1:104,094,954...104,097,244

G

asparaginase

decreases expression

ISO

bisphenol F results in decreased expression of ASPG mRNA

NCBI chr 6:136,997,832...137,017,417
Ensembl chr 6:136,998,023...137,017,417

G

aspartate beta-hydroxylase domain containing 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ASPHD2 mRNA

NCBI chr12:49,908,539...49,919,060
Ensembl chr12:49,908,241...49,925,254

G

asporin

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ASPN mRNA
bisphenol F results in decreased expression of ASPN mRNA

PMID:30951980 PMID:38685157

NCBI chr17:15,286,338...15,310,567
Ensembl chr17:15,287,065...15,310,632

G

aspartic peptidase, retroviral-like 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ASPRV1 mRNA

NCBI chr 4:120,634,793...120,636,265
Ensembl chr 4:120,634,793...120,636,260

G

ASPSCR1 tether for SLC2A4, UBX domain containing

decreases expression

ISO

bisphenol F results in decreased expression of ASPSCR1 mRNA

NCBI chr10:106,450,600...106,488,231
Ensembl chr10:106,450,567...106,488,579

G

asparaginase and isoaspartyl peptidase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ASRGL1 mRNA

NCBI chr 1:215,436,180...215,456,188
Ensembl chr 1:215,435,218...215,456,198

G

argininosuccinate synthase 1

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of ASS1 mRNA
bisphenol F results in increased expression of ASS1 protein

PMID:30951980 PMID:34186270

NCBI chr 3:35,144,765...35,194,632
Ensembl chr 3:35,144,999...35,194,627

G

astrotactin 2

increases expression

ISO

bisphenol F results in increased expression of ASTN2 mRNA

NCBI chr 5:83,772,988...84,759,439
Ensembl chr 5:83,773,633...84,759,485

G

ASXL transcriptional regulator 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ASXL2 mRNA

NCBI chr 6:32,090,497...32,234,487
Ensembl chr 6:32,145,607...32,227,851

G

ATPase family, AAA domain containing 3A

increases expression

ISO

bisphenol F results in increased expression of ATAD3A protein

NCBI chr 5:171,632,545...171,652,725
Ensembl chr 5:171,632,547...171,652,725

G

activating transcription factor 1

increases expression

ISO

bisphenol F results in increased expression of ATF1 mRNA

NCBI chr 7:133,240,774...133,283,488
Ensembl chr 7:133,241,197...133,283,485

G

activating transcription factor 2

increases expression

ISO

bisphenol F results in increased expression of ATF2 mRNA

NCBI chr 3:79,125,814...79,202,896
Ensembl chr 3:79,126,705...79,202,745

G

activating transcription factor 3

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of ATF3 mRNA
bisphenol F results in increased expression of ATF3 mRNA

PMID:30951980 PMID:37164221 PMID:38685157

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750

G

activating transcription factor 4

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ATF4 mRNA
bisphenol F results in decreased expression of ATF4 mRNA

PMID:38134982 PMID:38685157

NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739

G

activating transcription factor 6

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ATF6 mRNA
bisphenol F results in increased expression of ATF6 mRNA

PMID:28628672 PMID:38134982 PMID:38685157

NCBI chr13:85,460,312...85,639,959
Ensembl chr13:85,462,840...85,640,033

G

activating transcription factor 7 interacting protein

increases expression

ISO

bisphenol F results in increased expression of ATF7IP mRNA

NCBI chr 4:171,117,122...171,202,871
Ensembl chr 4:171,117,122...171,202,867

G

autophagy related 13

increases expression

ISO

bisphenol F results in increased expression of ATG13 mRNA

NCBI chr 3:98,102,831...98,136,741
Ensembl chr 3:98,101,552...98,136,743

G

autophagy related 16-like 2

decreases expression

ISO

bisphenol F results in decreased expression of ATG16L2 mRNA

NCBI chr 1:165,100,946...165,123,307
Ensembl chr 1:165,102,936...165,115,473

G

autophagy related 4C, cysteine peptidase

increases expression

ISO

bisphenol F results in increased expression of ATG4C mRNA

NCBI chr 5:118,977,594...119,050,894
Ensembl chr 5:118,982,918...119,052,695

G

autophagy related 4D, cysteine peptidase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ATG4D mRNA

NCBI chr 8:28,083,902...28,093,491
Ensembl chr 8:28,083,936...28,093,491

G

autophagy related 7

increases expression

ISO

bisphenol F results in increased expression of ATG7 protein

NCBI chr 4:149,390,000...149,597,534
Ensembl chr 4:149,391,390...149,598,319

G

autophagy related 9B

decreases expression

ISO

bisphenol F results in decreased expression of ATG9B mRNA

NCBI chr 4:11,678,548...11,686,097
Ensembl chr 4:11,678,299...11,686,079

G

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase

increases expression

ISO

bisphenol F results in increased expression of ATIC mRNA

NCBI chr 9:80,614,311...80,634,360
Ensembl chr 9:80,614,283...80,635,756

G

atlastin GTPase 2

increases expression

ISO

bisphenol F results in increased expression of ATL2 mRNA

NCBI chr 6:20,891,220...20,932,644
Ensembl chr 6:20,891,227...20,933,320

G

atlastin GTPase 3

increases expression

ISO

bisphenol F results in increased expression of ATL3 mRNA

NCBI chr 1:214,110,127...214,151,098
Ensembl chr 1:214,109,702...214,152,510

G

atrophin 1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of ATN1 gene

NCBI chr 4:159,240,573...159,254,378
Ensembl chr 4:159,237,562...159,254,418

G

atonal bHLH transcription factor 1

decreases expression

ISO

bisphenol F results in decreased expression of ATOH1 mRNA

NCBI chr 4:95,241,933...95,244,028
Ensembl chr 4:95,241,933...95,244,019

G

antioxidant 1 copper chaperone

decreases expression

ISO

bisphenol F results in decreased expression of ATOX1 mRNA

NCBI chr10:40,065,525...40,080,627
Ensembl chr10:40,065,527...40,080,585

G

ATPase phospholipid transporting 10A (putative)

increases expression

ISO

bisphenol F results in increased expression of ATP10A mRNA

NCBI chr 1:118,692,456...118,866,117
Ensembl chr 1:118,692,478...118,866,114

G

ATPase 13A1

decreases expression

ISO

bisphenol F results in decreased expression of ATP13A1 mRNA

NCBI chr16:19,649,065...19,665,126
Ensembl chr16:19,649,066...19,665,120

G

ATPase Na+/K+ transporting subunit alpha 1

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ATP1A1 mRNA
bisphenol F results in increased expression of ATP1A1 mRNA
bisphenol F results in increased expression of ATP1A1 protein

PMID:34186270 PMID:36041667 PMID:38685157

NCBI chr 2:191,709,311...191,737,414
Ensembl chr 2:191,709,311...191,737,425

G

ATPase Na+/K+ transporting subunit alpha 2

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ATP1A2 mRNA
bisphenol F results in decreased expression of ATP1A2 mRNA

PMID:30951980 PMID:38685157

NCBI chr13:87,261,964...87,286,911
Ensembl chr13:87,261,968...87,286,911

G

ATPase Na+/K+ transporting subunit alpha 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ATP1A3 mRNA

NCBI chr 1:89,700,645...89,729,782
Ensembl chr 1:89,700,649...89,729,825

G

ATPase Na+/K+ transporting subunit beta 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ATP1B1 mRNA

NCBI chr13:79,319,708...79,340,226
Ensembl chr13:79,319,706...79,340,549

G

ATPase Na+/K+ transporting subunit beta 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ATP1B2 mRNA

NCBI chr10:54,817,473...54,823,708
Ensembl chr10:54,817,476...54,823,708

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ATP2A1 mRNA
bisphenol F results in decreased expression of ATP2A1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 1:190,457,198...190,475,410
Ensembl chr 1:190,457,198...190,475,423

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ATP2A2 mRNA
bisphenol F results in increased expression of ATP2A2 protein

PMID:28628672 PMID:34186270

NCBI chr12:39,733,519...39,782,942
Ensembl chr12:39,733,458...39,782,934

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ATP2A3 mRNA
bisphenol F results in decreased expression of ATP2A3 mRNA

PMID:30951980 PMID:38685157

NCBI chr10:58,079,710...58,111,279
Ensembl chr10:58,079,852...58,111,278

G

ATPase plasma membrane Ca2+ transporting 1

increases expression

ISO

bisphenol F results in increased expression of ATP2B1 protein
bisphenol F results in increased expression of ATP2B1 mRNA

PMID:34186270 PMID:38685157

NCBI chr 7:35,622,267...35,731,904
Ensembl chr 7:35,622,461...35,731,904

G

ATPase secretory pathway Ca2+ transporting 2

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ATP2C2 mRNA
bisphenol F results in decreased expression of ATP2C2 mRNA

PMID:30951980 PMID:38685157

NCBI chr19:64,662,729...64,719,998
Ensembl chr19:64,662,715...64,719,996

G

ATP synthase F1 subunit alpha

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of ATP5F1A protein
bisphenol F results in increased expression of ATP5F1A mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ATP5F1A mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ATP5F1A mRNA

PMID:28628672 PMID:34186270 PMID:36041667 PMID:38685157

NCBI chr18:73,567,537...73,575,473
Ensembl chr18:73,567,526...73,575,922

G

ATP synthase F1 subunit beta

increases expression

ISO

bisphenol F results in increased expression of ATP5F1B protein
bisphenol F results in increased expression of ATP5F1B mRNA

PMID:34186270 PMID:38685157

NCBI chr 7:1,100,058...1,106,461
Ensembl chr 7:1,099,860...1,106,462

G

ATP synthase F1 subunit gamma

increases expression

ISO

bisphenol F results in increased expression of ATP5F1C protein

NCBI chr17:73,333,584...73,355,872
Ensembl chr17:73,333,588...73,383,073

G

ATP synthase F1 subunit epsilon

decreases expression

ISO

bisphenol F results in decreased expression of ATP5F1E mRNA

NCBI chr 3:183,677,270...183,680,172
Ensembl chr 3:183,677,273...183,680,214

G

ATP synthase membrane subunit e

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ATP5ME mRNA
bisphenol F results in decreased expression of ATP5ME mRNA

PMID:36041667 PMID:38568856

NCBI chr14:1,464,788...1,465,989
Ensembl chr14:1,464,800...1,465,988

G

ATP synthase membrane subunit f

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ATP5MF mRNA

NCBI chr12:14,535,435...14,542,007
Ensembl chr12:14,522,832...14,542,709

G

ATP synthase peripheral stalk-membrane subunit b

increases expression

ISO

bisphenol F results in increased expression of ATP5PB protein
bisphenol F results in increased expression of ATP5PB mRNA

PMID:34186270 PMID:38685157

NCBI chr 2:196,112,459...196,123,737
Ensembl chr 2:196,112,108...196,124,387

G

ATP synthase peripheral stalk subunit d

decreases expression

ISO

bisphenol F results in decreased expression of ATP5PD mRNA

NCBI chr10:101,156,673...101,161,926
Ensembl chr10:101,156,673...101,162,954

G

ATP synthase peripheral stalk subunit OSCP

increases expression

ISO

bisphenol F results in increased expression of ATP5PO protein

NCBI chr11:44,651,171...44,657,483
Ensembl chr11:44,651,173...44,657,520

G

ATPase H+ transporting accessory protein 1

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ATP6AP1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ATP6AP1 mRNA

PMID:28628672 PMID:36041667

NCBI chr X:157,231,243...157,238,323
Ensembl chr X:157,225,327...157,238,323

G

ATPase H+ transporting accessory protein 1 like

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ATP6AP1L mRNA

NCBI chr 2:23,772,724...23,814,913
Ensembl chr 2:23,772,745...23,814,618

G

ATPase H+ transporting V0 subunit a1

multiple interactions
decreases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ATP6V0A1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ATP6V0A1 mRNA
bisphenol F results in decreased expression of ATP6V0A1 mRNA

PMID:28628672 PMID:35387338 PMID:36041667

NCBI chr10:86,436,089...86,490,185
Ensembl chr10:86,436,141...86,490,181

G

ATPase H+ transporting V0 subunit B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ATP6V0B mRNA

NCBI chr 5:136,708,823...136,710,339
Ensembl chr 5:136,708,823...136,716,828

G

ATPase H+ transporting V0 subunit C

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in increased expression of ATP6V0C mRNA
bisphenol F results in increased expression of ATP6V0C protein

PMID:30951980 PMID:34186270

NCBI chr10:13,700,764...13,707,147
Ensembl chr10:13,700,764...13,706,245

G

ATPase H+ transporting V0 subunit D1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ATP6V0D1 mRNA

NCBI chr19:50,313,268...50,357,248
Ensembl chr19:50,313,273...50,357,395

G

ATPase H+ transporting V0 subunit D2

decreases expression

ISO

bisphenol F results in decreased expression of ATP6V0D2 mRNA

NCBI chr 5:38,133,151...38,182,245
Ensembl chr 5:38,133,158...38,182,245

G

ATPase, H+ transporting V0 subunit e2

increases expression

ISO

bisphenol F results in increased expression of ATP6V0E2 mRNA

NCBI chr 4:78,815,771...78,818,919
Ensembl chr 4:78,813,129...78,819,680

G

ATPase H+ transporting V1 subunit A

increases expression

ISO

bisphenol F results in increased expression of ATP6V1A mRNA

NCBI chr11:70,066,800...70,120,603
Ensembl chr11:70,035,134...70,120,603

G

ATPase H+ transporting V1 subunit B1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ATP6V1B1 mRNA

NCBI chr 4:117,781,444...117,800,103
Ensembl chr 4:117,781,444...117,800,103

G

ATPase H+ transporting V1 subunit B2

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ATP6V1B2 mRNA
bisphenol F results in increased expression of ATP6V1B2 mRNA
bisphenol F results in increased expression of ATP6V1B2 protein

PMID:34186270 PMID:36041667 PMID:38685157

NCBI chr16:25,384,254...25,408,388
Ensembl chr16:25,384,257...25,408,839

G

ATPase H+ transporting V1 subunit C1

increases expression

ISO

bisphenol F results in increased expression of ATP6V1C1 protein

NCBI chr 7:71,719,326...71,757,191
Ensembl chr 7:71,719,404...71,757,184

G

ATPase H+ transporting V1 subunit C2

decreases expression

ISO

bisphenol F results in decreased expression of ATP6V1C2 mRNA

NCBI chr 6:45,809,269...45,872,914
Ensembl chr 6:45,809,271...45,848,747

G

ATPase H+ transporting V1 subunit D

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ATP6V1D mRNA

NCBI chr 6:103,389,778...103,405,346
Ensembl chr 6:103,389,783...103,405,346

G

ATPase H+ transporting V1 subunit H

multiple interactions

ISO
EXP

[bisphenol F co-treated with Fulvestrant] results in increased methylation of ATP6V1H gene
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ATP6V1H mRNA

PMID:31601247 PMID:36041667

NCBI chr 5:19,176,849...19,282,516
Ensembl chr 5:19,176,849...19,282,516

G

ATPase copper transporting beta

affects expression

ISO

bisphenol F affects the expression of ATP7B mRNA

NCBI chr16:76,654,725...76,726,092
Ensembl chr16:76,653,660...76,728,801

G

ATPase phospholipid transporting 8A1

increases expression

ISO

bisphenol F results in increased expression of ATP8A1 mRNA

NCBI chr14:40,668,932...40,911,465
Ensembl chr14:40,731,846...40,911,463

G

ATP synthase mitochondrial F1 complex assembly factor 1

increases expression

ISO

bisphenol F results in increased expression of ATPAF1 mRNA

NCBI chr 5:134,503,164...134,530,323
Ensembl chr 5:134,499,687...134,530,321

G

ATP synthase c subunit lysine N-methyltransferase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ATPSCKMT mRNA

NCBI chr 2:84,313,991...84,329,195
Ensembl chr 2:84,313,921...84,329,194

G

attractin like 1

increases expression

ISO

bisphenol F results in increased expression of ATRNL1 mRNA

NCBI chr 1:266,676,051...267,216,847
Ensembl chr 1:266,675,852...267,216,842

G

ataxin 1

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ATXN1 mRNA
bisphenol F results in increased expression of ATXN1 mRNA

PMID:36041667 PMID:38685157

NCBI chr17:18,943,397...19,354,751
Ensembl chr17:19,208,200...19,356,790

G

ataxin 10

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ATXN10 mRNA
bisphenol F results in increased expression of ATXN10 mRNA

PMID:36041667 PMID:38685157

NCBI chr 7:118,321,516...118,444,967
Ensembl chr 7:118,319,490...118,445,636

G

ataxin 1 like

increases expression

ISO

bisphenol F results in increased expression of ATXN1L mRNA

NCBI chr19:54,609,852...54,621,024
Ensembl chr19:54,609,132...54,680,582

G

ataxin 2-like

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ATXN2L mRNA

NCBI chr 1:190,508,878...190,526,263
Ensembl chr 1:190,508,878...190,520,579

G

ataxin 7-like 2

decreases expression

ISO

bisphenol F results in decreased expression of ATXN7L2 mRNA

NCBI chr 2:198,527,066...198,535,899
Ensembl chr 2:198,527,066...198,534,062

G

AUP1, lipid droplet regulating VLDL assembly factor

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of AUP1 mRNA

NCBI chr 4:117,118,035...117,121,063
Ensembl chr 4:117,117,999...117,121,061

G

aurora kinase A

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of AURKA mRNA

NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771

G

advillin

decreases expression

ISO

bisphenol F results in decreased expression of AVIL mRNA

NCBI chr 7:64,711,294...64,729,436
Ensembl chr 7:64,711,403...64,729,436

G

AVL9 cell migration associated

increases expression

ISO

bisphenol F results in increased expression of AVL9 mRNA

NCBI chr 4:87,291,062...87,338,537
Ensembl chr 4:87,291,798...87,331,916

G

arginine vasopressin receptor 1A

increases expression

ISO

bisphenol F results in increased expression of AVPR1A mRNA

NCBI chr 7:59,999,743...60,003,667
Ensembl chr 7:59,999,738...60,003,837

G

Axl receptor tyrosine kinase

multiple interactions

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of AXL mRNA

NCBI chr 1:90,392,864...90,424,123
Ensembl chr 1:90,392,864...90,424,009

G

antizyme inhibitor 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of AZIN2 mRNA

NCBI chr 5:146,568,187...146,594,777
Ensembl chr 5:146,565,437...146,594,777

G

beta-2 microglobulin

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of B2M mRNA
bisphenol F results in increased expression of B2M protein

PMID:30951980 PMID:34186270

NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:129,549,318...129,555,356

G

Beta-1,3-galactosyltransferase 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of B3GALT4 mRNA

NCBI chr20:4,937,974...4,939,549
Ensembl chr20:4,937,674...4,939,885

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of B3GNT2 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of B3GNT2 mRNA

PMID:28628672 PMID:36041667

NCBI chr14:101,009,682...101,034,507
Ensembl chr14:100,967,131...101,043,412

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of B3GNT5 mRNA

NCBI chr11:94,645,480...94,657,584
Ensembl chr11:94,645,480...94,660,514

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9

decreases expression

ISO

bisphenol F results in decreased expression of B3GNT9 mRNA

NCBI chr19:50,039,649...50,042,206
Ensembl chr19:50,030,866...50,043,339

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase-like 1

decreases expression

ISO

bisphenol F results in decreased expression of B3GNTL1 mRNA

NCBI chr10:107,363,036...107,431,988
Ensembl chr10:107,371,442...107,431,908

G

beta-1,4-N-acetyl-galactosaminyl transferase 2

decreases expression

ISO

bisphenol F results in decreased expression of B4GALNT2 mRNA

NCBI chr10:81,298,338...81,324,738
Ensembl chr10:81,299,421...81,382,557

G

beta-1,4-galactosyltransferase 1

multiple interactions

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of B4GALT1 mRNA

NCBI chr 5:60,731,601...60,778,456
Ensembl chr 5:60,731,602...60,778,445

G

beta-1,4-galactosyltransferase 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of B4GALT2 mRNA

NCBI chr 5:136,697,981...136,707,783
Ensembl chr 5:136,697,981...136,710,422

G

beta-1,4-galactosyltransferase 5

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of B4GALT5 mRNA
bisphenol F results in increased expression of B4GALT5 mRNA

PMID:28628672 PMID:38568856

NCBI chr 3:176,437,073...176,453,001
Ensembl chr 3:176,437,073...176,488,978

G

beta-1,4-galactosyltransferase 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of B4GALT7 mRNA

NCBI chr17:9,023,667...9,032,742
Ensembl chr17:9,023,618...9,032,745

G

beta-1,4-glucuronyltransferase 1

increases expression

ISO

bisphenol F results in increased expression of B4GAT1 mRNA

NCBI chr 1:211,772,644...211,774,866
Ensembl chr 1:211,772,606...211,775,442

G

B9 domain containing 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of B9D1 mRNA

NCBI chr10:46,685,410...46,698,580
Ensembl chr10:46,686,133...46,695,428

G

BRISC and BRCA1 A complex member 1

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BABAM1 mRNA
bisphenol F results in increased expression of BABAM1 protein

PMID:34186270 PMID:36041667

NCBI chr16:18,102,885...18,108,916
Ensembl chr16:18,102,815...18,108,932

G

BRISC and BRCA1 A complex member 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of BABAM2 mRNA

NCBI chr 6:30,089,065...30,467,508
Ensembl chr 6:30,071,611...30,467,341

G

BPTF associated chromatin complex component 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BACC1 mRNA

NCBI chr10:55,450,648...55,453,409
Ensembl chr10:55,450,250...55,453,311

G

beta-secretase 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of BACE1 mRNA

NCBI chr 8:55,038,842...55,061,138
Ensembl chr 8:55,038,823...55,064,918

G

BAG cochaperone 2

increases expression

ISO

bisphenol F results in increased expression of BAG2 protein

NCBI chr 9:43,465,993...43,476,637
Ensembl chr 9:43,465,995...43,476,752

G

BAG cochaperone 3

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of BAG3 mRNA
bisphenol F results in increased expression of BAG3 protein

PMID:30951980 PMID:34186270

NCBI chr 1:192,533,460...192,557,281
Ensembl chr 1:192,475,828...192,557,280

G

BAG cochaperone 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BAG4 mRNA

NCBI chr16:72,991,407...73,008,620
Ensembl chr16:72,991,362...73,013,273

G

BAG cochaperone 6

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BAG6 mRNA
bisphenol F results in increased expression of BAG6 protein

PMID:34186270 PMID:36041667

NCBI chr20:3,680,607...3,693,329
Ensembl chr20:3,680,607...3,693,329

G

BAR/IMD domain containing adaptor protein 2

increases expression
decreases expression

ISO

bisphenol F results in increased expression of BAIAP2 mRNA
bisphenol F results in decreased expression of BAIAP2 mRNA

PMID:30951980 PMID:38685157

NCBI chr10:105,721,371...105,788,549
Ensembl chr10:105,721,417...105,788,549

G

BAI1-associated protein 3

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of BAIAP3 mRNA
bisphenol F results in decreased expression of BAIAP3 mRNA

PMID:36041667 PMID:38685157

NCBI chr10:14,764,768...14,777,516
Ensembl chr10:14,756,693...14,777,516

G

BCL2-antagonist/killer 1

increases expression

ISO

bisphenol F results in increased expression of BAK1 mRNA

NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974

G

BMP and activin membrane-bound inhibitor

increases expression

ISO

bisphenol F results in increased expression of BAMBI mRNA

NCBI chr17:58,816,438...58,821,003
Ensembl chr17:58,816,442...58,821,247

G

barrier to autointegration nuclear assembly factor 1

increases expression
decreases expression

ISO

bisphenol F results in increased expression of BANF1 protein
bisphenol F results in decreased expression of BANF1 mRNA

PMID:34186270 PMID:38685157

NCBI chr 1:212,101,523...212,103,568
Ensembl chr 1:212,101,523...212,103,552

G

Btg3 associated nuclear protein

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of BANP mRNA
bisphenol F results in decreased expression of BANP mRNA

PMID:36041667 PMID:38685157

NCBI chr19:66,916,417...66,994,286
Ensembl chr19:66,916,267...66,991,317

G

BarH-like homeobox 1

decreases expression

ISO

bisphenol F results in decreased expression of BARHL1 mRNA

NCBI chr 3:32,639,283...32,646,605
Ensembl chr 3:32,638,644...32,646,605

G

BarH-like homeobox 2

decreases expression

ISO

bisphenol F results in decreased expression of BARHL2 mRNA

NCBI chr14:3,485,309...3,490,206
Ensembl chr14:3,485,309...3,490,197

G

BARX homeobox 2

increases expression

ISO

bisphenol F results in increased expression of BARX2 mRNA

NCBI chr 8:38,509,277...38,576,978
Ensembl chr 8:38,509,277...38,576,978

G

brain abundant, membrane attached signal protein 1

increases expression

ISO

bisphenol F results in increased expression of BASP1 protein

NCBI chr 2:77,546,628...77,594,297
Ensembl chr 2:77,546,092...77,597,178

G

basic leucine zipper ATF-like transcription factor 3

decreases expression

ISO

bisphenol F results in decreased expression of BATF3 mRNA

NCBI chr13:105,220,782...105,232,365
Ensembl chr13:105,220,390...105,232,369

G

BCL2 associated X, apoptosis regulator

multiple interactions
decreases expression
increases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BAX mRNA
bisphenol F results in decreased expression of BAX mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BAX mRNA
bisphenol F results in increased expression of BAX mRNA

PMID:28628672 PMID:31453682 PMID:36041667 PMID:38685157

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

bromodomain adjacent to zinc finger domain, 2A

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BAZ2A mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BAZ2A mRNA

PMID:28628672 PMID:36041667

NCBI chr 7:1,107,377...1,145,507
Ensembl chr 7:1,107,796...1,145,507

G

bromodomain adjacent to zinc finger domain, 2B

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of BAZ2B gene

NCBI chr 3:64,792,984...65,034,547
Ensembl chr 3:64,794,001...65,001,781

G

BBSome interacting protein 1

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BBIP1 mRNA
bisphenol F results in decreased expression of BBIP1 mRNA

PMID:28628672 PMID:38685157

NCBI chr 1:262,950,459...262,964,410
Ensembl chr 1:262,950,462...262,964,394

G

bublin coiled coil protein

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BBLN mRNA
bisphenol F results in increased expression of BBLN mRNA

PMID:28628672 PMID:38685157

NCBI chr 3:36,072,325...36,075,070
Ensembl chr 3:36,072,328...36,075,093

G

basal body orientation factor 1

increases expression

ISO

bisphenol F results in increased expression of BBOF1 mRNA

NCBI chr 6:109,786,363...109,812,153
Ensembl chr 6:109,786,363...109,812,147

G

gamma-butyrobetaine hydroxylase 1

increases expression

ISO

bisphenol F results in increased expression of BBOX1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 3:117,277,226...117,326,383
Ensembl chr 3:117,277,226...117,326,064

G

Bardet-Biedl syndrome 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BBS1 mRNA

NCBI chr 1:211,614,195...211,633,504
Ensembl chr 1:211,615,533...211,633,468

G

Bardet-Biedl syndrome 2

decreases expression

ISO

bisphenol F results in decreased expression of BBS2 mRNA

NCBI chr19:10,915,566...10,950,911
Ensembl chr19:10,915,476...10,950,921

G

Bardet-Biedl syndrome 5

increases methylation

ISO

bisphenol F results in increased methylation of BBS5 gene

NCBI chr 3:74,818,104...74,839,658
Ensembl chr 3:74,818,473...74,857,023

G

Bardet-Biedl syndrome 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BBS7 mRNA

NCBI chr 2:121,362,884...121,402,473
Ensembl chr 2:121,362,885...121,402,473

G

basal cell adhesion molecule (Lutheran blood group)

increases expression

ISO

bisphenol F results in increased expression of BCAM mRNA

NCBI chr 1:88,542,971...88,557,358
Ensembl chr 1:88,542,972...88,557,888

G

brevican

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of BCAN mRNA

NCBI chr 2:175,752,333...175,765,766
Ensembl chr 2:175,752,336...175,765,314

G

B-cell receptor-associated protein 31

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BCAP31 mRNA

NCBI chr X:156,548,911...156,581,002
Ensembl chr X:156,548,911...156,579,371

G

BCAR1 scaffold protein, Cas family member

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BCAR1 mRNA

NCBI chr19:56,588,500...56,623,190
Ensembl chr19:56,588,500...56,623,190

G

brain enriched myelin associated protein 1

increases expression

ISO

bisphenol F results in increased expression of BCAS1 mRNA

NCBI chr 3:179,554,754...179,637,800
Ensembl chr 3:179,551,704...179,637,743

G

BCAS3, microtubule associated cell migration factor

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BCAS3 mRNA

NCBI chr10:70,711,084...71,170,492
Ensembl chr10:70,711,525...71,170,803

G

branched chain amino acid transaminase 1

increases expression

ISO

bisphenol F results in increased expression of BCAT1 protein

NCBI chr 4:179,695,662...179,777,973
Ensembl chr 4:179,695,662...179,777,288

G

branched chain amino acid transaminase 2

increases expression

ISO

bisphenol F results in increased expression of BCAT2 protein

NCBI chr 1:105,175,157...105,196,474
Ensembl chr 1:105,176,977...105,196,463

G

BRCA2 and CDKN1A interacting protein

increases expression

ISO

bisphenol F results in increased expression of BCCIP protein

NCBI chr 1:197,942,535...197,954,948
Ensembl chr 1:197,942,190...197,956,378

G

butyrylcholinesterase

increases expression

ISO

bisphenol F results in increased expression of BCHE mRNA

NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:160,606,288...160,699,760

G

branched chain keto acid dehydrogenase E1 subunit alpha

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BCKDHA mRNA

NCBI chr 1:90,266,731...90,295,521
Ensembl chr 1:90,261,629...90,295,749

G

BCL2, apoptosis regulator

decreases expression
multiple interactions
decreases methylation

EXP
ISO

bisphenol F results in decreased expression of BCL2 protein
[bisphenol B co-treated with bisphenol F co-treated with bisphenol S co-treated with NG-Nitroarginine Methyl Ester] results in decreased expression of BCL2 mRNA; [bisphenol B co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BCL2 mRNA; thymoquinone inhibits the reaction [[bisphenol B co-treated with bisphenol F co-treated with bisphenol S co-treated with NG-Nitroarginine Methyl Ester] results in decreased expression of BCL2 mRNA]; thymoquinone inhibits the reaction [[bisphenol B co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BCL2 mRNA]
bisphenol F results in decreased methylation of BCL2 gene

PMID:37601897 PMID:38338858 PMID:39577800

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

BCL2-related protein A1

decreases expression

ISO

bisphenol F results in decreased expression of BCL2A1B mRNA

NCBI chr 8:98,596,806...98,604,890
Ensembl chr 8:98,596,650...98,604,890

G

Bcl2 like 12

decreases expression

ISO

bisphenol F results in decreased expression of BCL2L12 mRNA

NCBI chr 1:104,608,753...104,617,472
Ensembl chr 1:104,608,753...104,617,472

G

Bcl2-like 13

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BCL2L13 mRNA

NCBI chr 4:155,728,284...155,785,058
Ensembl chr 4:155,728,284...155,781,158

G

Bcl2-like 2

increases expression

ISO

bisphenol F results in increased expression of BCL2L2 mRNA

NCBI chr15:32,326,686...32,337,834
Ensembl chr15:32,326,020...32,335,379

G

BCL3, transcription coactivator

increases expression

ISO

bisphenol F results in increased expression of BCL3 mRNA

NCBI chr 1:88,599,321...88,613,555
Ensembl chr 1:88,599,321...88,614,368

G

BCL6B, transcription repressor

increases expression

ISO

bisphenol F results in increased expression of BCL6B mRNA

NCBI chr10:55,439,566...55,444,631
Ensembl chr10:55,432,382...55,444,631

G

BAF chromatin remodeling complex subunit BCL7A

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BCL7A mRNA
bisphenol F results in decreased expression of BCL7A mRNA

PMID:28628672 PMID:38685157

NCBI chr12:38,872,851...38,904,770
Ensembl chr12:38,872,851...38,904,770

G

BAF chromatin remodeling complex subunit BCL7B

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BCL7B mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BCL7B mRNA

PMID:28628672 PMID:36041667

NCBI chr12:27,133,412...27,146,631
Ensembl chr12:27,133,412...27,146,636

G

BAF chromatin remodeling complex subunit BCL7C

decreases expression

ISO

bisphenol F results in decreased expression of BCL7C mRNA

NCBI chr 1:191,703,432...191,754,751
Ensembl chr 1:191,691,089...191,754,641

G

BCL9, transcription coactivator

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of BCL9 gene

NCBI chr 2:187,449,425...187,475,241
Ensembl chr 2:187,449,425...187,475,241

G

BCL2-associated transcription factor 1

increases expression

ISO

bisphenol F results in increased expression of BCLAF1 protein

NCBI chr 1:16,904,572...16,937,106
Ensembl chr 1:16,914,118...16,936,801

G

beta-carotene oxygenase 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BCO1 mRNA

NCBI chr19:62,058,061...62,094,923
Ensembl chr19:62,058,089...62,094,917

G

beta-carotene oxygenase 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of BCO2 mRNA

NCBI chr 8:59,778,571...59,803,597
Ensembl chr 8:59,778,575...59,799,168

G

BCL6 co-repressor-like 1

decreases expression

ISO

bisphenol F results in decreased expression of BCORL1 mRNA

NCBI chr X:132,394,703...132,462,414
Ensembl chr X:132,397,069...132,461,976

G

brain-derived neurotrophic factor

decreases expression
decreases methylation
increases expression

EXP
ISO

4,4'-bisphenol F results in decreased expression of BDNF mRNA
bisphenol F results in decreased methylation of BDNF gene
bisphenol F results in increased expression of BDNF mRNA

PMID:26186136 PMID:30951980 PMID:38338858

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657

G

beclin 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BECN1 mRNA

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

brain-enriched guanylate kinase-associated

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BEGAIN mRNA

NCBI chr 6:133,708,010...133,744,264
Ensembl chr 6:133,708,007...133,744,526

G

BEN domain containing 3

increases expression

ISO

bisphenol F results in increased expression of BEND3 mRNA

NCBI chr20:48,562,383...48,599,194
Ensembl chr20:48,576,311...48,596,808

G

bestrophin 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BEST2 mRNA

NCBI chr19:40,047,191...40,053,216
Ensembl chr19:40,047,191...40,053,216

G

brain expressed X-linked 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BEX1 mRNA

NCBI chr X:103,811,458...103,812,986
Ensembl chr X:103,808,935...103,812,092

G

brain expressed X-linked 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of BEX3 mRNA

NCBI chr X:104,064,896...104,066,425
Ensembl chr X:104,064,515...104,075,906

G

bifunctional apoptosis regulator

decreases expression

ISO

bisphenol F results in decreased expression of BFAR mRNA

NCBI chr10:2,059,189...2,092,207
Ensembl chr10:2,059,058...2,094,183

G

biglycan

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of BGN mRNA
bisphenol F results in increased expression of BGN mRNA

NCBI chr X:156,348,633...156,360,797
Ensembl chr X:156,348,615...156,360,799

G

basic helix-loop-helix family, member e23

decreases expression

ISO

bisphenol F results in decreased expression of BHLHE23 mRNA

NCBI chr 3:188,266,572...188,268,786
Ensembl chr 3:188,238,188...188,269,089

G

basic helix-loop-helix family, member e40

multiple interactions

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of BHLHE40 mRNA

NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:143,174,048...143,180,783

G

basic helix-loop-helix family, member e41

decreases expression

ISO

bisphenol F results in decreased expression of BHLHE41 mRNA

NCBI chr 4:180,565,003...180,569,415
Ensembl chr 4:180,565,003...180,569,355

G

BicC family RNA binding protein 1

increases expression

ISO

bisphenol F results in increased expression of BICC1 mRNA

NCBI chr20:17,448,745...17,685,887
Ensembl chr20:17,448,765...17,685,885

G

BICD family like cargo adaptor 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BICDL2 mRNA

NCBI chr10:13,196,205...13,204,642
Ensembl chr10:13,195,913...13,204,642

G

BICRA like chromatin remodeling complex associated protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BICRAL mRNA

NCBI chr 9:21,597,886...21,682,985
Ensembl chr 9:21,597,855...21,682,983

G

BCL2-interacting killer

decreases expression

ISO

bisphenol F results in decreased expression of BIK mRNA

NCBI chr 7:116,552,303...116,571,317
Ensembl chr 7:116,552,303...116,571,317

G

bridging integrator 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BIN1 mRNA

NCBI chr18:24,282,840...24,341,461
Ensembl chr18:24,283,801...24,341,458

G

baculoviral IAP repeat-containing 2

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BIRC2 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BIRC2 mRNA

PMID:28628672 PMID:36041667

NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:13,253,706...13,271,911

G

baculoviral IAP repeat-containing 3

increases expression

ISO

bisphenol F results in increased expression of BIRC3 mRNA

NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590

G

BLCAP, apoptosis inducing factor

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BLCAP mRNA

NCBI chr 3:166,642,676...166,656,924
Ensembl chr 3:166,642,677...166,652,829

G

bleomycin hydrolase

increases expression

ISO

bisphenol F results in increased expression of BLMH mRNA

NCBI chr10:62,270,170...62,313,349
Ensembl chr10:62,270,033...62,313,345

G

biogenesis of lysosomal organelles complex-1, subunit 1

decreases expression

ISO

bisphenol F results in decreased expression of BLOC1S1 mRNA

NCBI chr 7:1,931,985...1,935,614
Ensembl chr 7:1,925,335...1,936,049

G

biogenesis of lysosomal organelles complex-1, subunit 3

increases expression

ISO

bisphenol F results in increased expression of BLOC1S3 mRNA

NCBI chr 1:88,283,864...88,286,244
Ensembl chr 1:88,280,115...88,294,060

G

biogenesis of lysosomal organelles complex 1 subunit 5

increases expression

ISO

bisphenol F results in increased expression of BLOC1S5 mRNA

NCBI chr17:26,377,549...26,402,869
Ensembl chr17:26,377,560...26,402,865

G

biliverdin reductase A

increases expression

ISO

bisphenol F results in increased expression of BLVRA protein

NCBI chr 3:134,793,397...134,819,367
Ensembl chr 3:134,794,203...134,819,785

G

biliverdin reductase B

increases expression

ISO

bisphenol F results in increased expression of BLVRB protein

NCBI chr 1:91,866,258...91,883,921
Ensembl chr 1:91,866,258...91,884,225

G

basic helix-loop-helix ARNT like 1

decreases expression

ISO

bisphenol F results in decreased expression of BMAL1 mRNA

NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:176,829,305...176,864,739

G

BMI1 proto-oncogene, polycomb ring finger

decreases expression

ISO

bisphenol F results in decreased expression of BMI1 mRNA

NCBI chr17:86,240,683...86,250,044
Ensembl chr17:86,243,491...86,250,024

G

bone morphogenetic protein 2

increases expression

ISO

bisphenol F results in increased expression of BMP2 mRNA

NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760

G

BMP-2 inducible kinase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BMP2K mRNA

NCBI chr14:12,785,169...12,882,676
Ensembl chr14:12,785,169...12,882,657

G

bone morphogenetic protein 3

increases expression
decreases expression

ISO

bisphenol F results in increased expression of BMP3 mRNA
bisphenol F results in decreased expression of BMP3 mRNA

PMID:30951980 PMID:36706583

NCBI chr14:11,012,564...11,041,282
Ensembl chr14:11,016,620...11,041,282

G

bone morphogenetic protein 4

multiple interactions
decreases expression
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of BMP4 mRNA
bisphenol F results in decreased expression of BMP4 mRNA
bisphenol F results in increased expression of BMP4 mRNA

PMID:30951980 PMID:38685157

NCBI chr15:22,098,191...22,113,145
Ensembl chr15:22,098,470...22,105,172

G

bone morphogenetic protein 5

increases expression

ISO

bisphenol F results in increased expression of BMP5 mRNA

PMID:30951980 PMID:38685157

NCBI chr 8:85,397,629...85,520,374
Ensembl chr 8:85,396,925...85,520,189

G

bone morphogenetic protein 6

multiple interactions
affects expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BMP6 mRNA
bisphenol F affects the expression of BMP6 mRNA

PMID:28628672 PMID:30951980

NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,523,704...26,675,261

G

bone morphogenetic protein 7

increases expression

ISO

bisphenol F results in increased expression of BMP7 mRNA

NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:182,052,337...182,135,137

G

BMP-binding endothelial regulator

multiple interactions

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of BMPER mRNA
[bisphenol F co-treated with Fulvestrant] results in increased methylation of BMPER gene

PMID:30951980 PMID:31601247

NCBI chr 8:30,008,049...30,253,201
Ensembl chr 8:30,008,148...30,434,359

G

bone morphogenetic protein receptor type 1A

increases expression

ISO

bisphenol F results in increased expression of BMPR1A mRNA

NCBI chr16:9,740,751...9,786,861
Ensembl chr16:9,742,875...9,786,861

G

bone morphogenetic protein receptor type 1B

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of BMPR1B gene

NCBI chr 2:233,211,525...233,544,344
Ensembl chr 2:233,211,525...233,544,311

G

bone morphogenetic protein receptor type 2

increases expression

ISO

bisphenol F results in increased expression of BMPR2 mRNA

PMID:38568856 PMID:38685157

NCBI chr 9:68,685,942...68,801,353
Ensembl chr 9:68,685,988...68,801,350

G

brain expressed myelocytomatosis oncogene

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of BMYC mRNA

NCBI chr 3:28,910,689...28,911,448
Ensembl chr 3:28,910,220...28,912,171

G

basonuclin zinc finger protein 1

multiple interactions
increases expression

ISO
EXP

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of BNC1 gene; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BNC1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BNC1 mRNA
bisphenol F results in increased expression of BNC1 mRNA

PMID:28628672 PMID:30951980 PMID:31601247 PMID:36041667

NCBI chr 1:145,326,881...145,352,534
Ensembl chr 1:145,326,892...145,353,510

G

basonuclin zinc finger protein 2

multiple interactions
decreases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of BNC2 gene
bisphenol F results in decreased expression of BNC2 mRNA

PMID:31601247 PMID:38685157

NCBI chr 5:103,724,934...104,061,890
Ensembl chr 5:103,724,934...104,125,428

G

BCL2 interacting protein 1

decreases expression

ISO

bisphenol F results in decreased expression of BNIP1 mRNA

NCBI chr10:16,891,317...16,903,561
Ensembl chr10:16,891,317...16,903,561

G

biorientation of chromosomes in cell division 1-like 1

increases expression

ISO

bisphenol F results in increased expression of BOD1L mRNA

NCBI chr14:73,320,880...73,375,662
Ensembl chr14:73,320,832...73,375,658

G

bolA family member 1

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BOLA1 mRNA
bisphenol F results in decreased expression of BOLA1 mRNA

PMID:36041667 PMID:38685157

NCBI chr 2:186,447,386...186,448,402
Ensembl chr 2:186,443,583...186,501,358

G

bolA family member 2

decreases expression

ISO

bisphenol F results in decreased expression of BOLA2 mRNA

NCBI chr 1:190,722,535...190,723,401
Ensembl chr 8:64,800,454...64,800,714
Ensembl chr 1:64,800,454...64,800,714

G

bolA family member 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of BOLA3 mRNA

NCBI chr 4:117,411,044...117,420,491
Ensembl chr 4:117,410,680...117,420,491

G

bora, aurora kinase A activator

decreases expression

ISO

bisphenol F results in decreased expression of BORA mRNA

NCBI chr15:82,205,467...82,243,499
Ensembl chr15:82,205,697...82,244,052

G

BLOC-1 related complex subunit 5

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BORCS5 mRNA
bisphenol F results in decreased expression of BORCS5 mRNA

PMID:28628672 PMID:38685157

NCBI chr 4:169,190,025...169,272,335
Ensembl chr 4:169,204,528...169,271,819

G

BPI fold containing family A, member 1

increases expression

ISO

bisphenol F results in increased expression of BPIFA1 mRNA

NCBI chr 3:163,087,965...163,093,708
Ensembl chr 3:163,087,965...163,093,708

G

3'(2'), 5'-bisphosphate nucleotidase 1

increases expression

ISO

bisphenol F results in increased expression of BPNT1 mRNA

NCBI chr13:99,397,127...99,425,056
Ensembl chr13:99,400,115...99,425,053

G

3'(2'), 5'-bisphosphate nucleotidase 2

multiple interactions
increases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BPNT2 mRNA
bisphenol F results in increased expression of BPNT2 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of BPNT2 mRNA

PMID:28628672 PMID:36041667 PMID:38685157

NCBI chr 5:22,573,241...22,600,126
Ensembl chr 5:22,570,165...22,600,126

G

BRCA1-associated ATM activator 1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of BRAT1 gene

NCBI chr12:19,043,004...19,065,686
Ensembl chr12:19,042,591...19,055,369

G

bromodomain containing 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BRD1 mRNA

NCBI chr 7:121,653,859...121,701,700
Ensembl chr 7:121,653,859...121,701,700

G

bromodomain containing 10

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BRD10 mRNA

NCBI chr 1:236,904,520...236,984,414
Ensembl chr 1:236,904,520...236,983,923

G

bromodomain containing 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BRD3 mRNA

NCBI chr 3:31,173,332...31,227,749
Ensembl chr 3:31,173,332...31,227,629

G

bromodomain containing 4

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of BRD4 gene
bisphenol F results in increased expression of BRD4 mRNA

PMID:31601247 PMID:38568856

NCBI chr 7:11,866,997...11,946,575
Ensembl chr 7:11,866,997...11,946,923

G

bromodomain containing 9

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BRD9 mRNA
bisphenol F results in decreased expression of BRD9 mRNA

PMID:28628672 PMID:38685157

NCBI chr 1:31,158,546...31,185,812
Ensembl chr 1:31,158,546...31,186,125

G

BRF2 general transcription factor 3B subunit

increases expression

ISO

bisphenol F results in increased expression of BRF2 mRNA

NCBI chr16:71,626,146...71,635,909
Ensembl chr16:71,623,238...71,635,903

G

BMP/retinoic acid inducible neural specific 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BRINP1 mRNA

NCBI chr 5:87,363,621...87,565,580
Ensembl chr 5:87,364,050...87,508,256

G

BMP/retinoic acid inducible neural specific 3

increases expression

ISO

bisphenol F results in increased expression of BRINP3 mRNA

NCBI chr13:60,964,127...61,397,044
Ensembl chr13:60,966,100...61,397,039

G

BRCA1 interacting DNA helicase 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BRIP1 mRNA

NCBI chr10:71,402,035...71,528,083
Ensembl chr10:71,401,151...71,575,206

G

BRO1 domain and CAAX motif containing

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BROX mRNA

NCBI chr13:97,451,736...97,471,598
Ensembl chr13:97,451,737...97,471,519

G

bromodomain and PHD finger containing, 1

decreases expression

ISO

bisphenol F results in decreased expression of BRPF1 mRNA

NCBI chr 4:148,011,977...148,028,431
Ensembl chr 4:148,011,931...148,028,424

G

BR serine/threonine kinase 1

decreases expression

ISO

bisphenol F results in decreased expression of BRSK1 mRNA

NCBI chr 1:78,162,944...78,193,598
Ensembl chr 1:78,163,341...78,188,922

G

BR serine/threonine kinase 2

decreases expression

ISO

bisphenol F results in decreased expression of BRSK2 mRNA

NCBI chr 1:206,465,040...206,518,156
Ensembl chr 1:206,465,040...206,518,156

G

bromodomain and WD repeat domain containing 3

increases expression

ISO

bisphenol F results in increased expression of BRWD3 mRNA

NCBI chr X:77,843,766...77,937,240
Ensembl chr X:77,848,982...77,937,745

G

BSCL2 lipid droplet biogenesis associated, seipin

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of BSCL2 mRNA

NCBI chr 1:215,160,764...215,172,540
Ensembl chr 1:215,160,957...215,172,536

G

basigin

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of BSG protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BSG mRNA

PMID:34186270 PMID:36041667

NCBI chr 7:10,643,788...10,651,005
Ensembl chr 7:10,643,789...10,651,005

G

B-box and SPRY domain containing

increases expression

ISO

bisphenol F results in increased expression of BSPRY mRNA

NCBI chr 5:80,942,974...80,965,157
Ensembl chr 5:80,942,979...80,988,154

G

bone marrow stromal cell antigen 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BST1 mRNA
bisphenol F results in increased expression of BST1 protein

PMID:28628672 PMID:34186270

NCBI chr14:71,466,179...71,482,671
Ensembl chr14:71,466,180...71,482,647

G

B-TFIID TATA-box binding protein associated factor 1

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of BTAF1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of BTAF1 mRNA

PMID:28628672 PMID:36041667

NCBI chr 1:244,065,728...244,156,457
Ensembl chr 1:244,065,743...244,156,457

G

BTB domain containing 16

increases expression

ISO

bisphenol F results in increased expression of BTBD16 mRNA

NCBI chr 1:194,765,241...194,819,786
Ensembl chr 1:194,765,903...194,819,785

G

BTB domain containing 17

increases expression

ISO

bisphenol F results in increased expression of BTBD17 mRNA

NCBI chr10:100,325,177...100,331,669
Ensembl chr10:100,325,177...100,331,771

G

BTB domain containing 7

increases expression

ISO

bisphenol F results in increased expression of BTBD7 mRNA

NCBI chr 6:127,685,185...127,774,947
Ensembl chr 6:127,688,421...127,737,222

G

biotinidase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of BTD mRNA

NCBI chr16:6,869,448...6,900,711
Ensembl chr16:6,869,291...6,901,410

G

basic transcription factor 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of BTF3 mRNA

NCBI chr 2:31,394,010...31,401,138
Ensembl chr 2:31,394,011...31,401,125
Ensembl chr13:31,394,011...31,401,125

G

BTG anti-proliferation factor 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of BTG1 mRNA

NCBI chr 7:33,228,149...33,230,406
Ensembl chr 7:33,227,833...33,230,406

G

BTG anti-proliferation factor 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BTG2 mRNA

NCBI chr13:48,083,931...48,087,690
Ensembl chr13:48,083,931...48,087,690

G

butyrophilin-like 2

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of BTNL2 gene

NCBI chr20:4,492,100...4,505,932
Ensembl chr20:4,492,111...4,505,932

G

BUB1 mitotic checkpoint serine/threonine kinase B

affects expression

ISO

bisphenol F affects the expression of BUB1B mRNA

NCBI chr 3:126,017,019...126,069,470
Ensembl chr 3:126,017,045...126,069,796

G

BUD13 homolog

decreases expression

ISO

bisphenol F results in decreased expression of BUD13 mRNA

NCBI chr 8:55,471,818...55,487,652
Ensembl chr 8:55,471,810...55,487,649

G

BUD31 homolog

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of BUD31 mRNA

NCBI chr12:14,576,602...14,584,132
Ensembl chr12:14,576,605...14,584,039

G

similar to human chromosome 5 open reading frame 15

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C5ORF15 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of C10H5ORF15 mRNA

PMID:28628672 PMID:36041667

NCBI chr10:37,064,889...37,077,493
Ensembl chr10:37,064,728...37,077,493

G

similar to human chromosome 21 open reading frame 91

increases expression

ISO

bisphenol F results in increased expression of D16ERTD472E mRNA

NCBI chr11:30,716,034...30,749,292
Ensembl chr11:30,716,034...30,749,415

G

similar to human chromosome 1 open reading frame 53

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of C13H1ORF53 mRNA

NCBI chr13:52,965,244...52,970,432
Ensembl chr13:52,965,244...52,970,607

G

similar to human chromosome 19 open reading frame 53

decreases expression

ISO

bisphenol F results in decreased expression of D8ERTD738E mRNA

NCBI chr19:40,819,830...40,822,609

G

core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1

increases expression

ISO

bisphenol F results in increased expression of C1GALT1 mRNA

NCBI chr 4:36,894,440...36,932,434
Ensembl chr 4:36,894,488...36,932,441

G

similar to human chromosome 10 open reading frame 143

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of C10ORF143 gene

NCBI chr 1:201,614,151...201,654,142
Ensembl chr 1:201,561,396...201,652,127

G

similar to human chromosome 10 open reading frame 90

increases expression

ISO

bisphenol F results in increased expression of C10ORF90 mRNA

NCBI chr 1:198,489,686...198,723,260
Ensembl chr 1:198,489,521...198,722,979

G

similar to human chromosome 11 open reading frame 16

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of C1H11ORF16 mRNA

NCBI chr 1:173,177,827...173,188,958
Ensembl chr 1:173,177,834...173,188,919

G

similar to human chromosome 11 open reading frame 58

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of C1H11ORF58 mRNA

NCBI chr 1:179,769,283...179,780,437
Ensembl chr 1:179,769,293...179,782,729

G

similar to human chromosome 15 open reading frame 40

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of C1H15ORF40 mRNA

NCBI chr 1:145,135,088...145,144,826
Ensembl chr 1:145,126,868...145,141,356

G

similar to human chromosome 19 open reading frame 12

increases expression

ISO

bisphenol F results in increased expression of C19ORF12 protein

NCBI chr 1:100,010,280...100,023,907
Ensembl chr 1:100,010,323...100,023,903

G

similar to human chromosome 19 open reading frame 81

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of C1H19ORF81 mRNA

NCBI chr 1:103,993,832...104,008,301
Ensembl chr 1:103,993,832...104,008,577

G

complement C1q A chain

increases expression

ISO

bisphenol F results in increased expression of C1QA mRNA

NCBI chr 5:154,417,086...154,419,933
Ensembl chr 5:154,417,087...154,427,732

G

complement C1q B chain

increases expression

ISO

bisphenol F results in increased expression of C1QB mRNA

NCBI chr 5:154,402,276...154,407,827
Ensembl chr 5:154,402,279...154,407,840

G

complement C1q C chain

increases expression

ISO

bisphenol F results in increased expression of C1QC mRNA

NCBI chr 5:154,410,845...154,414,208
Ensembl chr 5:154,410,848...154,414,468

G

complement C1q like 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of C1QL1 mRNA

NCBI chr10:88,402,219...88,409,649
Ensembl chr10:88,402,219...88,409,649

G

complement C1q like 3

increases expression

ISO

bisphenol F results in increased expression of C1QL3 mRNA

NCBI chr17:81,028,418...81,038,244
Ensembl chr17:81,028,418...81,038,244

G

C1q and TNF related 1

multiple interactions
affects expression
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C1QTNF1 mRNA
bisphenol F affects the expression of C1QTNF1 mRNA
bisphenol F results in increased expression of C1QTNF1 mRNA

PMID:28628672 PMID:30951980 PMID:38685157

NCBI chr10:104,159,021...104,180,253
Ensembl chr10:104,158,886...104,180,251

G

C1q and TNF related 12

decreases expression

ISO

bisphenol F results in decreased expression of C1QTNF12 mRNA

NCBI chr 5:171,833,854...171,838,229
Ensembl chr 5:171,833,854...171,838,800

G

C1q and TNF related 4

decreases expression

ISO

bisphenol F results in decreased expression of C1QTNF4 mRNA

NCBI chr 3:97,310,220...97,328,818
Ensembl chr 3:97,327,670...97,342,587

G

C1q and TNF related 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C1QTNF5 mRNA

NCBI chr 8:53,347,754...53,349,912
Ensembl chr 8:53,347,711...53,349,912

G

C1q and TNF related 6

increases expression

ISO

bisphenol F results in increased expression of C1QTNF6 mRNA

NCBI chr 7:111,958,348...111,964,948
Ensembl chr 7:111,958,350...111,966,871

G

C1q and TNF related 7

increases expression

ISO

bisphenol F results in increased expression of C1QTNF7 mRNA

NCBI chr14:71,680,415...71,792,931
Ensembl chr14:71,680,479...71,792,865

G

complement C1r

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C1R mRNA

NCBI chr 4:159,099,013...159,109,770
Ensembl chr 4:159,098,918...159,109,714

G

complement C1s

multiple interactions
decreases expression
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C1S mRNA
bisphenol F results in decreased expression of C1S1 mRNA
bisphenol F results in increased expression of C1S1 mRNA

PMID:28628672 PMID:30951980 PMID:38685157

NCBI chr 4:159,116,549...159,128,736
Ensembl chr 4:159,116,549...159,128,736

G

similar to human chromosome 21 open reading frame 58

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of C20H21ORF58 mRNA

NCBI chr20:12,165,853...12,187,271
Ensembl chr20:12,174,928...12,186,503

G

C2 calcium-dependent domain containing 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of C2CD2 mRNA

NCBI chr11:50,694,680...50,759,096
Ensembl chr11:50,694,563...50,759,016

G

C2CD2-like

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of C2CD2L mRNA
bisphenol F results in increased expression of C2CD2L mRNA

PMID:36041667 PMID:38685157

NCBI chr 8:53,544,887...53,557,127
Ensembl chr 8:53,544,892...53,555,153

G

C2 calcium-dependent domain containing 4C

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of C2CD4C gene

NCBI chr 7:10,742,534...10,746,033
Ensembl chr 7:10,742,545...10,751,973

G

similar to human chromosome 1 open reading frame 54

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C1ORF54 mRNA

NCBI chr 2:186,113,922...186,124,637
Ensembl chr 2:186,113,922...186,124,335

G

similar to human chromosome 4 open reading frame 46

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of C2H4ORF46 mRNA

NCBI chr 2:167,061,141...167,064,273
Ensembl chr 2:167,060,941...167,064,271

G

complement C3

increases expression

ISO

bisphenol F results in increased expression of C3 mRNA

NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,174,412...2,201,339

G

complement C3a receptor 1

increases expression

ISO

bisphenol F results in increased expression of C3AR1 mRNA

NCBI chr 4:157,747,419...157,756,609
Ensembl chr 4:157,746,089...157,776,323

G

similar to human chromosome 11 open reading frame 96

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of C3H11ORF96 mRNA

NCBI chr 3:100,375,474...100,376,717
Ensembl chr 3:100,351,199...100,378,346

G

similar to human chromosome 9 open reading frame 50

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of C9ORF50 gene

NCBI chr 3:34,477,535...34,484,791
Ensembl chr 3:34,478,508...34,484,805

G

complement C4A (Rodgers blood group)

decreases expression

ISO

bisphenol F results in decreased expression of C4A mRNA

NCBI chr20:4,010,306...4,024,707

G

complement C4B

increases expression

ISO

bisphenol F results in increased expression of C4B mRNA

PMID:30951980 PMID:37611474

NCBI chr20:4,201,979...4,216,292
Ensembl chr20:4,201,961...4,216,289

G

similar to human chromosome 1 open reading frame 159

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C1ORF159 mRNA

NCBI chr 5:171,983,700...172,001,373
Ensembl chr 5:171,983,936...172,001,373

G

similar to human chromosome 1 open reading frame 216

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of C5H1ORF216 mRNA

NCBI chr 5:144,168,240...144,189,761
Ensembl chr 5:144,184,603...144,190,546

G

complement C6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of C6 mRNA

NCBI chr 2:55,573,596...55,648,857
Ensembl chr 2:55,573,653...55,649,120

G

similar to human chromosome 12 open reading frame 42

decreases expression

ISO

bisphenol F results in decreased expression of C12ORF42 mRNA

NCBI chr 7:23,351,247...23,540,772
Ensembl chr 7:23,372,782...23,540,784

G

similar to human chromosome 11 open reading frame 54

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of BKGD mRNA

NCBI chr 8:20,405,240...20,427,811
Ensembl chr 8:20,405,241...20,427,811

G

similar to human chromosome 11 open reading frame 71

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of C11ORF71 mRNA

NCBI chr 8:57,735,075...57,735,489
Ensembl chr 8:57,734,900...57,738,597

G

similar to human chromosome 15 open reading frame 39

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of C15ORF39 mRNA

NCBI chr 8:66,542,269...66,551,835
Ensembl chr 8:66,542,269...66,554,782

G

similar to human chromosome 15 open reading frame 61

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of C8H15ORF61 mRNA

NCBI chr 8:72,763,513...72,768,248
Ensembl chr 8:72,757,256...72,768,748

G

complement C9

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of C9 mRNA

NCBI chr 2:57,300,510...57,348,759
Ensembl chr 2:57,300,427...57,348,752

G

similar to human chromosome 6 open reading frame 132

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of C6ORF132 gene

NCBI chr 9:21,022,482...21,058,942
Ensembl chr 9:21,023,092...21,059,125

G

carbonic anhydrase 11

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CAR11 mRNA

NCBI chr 1:105,306,347...105,311,651
Ensembl chr 1:105,302,289...105,311,832

G

carbonic anhydrase 13

decreases expression

ISO

bisphenol F results in decreased expression of CAR13 mRNA

NCBI chr 2:88,649,643...88,680,763
Ensembl chr 2:88,649,625...88,680,763

G

carbonic anhydrase 3

increases expression

ISO

bisphenol F results in increased expression of CAR3 mRNA

NCBI chr 2:88,491,666...88,501,299
Ensembl chr 2:88,491,670...88,500,524

G

carbonic anhydrase 4

increases expression

ISO

bisphenol F results in increased expression of CAR4 mRNA

NCBI chr10:70,325,102...70,333,916
Ensembl chr10:70,325,358...70,333,916

G

carbonic anhydrase 5A

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CAR5A mRNA
bisphenol F results in increased expression of CAR5A mRNA

PMID:36041667 PMID:38685157

NCBI chr19:66,881,678...66,911,486
Ensembl chr19:66,881,693...66,911,486

G

carbonic anhydrase 5B

increases expression

ISO

bisphenol F results in increased expression of CA5B protein

NCBI chr X:34,106,553...34,166,651
Ensembl chr X:34,067,403...34,166,653

G

carbonic anhydrase 6

increases expression

ISO

bisphenol F results in increased expression of CAR6 mRNA

NCBI chr 5:165,941,028...165,959,566
Ensembl chr 5:165,941,029...165,959,566

G

calcineurin binding protein 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CABIN1 mRNA

NCBI chr20:12,892,750...13,014,801
Ensembl chr20:12,892,771...13,014,800

G

calcium binding protein 1

decreases expression
multiple interactions

ISO
EXP

bisphenol F results in decreased expression of CABP1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CABP1 mRNA
[bisphenol F co-treated with Fulvestrant] results in increased methylation of CABP1 gene

PMID:30951980 PMID:31601247 PMID:36041667 PMID:38685157

NCBI chr12:47,045,914...47,109,614
Ensembl chr12:47,085,292...47,109,611

G

calcium binding protein 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CABP4 mRNA

NCBI chr 1:210,857,223...210,872,431
Ensembl chr 1:210,858,133...210,862,632

G

calcium binding protein 7

decreases expression

ISO

bisphenol F results in decreased expression of CABP7 mRNA

PMID:33476716 PMID:38685157

NCBI chr14:83,822,322...83,832,667
Ensembl chr14:83,822,327...83,832,735

G

calcium binding tyrosine phosphorylation regulated

decreases expression

ISO

bisphenol F results in decreased expression of CABYR mRNA

NCBI chr18:4,166,790...4,178,570
Ensembl chr18:4,166,858...4,179,507

G

calcium voltage-gated channel subunit alpha1 A

decreases expression

EXP
ISO

4,4'-bisphenol F results in decreased expression of CACNA1A mRNA

PMID:26186136 PMID:38685157

NCBI chr19:40,425,560...40,724,810
Ensembl chr19:40,425,560...40,724,599

G

calcium voltage-gated channel subunit alpha1 B

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CACNA1B mRNA

NCBI chr 3:27,779,133...27,944,292
Ensembl chr 3:27,779,166...27,944,285

G

calcium voltage-gated channel subunit alpha1 C

increases expression

ISO

bisphenol F results in increased expression of CACNA1C mRNA

NCBI chr 4:153,431,169...154,051,932
Ensembl chr 4:153,436,427...154,051,762

G

calcium voltage-gated channel subunit alpha1 D

decreases expression

ISO

bisphenol F results in decreased expression of CACNA1D mRNA

NCBI chr16:5,233,682...5,527,549
Ensembl chr16:5,233,690...5,674,692

G

calcium voltage-gated channel subunit alpha1 G

decreases expression

ISO

bisphenol F results in decreased expression of CACNA1G mRNA

NCBI chr10:79,851,886...79,919,926
Ensembl chr10:79,851,896...79,919,634

G

calcium voltage-gated channel subunit alpha1 I

decreases expression

ISO

bisphenol F results in decreased expression of CACNA1I mRNA

NCBI chr 7:113,716,266...113,827,670
Ensembl chr 7:113,716,266...113,827,670

G

calcium voltage-gated channel auxiliary subunit alpha2delta 1

increases expression

ISO

bisphenol F results in increased expression of CACNA2D1 protein

NCBI chr 4:19,902,324...20,330,287
Ensembl chr 4:19,905,764...20,330,147

G

calcium voltage-gated channel auxiliary subunit beta 1

decreases expression

ISO

bisphenol F results in decreased expression of CACNB1 mRNA

NCBI chr10:83,494,509...83,515,164
Ensembl chr10:83,494,509...83,515,146

G

calcium voltage-gated channel auxiliary subunit beta 2

increases expression

ISO

bisphenol F results in increased expression of CACNB2 mRNA

NCBI chr17:82,473,097...82,818,564
Ensembl chr17:82,473,129...82,818,564

G

calcium voltage-gated channel auxiliary subunit beta 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CACNB3 mRNA

NCBI chr 7:131,663,810...131,676,085
Ensembl chr 7:131,662,545...131,676,085

G

calcium voltage-gated channel auxiliary subunit gamma 2

decreases expression

ISO

bisphenol F results in decreased expression of CACNG2 mRNA

NCBI chr 7:111,451,605...111,579,071
Ensembl chr 7:111,455,006...111,577,757

G

calcium voltage-gated channel auxiliary subunit gamma 3

decreases expression

ISO

bisphenol F results in decreased expression of CACNG3 mRNA

NCBI chr 1:186,632,334...186,728,220
Ensembl chr 1:186,632,323...186,728,214

G

calcium voltage-gated channel auxiliary subunit gamma 4

decreases expression

ISO

bisphenol F results in decreased expression of CACNG4 mRNA

NCBI chr10:93,183,410...93,245,470
Ensembl chr10:93,183,410...93,245,470

G

calcium voltage-gated channel auxiliary subunit gamma 5

decreases expression

ISO

bisphenol F results in decreased expression of CACNG5 mRNA

NCBI chr10:93,327,142...93,369,244
Ensembl chr10:93,327,150...93,336,667

G

calcium voltage-gated channel auxiliary subunit gamma 7

multiple interactions

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CACNG7 mRNA

NCBI chr 1:74,715,483...74,746,669
Ensembl chr 1:74,715,483...74,746,669

G

CDK2-associated, cullin domain 1

increases expression

ISO

bisphenol F results in increased expression of CACUL1 mRNA

NCBI chr 1:269,652,356...269,712,265
Ensembl chr 1:269,652,356...269,712,112

G

calcyclin binding protein

increases expression

ISO

bisphenol F results in increased expression of CACYBP protein

NCBI chr13:74,970,917...74,981,298
Ensembl chr13:74,970,923...74,981,505

G

carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CAD mRNA
bisphenol F results in increased expression of CAD protein

PMID:28628672 PMID:34186270

NCBI chr 6:31,012,091...31,035,098
Ensembl chr 6:31,012,091...31,035,297

G

cell adhesion molecule 3

decreases expression

ISO

bisphenol F results in decreased expression of CADM3 mRNA

NCBI chr13:88,317,124...88,349,718
Ensembl chr13:88,317,124...88,350,114

G

calcium dependent secretion activator 2

increases expression

ISO

bisphenol F results in increased expression of CADPS2 mRNA

PMID:30951980 PMID:38685157

NCBI chr 4:52,746,054...53,275,252
Ensembl chr 4:52,746,065...53,275,004

G

calbindin 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CALB2 mRNA
bisphenol F results in increased expression of CALB2 protein

PMID:28628672 PMID:34186270

NCBI chr19:55,023,849...55,050,858
Ensembl chr19:55,023,838...55,057,952

G

calcitonin receptor like receptor

increases expression

ISO

bisphenol F results in increased expression of CALCRL mRNA

NCBI chr 3:89,835,071...89,932,616
Ensembl chr 3:89,835,077...89,887,350

G

caldesmon 1

increases expression

ISO

bisphenol F results in increased expression of CALD1 mRNA
bisphenol F results in increased expression of CALD1 protein

PMID:30951980 PMID:34186270 PMID:38685157

NCBI chr 4:64,232,906...64,414,085
Ensembl chr 4:64,233,171...64,414,085

G

calmodulin 2

increases expression

ISO

bisphenol F results in increased expression of CALM2 mRNA

NCBI chr 6:12,845,170...12,857,830
Ensembl chr15:64,519,554...64,520,657
Ensembl chr 6:64,519,554...64,520,657

G

calmodulin-like 4

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CALML4 mRNA
bisphenol F results in increased expression of CALML4 mRNA

PMID:28628672 PMID:30951980

NCBI chr 8:72,218,870...72,230,650
Ensembl chr 8:72,218,613...72,230,650

G

calneuron 1

increases methylation
increases expression

ISO

bisphenol F results in increased methylation of CALN1 gene
bisphenol F results in increased expression of CALN1 mRNA

PMID:31601247 PMID:38685157

NCBI chr12:31,447,964...31,939,847

G

calreticulin

increases expression

ISO

bisphenol F results in increased expression of CALR protein

NCBI chr19:40,213,367...40,218,262
Ensembl chr19:40,213,239...40,219,236

G

calumenin

increases expression

ISO

bisphenol F results in increased expression of CALU mRNA

NCBI chr 4:58,914,456...58,941,957
Ensembl chr 4:58,914,421...58,941,956

G

calcyon neuron-specific vesicular protein

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CALY mRNA

NCBI chr 1:204,292,317...204,303,506
Ensembl chr 1:204,292,318...204,303,196

G

calcium/calmodulin-dependent protein kinase I

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CAMK1 mRNA

NCBI chr 4:148,036,843...148,047,675
Ensembl chr 4:148,036,824...148,047,245

G

calcium/calmodulin-dependent protein kinase ID

increases expression

ISO

bisphenol F results in increased expression of CAMK1D mRNA

NCBI chr17:77,491,191...77,892,018
Ensembl chr17:77,491,220...77,892,012

G

calcium/calmodulin-dependent protein kinase II beta

increases expression

ISO

bisphenol F results in increased expression of CAMK2B mRNA

NCBI chr14:85,059,166...85,148,121
Ensembl chr14:85,059,191...85,148,485

G

calcium/calmodulin-dependent protein kinase II delta

increases expression
decreases expression

ISO

bisphenol F results in increased expression of CAMK2D protein
bisphenol F results in decreased expression of CAMK2D mRNA

PMID:34186270 PMID:38685157

NCBI chr 2:217,698,324...217,961,898
Ensembl chr 2:217,698,551...217,960,276

G

calcium/calmodulin-dependent protein kinase II inhibitor 2

increases expression

ISO

bisphenol F results in increased expression of CAMK2N2 mRNA

NCBI chr11:93,792,112...93,796,153
Ensembl chr11:93,794,095...93,795,222

G

calcium/calmodulin-dependent protein kinase IV

decreases expression

ISO

bisphenol F results in decreased expression of CAMK4 mRNA

NCBI chr18:24,857,152...25,076,054
Ensembl chr18:24,857,146...25,077,193

G

CaM kinase-like vesicle-associated

decreases expression
multiple interactions

ISO
EXP

bisphenol F results in decreased expression of CAMKV mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CAMKV mRNA

PMID:30951980 PMID:36041667

NCBI chr 8:117,505,439...117,519,785
Ensembl chr 8:117,505,408...117,519,797

G

calmodulin regulated spectrin-associated protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CAMSAP1 mRNA

NCBI chr 3:29,144,318...29,206,382
Ensembl chr 3:29,144,318...29,204,184

G

calmodulin regulated spectrin-associated protein family, member 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CAMSAP2 mRNA
bisphenol F results in increased expression of CAMSAP2 mRNA

PMID:28628672 PMID:38685157

NCBI chr13:50,274,950...50,354,298
Ensembl chr13:50,274,950...50,354,298

G

calmodulin binding transcription activator 2

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CAMTA2 mRNA
bisphenol F results in decreased expression of CAMTA2 mRNA

PMID:36041667 PMID:38685157

NCBI chr10:55,882,071...55,900,575
Ensembl chr10:55,882,071...55,900,179

G

cullin-associated and neddylation-dissociated 1

increases expression

ISO

bisphenol F results in increased expression of CAND1 protein
bisphenol F results in increased expression of CAND1 mRNA

PMID:34186270 PMID:38685157

NCBI chr 7:56,566,765...56,604,653
Ensembl chr 7:56,551,394...56,604,655

G

cullin-associated and neddylation-dissociated 2 (putative)

decreases expression

ISO

bisphenol F results in decreased expression of CAND2 mRNA

NCBI chr 4:150,507,659...150,535,755
Ensembl chr 4:150,507,657...150,541,293

G

calnexin

affects expression
increases expression

ISO

bisphenol F affects the expression of CANX mRNA
bisphenol F results in increased expression of CANX mRNA

PMID:35387338 PMID:38685157

NCBI chr10:35,124,941...35,157,954
Ensembl chr10:35,124,941...35,157,857

G

cyclase associated actin cytoskeleton regulatory protein 1

increases expression

ISO

bisphenol F results in increased expression of CAP1 protein

NCBI chr 5:140,427,265...140,507,678
Ensembl chr 5:140,427,269...140,453,470

G

capping actin protein, gelsolin like

increases expression

ISO

bisphenol F results in increased expression of CAPG mRNA
bisphenol F results in increased expression of CAPG protein

PMID:30951980 PMID:34186270

NCBI chr 4:106,152,912...106,170,010
Ensembl chr 4:106,152,890...106,170,672

G

calpain 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] affects the expression of CAPN1 mRNA
bisphenol F results in increased expression of CAPN1 mRNA

PMID:28628672 PMID:30951980

NCBI chr 1:212,705,219...212,736,134
Ensembl chr 1:212,705,222...212,729,445

G

calpain 10

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CAPN10 mRNA

NCBI chr 9:100,943,665...100,957,910
Ensembl chr 9:100,945,551...100,957,912

G

calpain 12

decreases expression

ISO

bisphenol F results in decreased expression of CAPN12 mRNA

NCBI chr 1:93,298,571...93,311,220
Ensembl chr 1:93,298,571...93,310,630

G

calpain 2

increases expression

ISO

bisphenol F results in increased expression of CAPN2 protein

NCBI chr13:96,681,902...96,732,625
Ensembl chr13:96,681,848...96,732,625

G

calpain 5

increases expression

ISO

bisphenol F results in increased expression of CAPN5 protein

NCBI chr 1:161,827,474...161,884,142
Ensembl chr 1:161,827,474...161,884,142

G

calpain 6

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of CAPN6 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of CAPN6 mRNA

NCBI chr X:112,177,467...112,202,178
Ensembl chr X:112,177,467...112,202,178

G

calpain, small subunit 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CAPNS1 mRNA

NCBI chr 1:94,572,083...94,582,332
Ensembl chr 1:94,572,083...94,583,368

G

calpain, small subunit 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CAPNS2 mRNA

NCBI chr19:30,277,324...30,278,266

G

cell cycle associated protein 1

increases expression

ISO

bisphenol F results in increased expression of CAPRIN1 protein
bisphenol F results in increased expression of CAPRIN1 mRNA

PMID:34186270 PMID:38685157

NCBI chr 3:110,606,489...110,685,408
Ensembl chr 3:110,606,489...110,685,562

G

caprin family member 2

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CAPRIN2 mRNA
bisphenol F results in decreased expression of CAPRIN2 mRNA

PMID:28628672 PMID:38685157

NCBI chr 4:183,537,935...183,592,162
Ensembl chr 4:183,537,430...183,592,809

G

calcyphosine-like

increases expression

ISO

bisphenol F results in increased expression of CAPSL mRNA

NCBI chr 2:60,122,162...60,152,692
Ensembl chr 2:60,138,589...60,152,838

G

capping actin protein of muscle Z-line subunit alpha 1

increases expression

ISO

bisphenol F results in increased expression of CAPZA1 protein
bisphenol F results in increased expression of CAPZA1 mRNA

PMID:34186270 PMID:38685157

NCBI chr 2:195,008,035...195,053,100
Ensembl chr 2:195,008,039...195,053,100

G

capping actin protein of muscle Z-line subunit alpha 2

increases expression

ISO

bisphenol F results in increased expression of CAPZA2 protein

NCBI chr 4:46,944,040...46,979,930
Ensembl chr 4:46,895,701...46,979,938

G

capping actin protein of muscle Z-line subunit beta

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CAPZB mRNA

NCBI chr 5:156,718,619...156,818,623
Ensembl chr 5:156,650,432...156,818,619

G

carbonic anhydrase 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CA2 mRNA
bisphenol F results in increased expression of CAR2 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of CAR2 mRNA

PMID:28628672 PMID:30951980

NCBI chr 2:88,462,883...88,478,012
Ensembl chr 2:88,462,872...88,478,064

G

carbonic anhydrase 7

increases expression
increases methylation
multiple interactions

ISO

bisphenol F results in increased expression of CAR7 mRNA
bisphenol F results in increased methylation of CA7 gene
[bisphenol F co-treated with Fulvestrant] results in increased methylation of CA7 gene

PMID:30951980 PMID:31601247

NCBI chr19:435,520...444,927
Ensembl chr19:435,522...452,384

G

caspase recruitment domain family, member 10

decreases expression

ISO

bisphenol F results in decreased expression of CARD10 mRNA

NCBI chr 7:112,210,944...112,252,044
Ensembl chr 7:112,210,776...112,239,806

G

coactivator-associated arginine methyltransferase 1

decreases expression

ISO

bisphenol F results in decreased expression of CARM1 mRNA

NCBI chr 8:28,373,370...28,418,056
Ensembl chr 8:28,373,362...28,418,056

G

capping protein regulator and myosin 1 linker 1

multiple interactions
decreases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CARMIL1 gene
bisphenol F results in decreased expression of CARMIL1 mRNA

PMID:31601247 PMID:38685157

NCBI chr17:41,235,819...41,516,204
Ensembl chr17:41,236,229...41,516,221

G

capping protein regulator and myosin 1 linker 2

decreases expression

ISO

bisphenol F results in decreased expression of CARMIL2 mRNA

NCBI chr19:50,481,911...50,496,672
Ensembl chr19:50,484,324...50,496,669

G

capping protein regulator and myosin 1 linker 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CARMIL3 mRNA

NCBI chr15:32,948,228...32,965,829
Ensembl chr15:32,948,856...32,965,811

G

cardiac mesoderm enhancer-associated non-coding RNA

decreases expression

ISO

bisphenol F results in decreased expression of CARMN mRNA

NCBI chr18:57,368,191...57,389,112
Ensembl chr18:57,360,134...57,389,921

G

carnosine N-methyltransferase 1

increases expression

ISO

bisphenol F results in increased expression of CARNMT1 mRNA

NCBI chr 1:225,520,345...225,549,971
Ensembl chr 1:225,520,151...225,550,232

G

cysteinyl-tRNA synthetase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CARS1 mRNA

NCBI chr 1:208,183,092...208,225,425
Ensembl chr 1:208,182,788...208,225,407

G

cysteinyl-tRNA synthetase 2, mitochondrial

increases expression

ISO

bisphenol F results in increased expression of CARS2 protein

NCBI chr16:84,649,617...84,689,254
Ensembl chr16:84,645,627...84,690,192

G

CASC3 exon junction complex subunit

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CASC3 gene

NCBI chr10:84,264,157...84,286,639
Ensembl chr10:84,265,033...84,286,637

G

CASK interacting protein 1

decreases expression

ISO

bisphenol F results in decreased expression of CASKIN1 mRNA

NCBI chr10:14,016,780...14,037,927
Ensembl chr10:14,018,012...14,037,924

G

caspase 1

decreases expression
increases activity

ISO

bisphenol F results in decreased expression of CASP1 mRNA
bisphenol F results in increased activity of CASP1 protein

PMID:33312107 PMID:33916708

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275

G

caspase 12

increases expression

ISO

bisphenol F results in increased expression of CASP12 mRNA

NCBI chr 8:10,927,188...10,954,442
Ensembl chr 8:10,926,994...10,954,442

G

caspase 3

decreases expression
increases expression
decreases activity

EXP
ISO

4,4'-bisphenol F results in decreased expression of CASP3 mRNA
bisphenol F results in increased expression of CASP3 protein
bisphenol F results in decreased activity of CASP3 protein
bisphenol F results in increased expression of CASP3 mRNA

PMID:26186136 PMID:31453682 PMID:37601897 PMID:38685157 PMID:39736419 More...

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 4

decreases expression

ISO

bisphenol F results in decreased expression of CASP4 mRNA

PMID:33312107 PMID:38685157

NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:10,883,769...10,920,727

G

caspase 6

increases expression

ISO

bisphenol F results in increased expression of CASP6 mRNA

NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:221,140,256...221,152,726

G

caspase 7

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CASP7 mRNA
bisphenol F results in increased expression of CASP7 mRNA

PMID:28628672 PMID:31453682

NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512

G

caspase 8

increases expression
increases activity

ISO

bisphenol F results in increased expression of CASP8 mRNA
bisphenol F results in increased activity of CASP8 protein

PMID:30951980 PMID:31453682 PMID:33916708

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

increases expression
increases activity

ISO

bisphenol F results in increased expression of CASP9 mRNA
bisphenol F results in increased activity of CASP9 protein

PMID:31453682 PMID:33916708 PMID:38685157 PMID:39929295

Ensembl chr 5:159,391,188...159,409,648

G

calsequestrin 1

decreases expression

ISO

bisphenol F results in decreased expression of CASQ1 mRNA

NCBI chr13:87,203,021...87,212,710
Ensembl chr13:87,202,485...87,213,463

G

calsequestrin 2

increases expression

ISO

bisphenol F results in increased expression of CASQ2 mRNA

NCBI chr 2:192,214,556...192,270,821
Ensembl chr 2:192,214,537...192,270,820

G

castor zinc finger 1

increases methylation

ISO

bisphenol F results in increased methylation of CASZ1 gene

NCBI chr 5:164,527,083...164,677,037
Ensembl chr 5:164,527,112...164,677,014

G

catalase

decreases activity
increases expression

ISO
EXP

4,4'-bisphenol F results in decreased activity of CAT protein
bisphenol F results in increased expression of CAT protein
4,4'-bisphenol F results in decreased activity of CAT protein; bisphenol F results in decreased activity of CAT protein

PMID:28259788 PMID:29940534 PMID:31424294 PMID:34186270 PMID:37601897

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

cation channel, sperm associated 2

decreases expression

ISO

bisphenol F results in decreased expression of CATSPER2 mRNA

NCBI chr 3:128,822,387...128,842,501
Ensembl chr 3:128,822,391...128,842,261

G

cation channel, sperm associated 4

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CATSPER4 gene

NCBI chr 5:151,711,415...151,731,083
Ensembl chr 5:151,711,194...151,730,750

G

cation channel sperm associated auxiliary subunit gamma

decreases expression

ISO

bisphenol F results in decreased expression of CATSPERG1 mRNA

NCBI chr 1:93,616,209...93,646,970
Ensembl chr 1:93,616,209...93,661,618

G

caveolin 1

increases expression

ISO

bisphenol F results in increased expression of CAV1 mRNA
bisphenol F results in increased expression of CAV1 protein

PMID:30951980 PMID:34186270

NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740

G

caveolin 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CAV2 mRNA
bisphenol F results in increased expression of CAV2 protein
bisphenol F results in increased expression of CAV2 mRNA

PMID:28628672 PMID:30951980 PMID:34186270

NCBI chr 4:46,582,681...46,590,058
Ensembl chr 4:46,582,096...46,591,425

G

caveolae associated protein 1

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of PTRF mRNA
bisphenol F results in increased expression of CAVIN1 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of PTRF mRNA

PMID:30951980 PMID:34186270

NCBI chr10:86,384,401...86,398,240
Ensembl chr10:86,384,401...86,396,383

G

caveolae associated protein 2

increases expression

ISO

bisphenol F results in increased expression of CAVIN2 mRNA
bisphenol F results in increased expression of CAVIN2 protein

PMID:30951980 PMID:34186270

NCBI chr 9:57,794,007...57,806,024
Ensembl chr 9:57,794,019...57,806,024

G

caveolae associated protein 3

increases expression

ISO

bisphenol F results in increased expression of PRKCDBP mRNA
bisphenol F results in increased expression of CAVIN3 protein

PMID:30951980 PMID:34186270

NCBI chr 1:169,238,384...169,239,973
Ensembl chr 1:169,238,384...169,239,981

G

CACN subunit beta associated regulatory protein

decreases expression

ISO

bisphenol F results in decreased expression of CBARP mRNA

NCBI chr 7:10,217,314...10,225,855
Ensembl chr 7:10,217,328...10,225,854

G

CBFA2/RUNX1 partner transcriptional co-repressor 3

decreases expression

ISO

bisphenol F results in decreased expression of CBFA2T3 mRNA

NCBI chr19:67,584,319...67,658,533
Ensembl chr19:67,589,258...67,658,136

G

Cbl proto-oncogene

increases expression

ISO

bisphenol F results in increased expression of CBL mRNA

NCBI chr 8:53,384,656...53,468,067
Ensembl chr 8:53,384,656...53,468,067

G

Cbl proto-oncogene C

decreases expression

ISO

bisphenol F results in decreased expression of CBLC mRNA

NCBI chr 1:88,567,930...88,584,709
Ensembl chr 1:88,567,932...88,584,709

G

cerebellin 1 precursor

decreases expression
increases methylation

ISO

bisphenol F results in decreased expression of CBLN1 mRNA
bisphenol F results in increased methylation of CBLN1 gene

PMID:30951980 PMID:31601247

NCBI chr19:35,782,151...35,785,960
Ensembl chr19:35,781,952...35,785,960

G

cerebellin 2 precursor

increases expression

ISO

bisphenol F results in increased expression of CBLN2 mRNA

NCBI chr18:82,215,210...82,222,648
Ensembl chr18:82,215,220...82,222,648

G

carbonyl reductase 1

increases expression

ISO

bisphenol F results in increased expression of CBR1 protein

NCBI chr11:46,346,405...46,348,815
Ensembl chr11:46,378,411...46,381,104
Ensembl chr11:46,378,411...46,381,104

G

carbonyl reductase 2

increases expression

ISO

bisphenol F results in increased expression of CBR2 mRNA

NCBI chr10:106,508,964...106,511,614
Ensembl chr10:106,509,136...106,511,180

G

carbonyl reductase 3

increases expression

ISO

bisphenol F results in increased expression of CBR3 mRNA

NCBI chr11:46,478,295...46,486,555
Ensembl chr11:46,478,274...46,486,558

G

cystathionine beta synthase

decreases expression

ISO

bisphenol F results in decreased expression of CBS mRNA

NCBI chr20:9,709,394...9,733,925
Ensembl chr20:9,709,395...9,734,066

G

chromobox 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CBX1 mRNA

NCBI chr10:82,266,746...82,286,431
Ensembl chr10:82,266,759...82,287,242

G

chromobox 3

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CBX3 mRNA
bisphenol F results in increased expression of CBX3 mRNA

PMID:36041667 PMID:38685157

NCBI chr 4:81,876,155...81,889,912
Ensembl chr 4:81,876,649...81,889,911

G

chromobox 6

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CBX6 mRNA
bisphenol F results in decreased expression of CBX6 mRNA

PMID:36041667 PMID:38685157

NCBI chr 7:113,253,364...113,263,413
Ensembl chr 7:113,253,364...113,263,413

G

chromobox 7

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CBX7 mRNA

NCBI chr 7:113,341,030...113,358,716
Ensembl chr 7:113,341,030...113,358,346

G

chromobox 8

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CBX8 mRNA
bisphenol F results in increased expression of CBX8 mRNA

PMID:28628672 PMID:38685157

NCBI chr10:104,793,062...104,795,500
Ensembl chr10:104,793,062...104,795,500

G

coiled-coil and C2 domain containing 1A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CC2D1A mRNA

NCBI chr19:40,916,587...40,931,702
Ensembl chr19:40,916,532...40,931,701

G

coiled-coil and C2 domain containing 1B

decreases expression

ISO

bisphenol F results in decreased expression of CC2D1B mRNA

NCBI chr 5:128,581,962...128,596,045
Ensembl chr 5:128,581,994...128,596,022

G

collagen and calcium binding EGF domains 1

increases expression

ISO

bisphenol F results in increased expression of CCBE1 mRNA

NCBI chr18:61,849,821...62,093,876
Ensembl chr18:61,853,149...62,094,075

G

coiled-coil domain containing 102A

increases expression

ISO

bisphenol F results in increased expression of CCDC102A mRNA

NCBI chr19:10,108,553...10,124,652
Ensembl chr19:10,109,364...10,124,652

G

coiled-coil domain containing 107

affects expression

ISO

bisphenol F affects the expression of CCDC107 mRNA

NCBI chr 5:62,545,273...62,548,711
Ensembl chr 5:62,544,714...62,548,709

G

coiled-coil domain containing 117

increases expression

ISO

bisphenol F results in increased expression of CCDC117 mRNA

NCBI chr14:84,614,282...84,623,648
Ensembl chr14:84,614,283...84,624,087

G

coiled-coil domain containing 12

decreases expression

ISO

bisphenol F results in decreased expression of CCDC12 mRNA

NCBI chr 8:119,513,007...119,564,802
Ensembl chr 8:119,514,094...119,564,802

G

coiled-coil domain containing 120

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CCDC120 mRNA

NCBI chr X:17,437,219...17,443,716
Ensembl chr X:17,425,624...17,444,717

G

coiled-coil domain containing 124

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CCDC124 mRNA
bisphenol F results in increased expression of CCDC124 protein

PMID:34186270 PMID:36041667

NCBI chr16:18,600,737...18,606,556
Ensembl chr16:18,600,737...18,606,556

G

coiled-coil domain containing 126

increases expression

ISO

bisphenol F results in increased expression of CCDC126 mRNA

NCBI chr 4:79,628,483...79,649,513
Ensembl chr 4:79,628,412...79,649,508

G

coiled-coil domain containing 127

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CCDC127 mRNA

NCBI chr 1:30,757,010...30,764,473
Ensembl chr 1:30,757,010...30,764,473

G

coiled-coil domain containing 141

increases expression

ISO

bisphenol F results in increased expression of CCDC141 mRNA

NCBI chr 3:82,357,046...82,517,199
Ensembl chr 3:82,357,681...82,517,710

G

coiled-coil domain containing 146

increases expression

ISO

bisphenol F results in increased expression of CCDC146 mRNA

NCBI chr 4:14,554,966...14,703,801
Ensembl chr 4:14,554,966...14,703,799

G

coiled-coil domain containing 15

decreases expression

ISO

bisphenol F results in decreased expression of CCDC15 mRNA

NCBI chr 8:45,165,297...45,257,641
Ensembl chr 8:45,134,596...45,277,989

G

coiled-coil domain containing 152

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CCDC152 mRNA
bisphenol F results in decreased expression of CCDC152 mRNA

PMID:36041667 PMID:38685157

NCBI chr 2:54,236,013...54,260,531
Ensembl chr 2:54,236,013...54,264,065

G

coiled-coil domain containing 160

decreases expression

ISO

bisphenol F results in decreased expression of CCDC160 mRNA

NCBI chr X:137,389,066...137,399,452
Ensembl chr X:137,389,032...137,400,325

G

coiled-coil domain containing 162

increases expression

ISO

bisphenol F results in increased expression of CCDC162 mRNA

NCBI chr20:46,627,277...46,820,216
Ensembl chr20:46,627,277...46,818,249

G

coiled-coil domain containing 163

decreases expression

ISO

bisphenol F results in decreased expression of CCDC163 mRNA

NCBI chr 5:135,408,981...135,415,574
Ensembl chr 5:135,409,003...135,415,577

G

coiled-coil domain containing 167

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CCDC167 mRNA

NCBI chr20:7,768,425...7,783,181
Ensembl chr20:7,753,072...7,783,181

G

coiled-coil domain containing 171

decreases expression

ISO

bisphenol F results in decreased expression of CCDC171 mRNA

NCBI chr 5:102,965,763...103,449,740
Ensembl chr 5:102,965,911...103,533,290

G

coiled-coil domain containing 177

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CCDC177 mRNA

NCBI chr 6:106,135,827...106,142,413
Ensembl chr 6:106,134,333...106,144,441

G

coiled-coil domain containing 18

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CCDC18 mRNA

NCBI chr14:1,646,725...1,752,581
Ensembl chr14:1,646,809...1,750,470

G

coiled-coil domain containing 180

increases expression

ISO

bisphenol F results in increased expression of CCDC180 mRNA

NCBI chr 5:64,950,522...65,019,127
Ensembl chr 5:64,950,515...65,019,127

G

coiled-coil domain containing 183

decreases expression

ISO

bisphenol F results in decreased expression of CCDC183 mRNA

NCBI chr 3:28,826,918...28,837,072
Ensembl chr 3:28,826,921...28,835,326

G

coiled-coil domain containing 186

increases expression

ISO

bisphenol F results in increased expression of CCDC186 mRNA

NCBI chr 1:265,840,429...265,878,082
Ensembl chr 1:265,843,039...265,877,131

G

coiled-coil domain containing 191

decreases expression

ISO

bisphenol F results in decreased expression of CCDC191 mRNA

NCBI chr11:70,241,562...70,312,288
Ensembl chr11:70,241,562...70,312,431

G

coiled-coil domain containing 198

decreases methylation
multiple interactions

ISO

bisphenol F results in decreased methylation of CCDC198 gene
[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CCDC198 gene

NCBI chr15:24,979,764...25,006,608
Ensembl chr15:24,979,531...25,006,542

G

coiled-coil domain containing 24

decreases expression

ISO

bisphenol F results in decreased expression of CCDC24 mRNA

NCBI chr 5:136,684,206...136,697,855
Ensembl chr 5:136,693,499...136,697,469

G

coiled-coil domain containing 25

increases expression

ISO

bisphenol F results in increased expression of CCDC25 mRNA

NCBI chr15:44,230,927...44,263,317
Ensembl chr15:44,230,940...44,265,236

G

coiled-coil domain containing 28A

decreases expression

ISO

bisphenol F results in decreased expression of CCDC28A mRNA

NCBI chr 1:14,677,451...14,692,729
Ensembl chr 1:14,677,449...14,692,522

G

coiled-coil domain containing 3

increases expression

ISO

bisphenol F results in increased expression of CCDC3 mRNA

NCBI chr17:77,941,148...78,044,820
Ensembl chr17:77,944,977...78,044,470

G

coiled-coil domain containing 33

increases expression

ISO

bisphenol F results in increased expression of CCDC33 mRNA

NCBI chr 8:67,331,519...67,430,194
Ensembl chr 8:67,331,519...67,413,485

G

coiled-coil domain containing 34

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CCDC34 mRNA

NCBI chr 3:117,007,652...117,042,885
Ensembl chr 3:117,005,760...117,042,226

G

coiled-coil domain containing 38

decreases expression

ISO

bisphenol F results in decreased expression of CCDC38 mRNA

NCBI chr 7:29,943,046...30,017,512
Ensembl chr 7:29,946,783...30,017,504

G

coiled-coil domain 39 molecular ruler complex subunit

decreases expression

ISO

bisphenol F results in decreased expression of CCDC39 mRNA

NCBI chr 2:118,593,881...118,631,584
Ensembl chr 2:118,593,881...118,631,647

G

coiled-coil domain 40 molecular ruler complex subunit

increases expression

ISO

bisphenol F results in increased expression of CCDC40 mRNA

NCBI chr10:104,985,283...105,025,813
Ensembl chr10:104,985,283...105,026,197

G

coiled-coil domain containing 47

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CCDC47 mRNA

NCBI chr10:91,630,101...91,648,626
Ensembl chr10:91,630,106...91,648,626

G

coiled-coil domain containing 57

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CCDC57 mRNA
bisphenol F results in decreased expression of CCDC57 mRNA

PMID:36041667 PMID:38685157

NCBI chr10:106,591,106...106,694,740
Ensembl chr10:106,590,551...106,684,983

G

coiled-coil domain containing 59

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CCDC59 mRNA

NCBI chr 7:43,029,272...43,035,655
Ensembl chr 7:43,029,272...43,035,655

G

coiled-coil domain containing 60

increases expression

ISO

bisphenol F results in increased expression of CCDC60 mRNA

NCBI chr12:45,975,394...46,141,078
Ensembl chr12:45,975,403...46,141,132

G

coiled-coil domain containing 62

decreases expression

ISO

bisphenol F results in decreased expression of CCDC62 mRNA

NCBI chr12:38,284,089...38,320,828
Ensembl chr12:38,284,089...38,320,965

G

coiled-coil domain containing 65

increases expression

ISO

bisphenol F results in increased expression of CCDC65 mRNA

NCBI chr 7:131,736,002...131,749,761
Ensembl chr 7:131,736,011...131,749,719

G

coiled-coil domain containing 66

decreases expression

ISO

bisphenol F results in decreased expression of CCDC66 mRNA

NCBI chr16:2,668,810...2,700,717
Ensembl chr16:2,658,131...2,701,012

G

coiled-coil domain containing 68

increases expression

ISO

bisphenol F results in increased expression of CCDC68 mRNA

NCBI chr18:65,817,232...65,859,529
Ensembl chr18:65,786,926...65,859,526

G

coiled-coil domain containing 73

decreases expression

ISO

bisphenol F results in decreased expression of CCDC73 mRNA

NCBI chr 3:111,737,771...111,879,588
Ensembl chr 3:111,737,730...111,880,105

G

coiled-coil domain containing 74A

increases expression

ISO

bisphenol F results in increased expression of CCDC74A mRNA

NCBI chr11:96,860,161...96,864,540
Ensembl chr11:96,860,161...96,864,540

G

coiled-coil domain containing 77

decreases expression

ISO

bisphenol F results in decreased expression of CCDC77 mRNA

NCBI chr 4:155,206,402...155,238,235
Ensembl chr 4:155,193,275...155,239,207

G

coiled-coil domain containing 78

increases expression

ISO

bisphenol F results in increased expression of CCDC78 mRNA

NCBI chr10:15,312,403...15,316,800
Ensembl chr10:15,311,868...15,319,425

G

coiled-coil domain containing 8

increases expression

ISO

bisphenol F results in increased expression of CCDC8 mRNA

NCBI chr 1:86,807,607...86,810,935
Ensembl chr 1:86,806,942...86,814,204

G

coiled-coil domain containing 80

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of CCDC80 mRNA
bisphenol F results in increased expression of CCDC80 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of CCDC80 mRNA

PMID:30951980 PMID:34186270

NCBI chr11:69,191,188...69,224,844
Ensembl chr11:69,191,189...69,224,844

G

coiled-coil domain containing 82

decreases expression

ISO

bisphenol F results in decreased expression of CCDC82 mRNA

NCBI chr 8:18,509,293...18,665,008
Ensembl chr 8:18,509,382...18,550,529

G

coiled-coil domain containing 85A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CCDC85A mRNA

NCBI chr14:106,327,580...106,560,205
Ensembl chr14:106,327,580...106,560,165

G

coiled-coil domain containing 85C

increases expression

ISO

bisphenol F results in increased expression of CCDC85C mRNA

NCBI chr 6:132,877,851...132,948,744
Ensembl chr 6:132,879,562...132,948,623

G

coiled-coil domain containing 91

increases expression

ISO

bisphenol F results in increased expression of CCDC91 mRNA

NCBI chr 4:182,132,931...182,304,948
Ensembl chr 4:182,132,942...182,304,948

G

coiled-coil domain containing 92

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CCDC92 mRNA

NCBI chr12:37,457,676...37,484,080
Ensembl chr12:37,457,068...37,484,327

G

coiled-coil alpha-helical rod protein 1

increases expression
decreases expression

ISO

bisphenol F results in increased expression of CCHCR1 mRNA
bisphenol F results in decreased expression of CCHCR1 mRNA

PMID:30951980 PMID:38685157

NCBI chr20:3,210,383...3,223,187
Ensembl chr20:3,210,384...3,222,765

G

cholecystokinin A receptor

increases expression

ISO

bisphenol F results in increased expression of CCKAR mRNA

NCBI chr14:61,505,270...61,513,618
Ensembl chr14:61,505,270...61,513,618

G

cholecystokinin B receptor

increases expression

ISO

bisphenol F results in increased expression of CCKBR mRNA

NCBI chr 1:169,183,578...169,193,583
Ensembl chr 1:169,183,194...169,193,745

G

C-C motif chemokine ligand 19

decreases expression

ISO

bisphenol F results in decreased expression of CCL19 mRNA

NCBI chr 5:61,759,220...61,761,164
Ensembl chr 5:61,759,220...61,772,022

G

C-C motif chemokine ligand 2

increases expression

ISO

4,4'-bisphenol F results in increased expression of CCL2 mRNA; bisphenol F results in increased expression of CCL2 mRNA

PMID:30951980 PMID:32044397 PMID:35278557

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 24

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CCL24 mRNA

NCBI chr12:26,737,423...26,741,420
Ensembl chr12:26,737,439...26,750,924

G

C-C motif chemokine ligand 27

decreases expression

ISO

bisphenol F results in decreased expression of CCL27A mRNA

NCBI chr 5:61,737,261...61,744,375
Ensembl chr 5:61,737,261...61,743,522

G

C-C motif chemokine ligand 7

increases expression

ISO

bisphenol F results in increased expression of CCL7 mRNA

NCBI chr10:67,514,095...67,515,945
Ensembl chr10:67,514,091...67,515,947

G

C-C motif chemokine ligand 9

increases expression

ISO

bisphenol F results in increased expression of CCL6 mRNA

PMID:30951980 PMID:38685157

NCBI chr10:68,863,994...68,868,928
Ensembl chr10:68,863,995...68,868,877

G

CCM2 scaffold protein

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CCM2 mRNA

NCBI chr14:85,632,338...85,678,016
Ensembl chr14:85,632,001...85,678,028

G

CCM2 like scaffold protein

decreases expression

ISO

bisphenol F results in decreased expression of CCM2L mRNA

NCBI chr 3:161,993,717...162,009,372
Ensembl chr 3:161,859,312...162,009,371

G

cellular communication network factor 1

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of CCN1 mRNA
bisphenol F results in increased expression of CCN1 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of CCN1 mRNA

PMID:30951980 PMID:34186270

NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883

G

cellular communication network factor 2

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CCN2 mRNA
bisphenol F results in increased expression of CCN2 mRNA

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

cellular communication network factor 4

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CCN4 mRNA
bisphenol F results in increased expression of CCN4 mRNA

PMID:30951980 PMID:38685157

NCBI chr 7:100,534,578...100,566,287
Ensembl chr 7:100,534,505...100,563,094

G

cellular communication network factor 6

decreases expression

ISO

bisphenol F results in decreased expression of CCN6 mRNA

NCBI chr20:44,123,932...44,139,745
Ensembl chr20:44,123,932...44,139,793

G

cyclin A2

decreases expression

ISO

bisphenol F results in decreased expression of CCNA2 mRNA

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701

G

cyclin C

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CCNC mRNA

NCBI chr 5:40,063,589...40,081,731
Ensembl chr 5:40,063,623...40,093,370

G

cyclin D1

increases expression
decreases expression
multiple interactions

ISO

4,4'-bisphenol F results in increased expression of CCND1 protein; bisphenol F results in increased expression of CCND1 protein
bisphenol F results in decreased expression of CCND1 mRNA
fulvestrant inhibits the reaction [bisphenol F results in increased expression of CCND1 protein]

PMID:28808208 PMID:30195206 PMID:35278557

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin D2

increases expression
affects expression

ISO

bisphenol F results in increased expression of CCND2 mRNA
bisphenol F affects the expression of CCND2 mRNA
bisphenol F results in increased expression of CCND2 mRNA; bisphenol F results in increased expression of CCND2 protein

PMID:30951980 PMID:37717640 PMID:38685157

NCBI chr 4:161,653,048...161,675,422
Ensembl chr 4:161,653,048...161,680,301
Ensembl chr 4:161,653,048...161,680,301

G

cyclin D3

multiple interactions

ISO
EXP

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CCND3 gene
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CCND3 mRNA

PMID:31601247 PMID:36041667

NCBI chr 9:20,891,696...20,987,199
Ensembl chr 9:20,891,704...20,987,033

G

cyclin E1

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of CCNE1 protein
bisphenol F results in increased expression of CCNE1 mRNA
fulvestrant inhibits the reaction [bisphenol F results in increased expression of CCNE1 protein]

PMID:28808208 PMID:38685157

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822

G

cyclin I

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CCNI mRNA

NCBI chr14:15,164,047...15,186,885
Ensembl chr14:15,164,095...15,186,885

G

cyclin L1

decreases expression

ISO

bisphenol F results in decreased expression of CCNL1 mRNA

NCBI chr 2:152,495,169...152,508,855
Ensembl chr 2:152,495,172...152,507,468

G

cyclin L2

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CCNL2 mRNA
bisphenol F results in decreased expression of CCNL2 mRNA

PMID:28628672 PMID:38685157

NCBI chr 5:171,698,951...171,711,037
Ensembl chr 5:171,699,689...171,711,231

G

cyclin O

increases expression

ISO

bisphenol F results in increased expression of CCNO mRNA

NCBI chr 2:46,364,074...46,367,113
Ensembl chr 2:46,350,717...46,367,113

G

cyclin Y

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CCNY mRNA
bisphenol F results in increased expression of CCNY mRNA

PMID:36041667 PMID:38685157

NCBI chr17:62,079,925...62,207,780
Ensembl chr17:62,079,925...62,207,979

G

cell cycle progression 1

increases expression

ISO

bisphenol F results in increased expression of CCPG1 mRNA

NCBI chr 8:82,600,677...82,633,082
Ensembl chr 8:82,600,536...82,660,246

G

C-C motif chemokine receptor 1

increases expression

ISO

bisphenol F results in increased expression of CCR1 mRNA

NCBI chr 8:132,433,711...132,439,266
Ensembl chr 8:132,431,592...132,439,374

G

C-C motif chemokine receptor 5

increases expression

ISO

bisphenol F results in increased expression of CCR5 mRNA

PMID:30951980 PMID:38685157

NCBI chr 8:132,629,097...132,660,980
Ensembl chr 8:132,629,683...132,637,594

G

C-C motif chemokine receptor 9

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CCR9 mRNA

NCBI chr 8:132,273,581...132,287,651
Ensembl chr 8:132,273,544...132,287,883

G

copper chaperone for superoxide dismutase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CCS mRNA

NCBI chr 1:211,543,192...211,564,354
Ensembl chr 1:211,542,701...211,564,260

G

chaperonin containing TCP1 subunit 2

increases expression

ISO

bisphenol F results in increased expression of CCT2 protein

NCBI chr 7:54,578,654...54,591,428
Ensembl chr 7:54,578,663...54,592,977

G

chaperonin containing TCP1 subunit 3

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of CCT3 protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CCT3 mRNA

PMID:34186270 PMID:36041667

NCBI chr 2:176,063,529...176,088,180
Ensembl chr 2:176,063,526...176,089,925

G

chaperonin containing TCP1 subunit 4

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CCT4 mRNA
bisphenol F results in increased expression of CCT4 mRNA
bisphenol F results in increased expression of CCT4 protein

PMID:28628672 PMID:34186270 PMID:38685157

NCBI chr14:101,193,057...101,205,935
Ensembl chr14:101,192,772...101,205,770

G

chaperonin containing TCP1 subunit 5

increases expression

ISO

bisphenol F results in increased expression of CCT5 protein
bisphenol F results in increased expression of CCT5 mRNA

PMID:34186270 PMID:38685157

NCBI chr 2:84,302,621...84,313,773
Ensembl chr 2:84,302,623...84,313,779

G

chaperonin containing TCP1 subunit 6A

increases expression

ISO

bisphenol F results in increased expression of CCT6A protein

NCBI chr12:32,508,842...32,519,072
Ensembl chr12:32,508,675...32,519,119

G

chaperonin containing TCP1 subunit 7

increases expression

ISO

bisphenol F results in increased expression of CCT7 protein

NCBI chr 4:119,546,730...119,563,973
Ensembl chr 4:119,546,730...119,563,973

G

chaperonin containing TCP1 subunit 8

increases expression

ISO

bisphenol F results in increased expression of CCT8 protein

NCBI chr11:40,196,619...40,208,328
Ensembl chr11:40,196,619...40,208,328

G

CD109 molecule

increases expression

ISO

bisphenol F results in increased expression of CD109 mRNA

NCBI chr 8:88,334,736...88,449,463
Ensembl chr 8:88,334,736...88,449,462

G

CD14 molecule

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CD14 mRNA

NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,608,883...28,611,292

G

CD151 molecule (Raph blood group)

increases expression

ISO

bisphenol F results in increased expression of CD151 protein

NCBI chr 1:205,994,300...205,998,307
Ensembl chr 1:205,994,738...205,998,784

G

CD163 molecule

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CD163 mRNA

NCBI chr 4:158,770,751...158,804,146
Ensembl chr 4:158,770,749...158,804,146

G

CD19 molecule

decreases expression

ISO

bisphenol F results in decreased expression of CD19 mRNA

NCBI chr 1:190,417,853...190,424,494
Ensembl chr 1:190,417,853...190,424,355

G

Cd2 molecule

decreases expression

ISO

bisphenol F results in decreased expression of CD2 mRNA

NCBI chr 2:191,399,510...191,412,659
Ensembl chr 2:191,399,510...191,413,665

G

Cd200 molecule

decreases expression

ISO

bisphenol F results in decreased expression of CD200 mRNA

NCBI chr11:68,916,200...68,943,570
Ensembl chr11:68,916,224...68,943,569

G

Cd247 molecule

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CD247 mRNA
bisphenol F results in increased expression of CD247 mRNA

PMID:36041667 PMID:38685157

NCBI chr13:80,576,264...80,651,422
Ensembl chr13:80,576,202...80,655,248

G

CD248 molecule

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of CD248 mRNA
bisphenol F results in increased expression of CD248 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of CD248 mRNA

PMID:30951980 PMID:34186270

NCBI chr 1:211,803,052...211,805,616
Ensembl chr 1:211,801,934...211,805,776

G

Cd2 (cytoplasmic tail) binding protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CD2BP2 mRNA

NCBI chr 1:191,239,899...191,244,395
Ensembl chr 1:191,239,901...191,243,398

G

CD302 molecule

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CD302 mRNA
bisphenol F results in increased expression of CD302 mRNA

PMID:28628672 PMID:38685157

NCBI chr 3:65,131,017...65,164,737
Ensembl chr 3:65,113,102...65,164,737

G

CD34 molecule

increases expression

ISO

bisphenol F results in increased expression of CD34 mRNA

NCBI chr13:109,008,786...109,029,317
Ensembl chr13:109,008,623...109,029,315

G

CD36 molecule

increases expression

ISO

bisphenol F results in increased expression of CD36 mRNA
bisphenol F results in increased expression of CD36 protein

PMID:30951980 PMID:34186270

NCBI chr 4:18,209,088...18,302,142

G

CD38 molecule

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CD38 mRNA

NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505

G

CD40 molecule

increases expression
decreases expression
multiple interactions

ISO

bisphenol F results in increased expression of CD40 mRNA
bisphenol F results in decreased expression of CD40 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of CD40 mRNA

PMID:30951980 PMID:33312107

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847

G

CD40 ligand

decreases expression

ISO

bisphenol F results in decreased expression of CD40LG mRNA

NCBI chr X:140,164,341...140,176,057
Ensembl chr X:140,164,302...140,176,475

G

CD44 molecule

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CD44 mRNA
bisphenol F results in increased expression of CD44 protein

PMID:30951980 PMID:34186270

NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424

G

Cd47 molecule

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of CD47 protein
bisphenol F results in increased expression of CD47 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CD47 mRNA

PMID:34186270 PMID:36041667 PMID:38685157

NCBI chr11:64,374,816...64,438,763
Ensembl chr11:64,377,926...64,438,272

G

CD52 molecule

increases expression

ISO

bisphenol F results in increased expression of CD52 mRNA

NCBI chr 5:151,603,537...151,605,096
Ensembl chr 5:151,603,524...151,605,086

G

Cd53 molecule

increases expression

ISO

bisphenol F results in increased expression of CD53 mRNA

NCBI chr 2:197,040,369...197,087,925
Ensembl chr 2:197,040,369...197,218,593

G

CD55 molecule (Cromer blood group)

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CD55 mRNA
bisphenol F results in increased expression of CD55 mRNA

NCBI chr13:44,409,574...44,438,913
Ensembl chr13:44,409,587...44,438,107

G

CD59b molecule

increases expression

ISO

bisphenol F results in increased expression of CD59 protein

NCBI chr 3:110,914,008...110,932,489
Ensembl chr 3:110,914,091...110,935,310

G

Cd5 molecule-like

increases expression

ISO

bisphenol F results in increased expression of CD5L mRNA

NCBI chr 2:175,088,915...175,099,928
Ensembl chr 2:175,088,884...175,099,926

G

Cd63 molecule

increases expression
decreases expression

ISO

bisphenol F results in increased expression of CD63 protein
bisphenol F results in decreased expression of CD63 mRNA

PMID:34186270 PMID:38685157

NCBI chr 7:1,909,538...1,924,937
Ensembl chr 7:1,922,169...1,924,938

G

Cd70 molecule

decreases expression

ISO

bisphenol F results in decreased expression of CD70 mRNA

NCBI chr 9:2,093,540...2,096,692
Ensembl chr 9:2,086,848...2,096,692

G

Cd72 molecule

decreases expression

ISO

bisphenol F results in decreased expression of CD72 mRNA

NCBI chr 5:62,493,155...62,500,779
Ensembl chr 5:62,493,161...62,500,519

G

CD74 molecule

increases expression

ISO

bisphenol F results in increased expression of CD74 mRNA

PMID:30951980 PMID:38685157

NCBI chr18:56,527,071...56,536,406
Ensembl chr18:56,527,132...56,536,410

G

Cd80 molecule

increases expression

ISO

4,4'-bisphenol F results in increased expression of CD80 mRNA

NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540

G

Cd81 molecule

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CD81 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CD81 mRNA

PMID:28628672 PMID:36041667

NCBI chr 1:207,665,274...207,681,094
Ensembl chr 1:207,664,885...207,681,092

G

Cd82 molecule

increases expression

ISO

bisphenol F results in increased expression of CD82 mRNA

NCBI chr 3:99,842,748...99,887,298
Ensembl chr 3:99,842,757...99,886,744

G

CD83 molecule

decreases methylation

ISO

bisphenol F results in decreased methylation of CD83 gene

NCBI chr17:21,093,281...21,113,223
Ensembl chr17:21,093,281...21,113,047

G

CD86 molecule

increases expression
multiple interactions

ISO
EXP

4,4'-bisphenol F results in increased expression of CD86 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CD86 mRNA

PMID:32044397 PMID:36041667

NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361

G

CD9 molecule

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CD9 mRNA

NCBI chr 4:159,942,553...159,975,463
Ensembl chr 4:159,942,560...159,975,444

G

CD93 molecule

increases expression

ISO

bisphenol F results in increased expression of CD93 mRNA

PMID:30951980 PMID:38685157

NCBI chr 3:156,345,019...156,351,537
Ensembl chr 3:156,345,019...156,351,537

G

CD99 molecule (Xg blood group)

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] affects the expression of CD99 mRNA

NCBI chr20:56,000,494...56,005,140

G

codanin 1

decreases expression

ISO

bisphenol F results in decreased expression of CDAN1 mRNA

NCBI chr 3:128,129,664...128,143,520
Ensembl chr 3:128,129,301...128,143,549

G

cell division cycle 14B

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CDC14B mRNA

NCBI chr17:850,272...938,972
Ensembl chr17:850,390...971,164

G

cell division cycle 20

increases expression

ISO

bisphenol F results in increased expression of CDC20 mRNA

NCBI chr 5:137,251,596...137,255,799
Ensembl chr 5:137,251,596...137,255,799

G

cell division cycle 20B

increases expression

ISO

bisphenol F results in increased expression of CDC20B mRNA

G

cell division cycle 23

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CDC23 mRNA

NCBI chr18:26,511,019...26,534,872
Ensembl chr18:26,510,355...26,532,646

G

cell division cycle 26

increases expression

ISO

bisphenol F results in increased expression of CDC26 mRNA

NCBI chr 5:80,861,658...80,875,326
Ensembl chr 5:80,861,659...80,875,326

G

cell division cycle 34, ubiquitin conjugating enzyme

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDC34 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CDC34 mRNA

PMID:28628672 PMID:36041667

NCBI chr 7:10,668,209...10,674,206
Ensembl chr 7:10,668,210...10,674,526

G

cell division cycle 37, HSP90 cochaperone

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CDC37 mRNA
bisphenol F results in increased expression of CDC37 mRNA

PMID:36041667 PMID:38685157

NCBI chr 8:27,954,292...27,966,935
Ensembl chr 8:27,948,016...27,983,931

G

cell division cycle 37-like 1

multiple interactions
increases expression
decreases methylation

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CDC37L1 gene
bisphenol F results in increased expression of CDC37L1 mRNA
bisphenol F results in decreased methylation of CDC37L1 gene

PMID:31601247 PMID:38685157

NCBI chr 1:236,118,630...236,147,527
Ensembl chr 1:236,118,555...236,207,079

G

cell division cycle 42

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CDC42 mRNA
bisphenol F results in increased expression of CDC42 protein

PMID:34186270 PMID:36041667

NCBI chr 5:154,838,478...154,876,629
Ensembl chr 5:154,839,631...154,876,627

G

CDC42 binding protein kinase beta

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDC42BPB mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CDC42BPB mRNA

PMID:28628672 PMID:36041667

NCBI chr 6:136,154,905...136,241,259
Ensembl chr 6:136,154,905...136,237,570

G

CDC42 effector protein 1

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of CDC42EP1 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of CDC42EP1 mRNA

NCBI chr 7:112,275,759...112,283,665
Ensembl chr 7:112,275,792...112,283,664

G

CDC42 effector protein 3

increases expression

ISO

bisphenol F results in increased expression of CDC42EP3 mRNA

NCBI chr 6:21,463,081...21,483,553
Ensembl chr 6:21,461,762...21,508,540

G

CDC42 effector protein 4

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDC42EP4 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CDC42EP4 mRNA

PMID:28628672 PMID:36041667

NCBI chr10:99,271,750...99,298,551
Ensembl chr10:99,267,540...99,300,168

G

CDC42 small effector 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDC42SE1 mRNA

NCBI chr 2:185,494,692...185,502,519
Ensembl chr 2:185,496,547...185,502,514

G

CDC42 small effector 2

increases expression

ISO

bisphenol F results in increased expression of CDC42SE2 mRNA

NCBI chr10:39,337,269...39,405,772
Ensembl chr 1:100,424,547...100,424,801
Ensembl chr10:100,424,547...100,424,801

G

cell division cycle 5-like

increases expression

ISO

bisphenol F results in increased expression of CDC5L mRNA

NCBI chr 9:23,062,397...23,100,901
Ensembl chr 9:23,062,205...23,100,899

G

cell division cycle 73

increases expression

ISO

bisphenol F results in increased expression of CDC73 mRNA

NCBI chr13:57,897,924...58,000,031
Ensembl chr13:57,883,983...57,999,978

G

cell division cycle associated 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDCA2 mRNA

NCBI chr15:46,071,360...46,117,524
Ensembl chr15:46,071,360...46,116,639

G

cell division cycle associated 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDCA4 mRNA

NCBI chr 6:137,713,390...137,722,652
Ensembl chr 6:137,713,051...137,722,580

G

cell division cycle associated 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDCA7 mRNA

NCBI chr 3:77,730,315...77,740,950
Ensembl chr 3:77,729,970...77,740,947

G

cell division cycle associated 7 like

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDCA7L mRNA

NCBI chr 6:144,936,885...144,982,844
Ensembl chr 6:144,908,171...144,982,843

G

CUB domain containing protein 1

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CDCP1 mRNA
bisphenol F results in increased expression of CDCP1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 8:131,706,140...131,742,799
Ensembl chr 8:131,706,140...131,742,877

G

cadherin 1

multiple interactions
increases expression
decreases expression

ISO

fulvestrant inhibits the reaction [bisphenol F results in increased expression of CDH1 protein]
[bisphenol F co-treated with Tretinoin] results in decreased expression of CDH1 mRNA
bisphenol F results in increased expression of CDH1 mRNA
bisphenol F results in decreased expression of CDH1 protein

PMID:28808208 PMID:30951980

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cadherin 11

increases expression

ISO

bisphenol F results in increased expression of CDH11 mRNA

NCBI chr19:2,152,961...2,312,140
Ensembl chr19:2,154,840...2,312,140

G

cadherin 13

increases expression

ISO

bisphenol F results in increased expression of CDH13 protein

NCBI chr19:63,258,251...64,296,122
Ensembl chr19:63,258,122...64,296,119

G

cadherin 17

increases expression
decreases expression

ISO

bisphenol F results in increased expression of CDH17 mRNA
bisphenol F results in decreased expression of CDH17 mRNA

PMID:30951980 PMID:38685157

NCBI chr 5:30,024,544...30,112,226
Ensembl chr 5:30,060,090...30,112,226

G

cadherin 18

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CDH18 mRNA

NCBI chr 2:74,548,681...75,550,720
Ensembl chr 2:75,075,595...75,550,720

G

cadherin 2

multiple interactions
increases expression

ISO

fulvestrant inhibits the reaction [bisphenol F results in increased expression of CDH2 protein]

NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288

G

cadherin 20

decreases expression

ISO

bisphenol F results in decreased expression of CDH20 mRNA

NCBI chr13:21,252,272...21,583,526
Ensembl chr13:21,515,123...21,584,349

G

cadherin 24

decreases expression

ISO

bisphenol F results in decreased expression of CDH24 mRNA

PMID:30951980 PMID:38685157

NCBI chr15:32,061,588...32,071,323
Ensembl chr15:32,061,588...32,071,283

G

cadherin 26

increases expression

ISO

bisphenol F results in increased expression of CDH26 mRNA

NCBI chr 3:185,898,185...185,950,892
Ensembl chr 3:185,898,431...185,950,892

G

cadherin 3

multiple interactions
decreases expression
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CDH3 mRNA
bisphenol F results in decreased expression of CDH3 mRNA
bisphenol F results in increased expression of CDH3 mRNA

PMID:30951980 PMID:36706583

NCBI chr19:51,303,414...51,353,900
Ensembl chr19:51,300,083...51,354,257

G

cadherin 4

decreases expression

ISO

bisphenol F results in decreased expression of CDH4 mRNA

NCBI chr 3:186,902,763...187,381,020
Ensembl chr 3:186,902,751...187,381,020

G

cadherin 5

increases expression

ISO

bisphenol F results in increased expression of CDH5 mRNA

NCBI chr19:821,875...860,931
Ensembl chr19:822,464...860,822

G

cadherin 6

decreases expression

ISO

bisphenol F results in decreased expression of CDH6 mRNA

NCBI chr 2:63,801,630...63,952,309
Ensembl chr 2:63,806,135...63,952,287

G

cadherin 8

decreases expression

ISO

bisphenol F results in decreased expression of CDH8 mRNA

NCBI chr19:5,494,552...5,901,950
Ensembl chr19:5,500,221...5,902,627

G

cadherin 9

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CDH9 mRNA

NCBI chr 2:67,954,708...68,094,371
Ensembl chr 2:67,955,166...68,094,365

G

cadherin-related family member 1

affects expression

ISO

bisphenol F affects the expression of CDHR1 mRNA

NCBI chr16:12,863,696...12,883,579
Ensembl chr16:12,863,696...12,883,579

G

cadherin-related family member 3

increases expression

ISO

bisphenol F results in increased expression of CDHR3 mRNA

NCBI chr 6:55,369,215...55,429,454
Ensembl chr 6:55,369,851...55,429,458

G

CDIP transferase, opposite strand

decreases expression

ISO

bisphenol F results in decreased expression of CDIPTOS mRNA

NCBI chr 1:191,009,918...191,013,551
Ensembl chr 1:191,009,919...191,013,275

G

cyclin-dependent kinase 1

affects expression

ISO

bisphenol F affects the expression of CDK1 mRNA

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

cyclin-dependent kinase 10

decreases expression

ISO

bisphenol F results in decreased expression of CDK10 mRNA

NCBI chr19:68,168,040...68,184,923
Ensembl chr19:68,169,874...68,177,599

G

cyclin-dependent kinase 11B

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CDK11B mRNA
bisphenol F results in decreased expression of CDK11B mRNA

PMID:36041667 PMID:38685157

NCBI chr 5:171,495,042...171,521,143
Ensembl chr 5:171,495,776...171,521,145

G

cyclin dependent kinase 2

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CDK2 gene

NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878

G

cyclin-dependent kinase 4

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDK4 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CDK4 mRNA

PMID:28628672 PMID:36041667

NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163

G

cyclin-dependent kinase 5

decreases expression
multiple interactions

EXP
ISO

4,4'-bisphenol F results in decreased expression of CDK5 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CDK5 mRNA

PMID:26186136 PMID:36041667 PMID:38685157

NCBI chr 4:11,647,098...11,651,606
Ensembl chr 4:11,647,141...11,652,777

G

cyclin-dependent kinase 5 regulatory subunit 1

decreases expression

ISO

bisphenol F results in decreased expression of CDK5R1 mRNA

NCBI chr10:65,981,692...65,985,831
Ensembl chr10:65,978,911...65,989,272

G

CDK5 regulatory subunit associated protein 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CDK5RAP1 mRNA

NCBI chr 3:163,189,435...163,333,003
Ensembl chr 3:163,191,056...163,332,908

G

CDK5 regulatory subunit associated protein 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDK5RAP3 mRNA

NCBI chr10:82,390,845...82,402,814
Ensembl chr10:82,390,845...82,400,001

G

cyclin-dependent kinase 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDK6 mRNA

NCBI chr 4:31,592,384...31,784,732
Ensembl chr 4:31,601,192...31,781,701

G

cyclin-dependent kinase 9

decreases expression

ISO

bisphenol F results in decreased expression of CDK9 mRNA

NCBI chr 3:36,394,168...36,399,016
Ensembl chr 3:36,394,169...36,399,528

G

cyclin dependent kinase like 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CDKL1 mRNA

NCBI chr 6:93,960,157...94,005,207
Ensembl chr 6:93,959,911...94,006,115

G

cyclin dependent kinase like 2

increases expression

ISO

bisphenol F results in increased expression of CDKL2 mRNA

NCBI chr14:16,312,154...16,347,524
Ensembl chr14:16,312,932...16,347,523

G

cyclin-dependent kinase-like 4

increases expression

ISO

bisphenol F results in increased expression of CDKL4 mRNA

NCBI chr 6:20,202,047...20,244,821
Ensembl chr 6:20,217,916...20,244,002

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

ISO
EXP

[bisphenol F co-treated with cylindrospermopsin] results in increased expression of CDKN1A mRNA
bisphenol F results in increased expression of CDKN1A mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CDKN1A mRNA

PMID:32244372 PMID:36041667 PMID:38685157

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDKN1B mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CDKN1B mRNA

PMID:28628672 PMID:36041667

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498

G

cyclin-dependent kinase inhibitor 2A

increases expression

ISO

bisphenol F results in increased expression of CDKN2A mRNA

NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248

G

cyclin-dependent kinase inhibitor 2B

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of CDKN2B mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of CDKN2B mRNA

NCBI chr 5:109,123,308...109,134,906
Ensembl chr 5:109,114,322...109,134,855

G

cyclin-dependent kinase inhibitor 2C

increases expression

ISO

bisphenol F results in increased expression of CDKN2C mRNA

NCBI chr 5:129,639,736...129,645,564
Ensembl chr 5:129,639,736...129,644,891

G

cyclin-dependent kinase inhibitor 3

increases expression

ISO

bisphenol F results in increased expression of CDKN3 mRNA

NCBI chr15:22,502,299...22,513,725
Ensembl chr15:22,502,382...22,513,722

G

cysteine dioxygenase type 1

increases expression

ISO

bisphenol F results in increased expression of CDO1 mRNA

NCBI chr18:41,619,076...41,633,719
Ensembl chr18:41,619,070...41,633,891

G

cell adhesion associated, oncogene regulated

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDON mRNA

NCBI chr 8:42,032,921...42,119,451
Ensembl chr 8:42,033,042...42,119,345

G

cysteine rich, DPF motif domain containing 1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CDPF1 gene

NCBI chr 7:118,773,497...118,785,283
Ensembl chr 7:118,780,845...118,783,161

G

cerebellar degeneration-related protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CDR2 mRNA

NCBI chr 1:184,934,128...184,959,036
Ensembl chr 1:184,934,129...184,968,863

G

cerebellar degeneration-related protein 2-like

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CDR2L mRNA
bisphenol F results in decreased expression of CDR2L mRNA

PMID:36041667 PMID:38685157

NCBI chr10:101,123,777...101,137,634
Ensembl chr10:101,123,777...101,137,634

G

CDP-diacylglycerol synthase 1

increases expression

ISO

bisphenol F results in increased expression of CDS1 mRNA

NCBI chr14:8,126,678...8,187,243
Ensembl chr14:8,124,838...8,187,218

G

CDP-diacylglycerol synthase 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDS2 mRNA
bisphenol F results in increased expression of CDS2 mRNA

PMID:28628672 PMID:38685157

NCBI chr 3:139,967,870...140,006,459
Ensembl chr 3:139,967,742...140,009,201

G

carnitine deficiency-associated gene expressed in ventricle 3

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CDV3 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CDV3 mRNA

PMID:28628672 PMID:36041667

NCBI chr 8:112,812,898...112,826,073
Ensembl chr 8:112,813,952...112,826,056

G

CEA cell adhesion molecule 1

increases expression

ISO

bisphenol F results in increased expression of CEACAM1 mRNA

NCBI chr 1:90,171,401...90,187,810
Ensembl chr 1:90,171,401...90,187,798

G

CCAAT/enhancer binding protein alpha

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of CEBPA mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CEBPA mRNA; [bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CEBPA protein; [bisphenol F co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA; [bisphenol F co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein

PMID:30951980 PMID:33865937 PMID:35736896

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

CCAAT/enhancer binding protein beta

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CEBPB mRNA
bisphenol F results in decreased expression of CEBPB mRNA

PMID:28628672 PMID:38685157

NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072

G

CCAAT/enhancer binding protein delta

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CEBPD gene

NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824

G

CCAAT/enhancer binding protein epsilon

decreases expression

ISO

bisphenol F results in decreased expression of CEBPE mRNA

NCBI chr15:32,139,716...32,141,476
Ensembl chr15:32,139,716...32,141,476

G

CEBPZ opposite strand

decreases expression

ISO

bisphenol F results in decreased expression of CEBPZOS mRNA

NCBI chr 6:21,887,701...21,892,298
Ensembl chr 6:21,887,709...21,892,074

G

CUGBP, Elav-like family member 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CELF1 mRNA
bisphenol F results in increased expression of CELF1 mRNA

PMID:28628672 PMID:38685157

NCBI chr 3:97,380,407...97,455,253
Ensembl chr 3:97,380,424...97,452,791

G

CUGBP, Elav-like family member 2

increases methylation

ISO

bisphenol F results in increased methylation of CELF2 gene

NCBI chr17:75,813,928...76,639,300
Ensembl chr17:75,813,704...76,636,362

G

CUGBP, Elav-like family member 3

decreases expression

ISO

bisphenol F results in decreased expression of CELF3 mRNA

NCBI chr 2:184,805,078...184,819,189
Ensembl chr 2:184,805,081...184,819,187

G

CUGBP, Elav-like family member 4

decreases expression

ISO

bisphenol F results in decreased expression of CELF4 mRNA

NCBI chr18:17,061,284...17,339,747
Ensembl chr18:17,061,293...17,339,571

G

CUGBP, Elav-like family member 5

decreases expression

ISO

bisphenol F results in decreased expression of CELF5 mRNA

NCBI chr 7:8,876,551...8,901,078
Ensembl chr 7:8,876,564...8,901,069

G

cadherin, EGF LAG seven-pass G-type receptor 1

decreases expression

ISO

bisphenol F results in decreased expression of CELSR1 mRNA

NCBI chr 7:118,867,450...119,004,859
Ensembl chr 7:118,867,450...119,004,856

G

centrosomal AT-AC splicing factor

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CENATAC mRNA
bisphenol F results in decreased expression of CENATAC mRNA

PMID:36041667 PMID:38685157

NCBI chr 8:53,632,777...53,639,661
Ensembl chr 8:53,632,044...53,639,650

G

centromere protein A

decreases expression

ISO

bisphenol F results in decreased expression of CENPA mRNA

NCBI chr 6:31,420,062...31,431,703

G

centromere protein M

decreases expression

ISO

bisphenol F results in decreased expression of CENPM mRNA

NCBI chr 7:115,628,117...115,639,401
Ensembl chr 7:115,628,129...115,643,866

G

centromere protein T

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CENPT mRNA

NCBI chr19:50,644,548...50,651,048
Ensembl chr19:50,634,368...50,651,037

G

centromere protein V

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CENPV mRNA

NCBI chr10:47,713,778...47,746,800
Ensembl chr10:47,713,778...47,727,679

G

centromere protein X

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CENPX mRNA
bisphenol F results in decreased expression of CENPX mRNA

PMID:28628672 PMID:38685157

NCBI chr10:106,489,796...106,492,637
Ensembl chr10:106,489,796...106,492,637

G

centrosomal protein 104

increases expression

ISO

bisphenol F results in increased expression of CEP104 mRNA

NCBI chr 5:169,817,383...169,849,681
Ensembl chr 5:169,817,182...169,852,695

G

centrosomal protein 128

increases methylation

ISO

bisphenol F results in increased methylation of CEP128 gene

NCBI chr 6:115,681,753...116,059,758
Ensembl chr 6:115,681,712...116,057,167

G

centrosomal protein 131

multiple interactions
decreases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CEP131 mRNA
bisphenol F results in decreased expression of CEP131 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CEP131 mRNA

PMID:28628672 PMID:36041667 PMID:38685157

NCBI chr10:105,844,433...105,868,811
Ensembl chr10:105,844,433...105,868,797

G

centrosomal protein 135

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CEP135 mRNA

NCBI chr14:31,884,774...31,950,050
Ensembl chr14:31,884,781...31,950,050

G

centrosomal protein 164

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CEP164 mRNA

NCBI chr 8:54,967,621...55,031,264
Ensembl chr 8:54,967,621...55,031,206

G

centrosomal protein 170

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CEP170 gene
bisphenol F results in increased expression of CEP170 protein

PMID:31601247 PMID:34186270

NCBI chr13:91,201,808...91,285,990
Ensembl chr13:91,201,808...91,285,990

G

centrosomal protein 170B

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CEP170B gene; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CEP170B mRNA

PMID:28628672 PMID:31601247

NCBI chr 6:137,602,707...137,627,750
Ensembl chr 6:137,602,707...137,627,750

G

centrosomal protein 19

increases expression

ISO

bisphenol F results in increased expression of CEP19 mRNA

NCBI chr11:82,182,868...82,192,134
Ensembl chr11:82,182,868...82,192,032

G

centrosomal protein 250

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CEP250 mRNA

NCBI chr 3:164,931,033...164,976,210
Ensembl chr 3:164,931,066...164,976,210

G

centrosomal protein 57

decreases expression

ISO

bisphenol F results in decreased expression of CEP57 mRNA

NCBI chr 8:18,951,179...18,971,205
Ensembl chr 8:18,932,808...18,970,890

G

centrosomal protein 76

increases expression

ISO

bisphenol F results in increased expression of CEP76 mRNA

NCBI chr18:63,444,389...63,478,358
Ensembl chr18:63,443,746...63,478,358

G

centrosomal protein 95

decreases expression

ISO

bisphenol F results in decreased expression of CEP95 mRNA

NCBI chr10:92,231,829...92,259,813
Ensembl chr10:92,231,512...92,259,810

G

cerberus 1, DAN family BMP antagonist

increases expression

ISO

bisphenol F results in increased expression of CER1 mRNA

NCBI chr 5:102,352,364...102,355,720
Ensembl chr 5:102,352,368...102,355,720

G

cerebral endothelial cell adhesion molecule

increases expression

ISO

bisphenol F results in increased expression of CERCAM protein

NCBI chr 3:33,515,513...33,553,817
Ensembl chr 3:33,486,664...33,553,813

G

ceramide synthase 1

affects expression
multiple interactions

ISO

bisphenol F affects the expression of CERS1 mRNA
[bisphenol F co-treated with Fulvestrant] results in increased methylation of CERS1 gene
[bisphenol F co-treated with LIF protein] results in increased expression of CERS1 mRNA; [bisphenol F co-treated with Tretinoin] results in decreased expression of CERS1 mRNA

PMID:30951980 PMID:31601247

NCBI chr16:19,131,271...19,146,480
Ensembl chr16:19,131,276...19,146,480

G

ceramide synthase 2

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CERS2 gene

NCBI chr 2:185,579,511...185,587,789
Ensembl chr 2:185,579,119...185,588,839

G

ceramide synthase 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CERS3 mRNA

NCBI chr 1:129,728,136...129,833,182
Ensembl chr 1:129,677,781...129,833,181

G

ceramide synthase 4

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CERS4 mRNA

NCBI chr12:7,649,610...7,688,066
Ensembl chr12:7,649,610...7,688,070

G

ceramide synthase 5

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CERS5 mRNA

NCBI chr 7:132,738,834...132,776,920
Ensembl chr 7:132,738,834...132,776,786

G

ceramide transporter 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CERT1 mRNA

NCBI chr 2:29,617,202...29,721,734
Ensembl chr 2:29,617,023...29,721,729

G

carboxylesterase 1D

increases expression

ISO

bisphenol F results in increased expression of CES1D mRNA

PMID:30951980 PMID:38685157

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449

G

carboxylesterase 2E

increases expression

ISO

bisphenol F results in increased expression of CES2E mRNA

NCBI chr19:163,899...179,274
Ensembl chr19:163,859...179,308

G

carboxylesterase 2H

increases expression

ISO

bisphenol F results in increased expression of CES2 protein

NCBI chr19:49,884,164...49,898,764
Ensembl chr19:49,884,164...49,898,752

G

centrin 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CETN2 mRNA

NCBI chr X:155,812,212...155,817,186
Ensembl chr X:155,812,003...155,817,744

G

centrin 3

increases expression

ISO

bisphenol F results in increased expression of CETN3 mRNA

NCBI chr 2:13,817,760...13,837,502
Ensembl chr 2:13,824,803...13,837,502

G

cilia and flagella associated protein 100

increases methylation
multiple interactions

ISO

bisphenol F results in increased methylation of CFAP100 gene
[bisphenol F co-treated with Fulvestrant] results in increased methylation of CFAP100 gene

NCBI chr 4:124,471,913...124,495,990
Ensembl chr 4:124,472,023...124,495,799

G

cilia and flagella associated protein 119

decreases expression

ISO

bisphenol F results in decreased expression of CFAP119 mRNA

NCBI chr 1:191,627,662...191,647,429
Ensembl chr 1:191,623,673...191,632,829

G

cilia and flagella associated protein 126

increases expression

ISO

bisphenol F results in increased expression of CFAP126 mRNA

NCBI chr13:86,059,142...86,075,034
Ensembl chr13:86,059,142...86,075,034

G

cilia and flagella associated protein 141

decreases expression

ISO

bisphenol F results in decreased expression of CFAP141 mRNA

NCBI chr 2:177,805,290...177,808,324
Ensembl chr 2:177,805,290...177,808,324

G

cilia and flagella associated protein 144

increases expression

ISO

bisphenol F results in increased expression of CFAP144 mRNA

NCBI chr10:44,009,412...44,019,281
Ensembl chr10:44,009,412...44,019,281

G

cilia and flagella associated protein 157

increases expression

ISO

bisphenol F results in increased expression of CFAP157 mRNA

NCBI chr 3:36,464,219...36,471,193
Ensembl chr 3:36,464,219...36,471,193

G

cilia and flagella associated protein 161

increases expression

ISO

bisphenol F results in increased expression of CFAP161 mRNA

NCBI chr 1:147,152,923...147,177,821
Ensembl chr 1:147,152,924...147,178,015

G

cilia and flagella associated protein 184

increases expression

ISO

bisphenol F results in increased expression of CCDC96 mRNA

PMID:30951980 PMID:38685157

NCBI chr14:78,501,256...78,503,715
Ensembl chr14:78,486,414...78,507,808

G

cilia and flagella associated protein 206

increases expression

ISO

bisphenol F results in increased expression of CFAP206 mRNA

NCBI chr 5:54,050,697...54,095,438
Ensembl chr 5:54,050,701...54,095,383

G

cilia and flagella associated protein 251

decreases expression

ISO

bisphenol F results in decreased expression of CFAP251 mRNA

NCBI chr12:38,923,154...38,997,881
Ensembl chr12:38,922,330...38,954,783

G

cilia and flagella associated protein 263

increases expression

ISO

bisphenol F results in increased expression of CCDC113 mRNA

NCBI chr19:9,503,062...9,522,957
Ensembl chr19:9,503,066...9,522,957

G

cilia and flagella associated protein 276

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CFAP276 mRNA

NCBI chr 2:198,854,129...198,871,406
Ensembl chr 2:198,854,129...198,866,036

G

cilia and flagella associated protein 299

increases expression

ISO

bisphenol F results in increased expression of CFAP299 mRNA

NCBI chr14:11,091,314...11,576,981
Ensembl chr14:11,090,449...11,577,999

G

cilia and flagella associated protein 36

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CFAP36 mRNA

NCBI chr14:107,166,932...107,192,531
Ensembl chr14:107,166,947...107,192,406

G

cilia and flagella associated protein 418

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CFAP418 mRNA

NCBI chr 5:28,789,580...28,812,891
Ensembl chr 5:28,792,692...28,812,887

G

cilia and flagella associated protein 43

increases expression

ISO

bisphenol F results in increased expression of CFAP43 mRNA

NCBI chr 1:256,566,558...256,653,816
Ensembl chr 1:256,566,559...256,653,840

G

cilia and flagella associated protein 44

increases expression

ISO

bisphenol F results in increased expression of CFAP44 mRNA

NCBI chr11:69,704,997...69,789,998
Ensembl chr11:69,705,719...69,789,905

G

cilia and flagella associated protein 45

increases expression

ISO

bisphenol F results in increased expression of CFAP45 mRNA

NCBI chr13:87,521,831...87,545,236
Ensembl chr13:87,521,518...87,545,234

G

cilia and flagella associated protein 52

increases expression

ISO

bisphenol F results in increased expression of CFAP52 mRNA

NCBI chr10:53,112,692...53,153,844
Ensembl chr10:53,112,693...53,153,844

G

cilia and flagella associated protein 53

decreases expression

ISO

bisphenol F results in decreased expression of CFAP53 mRNA

NCBI chr18:70,159,900...70,227,543
Ensembl chr18:70,159,898...70,227,540

G

cilia and flagella associated protein 61

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CFAP61 gene

NCBI chr 3:153,807,672...154,086,591
Ensembl chr 3:153,807,735...154,086,590

G

cilia and flagella associated protein 65

increases expression

ISO

bisphenol F results in increased expression of CFAP65 mRNA

NCBI chr 9:83,907,882...83,942,812
Ensembl chr 9:83,907,276...83,942,714

G

cilia and flagella associated protein 70

increases expression

ISO

bisphenol F results in increased expression of CFAP70 mRNA

NCBI chr15:3,901,544...3,967,224
Ensembl chr15:3,901,610...3,967,220

G

cilia and flagella associated protein 77

increases expression

ISO

bisphenol F results in increased expression of CFAP77 mRNA

NCBI chr 3:32,656,410...32,779,261
Ensembl chr 3:32,656,410...32,779,261

G

cilia and flagella associated protein 91

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of CFAP91 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CFAP91 mRNA

PMID:30951980 PMID:36041667

NCBI chr11:75,919,129...75,962,786
Ensembl chr11:75,919,142...75,962,785

G

cilia and flagella associated protein 96

decreases expression

ISO

bisphenol F results in decreased expression of CFAP96 mRNA

NCBI chr16:53,023,623...53,048,176
Ensembl chr16:53,023,878...53,048,965

G

cilia and flagella associated protein 97

increases expression

ISO

bisphenol F results in increased expression of CFAP97 mRNA

NCBI chr16:52,818,693...52,867,775
Ensembl chr16:52,818,697...52,868,061

G

CFAP97 domain containing 1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CFAP97D1 gene

NCBI chr10:87,432,559...87,444,711
Ensembl chr10:87,434,008...87,441,577

G

cripto, FRL-1, cryptic family 1

increases expression

ISO

bisphenol F results in increased expression of CFC1 mRNA

NCBI chr 9:44,234,997...44,247,846
Ensembl chr 9:44,235,020...44,247,845

G

complement factor D

decreases expression
increases expression

ISO

bisphenol F results in decreased expression of CFD mRNA
bisphenol F results in increased expression of CFD mRNA

PMID:30959087 PMID:38388800

NCBI chr 7:10,463,773...10,465,496
Ensembl chr 7:10,463,775...10,465,572

G

complement factor H

increases expression

ISO

bisphenol F results in increased expression of CFH mRNA

PMID:30951980 PMID:38685157

NCBI chr13:54,063,079...54,164,523
Ensembl chr13:54,062,531...54,164,532

G

complement factor H-related 1

increases expression

ISO

bisphenol F results in increased expression of CFHR1 mRNA

NCBI chr13:53,946,298...53,961,282
Ensembl chr13:53,919,927...53,961,303

G

complement factor I

increases expression

ISO

bisphenol F results in increased expression of CFI mRNA

NCBI chr 2:221,062,206...221,104,790
Ensembl chr 2:221,062,212...221,104,786

G

cofilin 1

multiple interactions
increases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CFL1 mRNA
bisphenol F results in increased expression of CFL1 protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CFL1 mRNA

PMID:28628672 PMID:34186270 PMID:36041667

NCBI chr 1:212,227,124...212,230,656
Ensembl chr 1:212,226,121...212,231,353

G

cofilin 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CFL2 mRNA

NCBI chr 6:78,090,843...78,094,888
Ensembl chr 6:78,090,843...78,094,888

G

CASP8 and FADD-like apoptosis regulator

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CFLAR mRNA
bisphenol F results in increased expression of CFLAR mRNA

PMID:36041667 PMID:38685157

NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434

G

CGG triplet repeat binding protein 1

increases expression

ISO

bisphenol F results in increased expression of CGGBP1 mRNA

NCBI chr11:16,012,251...16,019,388
Ensembl chr11:16,011,456...16,020,356

G

cingulin

increases expression

ISO

bisphenol F results in increased expression of CGN mRNA

NCBI chr 2:184,997,425...185,024,785
Ensembl chr 2:184,997,425...185,023,635

G

cingulin-like 1

increases expression

ISO

bisphenol F results in increased expression of CGNL1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 8:81,154,169...81,305,598
Ensembl chr 8:81,140,091...81,305,747

G

ChaC glutathione-specific gamma-glutamylcyclotransferase 1

affects expression

ISO

bisphenol F affects the expression of CHAC1 mRNA

NCBI chr 3:126,796,131...126,799,352
Ensembl chr 3:126,796,024...126,799,361

G

chondroadherin-like

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CHADL mRNA

NCBI chr 7:115,085,447...115,097,565
Ensembl chr 7:115,085,165...115,097,435

G

chromatin assembly factor 1 subunit B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CHAF1B mRNA

NCBI chr11:46,670,560...46,690,739
Ensembl chr11:46,670,630...46,690,733

G

coiled-coil-helix-coiled-coil-helix domain containing 10

decreases expression

ISO

bisphenol F results in decreased expression of CHCHD10 mRNA

NCBI chr20:12,725,274...12,730,295
Ensembl chr20:12,725,277...12,745,677

G

coiled-coil-helix-coiled-coil-helix domain containing 3

increases expression

ISO

bisphenol F results in increased expression of CHCHD3 protein

NCBI chr 4:62,327,574...62,584,085
Ensembl chr 4:62,327,576...62,584,035

G

coiled-coil-helix-coiled-coil-helix domain containing 4

increases expression

ISO

bisphenol F results in increased expression of CHCHD4 mRNA

NCBI chr 4:125,525,428...125,534,562
Ensembl chr 4:125,525,429...125,534,562
Ensembl chr 1:125,525,429...125,534,562

G

chromodomain helicase DNA binding protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CHD1 mRNA

NCBI chr 1:65,334,905...65,402,270
Ensembl chr 1:65,335,218...65,401,280

G

chromodomain helicase DNA binding protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CHD2 mRNA

NCBI chr 1:136,597,993...136,726,874
Ensembl chr 1:136,599,900...136,710,335

G

chromodomain helicase DNA binding protein 3

decreases expression

ISO

bisphenol F results in decreased expression of CHD3 mRNA

NCBI chr10:54,562,437...54,588,842
Ensembl chr10:54,562,437...54,588,810

G

chromodomain helicase DNA binding protein 4

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CHD4 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CHD4 mRNA

PMID:28628672 PMID:36041667

NCBI chr 4:159,584,623...159,617,867
Ensembl chr 4:159,584,654...159,617,866

G

chromodomain helicase DNA binding protein 5

decreases expression
multiple interactions

ISO
EXP

bisphenol F results in decreased expression of CHD5 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CHD5 mRNA

PMID:30951980 PMID:36041667

NCBI chr 5:168,130,851...168,181,705
Ensembl chr 5:168,130,575...168,179,441

G

chromodomain helicase DNA binding protein 6

decreases expression

ISO

bisphenol F results in decreased expression of CHD6 mRNA

NCBI chr 3:170,016,204...170,177,480
Ensembl chr 3:170,016,204...170,177,558

G

chromodomain helicase DNA binding protein 8

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CHD8 mRNA

NCBI chr15:27,379,285...27,438,959
Ensembl chr15:27,379,285...27,417,851

G

chromodomain helicase DNA binding protein 9

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CHD9 gene

NCBI chr19:32,114,379...32,337,488
Ensembl chr19:32,115,920...32,319,042

G

checkpoint kinase 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CHEK2 mRNA

NCBI chr12:51,448,838...51,481,159
Ensembl chr12:51,449,140...51,480,667

G

chromogranin A

increases expression
decreases expression

ISO

bisphenol F results in increased expression of CHGA mRNA
bisphenol F results in decreased expression of CHGA mRNA

PMID:30951980 PMID:35278557

NCBI chr 6:127,460,895...127,472,238
Ensembl chr 6:127,460,854...127,472,237

G

cysteine-rich hydrophobic domain 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CHIC2 mRNA

NCBI chr14:33,511,839...33,546,181
Ensembl chr14:33,511,535...33,548,558

G

chitinase domain containing 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CHID1 mRNA

NCBI chr 1:206,024,059...206,059,259
Ensembl chr 1:205,998,801...206,059,227

G

choline kinase alpha

multiple interactions
decreases expression

ISO

[Dietary Fats co-treated with bisphenol F] results in increased expression of CHKA mRNA
bisphenol F results in decreased expression of CHKA mRNA

PMID:36632902 PMID:38685157

NCBI chr 1:210,506,069...210,554,753
Ensembl chr 1:210,506,056...210,554,752

G

choline kinase beta

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CHKB mRNA

NCBI chr 7:122,380,592...122,385,102
Ensembl chr 7:122,380,594...122,383,949

G

cell adhesion molecule L1-like

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of CHL1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CHL1 mRNA

PMID:30951980 PMID:36041667

NCBI chr 4:137,847,648...138,062,077
Ensembl chr 4:137,847,895...138,062,077

G

cholesin

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CHLSN gene

NCBI chr12:20,298,968...20,402,890
Ensembl chr12:20,388,520...20,402,922

G

CHM Rab escort protein

increases expression

ISO

bisphenol F results in increased expression of CHM mRNA

NCBI chr X:82,395,463...82,554,249
Ensembl chr X:82,396,816...82,568,642

G

charged multivesicular body protein 1A

multiple interactions
increases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CHMP1A mRNA
bisphenol F results in increased expression of CHMP1A protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CHMP1A mRNA

PMID:28628672 PMID:34186270 PMID:36041667

NCBI chr19:68,146,672...68,154,952
Ensembl chr19:68,146,672...68,154,952

G

charged multivesicular body protein 1B2

increases expression

ISO

bisphenol F results in increased expression of CHMP1B2 mRNA

NCBI chr X:76,933,194...76,974,018
Ensembl chr X:76,933,204...76,974,032

G

charged multivesicular body protein 2A

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CHMP2A mRNA
bisphenol F results in increased expression of CHMP2A protein

PMID:34186270 PMID:36041667

NCBI chr 1:82,731,212...82,735,088
Ensembl chr 1:82,732,231...82,738,613

G

charged multivesicular body protein 2B

increases expression

ISO

bisphenol F results in increased expression of CHMP2B mRNA

NCBI chr11:16,783,971...16,810,500
Ensembl chr11:16,783,971...16,828,868

G

charged multivesicular body protein 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CHMP3 mRNA

NCBI chr 4:105,134,860...105,180,862
Ensembl chr 4:105,134,755...105,182,262

G

charged multivesicular body protein 4B

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CHMP4B mRNA

NCBI chr 3:163,631,054...163,671,569
Ensembl chr 3:163,631,054...163,671,569

G

chromatin modifying protein 4B-like 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CHMP4BL1 mRNA

NCBI chr 4:69,016,565...69,017,614
Ensembl chr 4:69,016,527...69,017,617

G

charged multivesicular body protein 5

increases expression

ISO

bisphenol F results in increased expression of CHMP5 protein
bisphenol F results in increased expression of CHMP5 mRNA

PMID:34186270 PMID:38685157

NCBI chr 5:60,877,369...60,894,512
Ensembl chr 5:60,877,341...60,894,511

G

charged multivesicular body protein 6

increases expression

ISO

bisphenol F results in increased expression of CHMP6 mRNA

NCBI chr10:105,690,400...105,696,070
Ensembl chr10:105,690,398...105,696,333

G

chimerin 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CHN1 mRNA

NCBI chr 3:78,917,329...79,084,040
Ensembl chr 3:78,917,329...79,084,197

G

chondrolectin

increases expression

ISO

bisphenol F results in increased expression of CHODL mRNA

NCBI chr11:31,141,030...31,163,342
Ensembl chr11:31,141,021...31,163,334

G

cysteine and histidine rich domain containing 1

increases expression

ISO

bisphenol F results in increased expression of CHORDC1 mRNA

NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:23,650,865...23,677,696

G

calcineurin-like EF-hand protein 1

increases expression

ISO

bisphenol F results in increased expression of CHP1 protein

NCBI chr 3:126,989,800...127,025,071
Ensembl chr 3:126,989,579...127,042,443

G

calcineurin-like EF hand protein 2

increases expression

ISO

bisphenol F results in increased expression of CHP2 mRNA

NCBI chr 1:186,189,090...186,203,663
Ensembl chr 1:186,185,151...186,203,667

G

chondroitin polymerizing factor

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CHPF gene

NCBI chr 9:84,411,824...84,416,523
Ensembl chr 9:84,411,829...84,416,523

G

choline phosphotransferase 1

increases expression

ISO

bisphenol F results in increased expression of CHPT1 mRNA

NCBI chr 7:24,753,880...24,802,529
Ensembl chr 7:24,750,343...24,802,521

G

chordin

increases expression
decreases expression

ISO

bisphenol F results in increased expression of CHRD mRNA
bisphenol F results in decreased expression of CHRD mRNA

PMID:30951980 PMID:38685157

NCBI chr11:93,676,400...93,685,584
Ensembl chr11:93,676,400...93,685,278

G

chordin-like 1

multiple interactions
affects expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CHRDL1 mRNA
bisphenol F affects the expression of CHRDL1 mRNA

PMID:28628672 PMID:30951980

NCBI chr X:111,685,864...111,789,684
Ensembl chr X:111,685,866...111,789,661

G

chordin-like 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CHRDL2 mRNA

NCBI chr 1:163,755,316...163,782,758
Ensembl chr 1:163,755,316...163,782,757

G

cholinergic receptor, muscarinic 3

increases expression

ISO

bisphenol F results in increased expression of CHRM3 mRNA

NCBI chr17:64,696,549...65,158,622
Ensembl chr17:64,696,066...65,173,304

G

cholinergic receptor nicotinic alpha 2 subunit

increases expression

ISO

bisphenol F results in increased expression of CHRNA2 mRNA

NCBI chr15:44,517,862...44,534,144
Ensembl chr15:44,517,862...44,534,144

G

cholinergic receptor nicotinic alpha 4 subunit

decreases expression

ISO

bisphenol F results in decreased expression of CHRNA4 mRNA

PMID:30951980 PMID:38685157

NCBI chr 3:188,506,802...188,535,558
Ensembl chr 3:188,501,209...188,535,105

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CHRNA7 mRNA

NCBI chr 1:126,123,425...126,249,181
Ensembl chr 1:126,123,425...126,446,858

G

cholinergic receptor nicotinic beta 1 subunit

multiple interactions

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CHRNB1 mRNA

NCBI chr10:54,999,943...55,015,137
Ensembl chr10:55,002,788...55,015,107

G

cholinergic receptor nicotinic beta 4 subunit

increases expression

ISO

bisphenol F results in increased expression of CHRNB4 mRNA

NCBI chr 8:64,312,644...64,333,319
Ensembl chr 8:64,313,669...64,333,248

G

cholinergic receptor nicotinic delta subunit

decreases expression

ISO

bisphenol F results in decreased expression of CHRND mRNA

NCBI chr 9:95,310,316...95,318,734
Ensembl chr 9:95,310,298...95,318,745

G

carbohydrate sulfotransferase 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CHST1 mRNA

NCBI chr 3:99,003,987...99,030,214
Ensembl chr 3:99,009,958...99,031,262

G

carbohydrate sulfotransferase 12

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CHST12 mRNA

NCBI chr12:19,224,545...19,243,012
Ensembl chr12:19,220,141...19,243,047

G

carbohydrate sulfotransferase 6

increases expression

ISO

bisphenol F results in increased expression of CHST5 mRNA

NCBI chr19:56,769,991...56,790,276
Ensembl chr19:56,769,967...56,790,306

G

carbohydrate sulfotransferase 7

increases expression

ISO

bisphenol F results in increased expression of CHST7 mRNA

NCBI chr X:4,949,810...4,986,372
Ensembl chr X:4,938,757...4,986,907

G

carbohydrate sulfotransferase 8

decreases expression

ISO

bisphenol F results in decreased expression of CHST8 mRNA

NCBI chr 1:96,431,144...96,572,880
Ensembl chr 1:96,431,145...96,572,880

G

chondroitin sulfate synthase 3

increases expression

ISO

bisphenol F results in increased expression of CHSY3 mRNA

NCBI chr18:54,842,260...55,096,008
Ensembl chr18:54,842,180...55,095,981

G

chromosome transmission fidelity factor 8

increases expression

ISO

bisphenol F results in increased expression of CHTF8 mRNA

NCBI chr19:51,691,776...51,702,076
Ensembl chr19:51,678,543...51,707,144

G

cytosolic iron-sulfur assembly component 2A

increases expression

ISO

bisphenol F results in increased expression of CIAO2A mRNA

NCBI chr 8:75,565,620...75,577,542
Ensembl chr 8:75,565,567...75,577,541

G

cytosolic iron-sulfur assembly component 2B

decreases expression

ISO

bisphenol F results in decreased expression of CIAO2B mRNA

NCBI chr19:350,644...352,518
Ensembl chr19:350,653...352,518

G

cytosolic iron-sulfur assembly component 3

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CIAO3 gene; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CIAO3 mRNA

PMID:28628672 PMID:31601247

NCBI chr10:15,300,403...15,309,467
Ensembl chr10:15,300,471...15,309,468

G

circadian associated repressor of transcription

decreases expression

ISO

bisphenol F results in decreased expression of CIART mRNA

NCBI chr 2:186,108,744...186,113,778
Ensembl chr 2:186,108,752...186,112,246

G

calcium and integrin binding 1

decreases expression

ISO

bisphenol F results in decreased expression of CIB1 mRNA

NCBI chr 1:143,587,591...143,593,153
Ensembl chr 1:143,587,021...143,593,326

G

CBY1 interacting BAR domain containing 2

increases expression

ISO

bisphenol F results in increased expression of CIBAR2 mRNA

NCBI chr19:65,126,231...65,138,015
Ensembl chr19:65,125,383...65,138,032

G

cell death-inducing DFFA-like effector b

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CIDEB mRNA

NCBI chr15:33,222,135...33,226,407
Ensembl chr15:33,221,824...33,226,688

G

class II, major histocompatibility complex, transactivator

increases expression

ISO

bisphenol F results in increased expression of CIITA mRNA

NCBI chr10:5,646,854...5,694,393
Ensembl chr10:5,647,085...5,694,342

G

cartilage intermediate layer protein

increases expression

ISO

bisphenol F results in increased expression of CILP mRNA

NCBI chr 8:74,671,696...74,687,420
Ensembl chr 8:74,671,534...74,687,409

G

cartilage intermediate layer protein 2

decreases expression

ISO

bisphenol F results in decreased expression of CILP2 mRNA

NCBI chr16:19,573,821...19,581,100
Ensembl chr16:19,573,908...19,581,100

G

ciliary microtubule associated protein 1B

decreases expression

ISO

bisphenol F results in decreased expression of CIMAP1B mRNA

NCBI chr 7:122,323,860...122,326,921
Ensembl chr 7:122,323,860...122,326,876

G

ciliary microtubule associated protein 3

increases expression

ISO

bisphenol F results in increased expression of CIMAP3 mRNA

NCBI chr 2:196,164,103...196,181,466
Ensembl chr 2:196,163,275...196,181,604

G

ciliary microtubule inner protein 2A

multiple interactions
affects expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CIMIP2A mRNA
bisphenol F affects the expression of CIMIP2A mRNA

PMID:36041667 PMID:38685157

NCBI chr 3:28,429,413...28,437,210
Ensembl chr 3:28,431,410...28,436,125

G

ciliary microtubule inner protein 2B

decreases expression

ISO

bisphenol F results in decreased expression of CIMIP2B mRNA

NCBI chr 5:62,471,246...62,477,812
Ensembl chr 5:62,470,367...62,478,198

G

cold inducible RNA binding protein

increases expression

ISO

bisphenol F results in increased expression of CIRBP mRNA

NCBI chr 7:10,184,515...10,189,623

G

CDGSH iron sulfur domain 3

decreases expression

ISO

bisphenol F results in decreased expression of CISD3 mRNA

NCBI chr10:83,175,708...83,178,739
Ensembl chr10:83,175,568...83,178,751

G

CDKN1A interacting zinc finger protein 1

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CIZ1 mRNA
bisphenol F results in decreased expression of CIZ1 mRNA

PMID:28628672 PMID:38685157

NCBI chr 3:36,055,753...36,071,510
Ensembl chr 3:36,056,370...36,075,192

G

cytoskeleton associated protein 2-like

increases expression

ISO

bisphenol F results in increased expression of CKAP2L mRNA

NCBI chr 3:136,950,390...136,977,503
Ensembl chr 3:136,950,381...136,977,565

G

cytoskeleton-associated protein 4

increases expression

ISO

bisphenol F results in increased expression of CKAP4 protein

NCBI chr 7:21,118,527...21,126,624
Ensembl chr 7:21,118,085...21,126,624

G

cytoskeleton associated protein 5

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CKAP5 mRNA
bisphenol F results in increased expression of CKAP5 protein

PMID:28628672 PMID:34186270

NCBI chr 3:97,946,966...98,049,050
Ensembl chr 3:97,947,031...98,049,049

G

creatine kinase B

increases expression
decreases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of CKB protein
bisphenol F results in decreased expression of CKB mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CKB mRNA

PMID:34186270 PMID:36041667 PMID:38685157

NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:136,549,844...136,553,478

G

creatine kinase, mitochondrial 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CKMT1 mRNA

NCBI chr 3:128,783,408...128,789,485
Ensembl chr 3:128,783,597...128,789,483

G

creatine kinase, mitochondrial 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CKMT2 mRNA
bisphenol F results in increased expression of CKMT2 protein

PMID:28628672 PMID:34186270

NCBI chr 2:24,815,008...24,845,511
Ensembl chr 2:24,815,008...24,845,511

G

CLK4-associating serine/arginine rich protein

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CLASRP mRNA
bisphenol F results in decreased expression of CLASRP mRNA

PMID:36041667 PMID:38685157

NCBI chr 1:88,360,235...88,384,343
Ensembl chr 1:88,360,235...88,384,343

G

clathrin binding box of aftiphilin containing 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CLBA1 mRNA

NCBI chr 6:137,703,947...137,710,743
Ensembl chr 6:137,703,619...137,710,742

G

cardiotrophin-like cytokine factor 1

decreases expression

ISO

bisphenol F results in decreased expression of CLCF1 mRNA

NCBI chr 1:210,937,763...210,947,064
Ensembl chr 1:210,937,255...210,947,064

G

chloride voltage-gated channel 3

increases expression

ISO

bisphenol F results in increased expression of CLCN3 mRNA

NCBI chr16:34,138,004...34,210,984
Ensembl chr16:34,137,952...34,210,984

G

chloride voltage-gated channel 5

increases expression

ISO

bisphenol F results in increased expression of CLCN5 mRNA

NCBI chr X:17,857,260...18,011,844
Ensembl chr X:17,857,260...18,011,844

G

chloride voltage-gated channel 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CLCN7 mRNA

NCBI chr10:14,656,261...14,681,632
Ensembl chr10:14,656,245...14,681,631

G

claudin 1

increases expression
decreases expression
multiple interactions

ISO

bisphenol F results in increased expression of CLDN1 mRNA
bisphenol F results in decreased expression of CLDN1 mRNA
[bisphenol F co-treated with Lipopolysaccharides] results in decreased expression of CLDN1 mRNA; [bisphenol F co-treated with Lipopolysaccharides] results in decreased expression of CLDN1 protein

PMID:30951980 PMID:34774955 PMID:36706583

NCBI chr11:87,926,376...87,941,533
Ensembl chr11:87,926,337...87,941,529

G

claudin 10

increases expression

ISO

bisphenol F results in increased expression of CLDN10 mRNA

NCBI chr15:102,269,858...102,361,589
Ensembl chr15:102,269,858...102,361,589

G

claudin 11

increases expression

ISO

bisphenol F results in increased expression of CLDN11 mRNA

PMID:30951980 PMID:36706583

NCBI chr 2:114,136,234...114,149,539
Ensembl chr 2:114,136,234...114,149,539

G

claudin 12

increases expression

ISO

bisphenol F results in increased expression of CLDN12 mRNA

NCBI chr 4:29,477,468...29,488,465
Ensembl chr 4:29,477,342...29,493,776

G

claudin 14

increases expression

ISO

bisphenol F results in increased expression of CLDN14 mRNA

NCBI chr11:46,701,940...46,799,049
Ensembl chr11:46,701,940...46,799,096

G

claudin 15

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CLDN15 mRNA

NCBI chr12:25,334,849...25,345,104
Ensembl chr12:25,334,849...25,343,477

G

claudin 2

decreases expression
increases expression

ISO

bisphenol F results in decreased expression of CLDN2 mRNA
bisphenol F results in increased expression of CLDN2 mRNA

PMID:36706583 PMID:38685157

NCBI chr X:108,248,383...108,258,847
Ensembl chr X:108,237,676...108,262,377

G

claudin 3

multiple interactions
decreases expression
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CLDN3 mRNA
bisphenol F results in decreased expression of CLDN3 mRNA
bisphenol F results in increased expression of CLDN3 mRNA

PMID:30951980 PMID:38685157

NCBI chr12:27,345,075...27,346,547
Ensembl chr12:27,345,076...27,348,841

G

claudin 4

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of CLDN4 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of CLDN4 mRNA

NCBI chr12:27,388,160...27,389,958
Ensembl chr12:27,387,981...27,389,958

G

claudin 5

increases expression

ISO

bisphenol F results in increased expression of CLDN5 mRNA

NCBI chr11:95,717,172...95,718,598
Ensembl chr11:95,717,176...95,719,322

G

claudin 6

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CLDN6 mRNA
bisphenol F results in increased expression of CLDN6 mRNA

NCBI chr10:13,213,837...13,218,578
Ensembl chr10:13,213,956...13,218,581

G

claudin 7

increases expression

ISO

bisphenol F results in increased expression of CLDN7 mRNA

NCBI chr10:55,188,670...55,190,871
Ensembl chr10:55,188,684...55,190,905

G

claudin 8

increases expression

ISO

bisphenol F results in increased expression of CLDN8 mRNA

NCBI chr11:41,362,081...41,364,330

G

claudin domain containing 1

increases expression

ISO

bisphenol F results in increased expression of CLDND1 mRNA

NCBI chr11:55,352,321...55,358,779
Ensembl chr11:55,352,321...55,358,907

G

claudin domain containing 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CLDND2 mRNA

NCBI chr 1:102,985,122...102,988,010
Ensembl chr 1:102,985,122...102,987,808

G

C-type lectin domain containing 14A

increases expression

ISO

bisphenol F results in increased expression of CLEC14A mRNA

NCBI chr 6:81,616,414...81,619,556
Ensembl chr 6:81,612,953...81,619,614

G

C-type lectin domain family 1, member B

increases expression

ISO

bisphenol F results in increased expression of CLEC1B mRNA

NCBI chr 4:164,533,987...164,542,320
Ensembl chr 4:164,534,055...164,542,867

G

C-type lectin domain family 2, member G

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CLEC2G mRNA

NCBI chr 4:164,303,865...164,313,737
Ensembl chr 4:164,300,076...164,314,591

G

C-type lectin domain family 3, member B

increases expression

ISO

bisphenol F results in increased expression of CLEC3B mRNA

NCBI chr 8:131,687,575...131,693,292

G

C-type lectin domain family 4, member A1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CLEC4A1 mRNA

NCBI chr 4:157,845,811...157,857,926
Ensembl chr 4:157,845,752...157,858,273

G

C-type lectin domain containing 5A

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CLEC5A mRNA

NCBI chr 4:70,373,855...70,383,560
Ensembl chr 4:70,374,529...70,398,230

G

C-type lectin domain family 6, member A, pseudogene 1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CLEC6A gene

NCBI chr 4:158,225,100...158,244,722
Ensembl chr 4:158,225,099...158,244,295

G

C-type lectin domain containing 9A

decreases expression

ISO

bisphenol F results in decreased expression of CLEC9A mRNA

NCBI chr 4:164,546,323...164,561,380
Ensembl chr 4:164,546,311...164,561,380

G

chloride intracellular channel 4

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CLIC4 mRNA
bisphenol F results in increased expression of CLIC4 mRNA

PMID:28628672 PMID:38685157

NCBI chr 5:152,737,371...152,797,118
Ensembl chr 5:152,737,371...152,797,118

G

chloride intracellular channel 5

increases expression

ISO

bisphenol F results in increased expression of CLIC5 mRNA

NCBI chr 9:24,208,455...24,310,964
Ensembl chr 9:24,208,456...24,358,780

G

chloride intracellular channel 6

increases methylation

ISO

bisphenol F results in increased methylation of CLIC6 gene

NCBI chr11:45,223,715...45,266,261
Ensembl chr11:45,223,669...45,267,344

G

clathrin interactor 1

increases expression

ISO

bisphenol F results in increased expression of CLINT1 mRNA

NCBI chr10:30,799,936...30,854,513
Ensembl chr10:30,799,971...30,854,508

G

CAP-GLY domain containing linker protein 1

increases expression

ISO

bisphenol F results in increased expression of CLIP1 protein

NCBI chr12:38,571,533...38,678,779
Ensembl chr12:38,571,834...38,678,779

G

CDC-like kinase 1

decreases expression

ISO

bisphenol F results in decreased expression of CLK1 mRNA

NCBI chr 9:67,441,962...67,453,180
Ensembl chr 9:67,441,952...67,451,187

G

CDC-like kinase 2

decreases expression

ISO

bisphenol F results in decreased expression of CLK2 mRNA

NCBI chr 2:176,868,423...176,880,412
Ensembl chr 2:176,869,490...176,880,411

G

CDC-like kinase 3

decreases expression

ISO

bisphenol F results in decreased expression of CLK3 mRNA

NCBI chr 8:67,048,121...67,063,192
Ensembl chr 8:67,048,123...67,062,881

G

CDC-like kinase 4

decreases expression

ISO

bisphenol F results in decreased expression of CLK4 mRNA

NCBI chr10:36,024,364...36,042,366
Ensembl chr10:36,024,427...36,042,372

G

calmin

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CLMN gene

NCBI chr 6:129,470,613...129,572,079
Ensembl chr 6:129,478,149...129,572,027

G

cytokine-dependent hematopoietic cell linker

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CLNK gene

NCBI chr14:76,136,446...76,315,364
Ensembl chr14:76,136,881...76,313,512

G

clock circadian regulator

increases expression

ISO

bisphenol F results in increased expression of CLOCK mRNA

NCBI chr14:32,262,747...32,346,872
Ensembl chr14:32,262,750...32,346,872

G

cleavage factor polyribonucleotide kinase subunit 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CLP1 mRNA

NCBI chr 3:90,213,461...90,217,165
Ensembl chr 3:90,213,465...90,217,538

G

caseinolytic mitochondrial matrix peptidase proteolytic subunit

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CLPP mRNA
bisphenol F results in decreased expression of CLPP mRNA

PMID:36041667 PMID:38685157

NCBI chr 9:1,917,305...1,924,706
Ensembl chr 9:1,918,682...1,924,705

G

CLPTM1 regulator of GABA type A receptor forward trafficking

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of CLPTM1 protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CLPTM1 mRNA

PMID:34186270 PMID:36041667

NCBI chr 1:88,417,447...88,449,047
Ensembl chr 1:88,417,447...88,449,446

G

CLPTM1-like

increases expression

ISO

bisphenol F results in increased expression of CLPTM1L mRNA

NCBI chr 1:31,496,094...31,512,148
Ensembl chr 1:31,496,094...31,512,077

G

caseinolytic mitochondrial matrix peptidase chaperone subunit X

increases expression

ISO

bisphenol F results in increased expression of CLPX protein
bisphenol F results in increased expression of CLPX mRNA

PMID:34186270 PMID:38685157

NCBI chr 8:74,700,602...74,740,244
Ensembl chr 8:74,700,662...74,744,762

G

calsyntenin 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CLSTN1 mRNA

NCBI chr 5:165,314,128...165,377,627
Ensembl chr 5:165,314,309...165,377,625

G

calsyntenin 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CLSTN3 mRNA

NCBI chr 4:159,017,795...159,051,069
Ensembl chr 4:159,017,795...159,051,069

G

clathrin, light chain A

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CLTA mRNA

NCBI chr 5:63,022,046...63,059,223
Ensembl chr 5:63,041,184...63,059,215

G

clathrin, light chain B

increases expression

ISO

bisphenol F results in increased expression of CLTB protein

NCBI chr17:10,006,416...10,024,278
Ensembl chr17:10,006,656...10,024,915

G

clathrin heavy chain

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CLTC mRNA
bisphenol F results in increased expression of CLTC mRNA

PMID:36041667 PMID:38685157

NCBI chr10:72,014,984...72,073,308
Ensembl chr10:72,014,986...72,070,691

G

collectrin, amino acid transport regulator

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CLTRN gene

NCBI chr X:33,993,825...34,027,124
Ensembl chr X:33,993,825...34,027,181

G

clusterin

multiple interactions
increases expression

ISO
EXP

[bisphenol F co-treated with Tretinoin] results in decreased expression of CLU mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CLU mRNA
bisphenol F results in increased expression of CLU mRNA

PMID:30951980 PMID:36041667 PMID:38685157

NCBI chr15:44,336,619...44,375,861
Ensembl chr15:44,359,914...44,375,860

G

clavesin 1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CLVS1 gene

NCBI chr 5:27,107,255...27,401,649
Ensembl chr 5:27,205,751...27,401,638

G

calaxin

increases expression

ISO

bisphenol F results in increased expression of CLXN mRNA

NCBI chr11:99,410,925...99,500,713
Ensembl chr11:99,487,448...99,500,760

G

cytidine monophosphate N-acetylneuraminic acid synthetase

increases expression

ISO

bisphenol F results in increased expression of CMAS mRNA

NCBI chr 4:177,449,801...177,468,117
Ensembl chr 4:177,449,732...177,476,291

G

carboxymethylenebutenolidase homolog

increases expression

ISO

bisphenol F results in increased expression of CMBL protein

NCBI chr 2:84,280,128...84,301,878
Ensembl chr 2:84,242,512...84,301,880

G

C-x(9)-C motif containing 2

increases expression

ISO

bisphenol F results in increased expression of CMC2 mRNA

NCBI chr19:61,852,126...61,880,768
Ensembl chr19:61,852,126...61,881,019

G

C-X9-C motif containing 4

decreases expression

ISO

bisphenol F results in decreased expression of CMC4 mRNA

NCBI chr18:139,382...147,037

G

c-Maf-inducing protein

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CMIP mRNA

NCBI chr19:62,213,402...62,419,443
Ensembl chr19:62,213,365...62,417,500

G

chemerin chemokine-like receptor 1

increases expression

ISO

bisphenol F results in increased expression of CMKLR1 mRNA

PMID:30951980 PMID:38685157

NCBI chr12:48,634,929...48,687,833
Ensembl chr12:48,634,003...48,691,458

G

cms1 ribosomal small subunit homolog

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CMSS1 mRNA

NCBI chr11:56,403,620...56,701,751
Ensembl chr11:56,403,499...56,701,755

G

CKLF-like MARVEL transmembrane domain containing 3

multiple interactions

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CMTM3 mRNA

NCBI chr19:629,000...637,152
Ensembl chr19:628,895...636,225

G

CKLF-like MARVEL transmembrane domain containing 4

increases expression

ISO

bisphenol F results in increased expression of CMTM4 mRNA

NCBI chr19:582,642...622,546
Ensembl chr19:582,621...677,816

G

CKLF-like MARVEL transmembrane domain containing 6

increases expression

ISO

bisphenol F results in increased expression of CMTM6 mRNA

NCBI chr 8:123,301,131...123,319,230
Ensembl chr 8:123,300,918...123,319,230

G

cap methyltransferase 1

increases expression

ISO

bisphenol F results in increased expression of CMTR1 mRNA

NCBI chr20:7,724,286...7,784,787
Ensembl chr20:7,683,946...7,784,263

G

cyclic nucleotide binding domain containing 2

decreases expression

ISO

bisphenol F results in decreased expression of CNBD2 mRNA

NCBI chr 3:165,279,157...165,357,582
Ensembl chr 3:165,279,204...165,361,688

G

CCHC-type zinc finger, nucleic acid binding protein

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CNBP mRNA
bisphenol F results in increased expression of CNBP protein

PMID:28628672 PMID:34186270

NCBI chr 4:121,860,102...121,868,976
Ensembl chr 4:121,860,105...121,869,010

G

carnosine dipeptidase 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CNDP2 mRNA
bisphenol F results in increased expression of CNDP2 protein

PMID:28628672 PMID:34186270

NCBI chr18:80,314,799...80,331,900
Ensembl chr18:80,314,801...80,331,900

G

connector enhancer of kinase suppressor of Ras 1

decreases expression

ISO

bisphenol F results in decreased expression of CNKSR1 mRNA

NCBI chr 5:151,731,222...151,742,049
Ensembl chr 5:151,731,224...151,742,203

G

chondromodulin

decreases expression

ISO

bisphenol F results in decreased expression of CNMD mRNA

NCBI chr15:61,450,617...61,475,382
Ensembl chr15:61,450,450...61,475,350

G

calponin 1

multiple interactions
decreases expression
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CNN1 mRNA
bisphenol F results in decreased expression of CNN1 mRNA
bisphenol F results in increased expression of CNN1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 8:28,908,437...28,917,099
Ensembl chr 8:28,908,330...28,919,482

G

calponin 2

multiple interactions
decreases expression
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CNN2 mRNA
bisphenol F results in decreased expression of CNN2 mRNA
bisphenol F results in increased expression of CNN2 protein
bisphenol F results in increased expression of CNN2 mRNA

PMID:30951980 PMID:34186270 PMID:38685157

NCBI chr 7:10,363,141...10,370,312
Ensembl chr 7:10,363,102...10,370,312

G

calponin 3

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CNN3 mRNA
bisphenol F results in increased expression of CNN3 protein

PMID:28628672 PMID:34186270

NCBI chr 2:212,203,661...212,234,772
Ensembl chr 2:212,226,640...212,234,815

G

cyclin and CBS domain divalent metal cation transport mediator 1

decreases expression

ISO

bisphenol F results in decreased expression of CNNM1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 1:252,245,377...252,304,205
Ensembl chr 1:252,245,623...252,304,205

G

CCR4-NOT transcription complex, subunit 1

increases methylation
increases expression

ISO

bisphenol F results in increased methylation of CNOT1 gene
bisphenol F results in increased expression of CNOT1 mRNA

PMID:31601247 PMID:38685157

NCBI chr19:9,261,290...9,352,636
Ensembl chr19:9,261,294...9,352,636

G

CCR4-NOT transcription complex, subunit 4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CNOT4 mRNA

NCBI chr 4:64,679,903...64,781,432
Ensembl chr 4:64,679,904...64,738,083

G

CCR4-NOT transcription complex, subunit 6

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CNOT6 mRNA

NCBI chr10:34,479,892...34,532,166
Ensembl chr10:34,481,938...34,524,416

G

CCR4-NOT transcription complex, subunit 6-like

increases expression

ISO

bisphenol F results in increased expression of CNOT6L mRNA

NCBI chr14:13,714,475...13,806,481
Ensembl chr14:13,714,475...13,806,481

G

CCR4-NOT transcription complex, subunit 7

decreases expression

ISO

bisphenol F results in decreased expression of CNOT7 mRNA

NCBI chr16:58,478,882...58,498,046
Ensembl chr16:58,478,900...58,498,046

G

CCR4-NOT transcription complex subunit 9

increases expression

ISO

bisphenol F results in increased expression of CNOT9 mRNA

NCBI chr 9:83,533,369...83,558,207
Ensembl chr 9:83,533,369...83,558,197

G

2',3'-cyclic nucleotide 3' phosphodiesterase

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of CNP protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CNP mRNA

PMID:34186270 PMID:36041667

NCBI chr10:86,011,504...86,018,063
Ensembl chr10:86,011,495...86,018,063

G

cyclin Pas1/PHO80 domain containing 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CNPPD1 mRNA

NCBI chr 9:84,082,148...84,088,888
Ensembl chr 9:84,082,149...84,089,788

G

canopy FGF signaling regulator 1

decreases expression

ISO

bisphenol F results in decreased expression of CNPY1 mRNA

NCBI chr 4:7,870,403...7,925,266
Ensembl chr 4:7,869,829...7,925,266

G

canopy FGF signaling regulator 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CNPY2 mRNA

NCBI chr 7:1,332,293...1,338,081
Ensembl chr 7:1,334,335...1,340,333

G

cannabinoid receptor 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CNR1 mRNA
bisphenol F results in increased expression of CNR1 mRNA

PMID:28628672 PMID:30951980

NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252

G

cannabinoid receptor interacting protein 1

decreases expression

ISO

bisphenol F results in decreased expression of CNRIP1 mRNA

NCBI chr14:95,664,435...95,707,062
Ensembl chr14:95,664,774...95,694,371

G

cyclin N-terminal domain containing 1

decreases expression

ISO

bisphenol F results in decreased expression of CNTD1 mRNA

NCBI chr10:86,721,692...86,732,074

G

ciliary neurotrophic factor receptor

decreases expression

ISO

bisphenol F results in decreased expression of CNTFR mRNA

NCBI chr 5:61,619,326...61,657,359
Ensembl chr 5:61,619,326...61,645,795

G

contactin 2

increases expression

ISO

bisphenol F results in increased expression of CNTN2 mRNA

NCBI chr13:46,497,269...46,528,112
Ensembl chr13:46,499,396...46,528,027

G

contactin associated protein 1

decreases expression

ISO

bisphenol F results in decreased expression of CNTNAP1 mRNA

NCBI chr10:86,610,140...86,625,896
Ensembl chr10:86,611,890...86,631,730

G

contactin associated protein 2

decreases expression

ISO

bisphenol F results in decreased expression of CNTNAP2 mRNA

NCBI chr 4:75,109,358...77,366,258
Ensembl chr 4:75,109,858...77,366,258

G

cytochrome C oxidase assembly factor 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COA3 mRNA

NCBI chr10:86,720,454...86,721,435
Ensembl chr10:86,720,456...86,721,440

G

cytochrome c oxidase assembly factor 8

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of COA8 mRNA

NCBI chr 6:136,593,399...136,618,237
Ensembl chr 6:136,592,787...136,619,602

G

Coenzyme A synthase

increases expression

ISO

bisphenol F results in increased expression of COASY mRNA

NCBI chr10:86,514,850...86,519,130
Ensembl chr10:86,514,874...86,519,130

G

cordon-bleu WH2 repeat protein-like 1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of COBLL1 gene

NCBI chr 3:70,161,369...70,324,844
Ensembl chr 3:70,161,372...70,323,460

G

cochlin

increases expression

ISO

bisphenol F results in increased expression of COCH mRNA

NCBI chr 6:74,766,485...74,780,504
Ensembl chr 6:74,766,419...74,780,502

G

component of oligomeric golgi complex 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of COG1 mRNA

NCBI chr10:99,192,604...99,207,640
Ensembl chr10:99,194,568...99,208,437

G

component of oligomeric golgi complex 4

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of COG4 mRNA

NCBI chr19:55,729,854...55,763,902
Ensembl chr19:55,728,796...55,764,169

G

component of oligomeric golgi complex 5

increases expression

ISO

bisphenol F results in increased expression of COG5 mRNA

NCBI chr 6:53,969,967...54,267,869
Ensembl chr 6:53,969,979...54,278,973

G

component of oligomeric golgi complex 6

increases expression

ISO

bisphenol F results in increased expression of COG6 mRNA

NCBI chr 2:139,212,459...139,249,505
Ensembl chr 2:139,211,678...139,249,737

G

component of oligomeric golgi complex 7

increases expression

ISO

bisphenol F results in increased expression of COG7 mRNA

NCBI chr 1:185,921,053...185,980,711
Ensembl chr 1:185,889,348...185,983,421

G

component of oligomeric golgi complex 8

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of COG8 mRNA

NCBI chr19:51,861,376...51,872,126
Ensembl chr19:51,861,376...51,872,129

G

collagen type X alpha 1 chain

increases expression

ISO

bisphenol F results in increased expression of COL10A1 mRNA

NCBI chr20:39,737,536...39,744,518
Ensembl chr20:39,716,822...39,751,440

G

collagen type XI alpha 1 chain

increases expression

ISO

bisphenol F results in increased expression of COL11A1 mRNA

NCBI chr 2:204,509,136...204,702,264
Ensembl chr 2:204,509,136...204,702,264

G

collagen type XI alpha 2 chain

multiple interactions
decreases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of COL11A2 gene
bisphenol F results in decreased expression of COL11A2 mRNA

PMID:31601247 PMID:38685157

NCBI chr20:4,788,829...4,818,492
Ensembl chr20:4,788,829...4,817,648

G

collagen type XII alpha 1 chain

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of COL12A1 mRNA
bisphenol F results in increased expression of COL12A1 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of COL12A1 mRNA
bisphenol F results in increased expression of COL12A1 mRNA

PMID:28628672 PMID:30951980 PMID:34186270

NCBI chr 8:89,427,834...89,545,886
Ensembl chr 8:89,427,834...89,545,711

G

collagen type XIII alpha 1 chain

increases expression

ISO

bisphenol F results in increased expression of COL13A1 mRNA

NCBI chr20:30,326,744...30,466,800
Ensembl chr20:30,326,744...30,466,800

G

collagen type XIV alpha 1 chain

increases expression

ISO

bisphenol F results in increased expression of COL14A1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 7:88,611,827...88,826,939
Ensembl chr 7:88,611,828...88,826,938

G

collagen type XV alpha 1 chain

increases expression

ISO

bisphenol F results in increased expression of COL15A1 mRNA
bisphenol F results in increased expression of COL15A1 protein

PMID:30951980 PMID:34186270

NCBI chr 5:66,297,546...66,403,172
Ensembl chr 5:66,297,461...66,403,170

G

collagen type XVI alpha 1 chain

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of COL16A1 mRNA
bisphenol F results in increased expression of COL16A1 mRNA

NCBI chr 5:147,672,559...147,727,007
Ensembl chr 5:147,672,601...147,727,011

G

collagen type XVIII alpha 1 chain

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of COL18A1 mRNA
bisphenol F results in increased expression of COL18A1 mRNA

PMID:28628672 PMID:30951980

NCBI chr20:11,473,645...11,582,111
Ensembl chr20:11,473,645...11,582,112

G

collagen type I alpha 1 chain

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of COL1A1 mRNA
bisphenol F results in increased expression of COL1A1 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of COL1A1 mRNA

PMID:30951980 PMID:34186270

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type I alpha 2 chain

affects expression
increases expression
multiple interactions

ISO

bisphenol F affects the expression of COL1A2 mRNA
bisphenol F results in increased expression of COL1A2 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of COL1A2 mRNA

PMID:30951980 PMID:34186270

NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995

G

collagen type XX alpha 1 chain

decreases expression

ISO

bisphenol F results in decreased expression of COL20A1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 3:188,477,663...188,512,326
Ensembl chr 3:188,465,648...188,511,078

G

collagen type XXII alpha 1 chain

decreases methylation

ISO

bisphenol F results in decreased methylation of COL22A1 gene

NCBI chr 7:105,619,776...105,857,246
Ensembl chr 7:105,619,757...105,856,960

G

collagen type XXIII alpha 1 chain

increases expression

ISO

bisphenol F results in increased expression of COL23A1 mRNA

NCBI chr10:36,050,327...36,337,279
Ensembl chr10:36,050,259...36,337,897

G

collagen type XXIV alpha 1 chain

decreases expression

ISO

bisphenol F results in decreased expression of COL24A1 mRNA

NCBI chr 2:236,872,583...237,129,768
Ensembl chr 2:236,872,265...237,129,447

G

collagen type XXVI alpha 1 chain

increases expression

ISO

bisphenol F results in increased expression of COL26A1 mRNA

NCBI chr12:25,429,362...25,575,205
Ensembl chr12:25,429,387...25,575,206

G

collagen type XXVII alpha 1 chain

increases expression
decreases expression

ISO

bisphenol F results in increased expression of COL27A1 mRNA
bisphenol F results in decreased expression of COL27A1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 5:81,662,822...81,781,502
Ensembl chr 5:81,661,685...81,781,502

G

collagen type II alpha 1 chain

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of COL2A1 mRNA
bisphenol F results in increased expression of COL2A1 mRNA

NCBI chr 7:130,977,561...131,006,627
Ensembl chr 7:130,977,561...131,006,627

G

collagen type III alpha 1 chain

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of COL3A1 mRNA
bisphenol F results in increased expression of COL3A1 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of COL3A1 mRNA

PMID:30951980 PMID:34186270

NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232

G

collagen type IV alpha 1 chain

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of COL4A1 mRNA
bisphenol F results in increased expression of COL4A1 mRNA

NCBI chr16:84,885,597...84,996,482
Ensembl chr16:84,885,597...84,996,482

G

collagen type IV alpha 2 chain

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of COL4A2 mRNA
bisphenol F results in increased expression of COL4A2 mRNA

NCBI chr16:84,749,672...84,885,520
Ensembl chr16:84,749,672...84,885,520

G

collagen type IV alpha 5 chain

increases expression

ISO

bisphenol F results in increased expression of COL4A5 mRNA

NCBI chr X:109,907,251...110,111,214
Ensembl chr X:109,907,346...110,111,214

G

collagen type V alpha 1 chain

increases expression
decreases expression
multiple interactions

ISO

bisphenol F results in increased expression of COL5A1 mRNA
bisphenol F results in decreased expression of COL5A1 mRNA
bisphenol F results in increased expression of COL5A1 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of COL5A1 mRNA

PMID:30951980 PMID:34186270 PMID:38685157

NCBI chr 3:31,606,475...31,755,097
Ensembl chr 3:31,606,486...31,753,020

G

collagen type V alpha 2 chain

increases expression
decreases expression
multiple interactions

ISO

bisphenol F results in increased expression of COL5A2 mRNA
bisphenol F results in decreased expression of COL5A2 mRNA
[bisphenol F co-treated with Fulvestrant] results in decreased methylation of COL5A2 gene
[bisphenol F co-treated with Tretinoin] results in decreased expression of COL5A2 mRNA

PMID:30951980 PMID:31601247 PMID:38685157

NCBI chr 9:54,940,768...55,090,151
Ensembl chr 9:54,940,764...55,090,150

G

collagen type V alpha 3 chain

multiple interactions
decreases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of COL5A3 mRNA
bisphenol F results in decreased expression of COL5A3 mRNA

PMID:30951980 PMID:37611474 PMID:38685157

NCBI chr 8:27,580,768...27,626,002
Ensembl chr 8:27,580,768...27,626,122

G

collagen type VI alpha 1 chain

increases expression
decreases expression
multiple interactions

ISO

bisphenol F results in increased expression of COL6A1 mRNA
bisphenol F results in decreased expression of COL6A1 mRNA
bisphenol F results in increased expression of COL6A1 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of COL6A1 mRNA

PMID:30951980 PMID:34186270 PMID:38685157

NCBI chr20:11,905,690...11,924,111
Ensembl chr20:11,905,457...11,924,107

G

collagen type VI alpha 2 chain

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of COL6A2 mRNA
bisphenol F results in increased expression of COL6A2 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of COL6A2 mRNA

PMID:30951980 PMID:34186270

NCBI chr20:12,021,182...12,048,932
Ensembl chr20:12,021,265...12,057,042

G

collagen type VI alpha 3 chain

increases expression
decreases expression
multiple interactions

ISO

bisphenol F results in increased expression of COL6A3 mRNA
bisphenol F results in decreased expression of COL6A3 mRNA
bisphenol F results in increased expression of COL6A3 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of COL6A3 mRNA

PMID:30951980 PMID:34186270 PMID:38685157

NCBI chr 9:98,809,171...98,887,060
Ensembl chr 9:98,809,171...98,886,990

G

collagen type VII alpha 1 chain

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of COL7A1 mRNA
bisphenol F results in increased expression of COL7A1 mRNA

PMID:28628672 PMID:30951980

NCBI chr 8:118,483,364...118,515,736
Ensembl chr 8:118,483,364...118,517,439

G

collagen type VIII alpha 1 chain

multiple interactions
decreases expression
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of COL8A1 mRNA
bisphenol F results in decreased expression of COL8A1 mRNA
[bisphenol F co-treated with Fulvestrant] results in decreased methylation of COL8A1 gene
bisphenol F results in increased expression of COL8A1 mRNA

PMID:30951980 PMID:31601247 PMID:36706583

NCBI chr11:56,245,998...56,378,586
Ensembl chr11:56,369,868...56,376,229

G

collagen type VIII alpha 2 chain

affects expression

ISO

bisphenol F affects the expression of COL8A2 mRNA

NCBI chr 5:143,870,754...143,897,372
Ensembl chr 5:143,870,742...143,897,884

G

collagen type IX alpha 1 chain

increases expression

ISO

bisphenol F results in increased expression of COL9A1 mRNA

NCBI chr 9:34,081,364...34,164,552
Ensembl chr 9:34,003,905...34,164,543

G

collagen type IX alpha 3 chain

decreases expression

ISO

bisphenol F results in decreased expression of COL9A3 mRNA

NCBI chr 3:188,089,337...188,112,034
Ensembl chr 3:188,089,403...188,112,270

G

collectin subfamily member 10

increases expression

ISO

bisphenol F results in increased expression of COLEC10 mRNA

NCBI chr 7:87,634,686...87,695,465
Ensembl chr 7:87,634,654...87,699,534

G

collectin sub-family member 11

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COLEC11 mRNA

NCBI chr 6:50,952,357...50,984,845
Ensembl chr 6:50,952,357...50,999,493

G

collectin sub-family member 12

increases expression

ISO

bisphenol F results in increased expression of COLEC12 mRNA

NCBI chr18:1,005,787...1,193,455
Ensembl chr18:1,005,741...1,195,297

G

collagen beta(1-O)galactosyltransferase 1

increases expression

ISO

bisphenol F results in increased expression of COLGALT1 mRNA

NCBI chr16:18,353,779...18,366,087
Ensembl chr16:18,353,570...18,366,086

G

collagen beta(1-O)galactosyltransferase 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COLGALT2 mRNA
bisphenol F results in increased expression of COLGALT2 mRNA

PMID:28628672 PMID:30951980

NCBI chr13:67,073,551...67,178,194
Ensembl chr13:67,073,551...67,178,194

G

copper metabolism domain containing 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COMMD1 mRNA

NCBI chr14:101,081,667...101,185,738
Ensembl chr14:101,081,667...101,185,639

G

COMM domain containing 2

increases expression

ISO

bisphenol F results in increased expression of COMMD2 mRNA

NCBI chr 2:143,998,672...144,002,918
Ensembl chr 2:143,998,672...144,002,918

G

COMM domain containing 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COMMD6 mRNA

NCBI chr15:84,882,069...84,889,124
Ensembl chr15:84,882,548...84,889,194

G

catechol-O-methyltransferase

decreases expression
increases expression

EXP
ISO

4,4'-bisphenol F results in decreased expression of COMT mRNA
bisphenol F results in increased expression of COMT protein

PMID:26186136 PMID:34186270

NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533

G

catechol-O-methyltransferase domain containing 1

decreases expression

ISO

bisphenol F results in decreased expression of COMTD1 mRNA

NCBI chr15:2,509,121...2,512,232
Ensembl chr15:2,509,032...2,512,232

G

COPI coat complex subunit alpha

increases expression

ISO

bisphenol F results in increased expression of COPA protein

NCBI chr13:87,078,853...87,119,256
Ensembl chr13:87,078,383...87,119,256

G

COPI coat complex subunit beta 1

increases expression

ISO

bisphenol F results in increased expression of COPB1 protein

NCBI chr 1:177,838,751...177,876,688
Ensembl chr 1:177,838,752...177,872,840

G

COPI coat complex subunit beta 2

increases expression

ISO

bisphenol F results in increased expression of COPB2 mRNA

NCBI chr 8:108,040,687...108,062,810
Ensembl chr 8:108,040,693...108,064,550

G

COPI coat complex subunit epsilon

increases expression
decreases expression

ISO

bisphenol F results in increased expression of COPE protein
bisphenol F results in decreased expression of COPE mRNA

PMID:34186270 PMID:38685157

NCBI chr16:19,148,832...19,159,052
Ensembl chr16:19,148,832...19,159,212

G

COPI coat complex subunit gamma 1

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COPG1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of COPG1 mRNA

PMID:28628672 PMID:36041667

NCBI chr 4:121,923,644...121,949,819
Ensembl chr 4:121,923,873...121,949,812

G

coordinator of PRMT5 and differentiation stimulator

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of COPRS mRNA

NCBI chr16:82,423,426...82,428,821
Ensembl chr16:82,407,580...82,431,737

G

COP9 signalosome subunit 2

increases expression

ISO

bisphenol F results in increased expression of COPS2 protein

NCBI chr 3:133,537,729...133,563,493
Ensembl chr 3:133,537,732...133,563,369

G

COP9 signalosome subunit 3

increases expression

ISO

bisphenol F results in increased expression of COPS3 protein

NCBI chr10:45,117,664...45,151,868
Ensembl chr10:45,117,657...45,152,074

G

COP9 signalosome subunit 4

increases expression

ISO

bisphenol F results in increased expression of COPS4 protein
bisphenol F results in increased expression of COPS4 mRNA

PMID:34186270 PMID:38685157

NCBI chr14:9,382,897...9,413,216
Ensembl chr14:9,382,900...9,413,107

G

COP9 signalosome subunit 6

increases expression

ISO

bisphenol F results in increased expression of COPS6 mRNA

NCBI chr12:22,152,688...22,155,527
Ensembl chr12:22,147,482...22,161,106

G

COP9 signalosome subunit 8

increases expression

ISO

bisphenol F results in increased expression of COPS8 mRNA

NCBI chr 9:98,655,031...98,664,861
Ensembl chr 9:98,654,870...98,665,381

G

COP9 signalosome subunit 9

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of MYEOV2 mRNA
bisphenol F results in increased expression of COPS9 mRNA

PMID:28628672 PMID:38685157

NCBI chr 9:100,657,276...100,662,206
Ensembl chr 9:100,657,276...100,662,206

G

COPI coat complex subunit zeta 1

multiple interactions
increases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COPZ1 mRNA
bisphenol F results in increased expression of COPZ1 protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of COPZ1 mRNA

PMID:28628672 PMID:34186270 PMID:36041667

NCBI chr 7:136,287,696...136,314,131
Ensembl chr 7:136,288,032...136,314,135

G

COPI coat complex subunit zeta 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COPZ2 mRNA
bisphenol F results in increased expression of COPZ2 mRNA

PMID:28628672 PMID:30951980

NCBI chr10:82,328,888...82,341,959
Ensembl chr10:82,328,660...82,341,959

G

coenzyme Q6 monooxygenase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of COQ6 mRNA

NCBI chr 6:109,738,934...109,750,315
Ensembl chr 6:109,738,951...109,750,310

G

coenzyme Q8A

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of COQ8A gene

NCBI chr13:94,436,680...94,465,535
Ensembl chr13:94,436,546...94,463,378

G

coenzyme Q9

increases expression

ISO

bisphenol F results in increased expression of COQ9 protein

NCBI chr19:10,172,943...10,185,960
Ensembl chr19:10,172,949...10,185,937

G

corin, serine peptidase

increases expression

ISO

bisphenol F results in increased expression of CORIN mRNA

NCBI chr14:36,034,613...36,264,671
Ensembl chr14:36,034,993...36,264,649

G

coronin 1B

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of CORO1B protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CORO1B mRNA

PMID:34186270 PMID:36041667

NCBI chr 1:210,872,437...210,877,876
Ensembl chr 1:210,871,841...210,877,876

G

coronin 1C

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CORO1C mRNA
bisphenol F results in increased expression of CORO1C mRNA

PMID:28628672 PMID:38685157

NCBI chr12:48,373,573...48,445,718
Ensembl chr12:48,373,597...48,445,716

G

coronin 2B

multiple interactions
decreases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CORO2B gene
bisphenol F results in decreased expression of CORO2B mRNA

PMID:31601247 PMID:38685157

NCBI chr 8:71,802,329...71,912,739
Ensembl chr 8:71,802,329...71,912,739

G

coronin 6

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CORO6 mRNA

NCBI chr10:62,808,172...62,817,788
Ensembl chr10:62,809,689...62,817,787

G

coronin 7

decreases expression

ISO

bisphenol F results in decreased expression of CORO7 mRNA

NCBI chr10:11,386,683...11,447,422
Ensembl chr10:11,391,613...11,447,866

G

cytochrome c oxidase assembly homolog COX15

increases expression

ISO

bisphenol F results in increased expression of COX15 mRNA

NCBI chr 1:252,554,811...252,571,471
Ensembl chr 1:252,554,811...252,571,471

G

cytochrome c oxidase assembly factor COX16

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COX16 mRNA

NCBI chr 6:106,745,424...106,912,523
Ensembl chr 6:106,899,494...106,912,484

G

cytochrome c oxidase copper chaperone COX17

decreases expression

ISO

bisphenol F results in decreased expression of COX17 mRNA

NCBI chr11:75,906,245...75,912,036
Ensembl chr11:75,906,248...75,912,019

G

cytochrome c oxidase assembly factor COX18

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of COX18 mRNA

NCBI chr14:18,147,558...18,161,622
Ensembl chr14:18,149,992...18,161,619

G

cytochrome c oxidase assembly factor COX19

decreases expression

ISO

bisphenol F results in decreased expression of COX19 mRNA

NCBI chr12:20,417,389...20,426,868
Ensembl chr12:20,417,341...20,426,868

G

cytochrome c oxidase assembly factor COX20

decreases expression

ISO

bisphenol F results in decreased expression of COX20 mRNA

NCBI chr13:92,592,260...92,604,129
Ensembl chr14:6,872,315...6,872,638

G

cytochrome c oxidase subunit 4i1

increases expression

ISO

bisphenol F results in increased expression of COX4I1 protein

NCBI chr19:65,630,383...65,636,623
Ensembl chr19:65,630,432...65,636,624

G

cytochrome c oxidase subunit 5B

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of COX5B mRNA
bisphenol F results in decreased expression of COX5B mRNA

PMID:36041667 PMID:38685157

NCBI chr 9:46,417,735...46,419,664
Ensembl chr 9:46,417,838...46,420,403

G

cytochrome c oxidase subunit 6B1

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of COX6B1 mRNA
bisphenol F results in decreased expression of COX6B1 mRNA

PMID:36041667 PMID:38685157

NCBI chr 1:95,002,513...95,011,516
Ensembl chr 1:95,001,707...95,011,431
Ensembl chr 5:95,001,707...95,011,431

G

cytochrome c oxidase subunit 6B2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COX6B2 mRNA

NCBI chr 1:78,122,871...78,124,096
Ensembl chr 1:78,122,453...78,124,094

G

cytochrome c oxidase subunit 6C

increases expression
decreases expression

ISO

bisphenol F results in increased expression of COX6C protein
bisphenol F results in decreased expression of COX6C mRNA

PMID:34186270 PMID:38685157

NCBI chr 7:69,014,410...69,027,145
Ensembl chr 7:69,014,417...69,027,166

G

cytochrome c oxidase subunit 7A2 like

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of COX7A2L mRNA
bisphenol F results in increased expression of COX7A2L mRNA

PMID:36041667 PMID:38685157

NCBI chr 6:16,936,574...16,950,797
Ensembl chr 6:16,936,795...16,950,798

G

cytochrome c oxidase subunit 7B

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of COX7B mRNA
bisphenol F results in increased expression of CCDC17 mRNA

PMID:28628672 PMID:30951980

NCBI chr X:75,149,036...75,155,285
Ensembl chr X:75,148,996...75,155,284

G

cytochrome c oxidase subunit 7C

increases expression
decreases expression

ISO

bisphenol F results in increased expression of COX7C protein
bisphenol F results in decreased expression of COX7C mRNA

PMID:34186270 PMID:38685157

NCBI chr 2:18,577,145...18,579,170
Ensembl chr 2:18,577,149...18,579,170

G

cytochrome c oxidase subunit 8A

multiple interactions

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of COX8A mRNA

NCBI chr 1:213,831,302...213,833,623
Ensembl chr 1:213,831,298...213,833,623

G

ceruloplasmin

affects expression

ISO

bisphenol F affects the expression of CP mRNA

NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:104,368,456...104,427,087

G

carboxypeptidase B2

increases expression

ISO

bisphenol F results in increased expression of CPB2 mRNA

NCBI chr15:56,967,128...57,015,964
Ensembl chr15:56,966,839...57,015,962

G

cytoplasmic polyadenylation element binding protein 1

decreases expression

ISO

bisphenol F results in decreased expression of CPEB1 mRNA

NCBI chr 1:144,709,278...144,817,388
Ensembl chr 1:144,709,691...144,815,880

G

cytoplasmic polyadenylation element binding protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CPEB2 mRNA

NCBI chr14:71,999,958...72,056,012
Ensembl chr14:72,002,072...72,052,263

G

cadherin-like and PC-esterase domain containing 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CPED1 mRNA
bisphenol F results in increased expression of CPED1 mRNA

PMID:28628672 PMID:30951980 PMID:38685157

NCBI chr 4:51,482,497...51,755,440
Ensembl chr 4:51,482,545...51,755,442

G

candidate plasticity gene 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CPG1 mRNA

NCBI chr 6:124,041,902...124,053,895
Ensembl chr 6:124,041,902...124,053,895

G

complexin 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CPLX2 mRNA

NCBI chr17:10,224,673...10,297,974
Ensembl chr17:10,228,449...10,297,467

G

complexin 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CPLX3 mRNA

NCBI chr 8:66,899,438...66,906,200
Ensembl chr 8:66,899,438...66,906,200

G

carboxypeptidase M

increases expression

ISO

bisphenol F results in increased expression of CPM mRNA

PMID:30951980 PMID:38685157

NCBI chr 7:55,111,599...55,172,114
Ensembl chr 7:55,111,599...55,172,114

G

carboxypeptidase N subunit 1

increases expression

ISO

bisphenol F results in increased expression of CPN1 mRNA

NCBI chr 1:252,793,786...252,822,675
Ensembl chr 1:252,793,423...252,822,664

G

carboxypeptidase N subunit 2

increases expression

ISO

bisphenol F results in increased expression of CPN2 mRNA

NCBI chr11:83,990,943...84,000,821
Ensembl chr11:83,990,940...84,001,059

G

copine 2

decreases expression

ISO

bisphenol F results in decreased expression of CPNE2 mRNA

NCBI chr19:10,440,245...10,477,783
Ensembl chr19:10,434,647...10,477,783

G

copine 3

increases expression

ISO

bisphenol F results in increased expression of CPNE3 protein
bisphenol F results in increased expression of CPNE3 mRNA

PMID:34186270 PMID:38685157

NCBI chr 5:37,811,566...37,860,840
Ensembl chr 5:37,811,566...37,861,062

G

copine 5

decreases expression

ISO

bisphenol F results in decreased expression of CPNE5 mRNA

NCBI chr20:7,208,389...7,290,959
Ensembl chr20:7,208,389...7,292,064

G

copine 7

decreases expression

ISO

bisphenol F results in decreased expression of CPNE7 mRNA

NCBI chr19:68,072,165...68,091,197
Ensembl chr19:68,074,545...68,091,197

G

coproporphyrinogen oxidase

increases expression

ISO

bisphenol F results in increased expression of CPOX mRNA

NCBI chr11:55,405,778...55,415,761
Ensembl chr11:55,405,784...55,415,761

G

carboxypeptidase Q

increases expression

ISO

bisphenol F results in increased expression of CPQ protein

NCBI chr 7:66,148,973...66,719,189
Ensembl chr 7:66,149,377...66,716,137

G

carbamoyl-phosphate synthase 1

increases expression

ISO

bisphenol F results in increased expression of CPS1 mRNA

NCBI chr 9:76,063,863...76,186,739
Ensembl chr 9:76,000,754...76,186,734

G

cleavage and polyadenylation specific factor 1

decreases expression

ISO

bisphenol F results in decreased expression of CPSF1 mRNA

NCBI chr 7:110,200,078...110,210,644
Ensembl chr 7:110,199,066...110,210,644

G

cleavage and polyadenylation specific factor 4

decreases expression

ISO

bisphenol F results in decreased expression of CPSF4 mRNA

NCBI chr12:14,543,536...14,559,350
Ensembl chr12:14,543,338...14,559,350

G

cleavage and polyadenylation specific factor 4-like

decreases expression

ISO

bisphenol F results in decreased expression of CPSF4L mRNA

NCBI chr10:99,241,187...99,255,207
Ensembl chr10:99,242,794...99,257,172

G

cleavage and polyadenylation specific factor 7

decreases expression

ISO

bisphenol F results in decreased expression of CPSF7 mRNA

NCBI chr 1:216,592,745...216,616,860
Ensembl chr 1:216,592,463...216,616,855

G

carnitine palmitoyltransferase 1A

increases expression

ISO

bisphenol F results in increased expression of CPT1A protein
bisphenol F results in increased expression of CPT1A mRNA

PMID:34186270 PMID:38685157

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326

G

carnitine palmitoyltransferase 1c

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CPT1C mRNA
bisphenol F results in decreased expression of CPT1C mRNA

PMID:36041667 PMID:38685157

NCBI chr 1:104,579,297...104,593,824
Ensembl chr 1:104,579,298...104,593,763

G

carnitine palmitoyltransferase 2

increases expression

ISO

bisphenol F results in increased expression of CPT2 protein

NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:127,893,207...127,910,818

G

carboxypeptidase X (M14 family), member 2

increases expression

ISO

bisphenol F results in increased expression of CPXM2 mRNA

NCBI chr 1:196,266,930...196,377,350
Ensembl chr 1:196,266,930...196,377,347

G

carboxypeptidase Z

multiple interactions
decreases expression
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CPZ mRNA
bisphenol F results in decreased expression of CPZ mRNA
bisphenol F results in increased expression of CPZ mRNA

PMID:30951980 PMID:36706583

NCBI chr14:79,448,242...79,471,557
Ensembl chr14:79,448,139...79,471,556

G

cellular retinoic acid binding protein 1

decreases expression

ISO

bisphenol F results in decreased expression of CRABP1 mRNA

NCBI chr 8:64,047,431...64,055,469
Ensembl chr 8:64,047,060...64,055,470

G

cellular retinoic acid binding protein 2

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CRABP2 mRNA
bisphenol F results in decreased expression of CRABP2 mRNA

PMID:28628672 PMID:30951980

NCBI chr 2:175,714,862...175,719,208
Ensembl chr 2:175,707,312...175,728,385

G

calcium release activated channel regulator 2B

decreases expression

ISO

bisphenol F results in decreased expression of CRACR2B mRNA

NCBI chr 1:205,987,957...205,993,515
Ensembl chr 1:205,990,507...205,993,516

G

CASP2 and RIPK1 domain containing adaptor with death domain

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CRADD mRNA

NCBI chr 7:31,827,131...31,839,796
Ensembl chr 7:31,685,622...31,874,512

G

carnitine O-acetyltransferase

increases expression

ISO

bisphenol F results in increased expression of CRAT protein

NCBI chr 3:34,073,504...34,087,099
Ensembl chr 3:34,073,506...34,087,099

G

crumbs cell polarity complex component 3

increases expression

ISO

bisphenol F results in increased expression of CRB3 mRNA

NCBI chr 9:1,985,504...1,990,855
Ensembl chr 9:1,983,619...1,993,486

G

cAMP responsive element binding protein 1

increases acetylation

EXP

bisphenol F results in increased acetylation of CREB1 protein

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

cAMP responsive element binding protein 3-like 1

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CREB3L1 mRNA
bisphenol F results in increased expression of CREB3L1 mRNA

NCBI chr 3:98,408,240...98,449,104
Ensembl chr 3:98,408,058...98,449,104

G

cAMP responsive element binding protein 3-like 2

multiple interactions
increases methylation
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CREB3L2 mRNA
bisphenol F results in increased methylation of CREB3L2 gene
bisphenol F results in increased expression of CREB3L2 mRNA

PMID:30951980 PMID:31601247 PMID:38685157

NCBI chr 4:66,874,623...66,990,962
Ensembl chr 4:66,387,126...66,990,832

G

cAMP responsive element binding protein 5

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CREB5 gene

NCBI chr 4:83,723,587...84,124,786
Ensembl chr 4:83,723,194...84,120,793

G

CREB binding protein

increases expression

ISO

bisphenol F results in increased expression of CREBBP mRNA

NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266

G

cAMP responsive element binding protein-like 2

increases expression

ISO

bisphenol F results in increased expression of CREBL2 mRNA

NCBI chr 4:169,404,630...169,430,618
Ensembl chr 4:169,376,495...169,430,611

G

cysteine-rich with EGF-like domains 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CRELD1 mRNA

NCBI chr 4:148,187,510...148,197,120
Ensembl chr 4:148,187,265...148,197,116

G

cysteine-rich with EGF-like domains 2

increases expression

ISO

bisphenol F results in increased expression of CRELD2 protein

NCBI chr 7:121,788,754...121,796,230
Ensembl chr 7:121,788,745...121,796,228

G

corticotropin releasing hormone binding protein

decreases expression

ISO

bisphenol F results in decreased expression of CRHBP mRNA

NCBI chr 2:28,427,139...28,439,446
Ensembl chr 2:28,427,139...28,439,446

G

cysteine rich transmembrane BMP regulator 1

increases expression

ISO

bisphenol F results in increased expression of CRIM1 mRNA

NCBI chr 6:22,447,983...22,622,459
Ensembl chr 6:22,449,948...22,622,416

G

cysteine rich protein 1

increases expression

ISO

bisphenol F results in increased expression of CRIP1 mRNA

NCBI chr 6:138,047,801...138,055,672
Ensembl chr 6:138,047,801...138,055,672

G

cysteine-rich protein 3

decreases expression

ISO

bisphenol F results in decreased expression of CRIP3 mRNA

NCBI chr 9:22,052,039...22,054,933
Ensembl chr 9:22,052,039...22,054,891

G

cripto, EGF-CFC family member

increases expression

ISO

bisphenol F results in increased expression of CRIPTO mRNA

NCBI chr 8:119,803,182...119,808,714
Ensembl chr 8:119,803,220...119,808,948

G

cysteine-rich secretory protein LCCL domain containing 1

increases expression

ISO

bisphenol F results in increased expression of CRISPLD1 mRNA

NCBI chr 5:6,050,970...6,098,265
Ensembl chr 5:6,051,891...6,098,265

G

cysteine-rich secretory protein LCCL domain containing 2

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CRISPLD2 mRNA
bisphenol F results in increased expression of CRISPLD2 mRNA

NCBI chr19:64,961,764...65,020,099
Ensembl chr19:64,961,771...65,020,349

G

CRK proto-oncogene, adaptor protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CRK mRNA

NCBI chr10:61,028,736...61,054,971
Ensembl chr10:61,028,757...61,082,988

G

cytokine receptor-like factor 1

increases expression

ISO

bisphenol F results in increased expression of CRLF1 mRNA

NCBI chr16:18,958,695...18,970,026
Ensembl chr16:18,957,956...18,969,970

G

cytokine receptor-like factor 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CRLF2 mRNA

NCBI chr14:118,932...123,632
Ensembl chr14:115,497...123,631

G

crooked neck pre-mRNA splicing factor 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CRNKL1 mRNA

NCBI chr 3:153,764,718...153,807,973
Ensembl chr 6:6,894,292...6,896,635
Ensembl chr 3:6,894,292...6,896,635

G

ciliary rootlet coiled-coil, rootletin family member 2

increases expression

ISO

bisphenol F results in increased expression of CROCC2 mRNA

NCBI chr 9:101,155,815...101,217,036
Ensembl chr 9:101,156,158...101,216,057

G

C-reactive protein

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CRP mRNA
bisphenol F results in increased expression of CRP mRNA

PMID:36041667 PMID:38685157

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514

G

cartilage associated protein

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CRTAP mRNA
bisphenol F results in increased expression of CRTAP protein
bisphenol F results in increased expression of CRTAP mRNA

PMID:30951980 PMID:34186270

NCBI chr 8:122,926,117...122,945,843
Ensembl chr 8:122,926,117...122,945,843

G

CREB regulated transcription coactivator 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CRTC3 mRNA

NCBI chr 1:143,962,038...144,064,324
Ensembl chr 1:143,962,038...144,064,288

G

cone-rod homeobox

decreases expression

ISO

bisphenol F results in decreased expression of CRX mRNA

NCBI chr 1:85,667,971...85,681,852
Ensembl chr 1:85,667,971...85,681,852

G

cryptochrome circadian regulator 2

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CRY2 mRNA
bisphenol F results in increased expression of CRY2 mRNA

PMID:36041667 PMID:38685157

NCBI chr 3:98,830,479...98,860,437
Ensembl chr 3:98,830,483...98,860,447

G

crystallin, alpha A

decreases expression

ISO

bisphenol F results in decreased expression of CRYAA mRNA

NCBI chr20:9,784,872...9,788,656
Ensembl chr20:9,784,857...9,788,654

G

crystallin, alpha B

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CRYAB mRNA
bisphenol F results in increased expression of CRYAB mRNA

NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528

G

crystallin, beta A1

decreases expression

ISO

bisphenol F results in decreased expression of CRYBA1 mRNA

NCBI chr10:63,106,465...63,113,020
Ensembl chr10:63,106,475...63,112,817

G

crystallin, beta B1

decreases expression

ISO

bisphenol F results in decreased expression of CRYBB1 mRNA

NCBI chr12:50,030,146...50,043,756
Ensembl chr12:50,030,146...50,043,756

G

crystallin beta-gamma domain containing 1

increases expression

ISO

bisphenol F results in increased expression of CRYBG1 mRNA

NCBI chr20:49,007,673...49,204,040
Ensembl chr20:49,007,929...49,204,047

G

crystallin, gamma A

decreases expression

ISO

bisphenol F results in decreased expression of CRYGA mRNA

NCBI chr 9:73,975,914...74,006,614
Ensembl chr 9:73,975,914...74,003,290

G

crystallin, gamma C

decreases expression

ISO

bisphenol F results in decreased expression of CRYGC mRNA

NCBI chr 9:73,945,332...73,947,367
Ensembl chr 9:73,945,334...73,947,367

G

crystallin, mu

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of CRYM mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CRYM mRNA

PMID:30951980 PMID:36041667

NCBI chr 1:183,991,752...184,006,923
Ensembl chr 1:183,991,745...184,006,962

G

crystallin zeta

increases expression

ISO

bisphenol F results in increased expression of CRYZ protein
bisphenol F results in increased expression of CRYZ mRNA

PMID:34186270 PMID:38685157

NCBI chr 2:246,211,707...246,239,472
Ensembl chr 2:246,211,156...246,239,470

G

crystallin zeta like 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CRYZL1 mRNA

NCBI chr11:44,419,099...44,464,366
Ensembl chr11:44,419,103...44,463,793

G

citrate synthase

increases expression

ISO

bisphenol F results in increased expression of CS protein

NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:1,342,942...1,375,938

G

cysteine sulfinic acid decarboxylase

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CSAD gene
bisphenol F results in increased expression of CSAD mRNA
bisphenol F results in increased expression of CSAD protein

PMID:31601247 PMID:34186270 PMID:38685157

NCBI chr 7:135,187,175...135,216,495
Ensembl chr 7:135,187,175...135,215,581

G

cold shock domain containing E1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CSDE1 mRNA

NCBI chr 2:193,234,546...193,271,301
Ensembl chr 2:193,243,526...193,271,301

G

chromosome segregation 1 like

increases expression

ISO

bisphenol F results in increased expression of CSE1L protein

NCBI chr 3:176,060,183...176,097,909
Ensembl chr 3:176,060,215...176,108,734

G

colony stimulating factor 1

decreases expression
decreases methylation

ISO

bisphenol F results in decreased expression of CSF1 mRNA
bisphenol F results in decreased methylation of CSF1 gene

PMID:38338861 PMID:38685157

NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:198,065,405...198,084,468

G

colony stimulating factor 1 receptor

increases expression

ISO

bisphenol F results in increased expression of CSF1R mRNA

NCBI chr18:56,834,152...56,860,804
Ensembl chr18:56,817,049...56,860,806

G

colony stimulating factor 2 receptor subunit alpha

decreases expression

ISO

bisphenol F results in decreased expression of CSF2RA mRNA

NCBI chr14:113,219...118,808
Ensembl chr14:113,225...118,117

G

colony stimulating factor 2 receptor subunit beta

increases expression

ISO

bisphenol F results in increased expression of CSF2RB mRNA

NCBI chr 7:111,756,950...111,782,089
Ensembl chr 7:111,757,405...111,784,654

G

colony stimulating factor 3 receptor

decreases expression

ISO

bisphenol F results in decreased expression of CSF3R mRNA

NCBI chr 5:143,583,126...143,604,382
Ensembl chr 5:143,583,213...143,602,411

G

chondroitin sulfate N-acetylgalactosaminyltransferase 1

increases expression

ISO

bisphenol F results in increased expression of CSGALNACT1 mRNA

NCBI chr16:25,761,946...26,097,306
Ensembl chr16:26,002,530...26,096,065

G

CUB and Sushi multiple domains 1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CSMD1 gene

NCBI chr16:78,920,549...80,520,710
Ensembl chr16:78,921,002...80,519,944

G

CUB and Sushi multiple domains 2

decreases expression

ISO

bisphenol F results in decreased expression of CSMD2 mRNA

NCBI chr 5:145,626,823...146,196,815
Ensembl chr 5:145,626,845...146,196,812

G

casein kinase 1, gamma 1

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CSNK1G1 mRNA
bisphenol F results in increased expression of CSNK1G1 mRNA

PMID:36041667 PMID:38685157

NCBI chr 8:75,334,751...75,472,339
Ensembl chr 8:75,334,895...75,467,515

G

casein kinase 1, gamma 2

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CSNK1G2 mRNA
bisphenol F results in increased expression of CSNK1G2 mRNA

PMID:36041667 PMID:38568856

NCBI chr 7:9,727,430...9,746,341
Ensembl chr 7:9,727,431...9,745,741

G

casein kinase 1, gamma 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CSNK1G3 mRNA

NCBI chr18:49,497,839...49,584,828
Ensembl chr18:49,497,839...49,584,828

G

casein kinase 2 alpha 2

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CSNK2A2 mRNA
bisphenol F results in increased expression of CSNK2A2 mRNA

PMID:36041667 PMID:38568856

NCBI chr19:9,562,340...9,602,136
Ensembl chr19:9,562,321...9,602,136

G

casein kinase 2 beta

increases expression

ISO

bisphenol F results in increased expression of CSNK2B mRNA

NCBI chr20:3,704,833...3,709,999
Ensembl chr20:3,704,904...3,710,525

G

centrosome and spindle pole associated protein 1

decreases expression

ISO

bisphenol F results in decreased expression of CSPP1 mRNA

NCBI chr 5:13,860,072...13,975,299
Ensembl chr 5:13,860,072...13,975,321

G

cysteine and serine rich nuclear protein 1

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CSRNP1 mRNA
bisphenol F results in increased expression of CSRNP1 mRNA

NCBI chr 8:128,582,364...128,594,163
Ensembl chr 8:128,582,365...128,588,469

G

cysteine and serine rich nuclear protein 2

decreases expression

ISO

bisphenol F results in decreased expression of CSRNP2 mRNA

NCBI chr 7:133,473,027...133,488,868
Ensembl chr 7:133,473,027...133,488,868

G

cysteine and serine rich nuclear protein 3

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CSRNP3 gene

NCBI chr 3:70,906,587...71,102,596
Ensembl chr 3:70,906,380...71,094,009

G

cysteine and glycine-rich protein 1

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of CSRP1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CSRP1 mRNA
bisphenol F results in increased expression of CSRP1 protein

PMID:30951980 PMID:34186270 PMID:36041667

NCBI chr13:49,709,928...49,731,141
Ensembl chr13:49,709,914...49,731,139

G

cysteine and glycine rich protein 3

increases expression
decreases expression

ISO

bisphenol F results in increased expression of CSRP3 mRNA
bisphenol F results in decreased expression of CSRP3 mRNA

PMID:30951980 PMID:38685157

NCBI chr 1:107,664,338...107,682,916
Ensembl chr 1:107,664,338...107,682,916

G

cystatin D

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CST5 mRNA

NCBI chr 3:158,033,791...158,038,345
Ensembl chr 3:158,033,791...158,038,345

G

cystatin B

increases expression

ISO

bisphenol F results in increased expression of CSTB mRNA

NCBI chr20:10,245,157...10,247,199
Ensembl chr20:10,245,158...10,247,199

G

cleavage stimulation factor subunit 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CSTF1 mRNA

NCBI chr 3:181,562,953...181,574,727
Ensembl chr 3:181,562,955...181,574,727

G

cleavage stimulation factor subunit 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CSTF3 mRNA

NCBI chr 3:111,421,291...111,492,539
Ensembl chr 3:111,421,234...111,497,046

G

C-terminal binding protein 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CTBP2 mRNA

NCBI chr 1:197,208,536...197,348,802
Ensembl chr 1:197,212,133...197,254,261

G

CCCTC-binding factor like 1

decreases expression

ISO

bisphenol F results in decreased expression of CTCFL mRNA

NCBI chr 3:182,286,637...182,309,272
Ensembl chr 3:182,286,637...182,309,272

G

CTD phosphatase subunit 1

multiple interactions

ISO
EXP

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CTDP1 gene
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CTDP1 mRNA

PMID:31601247 PMID:36041667

NCBI chr18:76,129,243...76,193,404
Ensembl chr18:76,129,243...76,190,578

G

CTD small phosphatase like

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CTDSPL mRNA
bisphenol F results in increased expression of CTDSPL mRNA

PMID:28628672 PMID:38568856

NCBI chr 8:127,520,478...127,644,999
Ensembl chr 8:127,520,499...127,644,999

G

CTD small phosphatase like 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CTDSPL2 mRNA

NCBI chr 3:129,365,709...129,424,232
Ensembl chr 3:129,368,938...129,424,232

G

cystathionine gamma-lyase

increases expression

ISO

bisphenol F results in increased expression of CTH mRNA

NCBI chr 2:249,634,731...249,661,066
Ensembl chr 2:249,634,731...249,661,066

G

collagen triple helix repeat containing 1

increases expression

ISO

bisphenol F results in increased expression of CTHRC1 mRNA

NCBI chr 7:72,007,372...72,017,654
Ensembl chr 7:72,007,372...72,017,654

G

cap binding complex dependent translation initiation factor

increases expression

ISO

bisphenol F results in increased expression of CTIF mRNA

NCBI chr18:71,331,222...71,602,493
Ensembl chr18:71,307,314...71,602,492

G

catenin alpha 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CTNNA1 mRNA

NCBI chr18:27,002,330...27,135,009
Ensembl chr18:26,999,820...27,135,007

G

catenin alpha 2

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CTNNA2 gene

NCBI chr 4:110,852,265...112,001,351
Ensembl chr 4:110,852,265...112,001,365

G

catenin beta 1

multiple interactions
increases expression
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CTNNB1 mRNA
bisphenol F results in increased expression of CTNNB1 mRNA
bisphenol F results in decreased expression of CTNNB1 mRNA
bisphenol F results in increased expression of CTNNB1 protein

PMID:28628672 PMID:34186270 PMID:35278557 PMID:38685157

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

catenin, beta like 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CTNNBL1 mRNA

NCBI chr 3:166,807,899...166,968,932
Ensembl chr 3:166,807,858...166,968,931

G

catenin delta 1

increases expression

ISO

bisphenol F results in increased expression of CTNND1 mRNA

NCBI chr 3:90,090,025...90,141,247
Ensembl chr 3:90,090,564...90,141,189

G

CTP synthase 1

increases expression

ISO

bisphenol F results in increased expression of CTPS1 protein

NCBI chr 5:139,372,349...139,440,441
Ensembl chr 5:139,410,249...139,440,465

G

cathepsin A

multiple interactions
decreases expression
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CTSA mRNA
bisphenol F results in decreased expression of CTSA mRNA
bisphenol F results in increased expression of CTSA protein

PMID:34186270 PMID:36041667 PMID:38685157

NCBI chr 3:173,988,443...173,994,320
Ensembl chr 3:173,988,460...173,995,539

G

cathepsin B

increases expression

ISO

bisphenol F results in increased expression of CTSB protein

NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478

G

cathepsin C

increases expression

ISO

bisphenol F results in increased expression of CTSC mRNA

NCBI chr 1:151,440,860...151,472,430
Ensembl chr 1:151,441,032...151,474,082

G

cathepsin D

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CTSD mRNA
bisphenol F results in increased expression of CTSD protein

PMID:34186270 PMID:36041667

NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821

G

cathepsin F

increases expression

ISO

bisphenol F results in increased expression of CTSF mRNA

NCBI chr 1:211,582,169...211,587,917
Ensembl chr 1:211,582,098...211,587,916

G

cathepsin H

increases expression

ISO

bisphenol F results in increased expression of CTSH mRNA

PMID:30951980 PMID:38685157

NCBI chr 8:99,488,756...99,507,639
Ensembl chr 8:99,488,874...99,509,181

G

cathepsin K

increases expression

ISO

bisphenol F results in increased expression of CTSK protein

NCBI chr 2:185,747,548...185,758,512
Ensembl chr 2:185,747,165...185,765,582

G

cathepsin L

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CTSL mRNA

NCBI chr17:770,104...776,266
Ensembl chr17:770,093...777,113

G

cathepsin O

increases expression

ISO

bisphenol F results in increased expression of CTSO mRNA

NCBI chr 2:169,528,468...169,551,975
Ensembl chr 2:169,528,511...169,554,995

G

cathepsin S

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of CTSS mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CTSS mRNA

PMID:30951980 PMID:36041667 PMID:38685157

NCBI chr 2:185,775,316...185,803,440
Ensembl chr 2:185,775,296...185,803,440

G

cathepsin Z

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CTSZ mRNA

NCBI chr 3:183,643,077...183,653,847
Ensembl chr 3:183,643,077...183,657,012

G

cortactin

increases expression

ISO

bisphenol F results in increased expression of CTTN protein

NCBI chr 1:209,029,048...209,064,577
Ensembl chr 1:209,029,048...209,058,211

G

CTTNBP2 N-terminal like

increases expression

ISO

bisphenol F results in increased expression of CTTNBP2NL mRNA

NCBI chr 2:195,196,318...195,244,792
Ensembl chr 2:195,196,318...195,243,181

G

cytosolic thiouridylase subunit 2

decreases expression

ISO

bisphenol F results in decreased expression of CTU2 mRNA

NCBI chr19:67,447,762...67,453,169
Ensembl chr19:67,447,487...67,453,163

G

cortexin 1

decreases expression

ISO

bisphenol F results in decreased expression of CTXN1 mRNA

NCBI chr12:7,408,308...7,409,919
Ensembl chr12:7,408,309...7,409,919

G

cubilin

affects expression
multiple interactions

ISO

bisphenol F affects the expression of CUBN mRNA
[bisphenol F co-treated with LIF protein] results in decreased expression of CUBN mRNA

NCBI chr17:81,293,619...81,501,694
Ensembl chr17:81,293,619...81,501,694

G

CUE domain containing 1

decreases expression

ISO

bisphenol F results in decreased expression of CUEDC1 mRNA

NCBI chr10:73,389,798...73,484,914
Ensembl chr10:73,389,841...73,483,749

G

CUE domain containing 2

decreases expression

ISO

bisphenol F results in decreased expression of CUEDC2 mRNA

NCBI chr 1:255,133,479...255,142,016
Ensembl chr 1:255,133,421...255,141,956

G

cullin 4A

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CUL4A mRNA

NCBI chr16:83,086,688...83,124,503
Ensembl chr16:83,086,921...83,124,457

G

cullin 4B

increases expression

ISO

bisphenol F results in increased expression of CUL4B protein
bisphenol F results in increased expression of CUL4B mRNA

PMID:34186270 PMID:38685157

NCBI chr X:122,154,332...122,192,299
Ensembl chr X:122,154,332...122,192,299

G

cullin 9

multiple interactions
decreases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CUL9 mRNA
bisphenol F results in decreased expression of CUL9 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CUL9 mRNA

PMID:28628672 PMID:36041667 PMID:38685157

NCBI chr 9:21,933,699...21,977,145
Ensembl chr 9:21,933,803...21,977,145

G

cutA divalent cation tolerance homolog

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CUTA mRNA

NCBI chr20:5,024,816...5,026,446
Ensembl chr20:5,024,816...5,026,631

G

cut-like homeobox 1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CUX1 gene

NCBI chr12:25,728,393...26,062,497
Ensembl chr12:25,743,733...26,062,497

G

CWC25 spliceosome-associated protein homolog

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CWC25 mRNA

NCBI chr10:83,232,052...83,256,722
Ensembl chr10:83,232,052...83,256,722

G

CWC27 spliceosome associated cyclophilin

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CWC27 mRNA

NCBI chr 2:37,498,462...37,709,691
Ensembl chr 2:37,498,468...37,709,355

G

CWF19 like cell cycle control factor 1

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CWF19L1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CWF19L1 mRNA

PMID:28628672 PMID:36041667

NCBI chr 1:252,946,934...252,970,194
Ensembl chr 1:252,946,934...252,970,168

G

C-X3-C motif chemokine ligand 1

decreases expression

ISO

bisphenol F results in decreased expression of CX3CL1 mRNA

NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,233,329...10,242,999

G

C-X3-C motif chemokine receptor 1

increases expression

ISO

bisphenol F results in increased expression of CX3CR1 mRNA

NCBI chr 8:128,661,294...128,679,048
Ensembl chr 8:128,654,833...128,685,983

G

CXADR, Ig-like cell adhesion molecule

increases expression

ISO

bisphenol F results in increased expression of CXADR mRNA

NCBI chr11:30,469,778...30,516,990
Ensembl chr11:30,469,526...30,516,988

G

C-X-C motif chemokine ligand 11

decreases expression

ISO

bisphenol F results in decreased expression of CXCL11 mRNA

NCBI chr14:15,973,728...15,976,503
Ensembl chr14:15,973,720...15,976,567

G

C-X-C motif chemokine ligand 12

affects expression

ISO

bisphenol F affects the expression of CXCL12 mRNA

NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627

G

C-X-C motif chemokine ligand 13

increases expression

ISO

bisphenol F results in increased expression of CXCL13 mRNA

NCBI chr14:13,912,858...13,917,920
Ensembl chr14:13,912,858...13,917,920

G

C-X-C motif chemokine ligand 14

decreases expression

ISO

bisphenol F results in decreased expression of CXCL14 mRNA

NCBI chr17:8,323,150...8,331,176
Ensembl chr17:8,323,143...8,331,172

G

C-X-C motif chemokine ligand 17

decreases expression

ISO

bisphenol F results in decreased expression of CXCL17 mRNA

NCBI chr 1:90,112,561...90,124,648
Ensembl chr 1:90,112,771...90,124,535

G

C-X-C motif chemokine ligand 2

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CXCL2 mRNA
bisphenol F results in decreased expression of CXCL2 mRNA

PMID:28628672 PMID:38685157

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255

G

C-X-C motif chemokine receptor 5

decreases expression

ISO

bisphenol F results in decreased expression of CXCR5 mRNA

NCBI chr 8:53,738,878...53,756,813
Ensembl chr 8:53,740,197...53,754,816

G

similar to human chromosome X open reading frame 38

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of CXORF38 mRNA

NCBI chr X:12,800,935...12,823,632
Ensembl chr X:12,802,377...12,814,198

G

CXXC finger protein 5

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CXXC5 mRNA

NCBI chr18:27,701,650...27,732,633
Ensembl chr18:27,701,188...27,732,635

G

cytochrome b5 type A

increases expression

ISO

bisphenol F results in increased expression of CYB5A protein

NCBI chr18:80,487,923...80,520,544
Ensembl chr18:14,453,966...14,455,094
Ensembl chr18:14,453,966...14,455,094

G

cytochrome b5 type B

increases expression

ISO

bisphenol F results in increased expression of CYB5B mRNA

NCBI chr19:51,972,611...52,006,477
Ensembl chr19:51,972,547...52,026,980

G

cytochrome b5 domain containing 1

increases expression

ISO

bisphenol F results in increased expression of CYB5D1 mRNA

NCBI chr10:54,612,230...54,616,375
Ensembl chr10:54,612,230...54,616,713

G

cytochrome b5 domain containing 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CYB5D2 mRNA

NCBI chr10:57,892,799...57,911,831
Ensembl chr10:57,895,296...57,912,030

G

cytochrome b5 reductase 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CYB5R1 mRNA
bisphenol F results in increased expression of CYB5R1 protein

PMID:28628672 PMID:34186270

NCBI chr13:48,401,061...48,407,466
Ensembl chr13:48,399,106...48,407,465

G

cytochrome b5 reductase 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CYB5R3 mRNA

NCBI chr 7:116,186,729...116,204,290
Ensembl chr 7:116,186,729...116,204,306

G

cytochrome b5 reductase 4

increases expression

ISO

bisphenol F results in increased expression of CYB5R4 mRNA

NCBI chr 8:96,860,415...96,925,789
Ensembl chr 8:96,861,090...96,926,094

G

cytochrome b-245 alpha chain

multiple interactions

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of CYBA mRNA

NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214

G

cytochrome b-245 beta chain

increases expression

ISO

bisphenol F results in increased expression of CYBB mRNA

PMID:30951980 PMID:38685157

NCBI chr X:16,030,596...16,065,065
Ensembl chr X:16,030,596...16,065,065

G

cytochrome c-1

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CYC1 mRNA
bisphenol F results in increased expression of CYC1 protein

PMID:34186270 PMID:36041667

NCBI chr 7:109,947,750...109,950,142
Ensembl chr 7:109,947,766...109,950,657

G

cytochrome c, somatic

increases expression

ISO

bisphenol F results in increased expression of CYCS protein

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytoglobin

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of CYGB mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of CYGB mRNA

PMID:30951980 PMID:36041667

NCBI chr10:102,376,506...102,386,272
Ensembl chr10:102,376,507...102,386,272

G

CYLD lysine 63 deubiquitinase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CYLD mRNA

NCBI chr19:34,487,491...34,547,311
Ensembl chr19:34,488,583...34,547,118

G

chymosin

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of CYM mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of PGA5 mRNA

NCBI chr 2:197,516,947...197,527,307
Ensembl chr 2:197,516,950...197,527,837

G

cytochrome P450, family 11, subfamily a, polypeptide 1

increases expression
decreases expression

ISO
EXP

4,4'-bisphenol F results in increased expression of CYP11A1 mRNA
bisphenol F results in decreased expression of CYP11A1 mRNA; bisphenol F results in decreased expression of CYP11A1 protein

PMID:30196065 PMID:35803362

NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196

G

cytochrome P450, family 11, subfamily b, polypeptide 2

decreases expression
increases expression

ISO

4,4'-bisphenol F results in decreased expression of CYP11B1 mRNA
bisphenol F results in increased expression of CYP11B1 mRNA

PMID:26751127 PMID:38966215

NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:108,719,349...108,725,763

G

cytochrome P450, family 11, subfamily b, polypeptide 3

decreases expression

ISO

4,4'-bisphenol F results in decreased expression of CYP11B2 mRNA

NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:108,689,165...108,694,921

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression
increases expression

ISO

4,4'-bisphenol F results in decreased expression of CYP17A1 mRNA
bisphenol F results in increased expression of CYP17A1 mRNA
4,4'-bisphenol F results in increased expression of CYP17A1 mRNA

PMID:26751127 PMID:30196065 PMID:38966215

NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974

G

cytochrome P450, family 19, subfamily a, polypeptide 1

increases expression

ISO

4,4'-bisphenol F results in increased expression of CYP19A1 mRNA

PMID:30196065 PMID:33753083

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of CYP1A1
bisphenol F results in increased expression of CYP1A1 mRNA
[bisphenol F co-treated with cylindrospermopsin] results in decreased expression of CYP1A1 mRNA; [cylindrospermopsin co-treated with bisphenol F] results in increased expression of CYP1A1 mRNA

PMID:31207516 PMID:32244372 PMID:38685157

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases glutathionylation
decreases activity
increases hydroxylation

ISO

CYP1A2 protein results in increased glutathionylation of 4,4'-bisphenol F
bisphenol F results in decreased activity of CYP1A2 protein
CYP1A2 protein results in increased hydroxylation of 4,4'-bisphenol F

PMID:23470418 PMID:33312107

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of CYP1B1 mRNA
bisphenol F results in increased expression of CYP1B1 protein
[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CYP1B1 gene
[bisphenol F co-treated with Tretinoin] results in decreased expression of CYP1B1 mRNA

PMID:30951980 PMID:31601247 PMID:34186270

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 20, subfamily a, polypeptide 1

increases expression

ISO

bisphenol F results in increased expression of CYP20A1 mRNA

NCBI chr 9:69,249,841...69,299,146
Ensembl chr 9:69,249,844...69,299,291

G

cytochrome P450, family 26, subfamily a, polypeptide 1

increases expression
decreases expression

ISO

bisphenol F results in increased expression of CYP26A1 mRNA
bisphenol F results in decreased expression of CYP26A1 mRNA

PMID:30951980 PMID:33476716

NCBI chr 1:244,883,822...244,887,657
Ensembl chr 1:244,883,752...244,887,657

G

cytochrome P450, family 26, subfamily b, polypeptide 1

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of CYP26B1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CYP26B1 mRNA

PMID:30951980 PMID:36041667

NCBI chr 4:118,599,356...118,616,176
Ensembl chr 4:118,599,356...118,616,176

G

cytochrome P450, family 2, subfamily a, polypeptide 3

decreases expression

ISO

bisphenol F results in decreased expression of CYP2A4 mRNA

NCBI chr 1:91,299,584...91,307,650
Ensembl chr 1:91,299,561...91,307,649

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression

ISO

bisphenol F results in increased expression of CYP2B10 mRNA

NCBI chr 1:90,780,468...90,859,852

G

cytochrome P450, family 2, subfamily c, polypeptide 24

multiple interactions

ISO

[Dietary Fats co-treated with bisphenol F] results in increased expression of CYP2C55 mRNA

NCBI chr 1:246,286,341...246,348,607
Ensembl chr 1:246,286,341...246,348,607

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases glutathionylation
increases expression
increases hydroxylation

ISO

CYP2C19 protein results in increased glutathionylation of 4,4'-bisphenol F; CYP2C19 protein results in increased glutathionylation of 4,4'-bisphenol F metabolite
bisphenol F results in increased expression of CYP2C29 mRNA
CYP2C19 protein results in increased hydroxylation of 4,4'-bisphenol F

PMID:23470418 PMID:38685157

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798

G

cytochrome P450, family 2, subfamily c, polypeptide 79

increases glutathionylation
increases hydroxylation

ISO

CYP2C8 protein results in increased glutathionylation of 4,4'-bisphenol F
CYP2C8 protein results in increased hydroxylation of 4,4'-bisphenol F

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases expression

EXP

4,4'-bisphenol F results in increased expression of CYP2D4 mRNA

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases hydroxylation
increases glutathionylation

ISO

CYP2E1 protein results in increased hydroxylation of 4,4'-bisphenol F
CYP2E1 protein results in increased glutathionylation of 4,4'-bisphenol F metabolite

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 2, subfamily f, polypeptide 4

increases expression

ISO

bisphenol F results in increased expression of CYP2F2 mRNA

PMID:30951980 PMID:38685157

NCBI chr 1:91,543,768...91,557,553
Ensembl chr 1:91,543,768...91,557,553

G

cytochrome P450, family 2, subfamily j, polypeptide 4

decreases expression

ISO

bisphenol F results in decreased expression of CYP2J9 mRNA

NCBI chr 5:116,295,691...116,323,219
Ensembl chr 5:116,295,694...116,323,042

G

cytochrome P450, family 2, subfamily u, polypeptide 1

increases expression

ISO

bisphenol F results in increased expression of CYP2U1 mRNA

NCBI chr 2:222,523,516...222,541,055
Ensembl chr 2:222,523,518...222,541,124

G

cytochrome P450, family 39, subfamily a, polypeptide 1

increases expression
affects expression

ISO

bisphenol F results in increased expression of CYP39A1 mRNA
bisphenol F affects the expression of CYP39A1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 9:24,727,817...24,804,060
Ensembl chr 9:24,727,817...24,804,060

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases hydroxylation
increases glutathionylation

ISO

CYP3A4 protein results in increased hydroxylation of 4,4'-bisphenol F
CYP3A4 protein results in increased glutathionylation of 4,4'-bisphenol F

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression

ISO

bisphenol F results in increased expression of CYP3A13 mRNA

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

cytochrome P450, family 46, subfamily a, polypeptide 1

decreases expression

ISO

bisphenol F results in decreased expression of CYP46A1 mRNA

NCBI chr 6:133,011,948...133,039,167
Ensembl chr 6:133,011,989...133,041,971

G

cytochrome P450, family 4, subfamily a, polypeptide 8

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CYP4A8 mRNA

NCBI chr 5:133,938,882...133,970,226
Ensembl chr 5:133,938,883...133,970,226

G

cytochrome P450, family 4, subfamily f, polypeptide 6

multiple interactions

ISO
EXP

[bisphenol F co-treated with Tretinoin] results in decreased expression of CYP4F16 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CYP4F6 mRNA

PMID:30951980 PMID:36041667

NCBI chr 7:12,680,799...12,708,378
Ensembl chr 7:12,680,806...12,708,402

G

cytochrome P450, family 51

increases expression

ISO

4,4'-bisphenol F results in increased expression of CYP51 mRNA

NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,991,613...31,010,450

G

cytochrome P450 family 7 subfamily B member 1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of CYP7B1 gene

NCBI chr 2:102,419,011...102,586,047
Ensembl chr 2:102,419,011...102,451,804

G

CYFIP related Rac1 interactor A

increases expression

ISO

bisphenol F results in increased expression of CYRIA mRNA

NCBI chr 6:40,774,165...40,883,005
Ensembl chr 6:40,774,171...40,881,860

G

CYFIP related Rac1 interactor B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CYRIB mRNA

NCBI chr 7:97,524,941...97,649,846
Ensembl chr 7:97,523,121...97,649,853

G

cystin 1

decreases expression

ISO

bisphenol F results in decreased expression of CYS1 mRNA

NCBI chr 6:47,029,440...47,046,671
Ensembl chr 6:47,028,461...47,046,671

G

cysteine-rich transmembrane module containing 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of CYSTM1 mRNA

NCBI chr18:28,219,861...28,287,574
Ensembl chr18:28,220,004...28,287,574

G

cytohesin 3

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of CYTH3 gene

NCBI chr12:15,953,781...16,076,584
Ensembl chr12:15,953,791...16,047,506

G

cytohesin 4

increases expression

ISO

bisphenol F results in increased expression of CYTH4 mRNA

NCBI chr 7:112,032,711...112,057,204
Ensembl chr 7:112,032,775...112,057,204

G

CXXC motif containing zinc binding protein

decreases expression

ISO

bisphenol F results in decreased expression of CZIB mRNA

NCBI chr 5:127,875,408...127,885,100
Ensembl chr 5:127,877,173...127,886,538

G

D-2-hydroxyglutarate dehydrogenase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of D2HGDH mRNA

NCBI chr 9:101,796,287...101,815,727
Ensembl chr 9:101,797,895...101,815,727

G

dishevelled associated activator of morphogenesis 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DAAM2 mRNA

NCBI chr 9:18,926,620...19,044,672
Ensembl chr 9:18,926,623...19,044,671

G

DAB adaptor protein 2

multiple interactions
decreases expression
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of DAB2 mRNA
bisphenol F results in decreased expression of DAB2 mRNA
bisphenol F results in increased expression of DAB2 mRNA

PMID:30951980 PMID:38685157

NCBI chr 2:57,241,947...57,294,893
Ensembl chr 2:57,242,064...57,294,888

G

dishevelled-binding antagonist of beta-catenin 1

increases expression

ISO

bisphenol F results in increased expression of DACT1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 6:95,526,645...95,538,625
Ensembl chr 6:95,526,690...95,551,053

G

defender against cell death 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DAD1 mRNA
bisphenol F results in increased expression of DAD1 protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of DAD1 mRNA

PMID:28628672 PMID:30951980 PMID:34186270

NCBI chr15:31,647,326...31,667,159
Ensembl chr15:31,647,326...31,667,287

G

dystroglycan 1

increases expression

ISO

bisphenol F results in increased expression of DAG1 protein
bisphenol F results in increased expression of DAG1 mRNA

PMID:34186270 PMID:38685157

NCBI chr 8:117,769,517...117,834,347
Ensembl chr 8:117,769,517...117,782,199

G

diacylglycerol lipase, alpha

increases expression

ISO

bisphenol F results in increased expression of DAGLA mRNA

NCBI chr 1:216,315,515...216,372,219
Ensembl chr 1:216,315,516...216,372,111

G

diacylglycerol lipase, beta

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DAGLB mRNA

NCBI chr12:16,173,345...16,215,777
Ensembl chr12:16,173,345...16,215,758

G

DALR anticodon binding domain containing 3

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DALRD3 mRNA
bisphenol F results in decreased expression of DALRD3 mRNA

PMID:36041667 PMID:38685157

NCBI chr 8:118,142,009...118,147,082
Ensembl chr 8:118,144,197...118,147,822

G

differentiation antagonizing non-protein coding RNA

decreases expression

ISO

bisphenol F results in decreased expression of DANCR mRNA

NCBI chr14:34,481,052...34,482,032

G

death-associated protein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DAP mRNA

NCBI chr 2:83,910,113...83,962,673
Ensembl chr 2:83,910,060...83,962,673

G

death associated protein 3

increases expression

ISO

bisphenol F results in increased expression of DAP3 protein

NCBI chr 2:176,617,151...176,645,293
Ensembl chr 2:176,617,155...176,644,270

G

death-associated protein kinase 3

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DAPK3 mRNA
bisphenol F results in decreased expression of DAPK3 mRNA

PMID:36041667 PMID:38685157

NCBI chr 7:9,174,903...9,183,272
Ensembl chr 7:9,174,904...9,183,272

G

aspartyl-tRNA synthetase 1

increases expression

ISO

bisphenol F results in increased expression of DARS1 protein

NCBI chr13:42,410,351...42,465,467
Ensembl chr13:42,379,162...42,465,467

G

death-domain associated protein

multiple interactions
increases methylation

ISO
EXP

[bisphenol F co-treated with Fulvestrant] results in increased methylation of DAXX gene
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DAXX mRNA
bisphenol F results in increased methylation of DAXX gene

PMID:31601247 PMID:36041667

NCBI chr20:4,971,973...4,978,062
Ensembl chr20:4,971,941...4,977,720

G

DAZ associated protein 1

decreases expression

ISO

bisphenol F results in decreased expression of DAZAP1 mRNA

NCBI chr 7:10,074,342...10,098,810
Ensembl chr 7:10,074,849...10,095,599

G

deleted in azoospermia-like

multiple interactions
decreases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of DAZL mRNA
bisphenol F results in decreased expression of DAZL mRNA

PMID:30951980 PMID:33476716

NCBI chr 9:18,193,363...18,210,100
Ensembl chr 9:18,193,363...18,210,100

G

DBF4-CDC7 kinase regulatory subunit

affects expression

ISO

bisphenol F affects the expression of DBF4 mRNA

NCBI chr 4:26,631,491...26,656,080
Ensembl chr 4:26,631,514...26,656,562

G

dopamine beta-hydroxylase

decreases expression

EXP

4,4'-bisphenol F results in decreased expression of DBH mRNA

NCBI chr 3:30,886,313...30,903,313
Ensembl chr 3:30,886,328...30,903,316

G

drebrin 1

increases expression
decreases expression

ISO

bisphenol F results in increased expression of DBN1 protein
bisphenol F results in decreased expression of DBN1 protein

PMID:34186270 PMID:38266696

NCBI chr17:9,155,729...9,170,121
Ensembl chr17:9,155,787...9,170,122

G

dysbindin domain containing 1

increases expression

ISO

bisphenol F results in increased expression of DBNDD1 mRNA

NCBI chr19:68,447,641...68,461,272
Ensembl chr19:68,447,635...68,458,797

G

dysbindin domain containing 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DBNDD2 mRNA

NCBI chr 3:173,634,551...173,639,999

G

D-box binding PAR bZIP transcription factor

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DBP mRNA
bisphenol F results in decreased expression of DBP mRNA

PMID:36041667 PMID:38685157

NCBI chr 1:105,312,256...105,317,205
Ensembl chr 1:105,312,108...105,317,205

G

developing brain homeobox 1

decreases expression

ISO

bisphenol F results in decreased expression of DBX1 mRNA

NCBI chr 1:108,484,846...108,490,381
Ensembl chr 1:108,484,863...108,490,381

G

DDB1 and CUL4 associated factor 10

increases expression

ISO

bisphenol F results in increased expression of DCAF10 mRNA

NCBI chr 5:64,402,307...64,442,839
Ensembl chr 5:64,403,451...64,440,614

G

DDB1 and CUL4 associated factor 12

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DCAF12 mRNA

NCBI chr 5:61,256,353...61,278,155
Ensembl chr 5:61,256,353...61,278,119

G

DDB1 and CUL4 associated factor 12-like 1

increases expression

ISO

bisphenol F results in increased expression of DCAF12L1 mRNA

NCBI chr X:128,572,969...128,576,588
Ensembl chr X:128,572,811...128,577,222

G

DDB1 and CUL4 associated factor 15

decreases expression

ISO

bisphenol F results in decreased expression of DCAF15 mRNA

NCBI chr19:40,958,693...40,966,043
Ensembl chr19:40,958,693...40,966,043

G

DDB1 and CUL4 associated factor 7

increases expression

ISO

bisphenol F results in increased expression of DCAF7 mRNA

NCBI chr10:91,473,900...91,496,080
Ensembl chr10:91,473,900...91,496,080

G

dephospho-CoA kinase domain containing

increases expression

ISO

bisphenol F results in increased expression of DCAKD protein

NCBI chr10:88,457,829...88,489,011
Ensembl chr10:88,457,829...88,480,118

G

DCC netrin 1 receptor

decreases expression

ISO

bisphenol F results in decreased expression of DCC mRNA

NCBI chr18:67,144,272...68,248,159
Ensembl chr18:67,149,179...68,247,541

G

doublecortin domain containing 2

increases expression

ISO

bisphenol F results in increased expression of DCDC2A mRNA

NCBI chr17:40,274,009...40,459,757
Ensembl chr17:40,274,009...40,458,790

G

doublecortin domain containing 2B

decreases expression

ISO

bisphenol F results in decreased expression of DCDC2B mRNA

NCBI chr 5:147,235,365...147,241,776
Ensembl chr 5:147,219,366...147,241,232

G

doublecortin-like kinase 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DCLK2 mRNA

NCBI chr 2:174,506,660...174,636,353
Ensembl chr 2:174,506,660...174,636,192

G

DNA cross-link repair 1C

decreases expression

ISO

bisphenol F results in decreased expression of DCLRE1C mRNA

NCBI chr17:79,684,988...79,718,399
Ensembl chr17:79,678,698...79,718,734

G

decorin

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of DCN mRNA
bisphenol F results in increased expression of DCN protein
[bisphenol F co-treated with Tretinoin] results in decreased expression of DCN mRNA

PMID:30951980 PMID:34186270 PMID:38685157

NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926

G

decapping mRNA 1A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DCP1A mRNA

NCBI chr16:5,663,437...5,708,623
Ensembl chr16:5,663,203...5,708,618

G

decapping mRNA 1B

decreases expression

ISO

bisphenol F results in decreased expression of DCP1B mRNA

NCBI chr 4:154,030,181...154,068,038
Ensembl chr 4:154,030,690...154,068,035

G

decapping enzyme, scavenger

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of DCPS protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DCPS mRNA

PMID:34186270 PMID:36041667

NCBI chr 8:41,729,507...41,782,222
Ensembl chr 8:41,724,563...41,782,222

G

dCMP deaminase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DCTD mRNA

NCBI chr16:50,799,699...50,831,398
Ensembl chr16:50,787,875...50,831,186

G

dynactin subunit 1

increases expression

ISO

bisphenol F results in increased expression of DCTN1 protein

NCBI chr 4:117,228,722...117,261,528
Ensembl chr 4:117,219,349...117,261,528

G

dynactin subunit 4

increases expression

ISO

bisphenol F results in increased expression of DCTN4 protein
bisphenol F results in increased expression of DCTN4 mRNA

PMID:34186270 PMID:38685157

NCBI chr18:56,251,187...56,279,844
Ensembl chr18:56,252,780...56,279,842

G

dynactin subunit 6

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DCTN6 mRNA

NCBI chr16:64,780,759...64,799,766
Ensembl chr16:64,780,735...64,801,060

G

dCTP pyrophosphatase 1

decreases expression

ISO

bisphenol F results in decreased expression of DCTPP1 mRNA

NCBI chr 1:191,307,933...191,311,326
Ensembl chr 1:191,307,935...191,313,405

G

defective in cullin neddylation 1 domain containing 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DCUN1D1 mRNA

NCBI chr 2:120,649,445...120,700,879
Ensembl chr 2:120,649,445...120,700,870

G

defective in cullin neddylation 1 domain containing 4

increases expression

ISO

bisphenol F results in increased expression of DCUN1D4 mRNA

NCBI chr14:35,006,792...35,087,285
Ensembl chr14:35,006,792...35,088,520

G

dicarbonyl and L-xylulose reductase

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DCXR mRNA
bisphenol F results in increased expression of DCXR protein

PMID:28628672 PMID:34186270

NCBI chr10:106,504,730...106,506,619

G

DET1 and DDB1 associated 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DDA1 mRNA

NCBI chr16:18,190,280...18,197,914
Ensembl chr16:18,190,306...18,197,913

G

dimethylarginine dimethylaminohydrolase 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DDAH1 mRNA

NCBI chr 2:237,327,812...237,460,624
Ensembl chr 2:237,327,766...237,460,626

G

DDAH family member 2, ADMA-independent

increases expression

ISO

bisphenol F results in increased expression of DDAH2 protein

NCBI chr20:3,766,115...3,769,161
Ensembl chr20:3,766,120...3,769,183

G

damage-specific DNA binding protein 1

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DDB1 mRNA
bisphenol F results in increased expression of DDB1 mRNA

PMID:36041667 PMID:38685157

NCBI chr 1:216,677,810...216,703,605
Ensembl chr 1:216,677,810...216,703,596

G

dopa decarboxylase

decreases expression
increases expression

EXP
ISO

4,4'-bisphenol F results in decreased expression of DDC mRNA
bisphenol F results in increased expression of DDC mRNA

PMID:26186136 PMID:30951980 PMID:38685157

NCBI chr14:90,592,304...90,682,830
Ensembl chr14:90,592,304...90,682,806

G

DNA damage inducible 1 homolog 2

increases expression

ISO

bisphenol F results in increased expression of DDI2 mRNA

NCBI chr 5:159,272,625...159,318,365
Ensembl chr 5:159,272,625...159,318,310

G

DNA-damage inducible transcript 3

multiple interactions
decreases expression
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DDIT3 mRNA
bisphenol F results in decreased expression of DDIT3 mRNA
bisphenol F results in increased expression of DDIT3 mRNA; bisphenol F results in increased expression of DDIT3 protein

PMID:36041667 PMID:38134982 PMID:38685157

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

DNA-damage-inducible transcript 4

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DDIT4 mRNA
bisphenol F results in increased expression of DDIT4 mRNA

PMID:36041667 PMID:38685157

NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037

G

dendrin

decreases expression

ISO

bisphenol F results in decreased expression of DDN mRNA

NCBI chr 7:131,832,270...131,836,252
Ensembl chr 7:131,832,271...131,836,294

G

D-aspartate oxidase

increases expression

ISO

bisphenol F results in increased expression of DDO mRNA

NCBI chr20:45,673,486...45,693,056
Ensembl chr20:45,675,532...45,715,758

G

dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of DDOST gene

NCBI chr 5:155,805,612...155,812,728
Ensembl chr 5:155,805,454...155,813,121

G

discoidin domain receptor tyrosine kinase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DDR1 mRNA

NCBI chr20:3,047,269...3,069,277
Ensembl chr20:3,050,375...3,069,276

G

discoidin domain receptor tyrosine kinase 2

multiple interactions
decreases expression
increases expression

ISO
EXP

[bisphenol F co-treated with Tretinoin] results in decreased expression of DDR2 mRNA
bisphenol F results in decreased expression of DDR2 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DDR2 mRNA
bisphenol F results in increased expression of DDR2 mRNA

PMID:30951980 PMID:36041667 PMID:38685157

NCBI chr13:84,726,412...84,851,032
Ensembl chr13:84,731,180...84,850,288

G

DDRGK domain containing 1

increases expression

ISO

bisphenol F results in increased expression of DDRGK1 protein

NCBI chr 3:138,315,006...138,336,691
Ensembl chr 3:138,315,282...138,335,766

G

DEAD-box helicase 1

increases expression

ISO

bisphenol F results in increased expression of DDX1 protein

NCBI chr 6:41,725,365...41,756,236
Ensembl chr 6:41,725,367...41,758,302

G

DEAD-box helicase 10

increases expression

ISO

bisphenol F results in increased expression of DDX10 mRNA

NCBI chr 8:62,384,876...62,539,585
Ensembl chr 8:62,384,876...62,539,585

G

DEAD-box helicase 18

increases expression

ISO

bisphenol F results in increased expression of DDX18 mRNA

NCBI chr13:35,282,391...35,296,038
Ensembl chr13:35,282,467...35,295,972

G

DEAD-box helicase 19A

increases expression

ISO

bisphenol F results in increased expression of DDX19A mRNA

NCBI chr19:55,851,854...55,872,209
Ensembl chr19:55,851,854...55,872,209

G

DEAD-box helicase 19B

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DDX19B mRNA
bisphenol F results in increased expression of DDX19B mRNA
bisphenol F results in increased expression of DDX19B protein

PMID:28628672 PMID:34186270 PMID:38685157

NCBI chr19:55,877,567...55,910,134
Ensembl chr19:55,877,567...55,906,745

G

DEAD-box helicase 23

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DDX23 mRNA

NCBI chr 7:131,676,636...131,693,917
Ensembl chr 7:131,676,636...131,689,074

G

DEAD-box helicase 24

increases expression

ISO

bisphenol F results in increased expression of DDX24 protein

NCBI chr 6:128,329,554...128,346,818
Ensembl chr 6:128,329,554...128,349,625

G

DExD-box helicase 39A

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DDX39A mRNA

NCBI chr19:41,323,465...41,331,413
Ensembl chr19:41,322,836...41,332,306

G

DExD-box helicase 39B

increases expression
decreases expression

ISO

bisphenol F results in increased expression of DDX39B protein
bisphenol F results in decreased expression of DDX39B mRNA

PMID:34186270 PMID:38685157

NCBI chr20:3,577,200...3,589,651
Ensembl chr20:3,576,734...3,589,651

G

DEAD-box helicase 3, X-linked

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DDX3X mRNA
bisphenol F results in increased expression of DDX3X mRNA

PMID:36041667 PMID:38685157

NCBI chr X:12,152,346...12,165,983
Ensembl chr X:12,152,346...12,165,983

G

DEAD-box helicase 43

decreases expression
multiple interactions

ISO

bisphenol F results in decreased expression of DDX43 mRNA
[bisphenol F co-treated with Fulvestrant] results in increased methylation of DDX43 gene

PMID:31601247 PMID:33476716

NCBI chr 8:88,135,255...88,172,872
Ensembl chr 8:88,135,882...88,164,749

G

DEAD-box helicase 49

decreases expression

ISO

bisphenol F results in decreased expression of DDX49 mRNA

NCBI chr16:19,159,353...19,167,003
Ensembl chr16:19,159,087...19,167,580

G

DEAD-box helicase 5

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DDX5 mRNA

NCBI chr10:92,224,393...92,231,928
Ensembl chr10:92,224,395...92,231,300

G

DEAD-box helicase 55

decreases expression

ISO

bisphenol F results in decreased expression of DDX55 mRNA

NCBI chr12:37,695,444...37,711,198
Ensembl chr12:37,695,444...37,711,198

G

DEAD-box helicase 6

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DDX6 mRNA
bisphenol F results in increased expression of DDX6 mRNA
bisphenol F results in increased expression of DDX6 protein

PMID:28628672 PMID:34186270 PMID:38685157

NCBI chr 8:53,827,661...53,864,538
Ensembl chr 8:53,827,835...53,860,977

G

DEAF1 transcription factor

decreases expression

ISO

bisphenol F results in decreased expression of DEAF1 mRNA

NCBI chr 1:205,831,428...205,865,106
Ensembl chr 1:205,831,336...205,865,106

G

2,4-dienoyl-CoA reductase 1

increases expression

ISO

bisphenol F results in increased expression of DECR1 protein

NCBI chr 5:34,208,195...34,236,074
Ensembl chr 5:34,208,195...34,236,033

G

differentially expressed in FDCP 8 homolog

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DEF8 mRNA

NCBI chr19:68,383,293...68,404,133
Ensembl chr19:68,383,349...68,404,125

G

delta(4)-desaturase, sphingolipid 1

increases expression

ISO

bisphenol F results in increased expression of DEGS1 mRNA

NCBI chr13:96,478,645...96,485,302
Ensembl chr13:96,478,646...96,485,302

G

DENN domain containing 11

increases expression

ISO

bisphenol F results in increased expression of DENND11 mRNA

NCBI chr 4:70,163,869...70,232,731
Ensembl chr 4:70,163,869...70,195,800

G

DENN domain containing 1B

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DENND1B mRNA

NCBI chr13:53,096,717...53,324,372
Ensembl chr13:53,092,261...53,324,369

G

DENN domain containing 1C

decreases expression

ISO

bisphenol F results in decreased expression of DENND1C mRNA

NCBI chr 9:1,991,035...2,003,330
Ensembl chr 9:1,991,039...2,003,151

G

DENN domain containing 2D

decreases expression

ISO

bisphenol F results in decreased expression of DENND2D mRNA

NCBI chr 2:196,661,465...196,680,505
Ensembl chr 2:196,661,345...196,682,397

G

DENN domain containing 3

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DENND3 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DENND3 mRNA

PMID:28628672 PMID:36041667

NCBI chr 7:107,304,860...107,362,573
Ensembl chr 7:107,220,192...107,362,573

G

DENN domain containing 4B

decreases expression

ISO

bisphenol F results in decreased expression of DENND4B mRNA

NCBI chr 2:178,018,095...178,034,054
Ensembl chr 2:178,018,358...178,034,054

G

DENN domain containing 4C

increases expression

ISO

bisphenol F results in increased expression of DENND4C mRNA

NCBI chr 5:106,316,942...106,421,484
Ensembl chr 5:106,318,281...106,415,489

G

DENN domain containing 6A

increases expression

ISO

bisphenol F results in increased expression of DENND6A mRNA

NCBI chr16:1,843,803...1,892,165
Ensembl chr16:1,843,752...1,892,163

G

DENN domain containing 6B

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DENND6B mRNA
bisphenol F results in decreased expression of DENND6B mRNA

PMID:36041667 PMID:38685157

NCBI chr 7:122,139,159...122,154,720
Ensembl chr 7:122,141,317...122,153,131

G

DEPP autophagy regulator 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DEPP1 mRNA
bisphenol F results in increased expression of DEPP1 mRNA

PMID:28628672 PMID:30951980 PMID:38685157

NCBI chr 4:151,583,105...151,585,455
Ensembl chr 4:151,581,502...151,586,233

G

DEP domain containing MTOR-interacting protein

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DEPTOR mRNA
bisphenol F results in increased expression of DEPTOR mRNA

PMID:28628672 PMID:30951980 PMID:34831106

NCBI chr 7:88,404,745...88,574,065
Ensembl chr 7:88,404,620...88,574,041

G

deoxyribose-phosphate aldolase

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of DERA gene

NCBI chr 4:172,394,971...172,473,746
Ensembl chr 4:172,394,962...172,490,142

G

derlin 1

increases expression

ISO

bisphenol F results in increased expression of DERL1 protein

NCBI chr 7:91,293,963...91,316,639
Ensembl chr 7:91,258,382...91,316,678

G

derlin 3

increases expression

ISO

bisphenol F results in increased expression of DERL3 mRNA

NCBI chr20:12,753,926...12,766,478
Ensembl chr20:12,762,981...12,766,477

G

DERPC proline and glycine rich nuclear protein

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DERPC mRNA

NCBI chr19:51,692,005...51,702,076
Ensembl chr19:51,678,543...51,707,144

G

desmin

increases expression
decreases expression

ISO

bisphenol F results in increased expression of DES mRNA
bisphenol F results in decreased expression of DES mRNA

PMID:30951980 PMID:38685157

NCBI chr 9:84,299,626...84,307,344
Ensembl chr 9:84,298,447...84,307,347

G

deuterosome assembly protein 1

increases expression

ISO

bisphenol F results in increased expression of DEUP1 mRNA

NCBI chr 8:20,661,687...20,724,083
Ensembl chr 8:20,661,689...20,723,585

G

DNA fragmentation factor subunit beta

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DFFB mRNA
bisphenol F results in decreased expression of DFFB mRNA

PMID:28628672 PMID:38685157

NCBI chr 5:169,804,873...169,817,157
Ensembl chr 5:169,804,889...169,817,225

G

diacylglycerol O-acyltransferase 2

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DGAT2 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DGAT2 mRNA

PMID:28628672 PMID:36041667

NCBI chr 1:162,866,237...162,896,655
Ensembl chr 1:162,866,237...162,896,566

G

DiGeorge syndrome critical region gene 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DGCR2 mRNA

NCBI chr11:96,598,247...96,648,791
Ensembl chr11:96,597,197...96,648,786

G

DiGeorge syndrome critical region gene 6

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DGCR6 mRNA

NCBI chr11:96,432,024...96,442,766
Ensembl chr11:96,432,024...96,437,255

G

diacylglycerol kinase, alpha

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DGKA mRNA

NCBI chr 7:1,733,247...1,761,181
Ensembl chr 7:1,733,248...1,759,569

G

diacylglycerol kinase, beta

multiple interactions

ISO
EXP

[bisphenol F co-treated with Tretinoin] results in decreased expression of DGKB mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DGKB mRNA

PMID:30951980 PMID:36041667

NCBI chr 6:60,368,101...61,124,420
Ensembl chr 6:60,368,519...61,124,420

G

diacylglycerol kinase, delta

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of DGKD gene
bisphenol F results in increased expression of DGKD mRNA

PMID:31601247 PMID:38685157

NCBI chr 9:95,964,507...96,055,160
Ensembl chr 9:95,964,148...96,055,160

G

diacylglycerol kinase kappa

increases expression

ISO

bisphenol F results in increased expression of DGKK mRNA

NCBI chr X:18,253,849...18,385,805
Ensembl chr X:18,256,463...18,385,640

G

diacylglycerol kinase zeta

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of DGKZ gene

NCBI chr 3:98,359,804...98,401,847
Ensembl chr 3:98,359,804...98,401,951

G

deoxyguanosine kinase

decreases expression

ISO

bisphenol F results in decreased expression of DGUOK mRNA

NCBI chr 4:117,544,784...117,572,414
Ensembl chr 4:117,544,773...117,572,414

G

24-dehydrocholesterol reductase

increases expression

ISO

bisphenol F results in increased expression of DHCR24 protein
bisphenol F results in increased expression of DHCR24 mRNA

PMID:34186270 PMID:38685157

NCBI chr 5:126,573,366...126,599,940
Ensembl chr 5:126,573,338...126,599,936

G

7-dehydrocholesterol reductase

increases expression

ISO

bisphenol F results in increased expression of DHCR7 protein

NCBI chr 1:208,444,434...208,460,408
Ensembl chr 1:208,444,434...208,461,382

G

dehydrodolichyl diphosphate synthase subunit

increases expression

ISO

bisphenol F results in increased expression of DHDDS mRNA

NCBI chr 5:151,482,139...151,508,248
Ensembl chr 5:151,481,429...151,508,129

G

dihydrodiol dehydrogenase

increases expression

ISO

bisphenol F results in increased expression of DHDH mRNA

NCBI chr 1:105,088,108...105,102,560
Ensembl chr 1:105,090,309...105,101,567

G

desert hedgehog signaling molecule

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DHH mRNA

NCBI chr 7:131,929,857...131,935,352
Ensembl chr 7:131,929,857...131,935,352

G

deoxyhypusine synthase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DHPS mRNA

NCBI chr19:39,987,328...39,991,418
Ensembl chr19:39,987,324...39,991,432

G

dehydrogenase/reductase 1

increases expression

ISO

bisphenol F results in increased expression of DHRS1 mRNA

NCBI chr15:33,206,449...33,213,776
Ensembl chr15:33,206,451...33,213,734

G

dehydrogenase/reductase 11

increases expression

ISO

bisphenol F results in increased expression of DHRS11 protein

NCBI chr10:70,195,637...70,205,735
Ensembl chr10:70,195,637...70,205,893

G

dehydrogenase/reductase 3

increases expression

ISO

bisphenol F results in increased expression of DHRS3 mRNA

PMID:30951980 PMID:34831106

NCBI chr 5:162,031,853...162,065,655
Ensembl chr 5:162,031,386...162,065,653

G

dehydrogenase/reductase 7

increases expression

ISO

bisphenol F results in increased expression of DHRS7 mRNA

NCBI chr 6:97,068,149...97,083,744
Ensembl chr 6:97,068,149...97,083,744

G

dehydrogenase/reductase 9

increases expression

ISO

bisphenol F results in increased expression of DHRS9 mRNA

NCBI chr 3:74,553,357...74,579,535
Ensembl chr 3:74,555,606...74,581,376

G

dehydrogenase/reductase X-linked

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DHRSX mRNA
bisphenol F results in increased expression of DHRSX mRNA

PMID:36041667 PMID:38685157

NCBI chr12:21,413,563...21,418,319
Ensembl chr12:21,413,575...21,418,319

G

dehydrogenase E1 and transketolase domain containing 1

increases expression

ISO

bisphenol F results in increased expression of DHTKD1 mRNA

NCBI chr17:77,242,512...77,316,074
Ensembl chr17:77,264,514...77,316,071

G

DEAH-box helicase 15

increases expression

ISO

bisphenol F results in increased expression of DHX15 mRNA

NCBI chr14:62,999,886...63,037,829
Ensembl chr14:62,999,877...63,037,828

G

DEAH-box helicase 16

decreases expression

ISO

bisphenol F results in decreased expression of DHX16 mRNA

NCBI chr20:2,866,804...2,879,790
Ensembl chr20:2,866,804...2,879,751

G

DEAH-box helicase 35

decreases expression

ISO

bisphenol F results in decreased expression of DHX35 mRNA

NCBI chr 3:167,869,971...167,927,300
Ensembl chr 3:167,870,055...167,927,300

G

DEAH-box helicase 37

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DHX37 mRNA

NCBI chr12:36,856,119...36,876,245
Ensembl chr12:36,849,701...36,876,240

G

DEAH-box helicase 38

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DHX38 mRNA

NCBI chr19:54,422,418...54,439,434
Ensembl chr19:54,422,418...54,439,423

G

DEXH-box helicase 58

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DHX58 mRNA

NCBI chr10:86,120,677...86,132,095
Ensembl chr10:86,120,677...86,131,844

G

DExH-box helicase 9

increases expression

ISO

bisphenol F results in increased expression of DHX9 protein
bisphenol F results in increased expression of DHX9 mRNA

PMID:34186270 PMID:38685157

NCBI chr13:68,152,813...68,189,580
Ensembl chr13:68,152,813...68,189,546

G

diablo, IAP-binding mitochondrial protein

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DIABLO mRNA

NCBI chr12:38,716,668...38,731,285
Ensembl chr12:38,716,668...38,731,265

G

diaphanous-related formin 2

increases methylation

ISO

bisphenol F results in increased methylation of DIAPH2 gene

NCBI chr X:96,700,535...97,528,080
Ensembl chr X:96,700,726...97,528,080

G

DIM1 rRNA methyltransferase and ribosome maturation factor

decreases expression

ISO

bisphenol F results in decreased expression of DIMT1 mRNA

NCBI chr 2:40,076,622...40,101,792
Ensembl chr 2:40,076,570...40,101,787

G

iodothyronine deiodinase 1

decreases expression

EXP

4,4'-bisphenol F results in decreased expression of DIO1 mRNA

NCBI chr 5:127,303,089...127,319,784
Ensembl chr 5:127,303,083...127,319,771

G

iodothyronine deiodinase 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DIO2 mRNA
bisphenol F results in increased expression of DIO2 mRNA

PMID:28628672 PMID:30951980

NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594

G

DIO3 opposite strand upstream RNA

decreases expression

ISO

bisphenol F results in decreased expression of DIO3OS mRNA

G

disco-interacting protein 2 homolog B

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of DIP2B gene

NCBI chr 7:133,053,393...133,231,430
Ensembl chr 7:133,053,401...133,228,874

G

disco-interacting protein 2 homolog C

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] affects the methylation of DIP2C gene

NCBI chr17:65,338,711...65,724,111
Ensembl chr17:65,338,711...65,723,344

G

divergent protein kinase domain 1A

increases methylation

ISO

bisphenol F results in increased methylation of DIPK1A gene

NCBI chr14:1,917,353...1,988,188
Ensembl chr14:1,917,324...1,988,678

G

divergent protein kinase domain 1B

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of DIPK1B gene

NCBI chr 3:29,852,710...29,862,248
Ensembl chr 3:29,853,973...29,862,255

G

divergent protein kinase domain 2A

increases expression

ISO

bisphenol F results in increased expression of DIPK2A mRNA

NCBI chr 8:103,950,345...103,969,461
Ensembl chr 8:103,909,931...103,969,461

G

DIRAS family GTPase 1

decreases expression

ISO

bisphenol F results in decreased expression of DIRAS1 mRNA

NCBI chr 7:9,338,660...9,343,524
Ensembl chr 7:9,327,335...9,347,881

G

DIRAS family GTPase 2

decreases expression

ISO

bisphenol F results in decreased expression of DIRAS2 mRNA

NCBI chr17:12,882,224...12,913,366
Ensembl chr17:12,880,385...12,914,291

G

dyskerin pseudouridine synthase 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DKC1 mRNA

NCBI chr  X:157,751,651...157,757,796
Ensembl chr  Y:380,743...385,405
Ensembl chr  X:380,743...385,405

G

dickkopf WNT signaling pathway inhibitor 1

increases expression

ISO

bisphenol F results in increased expression of DKK1 mRNA

NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:237,794,969...237,798,650

G

dickkopf WNT signaling pathway inhibitor 2

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of DKK2 mRNA
[bisphenol F co-treated with Fulvestrant] results in decreased methylation of DKK2 gene

PMID:30951980 PMID:31601247

NCBI chr 2:223,242,375...223,334,249
Ensembl chr 2:223,242,377...223,334,724

G

dickkopf WNT signaling pathway inhibitor 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DKK3 mRNA

NCBI chr 1:175,672,834...175,715,867
Ensembl chr 1:175,672,834...175,715,186

G

dihydrolipoamide S-acetyltransferase

increases expression

ISO

bisphenol F results in increased expression of DLAT protein
bisphenol F results in increased expression of DLAT mRNA

PMID:34186270 PMID:38685157

NCBI chr 8:59,875,537...59,900,947
Ensembl chr 8:59,868,214...59,900,818
Ensembl chr 1:59,868,214...59,900,818

G

DLC1 Rho GTPase activating protein

increases expression

ISO

bisphenol F results in increased expression of DLC1 mRNA

NCBI chr16:61,954,177...62,374,819
Ensembl chr16:61,995,001...62,374,819

G

dihydrolipoamide dehydrogenase

increases expression

ISO

bisphenol F results in increased expression of DLD protein
bisphenol F results in increased expression of DLD mRNA

PMID:34186270 PMID:38685157

NCBI chr 6:53,631,686...53,655,059
Ensembl chr 6:53,619,631...53,652,354

G

DLEC1 cilia and flagella associated protein

increases expression
decreases expression

ISO

bisphenol F results in increased expression of DLEC1 mRNA
bisphenol F results in decreased expression of DLEC1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 8:127,704,181...127,750,929
Ensembl chr 8:127,704,232...127,750,931

G

deleted in lymphocytic leukemia, 7

decreases expression

ISO

bisphenol F results in decreased expression of DLEU7 mRNA

NCBI chr15:40,655,563...40,671,759
Ensembl chr15:40,655,563...40,671,759

G

discs large MAGUK scaffold protein 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DLG1 mRNA

NCBI chr11:82,416,853...82,607,797
Ensembl chr11:82,416,853...82,607,797

G

discs large MAGUK scaffold protein 4

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DLG4 mRNA
bisphenol F results in decreased expression of DLG4 protein

PMID:36041667 PMID:38266696

NCBI chr10:55,239,397...55,267,780
Ensembl chr10:55,236,869...55,265,839

G

DLG associated protein 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DLGAP3 mRNA

NCBI chr 5:144,776,414...144,847,097
Ensembl chr 5:144,777,295...144,847,097

G

DLG associated protein 4

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DLGAP4 mRNA
bisphenol F results in decreased expression of DLGAP4 mRNA

PMID:28628672 PMID:38685157

NCBI chr 3:165,584,271...165,731,868
Ensembl chr 3:165,584,360...165,730,604

G

delta like non-canonical Notch ligand 1

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of DLK1 mRNA
bisphenol F results in increased expression of DLK1 mRNA

NCBI chr 6:134,192,491...134,199,779
Ensembl chr 6:134,192,518...134,200,529

G

delta like non-canonical Notch ligand 2

increases expression

ISO

bisphenol F results in increased expression of DLK2 mRNA

NCBI chr 9:22,174,667...22,179,149
Ensembl chr 9:22,173,158...22,179,149

G

delta like canonical Notch ligand 1

decreases expression

ISO

bisphenol F results in decreased expression of DLL1 mRNA

PMID:35278557 PMID:38685157

NCBI chr 1:64,985,161...64,993,274
Ensembl chr 1:64,985,161...64,993,276

G

delta like canonical Notch ligand 3

increases expression

ISO

bisphenol F results in increased expression of DLL3 mRNA

NCBI chr 1:92,689,577...92,698,125
Ensembl chr 1:92,689,577...92,697,406

G

delta like canonical Notch ligand 4

increases expression
decreases expression

ISO

bisphenol F results in increased expression of DLL4 mRNA
bisphenol F results in decreased expression of DLL4 mRNA

PMID:33476716 PMID:35278557

NCBI chr 3:126,770,945...126,780,769
Ensembl chr 3:126,770,794...126,780,763

G

dihydrolipoamide S-succinyltransferase

increases expression

ISO

bisphenol F results in increased expression of DLST protein

NCBI chr 6:110,489,576...110,512,841
Ensembl chr 6:110,489,392...110,514,357

G

distal-less homeobox 1

decreases expression

ISO

bisphenol F results in decreased expression of DLX1 mRNA

NCBI chr 3:76,763,864...76,768,454
Ensembl chr 3:76,763,500...76,768,447

G

distal-less homeobox 2

decreases expression
increases expression

ISO

bisphenol F results in decreased expression of DLX2 mRNA
bisphenol F results in increased expression of DLX2 mRNA

PMID:30951980 PMID:33476716 PMID:38685157

NCBI chr 3:76,777,912...76,781,255
Ensembl chr 3:76,777,912...76,781,255

G

distal-less homeobox 3

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DLX3 mRNA
bisphenol F results in increased expression of DLX3 mRNA

PMID:36041667 PMID:38685157

NCBI chr10:80,561,335...80,566,730
Ensembl chr10:80,561,335...80,566,711

G

distal-less homeobox 4

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DLX4 mRNA

NCBI chr10:80,581,878...80,587,272
Ensembl chr10:80,582,303...80,587,294

G

distal membrane arm assembly component 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DMAC1 mRNA

NCBI chr 5:94,288,900...94,290,053
Ensembl chr 5:94,280,654...94,290,119

G

distal membrane arm assembly component 2

decreases expression

ISO

bisphenol F results in decreased expression of DMAC2 mRNA

NCBI chr 1:90,250,262...90,262,592
Ensembl chr 1:90,243,532...90,262,594

G

distal membrane arm assembly component 2 like

decreases expression

ISO

bisphenol F results in decreased expression of DMAC2L mRNA

NCBI chr 6:93,941,605...93,959,932
Ensembl chr 6:93,941,690...93,960,662

G

DNA methyltransferase 1-associated protein 1

decreases expression

ISO

bisphenol F results in decreased expression of DMAP1 mRNA

NCBI chr 5:136,380,211...136,388,229
Ensembl chr 5:136,380,216...136,388,219

G

diencephalon/mesencephalon homeobox 1

decreases expression

ISO

bisphenol F results in decreased expression of DMBX1 mRNA

NCBI chr 5:134,630,968...134,639,781
Ensembl chr 5:134,630,968...134,639,781

G

dystrophin

increases expression

ISO

bisphenol F results in increased expression of DMD mRNA

NCBI chr X:51,070,098...53,437,845
Ensembl chr X:51,070,273...53,437,835

G

DM1 protein kinase

decreases expression

ISO

bisphenol F results in decreased expression of DMPK mRNA

NCBI chr 1:87,858,294...87,868,624
Ensembl chr 1:87,858,316...87,868,910

G

DMRT-like family A2

decreases expression

ISO

bisphenol F results in decreased expression of DMRTA2 mRNA

PMID:30951980 PMID:38685157

NCBI chr 5:130,034,473...130,040,283
Ensembl chr 5:130,034,473...130,040,222

G

cyclin D binding myb-like transcription factor 1

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DMTF1 mRNA
bisphenol F results in decreased expression of DMTF1 mRNA

PMID:28628672 PMID:38685157

NCBI chr 4:25,864,891...25,905,916
Ensembl chr 4:25,865,447...25,905,943

G

DM1 locus, WD repeat containing

decreases expression

ISO

bisphenol F results in decreased expression of DMWD mRNA

NCBI chr 1:87,850,475...87,857,263
Ensembl chr 1:87,850,604...87,857,624

G

dynein, axonemal, assembly factor 1

increases expression
decreases expression

ISO

bisphenol F results in increased expression of DNAAF1 mRNA
bisphenol F results in decreased expression of DNAAF1 mRNA

PMID:30951980 PMID:38685157

NCBI chr19:64,532,859...64,560,942
Ensembl chr19:64,532,860...64,561,435

G

dynein axonemal assembly factor 19

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DNAAF19 mRNA
bisphenol F results in increased expression of CCDC103 mRNA

PMID:28628672 PMID:30951980

NCBI chr10:88,346,453...88,349,853
Ensembl chr10:88,346,453...88,349,853

G

dynein, axonemal, assembly factor 5

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of DNAAF5 gene; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DNAAF5 mRNA

PMID:28628672 PMID:31601247

NCBI chr12:20,567,482...20,606,600
Ensembl chr12:20,531,267...20,607,607

G

dynein axonemal assembly factor 9

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DNAAF9 mRNA

NCBI chr 3:138,370,971...138,505,711
Ensembl chr 3:138,372,531...138,505,695

G

dynein, axonemal, heavy chain 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DNAH1 mRNA

NCBI chr16:6,462,419...6,523,545
Ensembl chr16:6,462,419...6,524,760

G

dynein, axonemal, heavy chain 10

increases expression

ISO

bisphenol F results in increased expression of DNAH10 mRNA

NCBI chr12:37,484,444...37,607,810
Ensembl chr12:37,472,813...37,640,860

G

dynein, axonemal, heavy chain 11

increases expression

ISO

bisphenol F results in increased expression of DNAH11 mRNA

NCBI chr 6:144,982,130...145,298,523
Ensembl chr 6:144,973,797...145,298,692

G

dynein, axonemal, heavy chain 2

increases expression

ISO

bisphenol F results in increased expression of DNAH2 mRNA

NCBI chr10:54,641,450...54,766,502
Ensembl chr10:54,641,450...54,766,026

G

dynein, axonemal, heavy chain 3

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of DNAH3 gene

NCBI chr 1:183,738,013...183,910,831
Ensembl chr 1:183,738,013...183,910,432

G

dynein, axonemal, heavy chain 5

increases expression

ISO

bisphenol F results in increased expression of DNAH5 mRNA

NCBI chr 2:80,668,182...80,985,918
Ensembl chr 2:80,668,208...80,985,914

G

dynein, axonemal, heavy chain 6

increases expression

ISO

bisphenol F results in increased expression of DNAH6 mRNA

NCBI chr 4:106,622,235...106,842,461
Ensembl chr 4:106,612,973...106,842,417

G

dynein, axonemal, heavy chain 7

increases expression

ISO

bisphenol F results in increased expression of DNAH7B mRNA

NCBI chr 9:62,454,838...62,760,504
Ensembl chr 9:62,454,838...62,756,730

G

dynein, axonemal, heavy chain 8

decreases expression
multiple interactions

ISO

bisphenol F results in decreased expression of DNAH8 mRNA
[bisphenol F co-treated with LIF protein] results in decreased expression of DNAH8 mRNA

NCBI chr20:8,694,371...8,948,849
Ensembl chr20:8,694,398...8,948,849

G

dynein, axonemal, heavy chain 9

increases expression

ISO

bisphenol F results in increased expression of DNAH9 mRNA

NCBI chr10:50,996,796...51,363,977
Ensembl chr10:50,996,796...51,363,963

G

dynein, axonemal, intermediate chain 1

increases expression

ISO

bisphenol F results in increased expression of DNAI1 mRNA

NCBI chr 5:61,526,079...61,596,806
Ensembl chr 5:61,525,999...61,596,810

G

dynein, axonemal, intermediate chain 2

increases expression

ISO

bisphenol F results in increased expression of DNAI2 mRNA

NCBI chr10:100,259,022...100,292,427
Ensembl chr10:100,258,994...100,292,426

G

dynein axonemal intermediate chain 3

increases expression

ISO

bisphenol F results in increased expression of DNAI3 mRNA

NCBI chr 2:237,608,202...237,666,465
Ensembl chr 2:237,604,068...237,666,465

G

dynein axonemal intermediate chain 4

increases expression

ISO

bisphenol F results in increased expression of DNAI4 mRNA

NCBI chr 5:123,016,480...123,105,283
Ensembl chr 5:123,016,480...123,105,283

G

DnaJ heat shock protein family (Hsp40) member A1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DNAJA1 mRNA
bisphenol F results in increased expression of DNAJA1 protein

PMID:28628672 PMID:34186270

NCBI chr 5:60,638,404...60,649,315
Ensembl chr 5:60,638,410...60,650,160

G

DnaJ heat shock protein family (Hsp40) member A4

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DNAJA4 mRNA

NCBI chr 8:63,975,177...63,998,836
Ensembl chr 8:63,981,559...63,998,836

G

DnaJ heat shock protein family (Hsp40) member B13

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of DNAJB13 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DNAJB13 mRNA

PMID:30951980 PMID:36041667

NCBI chr 1:164,260,716...164,275,172
Ensembl chr 1:164,260,724...164,275,093

G

DnaJ heat shock protein family (Hsp40) member B5

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DNAJB5 mRNA

NCBI chr 5:61,972,637...61,981,887
Ensembl chr 5:61,972,706...61,981,860

G

DnaJ heat shock protein family (Hsp40) member B6

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DNAJB6 mRNA

NCBI chr 4:6,010,081...6,232,052
Ensembl chr 4:6,128,070...6,232,005

G

DnaJ heat shock protein family (Hsp40) member B9

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DNAJB9 mRNA
bisphenol F results in increased expression of DNAJB9 mRNA

PMID:28628672 PMID:34831106 PMID:38685157

NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:66,997,842...67,009,344

G

DnaJ heat shock protein family (Hsp40) member C10

increases expression

ISO

bisphenol F results in increased expression of DNAJC10 protein

NCBI chr 3:85,636,890...85,679,620
Ensembl chr 3:85,639,589...85,689,368

G

DnaJ heat shock protein family (Hsp40) member C12

increases expression

ISO

bisphenol F results in increased expression of DNAJC12 mRNA

NCBI chr20:25,245,475...25,266,238
Ensembl chr20:25,222,298...25,266,251

G

DnaJ heat shock protein family (Hsp40) member C13

increases expression

ISO

bisphenol F results in increased expression of DNAJC13 protein

NCBI chr 8:113,646,573...113,756,104
Ensembl chr 8:113,646,573...113,756,104

G

DnaJ heat shock protein family (Hsp40) member C14

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DNAJC14 mRNA

NCBI chr 7:1,818,360...1,831,642
Ensembl chr 7:1,820,247...1,831,658

G

DnaJ heat shock protein family (Hsp40) member C16

increases expression

ISO

bisphenol F results in increased expression of DNAJC16 mRNA

NCBI chr 5:159,355,279...159,389,267
Ensembl chr 5:159,361,314...159,389,298

G

DnaJ heat shock protein family (Hsp40) member C17

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DNAJC17 mRNA
bisphenol F results in decreased expression of DNAJC17 mRNA

PMID:36041667 PMID:38685157

NCBI chr 3:126,616,043...126,649,599
Ensembl chr 3:126,616,051...126,649,656

G

DnaJ heat shock protein family (Hsp40) member C19

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DNAJC19 mRNA

NCBI chr 2:118,851,497...118,875,813
Ensembl chr 2:118,869,413...118,873,781

G

DnaJ heat shock protein family (Hsp40) member C22

increases expression

ISO

bisphenol F results in increased expression of DNAJC22 mRNA

NCBI chr 7:132,136,516...132,141,802
Ensembl chr 7:132,136,545...132,142,758

G

DnaJ heat shock protein family (Hsp40) member C25

increases expression

ISO

bisphenol F results in increased expression of DNAJC25 mRNA

NCBI chr 5:78,620,608...78,642,921
Ensembl chr 5:78,620,581...78,642,920

G

DnaJ heat shock protein family (Hsp40) member C28

increases expression

ISO

bisphenol F results in increased expression of DNAJC28 mRNA

NCBI chr11:44,341,528...44,344,348
Ensembl chr11:44,338,646...44,344,482

G

DnaJ heat shock protein family (Hsp40) member C3

increases expression

ISO

bisphenol F results in increased expression of DNAJC3 mRNA

NCBI chr15:102,432,667...102,475,643
Ensembl chr15:102,432,663...102,475,643

G

DnaJ heat shock protein family (Hsp40) member C4

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DNAJC4 mRNA
bisphenol F results in decreased expression of DNAJC4 mRNA

PMID:28628672 PMID:38685157

NCBI chr 1:213,607,397...213,611,614
Ensembl chr 1:213,607,399...213,611,729

G

DnaJ heat shock protein family (Hsp40) member C6

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DNAJC6 mRNA

NCBI chr 5:121,232,532...121,398,775
Ensembl chr 5:121,235,425...121,398,775

G

DnaJ heat shock protein family (Hsp40) member C7

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DNAJC7 mRNA

NCBI chr10:86,018,977...86,055,419
Ensembl chr10:86,018,961...86,055,489

G

dynein, axonemal, light intermediate chain 1

increases expression
decreases expression

ISO

bisphenol F results in increased expression of DNALI1 mRNA
bisphenol F results in decreased expression of DNALI1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 5:142,603,132...142,611,970
Ensembl chr 5:142,603,134...142,611,993

G

deoxyribonuclease 1

decreases expression

ISO

bisphenol F results in decreased expression of DNASE1 mRNA

NCBI chr10:12,005,305...12,030,615
Ensembl chr10:12,005,306...12,010,497

G

deoxyribonuclease 1 like 2

decreases expression

ISO

bisphenol F results in decreased expression of DNASE1L2 mRNA

NCBI chr10:13,976,012...13,978,574
Ensembl chr10:13,976,012...13,978,366

G

DND microRNA-mediated repression inhibitor 1

decreases expression

ISO

bisphenol F results in decreased expression of DND1 mRNA

NCBI chr18:28,652,712...28,655,336
Ensembl chr18:28,652,712...28,655,336

G

delta/notch-like EGF repeat containing

decreases expression

ISO

bisphenol F results in decreased expression of DNER mRNA

NCBI chr 9:93,035,108...93,350,568
Ensembl chr 9:93,035,108...93,350,568

G

dynein heavy chain domain 1

decreases expression

ISO

bisphenol F results in decreased expression of DNHD1 mRNA

NCBI chr 1:169,402,615...169,486,684
Ensembl chr 1:169,394,884...169,487,646

G

dynamin 1

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DNM1 mRNA
bisphenol F results in decreased expression of DNM1 mRNA

PMID:36041667 PMID:38685157

NCBI chr 3:36,002,535...36,055,220
Ensembl chr 3:36,002,064...36,046,289

G

dynamin 1-like

multiple interactions
increases expression
decreases phosphorylation

ISO

[4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol co-treated with Cyclosporine] inhibits the reaction [bisphenol F results in decreased phosphorylation of DNM1L protein]; Cyclosporine inhibits the reaction [bisphenol F results in decreased phosphorylation of DNM1L protein]
bisphenol F results in increased expression of DNM1L protein

PMID:34023961 PMID:34186270

NCBI chr11:98,084,049...98,135,663
Ensembl chr11:98,085,397...98,137,420

G

dynamin 2

increases methylation

ISO

bisphenol F results in increased methylation of DNM2 gene

NCBI chr 8:28,254,344...28,336,297
Ensembl chr 8:28,254,529...28,336,295

G

DNA methyltransferase 1

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of DNMT1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DNMT1 mRNA

PMID:31601247 PMID:36041667

NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:27,716,797...27,763,119

G

DNA methyltransferase 3 alpha

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DNMT3A mRNA

NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970

G

DNA methyltransferase 3 beta

decreases expression

ISO

bisphenol F results in decreased expression of DNMT3B mRNA

NCBI chr 3:162,590,777...162,629,313
Ensembl chr 3:162,604,037...162,629,313

G

aspartyl aminopeptidase

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DNPEP mRNA
bisphenol F results in increased expression of DNPEP mRNA

PMID:36041667 PMID:38685157

NCBI chr 9:84,248,581...84,257,484
Ensembl chr 9:84,233,486...84,256,977

G

deoxynucleotidyltransferase, terminal, interacting protein 2

decreases methylation

ISO

bisphenol F results in decreased methylation of DNTTIP2 gene

NCBI chr 2:213,058,975...213,071,020
Ensembl chr 2:213,058,962...213,071,016

G

double C2 domain alpha

decreases expression

ISO

bisphenol F results in decreased expression of DOC2A mRNA

NCBI chr 1:190,887,306...190,893,057
Ensembl chr 1:190,888,214...190,893,384

G

dedicator of cyto-kinesis 1

increases expression

ISO

bisphenol F results in increased expression of DOCK1 mRNA

PMID:30951980 PMID:38685157

NCBI chr 1:198,897,021...199,413,636
Ensembl chr 1:198,897,045...199,413,627

G

dedicator of cytokinesis 4

increases methylation

ISO

bisphenol F results in increased methylation of DOCK4 gene

NCBI chr 6:63,240,050...63,629,772
Ensembl chr 6:63,240,136...63,629,772

G

dedicator of cytokinesis 6

decreases expression

ISO

bisphenol F results in decreased expression of DOCK6 mRNA

NCBI chr 8:28,618,523...28,670,741
Ensembl chr 8:28,618,523...28,670,648

G

dedicator of cytokinesis 7

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DOCK7 mRNA

NCBI chr 5:118,714,863...118,898,362
Ensembl chr 5:118,714,863...118,898,335

G

dedicator of cytokinesis 8

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of DOCK8 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DOCK8 mRNA

PMID:30951980 PMID:36041667 PMID:38685157

NCBI chr 1:232,075,468...232,268,830
Ensembl chr 1:232,075,588...232,268,833

G

deoxyhypusine hydroxylase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DOHH mRNA

NCBI chr 7:8,972,202...8,977,025
Ensembl chr 7:8,972,202...8,977,025

G

docking protein 1

increases expression

ISO

bisphenol F results in increased expression of DOK1 mRNA

NCBI chr 4:117,095,171...117,098,251
Ensembl chr 4:117,095,175...117,097,825

G

docking protein 3

decreases expression

ISO

bisphenol F results in decreased expression of DOK3 mRNA

NCBI chr17:9,114,763...9,121,781
Ensembl chr17:9,114,762...9,120,335

G

docking protein 4

increases expression
decreases expression

ISO

bisphenol F results in increased expression of DOK4 mRNA
bisphenol F results in decreased expression of DOK4 mRNA

PMID:30951980 PMID:38685157

NCBI chr19:10,152,511...10,163,182
Ensembl chr19:10,152,458...10,164,190

G

dolichol kinase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DOLK mRNA

NCBI chr 3:33,955,642...33,957,680
Ensembl chr 3:33,954,308...33,958,365

G

dolichyldiphosphatase 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DOLPP1 mRNA

NCBI chr 3:34,063,825...34,072,133
Ensembl chr 3:34,063,825...34,072,132

G

DNA replication fork stabilization factor DONSON

decreases expression

ISO

bisphenol F results in decreased expression of DONSON mRNA

NCBI chr11:44,405,794...44,419,099
Ensembl chr11:44,405,804...44,418,791

G

DOT1 like histone lysine methyltransferase

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of DOT1L gene

NCBI chr 7:9,569,439...9,607,095
Ensembl chr 7:9,569,439...9,607,095

G

dipeptidase 1

increases expression

ISO

bisphenol F results in increased expression of DPEP1 mRNA

NCBI chr19:68,118,270...68,143,781
Ensembl chr19:68,118,453...68,143,775

G

diphthamide biosynthesis 1

increases expression

ISO

bisphenol F results in increased expression of DPH1 mRNA

NCBI chr10:60,526,417...60,538,102
Ensembl chr10:60,527,680...60,535,816

G

dolichyl-phosphate mannosyltransferase subunit 1, catalytic

increases expression

ISO

bisphenol F results in increased expression of DPM1 protein

NCBI chr 3:177,338,855...177,358,398
Ensembl chr 3:177,338,855...177,358,412

G

dolichyl-phosphate mannosyltransferase subunit 2, regulatory

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DPM2 mRNA
bisphenol F results in decreased expression of DPM2 mRNA

PMID:28628672 PMID:38685157

NCBI chr 3:36,253,548...36,256,592

G

dolichyl-phosphate mannosyltransferase subunit 3, regulatory

multiple interactions
decreases expression
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of DPM3 mRNA
bisphenol F results in decreased expression of DPM3 mRNA
bisphenol F results in increased expression of DPM3 protein

PMID:30951980 PMID:34186270 PMID:38685157

NCBI chr 2:176,974,290...176,974,805
Ensembl chr15:52,612,418...52,612,696

G

dipeptidyl peptidase like 10

decreases methylation

ISO

bisphenol F results in decreased methylation of DPP10 gene

NCBI chr13:37,145,531...38,821,987
Ensembl chr13:37,145,531...38,822,801

G

dipeptidylpeptidase 3

increases expression

ISO

bisphenol F results in increased expression of DPP3 protein
bisphenol F results in increased expression of DPP3 mRNA

PMID:34186270 PMID:38685157

NCBI chr 1:211,634,067...211,657,898
Ensembl chr 1:211,634,068...211,658,310

G

dipeptidylpeptidase 4

increases expression

ISO

bisphenol F results in increased expression of DPP4 protein

NCBI chr 3:67,370,794...67,452,422
Ensembl chr 3:67,370,804...67,452,422

G

dipeptidylpeptidase 7

increases expression

ISO

bisphenol F results in increased expression of DPP7 protein

NCBI chr 3:28,563,240...28,567,492
Ensembl chr 3:28,563,240...28,567,492

G

dipeptidylpeptidase 8

increases expression

ISO

bisphenol F results in increased expression of DPP8 mRNA

NCBI chr 8:74,445,815...74,501,017
Ensembl chr 8:74,445,835...74,501,017

G

dipeptidyl peptidase 9

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DPP9 mRNA

NCBI chr 9:1,098,505...1,133,500
Ensembl chr 9:1,095,929...1,177,715

G

dermatopontin

decreases expression

ISO

bisphenol F results in decreased expression of DPT mRNA

NCBI chr13:79,656,341...79,684,759
Ensembl chr13:79,655,985...79,684,758

G

dpy-19 like C-mannosyltransferase 1

increases expression

ISO

bisphenol F results in increased expression of DPY19L1 protein

NCBI chr 8:31,209,025...31,297,485
Ensembl chr 8:31,209,025...31,297,518

G

dpy-19 like C-mannosyltransferase 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DPY19L3 mRNA

NCBI chr 1:97,487,206...97,554,232
Ensembl chr 1:97,487,206...97,554,232

G

dpy-19 like 4

increases expression

ISO

bisphenol F results in increased expression of DPY19L4 mRNA

NCBI chr 5:29,148,518...29,208,132
Ensembl chr 5:29,151,129...29,208,132

G

dpy-30 histone methyltransferase complex regulatory subunit

increases expression

ISO

bisphenol F results in increased expression of DPY30 mRNA

NCBI chr 6:26,872,812...26,893,580
Ensembl chr 6:26,872,732...26,894,930

G

dihydropyrimidinase

increases expression

ISO

bisphenol F results in increased expression of DPYS mRNA

NCBI chr 7:72,707,566...72,814,183
Ensembl chr 7:72,721,048...72,814,142

G

dihydropyrimidinase-like 2

increases expression
decreases expression

ISO

bisphenol F results in increased expression of DPYSL2 protein
bisphenol F results in decreased expression of DPYSL2 mRNA

PMID:34186270 PMID:38685157

NCBI chr15:45,181,041...45,287,065
Ensembl chr15:45,181,041...45,287,065

G

dihydropyrimidinase-like 4

increases expression

ISO

bisphenol F results in increased expression of DPYSL4 protein

NCBI chr 1:203,312,646...203,328,523
Ensembl chr 1:203,311,694...203,328,523

G

DEAQ box RNA-dependent ATPase 1

decreases expression

ISO

bisphenol F results in decreased expression of DQX1 mRNA

NCBI chr 4:117,121,216...117,130,315
Ensembl chr 4:117,121,452...117,130,307

G

dorsal inhibitory axon guidance protein

decreases expression

ISO

bisphenol F results in decreased expression of DRAXIN mRNA

NCBI chr 5:163,813,308...163,846,609
Ensembl chr 5:163,816,502...163,855,174

G

dynein regulatory complex subunit 1

increases expression

ISO

bisphenol F results in increased expression of DRC1 mRNA

NCBI chr 6:31,744,849...31,779,996
Ensembl chr 6:31,744,850...31,779,256

G

dynein regulatory complex subunit 12 homolog

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of CCDC153 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of CCDC153 mRNA

PMID:30951980 PMID:36041667

NCBI chr 8:53,468,344...53,481,168
Ensembl chr 8:53,472,849...53,486,567

G

dynein regulatory complex subunit 3

increases expression

ISO

bisphenol F results in increased expression of DRC3 mRNA

NCBI chr10:45,620,045...45,698,902
Ensembl chr10:45,648,410...45,698,900

G

dynein regulatory complex subunit 7

increases expression

ISO

bisphenol F results in increased expression of DRC7 mRNA

NCBI chr19:9,949,484...9,967,296
Ensembl chr19:9,949,486...9,967,192

G

dopamine receptor D1

decreases expression

EXP

4,4'-bisphenol F results in decreased expression of DRD1 mRNA

NCBI chr17:10,545,488...10,550,029
Ensembl chr17:10,545,111...10,567,166

G

dopamine receptor D3

decreases expression

EXP

4,4'-bisphenol F results in decreased expression of DRD3 mRNA

NCBI chr11:70,385,586...70,437,793
Ensembl chr11:70,385,586...70,446,760

G

developmentally regulated GTP binding protein 1

increases expression

ISO

bisphenol F results in increased expression of DRG1 protein

NCBI chr14:82,328,320...82,344,416
Ensembl chr14:82,328,320...82,344,348

G

developmentally regulated GTP binding protein 2

multiple interactions
decreases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DRG2 mRNA
bisphenol F results in decreased expression of DRG2 mRNA

PMID:28628672 PMID:38685157

NCBI chr10:45,755,072...45,769,493
Ensembl chr10:45,755,059...45,769,523

G

dystrophin related protein 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DRP2 mRNA

NCBI chr X:101,900,743...101,951,403
Ensembl chr X:101,901,011...101,951,403

G

desmocollin 2

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of DSC2 mRNA
bisphenol F results in increased expression of DSC2 mRNA

NCBI chr18:11,725,466...11,757,591
Ensembl chr18:11,725,466...11,757,466

G

DS cell adhesion molecule-like 1

decreases expression
multiple interactions

ISO
EXP

bisphenol F results in decreased expression of DSCAML1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DSCAML1 mRNA

PMID:30951980 PMID:36041667

NCBI chr 8:54,637,054...54,954,042
Ensembl chr 8:54,636,932...54,954,040

G

dermatan sulfate epimerase

increases expression

ISO

bisphenol F results in increased expression of DSE mRNA

NCBI chr20:26,661,326...26,740,011
Ensembl chr20:26,661,326...26,740,114

G

dermatan sulfate epimerase-like

increases expression

ISO

bisphenol F results in increased expression of DSEL mRNA

NCBI chr13:194,738...200,959
Ensembl chr13:179,618...200,993

G

desmoglein 2

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of DSG2 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of DSG2 mRNA

NCBI chr18:12,121,287...12,179,590
Ensembl chr18:12,121,181...12,179,590

G

desmoglein 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DSG3 mRNA

NCBI chr18:12,074,321...12,105,954
Ensembl chr18:12,074,321...12,111,766

G

desmoplakin

decreases expression
increases expression

ISO

bisphenol F results in decreased expression of DSP mRNA
bisphenol F results in increased expression of DSP mRNA

PMID:36706583 PMID:38685157

NCBI chr17:26,829,153...26,877,419
Ensembl chr17:26,829,153...26,877,121

G

dystonin

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DST mRNA

NCBI chr 9:43,631,716...44,025,535
Ensembl chr 9:43,631,517...44,025,533

G

destrin, actin depolymerizing factor

increases expression

ISO

bisphenol F results in increased expression of DSTN mRNA

NCBI chr 3:151,737,711...151,764,752
Ensembl chr 3:151,737,849...151,764,769

G

deltex E3 ubiquitin ligase 3

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DTX3 mRNA
bisphenol F results in decreased expression of DTX3 mRNA

PMID:36041667 PMID:38685157

NCBI chr 7:64,898,693...64,904,636
Ensembl chr 7:64,898,866...64,903,752

G

dihydrouridine synthase 1-like

increases expression

ISO

bisphenol F results in increased expression of DUS1L mRNA

NCBI chr10:106,553,841...106,560,977
Ensembl chr10:106,553,238...106,561,285

G

dihydrouridine synthase 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DUS2 mRNA

NCBI chr19:50,816,306...50,864,559
Ensembl chr19:50,816,310...50,864,559

G

dihydrouridine synthase 4-like

decreases expression

ISO

bisphenol F results in decreased expression of DUS4L mRNA

NCBI chr 6:53,955,609...53,970,050
Ensembl chr 6:53,955,609...53,970,087

G

dual specificity phosphatase 1

decreases expression

EXP

4,4'-bisphenol F results in decreased expression of DUSP1 mRNA

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

dual specificity phosphatase 11

decreases expression

ISO

bisphenol F results in decreased expression of DUSP11 mRNA

NCBI chr 4:119,928,533...119,942,643
Ensembl chr 4:119,928,537...119,942,567

G

dual specificity phosphatase 16

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of DUSP16 gene
bisphenol F results in increased expression of DUSP16 mRNA

PMID:31601247 PMID:38685157

NCBI chr 4:169,278,118...169,361,508
Ensembl chr 4:169,278,118...169,361,508

G

dual specificity phosphatase 19

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of DUSP19 gene

NCBI chr 3:85,945,289...86,081,289

G

dual specificity phosphatase 2

increases expression

ISO

bisphenol F results in increased expression of DUSP2 mRNA

NCBI chr 3:135,009,636...135,011,821
Ensembl chr 3:135,009,590...135,011,809

G

dual specificity phosphatase 23

decreases expression

ISO

bisphenol F results in decreased expression of DUSP23 mRNA

NCBI chr13:87,630,245...87,632,400
Ensembl chr13:87,630,245...87,632,400

G

dual specificity phosphatase 4

affects expression
increases expression

ISO

bisphenol F affects the expression of DUSP4 mRNA
bisphenol F results in increased expression of DUSP4 mRNA

PMID:30951980 PMID:38685157

NCBI chr16:64,079,893...64,101,396
Ensembl chr16:64,079,893...64,093,700

G

dual specificity phosphatase 5

increases expression

ISO

bisphenol F results in increased expression of DUSP5 mRNA

NCBI chr 1:262,543,774...262,557,201
Ensembl chr 1:262,543,738...262,562,417

G

dual specificity phosphatase 6

increases expression

ISO

bisphenol F results in increased expression of DUSP6 mRNA

NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833

G

dual specificity phosphatase 7

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DUSP7 mRNA

NCBI chr 8:115,888,091...115,895,126
Ensembl chr 8:115,887,892...115,895,126

G

double homeobox 4

multiple interactions
decreases expression

ISO

[bisphenol F co-treated with LIF protein] results in increased expression of DUXBL1 mRNA; [bisphenol F co-treated with Tretinoin] results in increased expression of DUXBL1 mRNA
bisphenol F results in decreased expression of DUXBL1 mRNA

NCBI chr16:1,565,290...1,575,317
Ensembl chr16:1,567,553...1,575,468

G

dishevelled segment polarity protein 1

decreases expression

ISO

bisphenol F results in decreased expression of DVL1 mRNA

NCBI chr 5:171,738,911...171,750,967
Ensembl chr 5:171,739,133...171,750,966

G

dishevelled segment polarity protein 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DVL2 mRNA
bisphenol F results in increased expression of DVL2 protein

PMID:28628672 PMID:34186270

NCBI chr10:55,222,245...55,231,506
Ensembl chr10:55,222,056...55,231,506

G

decapping exoribonuclease

decreases expression

ISO

bisphenol F results in decreased expression of DXO mRNA

NCBI chr20:3,997,953...4,000,115
Ensembl chr20:3,997,955...4,000,037

G

dynactin associated protein

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of DYNAP gene

NCBI chr18:66,160,548...66,227,999
Ensembl chr18:66,160,548...66,184,843

G

dynein cytoplasmic 1 heavy chain 1

multiple interactions
increases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of DYNC1H1 mRNA
bisphenol F results in increased expression of DYNC1H1 protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DYNC1H1 mRNA

PMID:28628672 PMID:34186270 PMID:36041667

NCBI chr 6:135,436,375...135,502,117
Ensembl chr 6:135,430,750...135,502,116

G

dynein cytoplasmic 1 intermediate chain 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DYNC1I2 mRNA
bisphenol F results in increased expression of DYNC1I2 protein

PMID:28628672 PMID:34186270

NCBI chr 3:76,441,621...76,492,782
Ensembl chr 3:76,424,469...76,492,782

G

dynein cytoplasmic 1 light intermediate chain 1

increases expression

ISO

bisphenol F results in increased expression of DYNC1LI1 mRNA

NCBI chr 8:123,254,823...123,288,496
Ensembl chr 8:123,254,859...123,289,167

G

dynein, cytoplasmic 1 light intermediate chain 2

increases expression

ISO

bisphenol F results in increased expression of DYNC1LI2 mRNA

NCBI chr19:538,207...561,110
Ensembl chr19:538,211...561,107

G

dynein 2 intermediate chain 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DYNC2I2 mRNA

NCBI chr 3:33,703,882...33,719,960
Ensembl chr 3:33,703,882...33,719,960

G

dynein light chain LC8-type 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DYNLL1 mRNA

NCBI chr12:46,945,291...46,976,867
Ensembl chr12:46,973,050...46,976,861

G

dynein light chain LC8-type 2

increases expression

ISO

bisphenol F results in increased expression of DYNLL2 mRNA

NCBI chr10:73,264,260...73,283,042
Ensembl chr10:73,264,261...73,272,285

G

dynein light chain roadblock-type 1

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of DYNLRB1 mRNA
bisphenol F results in decreased expression of DYNLRB1 mRNA

PMID:36041667 PMID:38685157

NCBI chr 3:164,197,892...164,224,409
Ensembl chr 3:164,202,953...164,224,409

G

dynein light chain roadblock-type 2

increases expression

ISO

bisphenol F results in increased expression of DYNLRB2 mRNA

NCBI chr19:61,428,782...61,440,331
Ensembl chr19:61,429,065...61,441,071

G

dynein light chain Tctex-type 4

increases expression
decreases expression

ISO

bisphenol F results in increased expression of DYNLT4 mRNA
bisphenol F results in decreased expression of DYNLT4 mRNA

PMID:30951980 PMID:38685157

NCBI chr 5:135,842,044...135,843,807
Ensembl chr 5:135,830,930...135,844,474

G

dual specificity tyrosine phosphorylation regulated kinase 1B

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of DYRK1B mRNA

NCBI chr 1:92,606,743...92,624,089
Ensembl chr 1:92,607,303...92,614,744

G

dual specificity tyrosine phosphorylation regulated kinase 2

increases expression

ISO

bisphenol F results in increased expression of DYRK2 mRNA

NCBI chr 7:56,235,276...56,265,741
Ensembl chr 7:56,235,276...56,265,942

G

dysferlin

increases expression

ISO

bisphenol F results in increased expression of DYSF mRNA

NCBI chr 4:118,048,460...118,248,273
Ensembl chr 4:118,047,989...118,248,273

G

DAZ interacting zinc finger protein 1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of DZIP1 gene

NCBI chr15:102,363,392...102,417,085
Ensembl chr15:102,363,392...102,417,085

G

DAZ interacting zinc finger protein 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DZIP3 mRNA

NCBI chr11:65,286,190...65,356,314
Ensembl chr11:65,286,190...65,356,314

G

E2F transcription factor 6

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of E2F6 mRNA
bisphenol F results in increased expression of E2F6 mRNA

PMID:36041667 PMID:38685157

NCBI chr 6:45,320,993...45,337,437
Ensembl chr 6:45,320,996...45,337,428

G

E2F transcription factor 7

increases expression

ISO

bisphenol F results in increased expression of E2F7 mRNA

NCBI chr 7:48,036,881...48,079,055
Ensembl chr 7:48,037,749...48,079,055

G

E2F transcription factor 8

decreases expression

ISO

bisphenol F results in decreased expression of E2F8 mRNA

NCBI chr 1:107,701,985...107,720,538
Ensembl chr 1:107,701,985...107,720,009

G

E4F transcription factor 1

decreases expression

ISO

bisphenol F results in decreased expression of E4F1 mRNA

NCBI chr10:13,978,975...13,999,646
Ensembl chr10:13,978,990...13,990,506

G

ELL associated factor 1

increases expression

ISO

bisphenol F results in increased expression of EAF1 mRNA

NCBI chr16:6,704,727...6,719,476
Ensembl chr16:6,704,727...6,719,476

G

E2F-associated phosphoprotein

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EAPP mRNA

NCBI chr 6:77,879,634...77,929,653
Ensembl chr 6:77,907,485...77,928,930

G

EBF transcription factor 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EBF3 mRNA

NCBI chr 1:201,426,446...201,544,444
Ensembl chr 1:201,426,450...201,544,305

G

EBP, cholestenol delta-isomerase

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of EBP protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EBP mRNA

PMID:34186270 PMID:36041667

NCBI chr X:16,971,372...16,977,782
Ensembl chr X:16,971,405...16,977,781

G

enoyl-CoA hydratase 1

increases expression

ISO

bisphenol F results in increased expression of ECH1 protein

NCBI chr 1:93,241,076...93,248,314
Ensembl chr 1:93,241,734...93,248,440

G

ethylmalonyl-CoA decarboxylase 1

increases expression

ISO

bisphenol F results in increased expression of ECHDC1 protein

NCBI chr 1:30,304,968...30,355,957
Ensembl chr 1:30,304,971...30,337,208

G

enoyl CoA hydratase domain containing 2

decreases expression

ISO

bisphenol F results in decreased expression of ECHDC2 mRNA

NCBI chr 5:128,144,241...128,163,611
Ensembl chr 5:128,144,425...128,163,610

G

enoyl-CoA hydratase, short chain 1

increases expression

ISO

bisphenol F results in increased expression of ECHS1 protein
bisphenol F results in increased expression of ECHS1 mRNA

PMID:34186270 PMID:38685157

NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:204,324,682...204,333,506

G

enoyl-CoA delta isomerase 1

increases expression

ISO

bisphenol F results in increased expression of ECI1 protein

NCBI chr10:13,961,250...13,974,595
Ensembl chr10:13,961,218...13,974,773

G

enoyl-Coenzyme A delta isomerase 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ECI3 mRNA

NCBI chr17:30,127,425...30,149,249
Ensembl chr17:30,128,588...30,149,137

G

extracellular matrix protein 1

increases expression
multiple interactions

ISO

bisphenol F results in increased expression of ECM1 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of ECM1 mRNA

NCBI chr 2:185,976,439...185,981,656
Ensembl chr 2:185,976,440...185,981,606

G

extracellular matrix protein 2

increases expression

ISO

bisphenol F results in increased expression of ECM2 mRNA

NCBI chr17:15,326,359...15,358,938
Ensembl chr17:15,326,359...15,358,855

G

ECRG4 augurin precursor

increases expression

ISO

bisphenol F results in increased expression of ECRG4 mRNA

NCBI chr 9:53,485,040...53,504,691
Ensembl chr 9:53,485,040...53,504,703

G

endothelial cell surface expressed chemotaxis and apoptosis regulator

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of ECSCR mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ECSCR mRNA

PMID:30951980 PMID:36041667

NCBI chr18:27,583,791...27,593,184
Ensembl chr18:27,583,195...27,593,195

G

epithelial cell transforming 2 like

increases expression

ISO

bisphenol F results in increased expression of ECT2L mRNA

NCBI chr 1:14,594,726...14,677,321
Ensembl chr 1:14,596,588...14,675,219

G

ectodysplasin A2 receptor

decreases expression

ISO

bisphenol F results in decreased expression of EDA2R mRNA

NCBI chr X:66,225,557...66,280,674
Ensembl chr X:66,236,111...66,280,663

G

EDAR associated via death domain

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EDARADD mRNA

NCBI chr17:92,850,791...92,894,808
Ensembl chr17:92,831,613...92,894,361

G

enhancer of mRNA decapping 3

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EDC3 mRNA

NCBI chr 8:67,002,032...67,047,563
Ensembl chr 8:67,002,014...67,047,559

G

enhancer of mRNA decapping 4

decreases expression

ISO

bisphenol F results in decreased expression of EDC4 mRNA

NCBI chr19:50,683,924...50,695,916
Ensembl chr19:50,683,897...50,697,620

G

ER degradation enhancing alpha-mannosidase like protein 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EDEM1 mRNA
bisphenol F results in increased expression of EDEM1 mRNA

PMID:28628672 PMID:38685157

NCBI chr 4:143,350,989...143,385,693
Ensembl chr 4:143,353,624...143,388,060

G

ER degradation enhancing alpha-mannosidase like protein 2

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EDEM2 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EDEM2 mRNA

PMID:28628672 PMID:36041667

NCBI chr 3:164,661,741...164,687,559
Ensembl chr 3:164,661,742...164,687,559

G

endothelial differentiation-related factor 1

decreases expression

ISO

bisphenol F results in decreased expression of EDF1 mRNA

NCBI chr 3:28,764,906...28,779,499

G

endothelin 1

affects expression

ISO

bisphenol F affects the expression of EDN1 mRNA

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

endothelin 3

increases expression

ISO

bisphenol F results in increased expression of EDN3 mRNA

NCBI chr 3:183,980,458...184,004,958
Ensembl chr 3:183,980,668...184,005,329

G

endothelin receptor type A

increases expression

ISO

bisphenol F results in increased expression of EDNRA mRNA

NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284

G

endothelin receptor type B

decreases expression

ISO

bisphenol F results in decreased expression of EDNRB mRNA

NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765

G

early endosome antigen 1

increases expression

ISO

bisphenol F results in increased expression of EEA1 mRNA

NCBI chr 7:32,441,281...32,608,808
Ensembl chr 7:32,441,272...32,608,476

G

eukaryotic translation elongation factor 1 alpha 1

multiple interactions
increases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EEF1A1 mRNA
bisphenol F results in increased expression of EEF1A1 mRNA
bisphenol F results in increased expression of EEF1A1 protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of EEF1A1 mRNA

PMID:28628672 PMID:34186270 PMID:36041667 PMID:38685157

NCBI chr 8:88,221,839...88,225,688
Ensembl chr 8:88,221,843...88,225,072

G

EEF1A lysine methyltransferase 1

increases expression

ISO

bisphenol F results in increased expression of EEF1AKMT1 mRNA

NCBI chr15:35,809,842...35,826,921
Ensembl chr15:35,809,842...35,827,129

G

eukaryotic translation elongation factor 1 beta 2

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EEF1B2 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EEF1B2 mRNA

PMID:28628672 PMID:36041667

NCBI chr 9:72,074,091...72,076,591
Ensembl chr 9:72,073,802...72,076,589

G

eukaryotic translation elongation factor 1 delta

increases expression

ISO

bisphenol F results in increased expression of EEF1D protein

NCBI chr 7:109,462,645...109,478,021
Ensembl chr 7:109,462,646...109,489,531

G

eukaryotic translation elongation factor 2

multiple interactions
increases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EEF2 mRNA
bisphenol F results in increased expression of EEF2 mRNA
bisphenol F results in increased expression of EEF2 protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of EEF2 mRNA

PMID:28628672 PMID:34186270 PMID:36041667 PMID:38685157

NCBI chr 7:9,183,836...9,196,255
Ensembl chr 7:9,183,961...9,189,544

G

eukaryotic elongation factor-2 kinase

increases expression

ISO

bisphenol F results in increased expression of EEF2K mRNA

NCBI chr 1:184,824,420...184,888,048
Ensembl chr 1:184,824,420...184,888,048

G

endonuclease/exonuclease/phosphatase family domain containing 1

increases expression

ISO

bisphenol F results in increased expression of EEPD1 mRNA

NCBI chr 8:32,233,834...32,340,148
Ensembl chr 8:32,233,070...32,340,147

G

EF-hand calcium binding domain 14

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of EFCAB14 mRNA
bisphenol F results in increased expression of EFCAB14 mRNA

PMID:36041667 PMID:38685157

NCBI chr 5:134,454,908...134,493,714
Ensembl chr 5:134,454,924...134,495,384

G

EF-hand and coiled-coil domain containing 1

decreases expression

ISO

bisphenol F results in decreased expression of EFCC1 mRNA

NCBI chr 4:121,745,547...121,778,475
Ensembl chr 4:121,745,633...121,775,220

G

EGF containing fibulin extracellular matrix protein 1

increases expression

ISO

bisphenol F results in increased expression of EFEMP1 mRNA

NCBI chr14:106,811,769...106,890,961
Ensembl chr14:106,802,304...106,892,808

G

EF-hand domain containing 1

increases expression

ISO

bisphenol F results in increased expression of EFHC1 mRNA

NCBI chr 9:30,872,238...30,910,703
Ensembl chr 9:30,871,565...30,910,703

G

ephrin A1

increases expression

ISO

bisphenol F results in increased expression of EFNA1 mRNA

NCBI chr 2:176,979,434...176,988,675
Ensembl chr 2:176,979,434...176,988,726

G

ephrin A2

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of EFNA2 gene

NCBI chr 7:10,167,091...10,177,719
Ensembl chr 7:10,167,091...10,177,719

G

ephrin B1

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EFNB1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EFNB1 mRNA

PMID:28628672 PMID:36041667

NCBI chr X:68,297,529...68,310,335
Ensembl chr X:68,297,492...68,349,546

G

ephrin B2

increases expression

ISO

bisphenol F results in increased expression of EFNB2 mRNA

NCBI chr16:87,485,215...87,529,224
Ensembl chr16:87,485,198...87,529,208

G

EFR3 homolog A

increases expression

ISO

bisphenol F results in increased expression of EFR3A mRNA

NCBI chr 7:99,441,764...99,522,454
Ensembl chr 7:99,441,767...99,522,454

G

embryonal Fyn-associated substrate

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EFS mRNA

NCBI chr15:32,362,401...32,374,490
Ensembl chr15:32,361,843...32,371,743

G

epidermal growth factor

decreases methylation

ISO

bisphenol F results in decreased methylation of EGF gene

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

EGF-like-domain, multiple 6

multiple interactions

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of EGFL6 mRNA

NCBI chr X:31,515,752...31,573,699
Ensembl chr X:31,515,767...31,574,632

G

EGF-like-domain, multiple 7

decreases expression

ISO

bisphenol F results in decreased expression of EGFL7 mRNA

NCBI chr 3:29,802,481...29,814,966
Ensembl chr 3:29,802,690...29,814,951

G

EGF-like-domain, multiple 8

decreases expression

ISO

bisphenol F results in decreased expression of EGFL8 mRNA

NCBI chr20:4,137,531...4,140,632
Ensembl chr20:4,138,053...4,141,681

G

EGF-like, fibronectin type III and laminin G domains

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EGFLAM mRNA
bisphenol F results in increased expression of EGFLAM mRNA

PMID:28628672 PMID:30951980

NCBI chr 2:58,029,934...58,204,010
Ensembl chr 2:58,029,935...58,203,643

G

epidermal growth factor receptor

increases expression
decreases methylation
multiple interactions

ISO

bisphenol F results in increased expression of EGFR mRNA
bisphenol F results in decreased methylation of EGFR gene
[bisphenol F co-treated with Tretinoin] results in decreased expression of EGFR mRNA

PMID:30951980 PMID:38338858

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

egl-9 family hypoxia-inducible factor 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of EGLN2 mRNA

NCBI chr 1:91,579,205...91,586,985
Ensembl chr 1:91,579,206...91,587,385

G

egl-9 family hypoxia-inducible factor 3

increases expression

ISO

bisphenol F results in increased expression of EGLN3 mRNA

NCBI chr 6:77,385,549...77,411,015
Ensembl chr 6:77,385,549...77,411,015

G

early growth response 1

multiple interactions
decreases expression
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of EGR1 mRNA
bisphenol F results in decreased expression of EGR1 mRNA
bisphenol F results in increased expression of EGR1 mRNA

PMID:30951980 PMID:33476716 PMID:34774955

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

early growth response 2

increases expression

ISO

bisphenol F results in increased expression of EGR2 mRNA

NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,050,149...21,057,748

G

early growth response 3

increases expression

ISO

bisphenol F results in increased expression of EGR3 mRNA

NCBI chr15:51,560,482...51,565,778
Ensembl chr15:51,560,344...51,565,712

G

early growth response 4

increases expression

ISO

bisphenol F results in increased expression of EGR4 mRNA

NCBI chr 4:119,605,358...119,607,817
Ensembl chr 4:119,605,357...119,608,368

G

EH domain binding protein 1

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in increased methylation of EHBP1 gene

NCBI chr14:100,294,585...100,581,764
Ensembl chr14:100,294,585...100,546,579

G

EH domain binding protein 1-like 1

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of EHBP1L1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of EHBP1L1 mRNA

PMID:30951980 PMID:36041667

NCBI chr 1:212,423,444...212,444,357
Ensembl chr 1:212,423,447...212,443,598

G

EH-domain containing 2

increases expression

ISO

bisphenol F results in increased expression of EHD2 mRNA
bisphenol F results in increased expression of EHD2 protein

PMID:30951980 PMID:34186270

NCBI chr 1:85,767,757...85,786,974
Ensembl chr 1:85,768,667...85,786,943

G

EH-domain containing 3

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of EHD3 mRNA

NCBI chr 6:27,392,709...27,417,445
Ensembl chr 6:27,392,709...27,417,445

G

EH-domain containing 4

increases expression

ISO

bisphenol F results in increased expression of EHD4 mRNA

NCBI chr 3:127,511,973...127,575,856
Ensembl chr 3:127,511,954...127,576,072

G

ets homologous factor

increases expression
decreases expression

ISO

bisphenol F results in increased expression of EHF mRNA
bisphenol F results in decreased expression of EHF mRNA

PMID:30951980 PMID:38685157

NCBI chr 3:110,094,770...110,134,991
Ensembl chr 3:110,096,756...110,134,928

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EHHADH mRNA
bisphenol F results in increased expression of EHHADH mRNA

PMID:36041667 PMID:38685157

NCBI chr11:92,746,409...92,779,647
Ensembl chr11:92,746,420...92,779,662

G

euchromatic histone lysine methyltransferase 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EHMT2 mRNA

NCBI chr20:3,924,263...3,941,238
Ensembl chr20:3,924,263...3,941,384

G

EP300 interacting inhibitor of differentiation 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EID2 mRNA

NCBI chr 1:92,665,837...92,667,162
Ensembl chr 1:92,665,481...92,675,307

G

eukaryotic translation initiation factor 1A domain containing

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EIF1AD mRNA

NCBI chr 1:212,103,715...212,109,015
Ensembl chr 1:212,103,892...212,109,017

G

eukaryotic translation initiation factor 1A, X-linked

increases expression

ISO

bisphenol F results in increased expression of EIF1AX protein

NCBI chr X:39,307,320...39,322,023
Ensembl chr X:39,307,137...39,322,021

G

eukaryotic translation initiation factor 2A

increases expression

ISO

bisphenol F results in increased expression of EIF2A protein

NCBI chr 2:144,911,247...144,944,705
Ensembl chr 2:144,911,153...144,945,201

G

eukaryotic translation initiation factor 2-alpha kinase 2

increases expression

ISO

bisphenol F results in increased expression of EIF2AK2 mRNA

NCBI chr 6:21,941,147...21,977,115
Ensembl chr 6:21,952,631...21,977,116

G

eukaryotic translation initiation factor 2 alpha kinase 3

increases expression

ISO

bisphenol F results in increased expression of EIF2AK3 mRNA

PMID:38134982 PMID:38685157

NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268

G

eukaryotic translation initiation factor 2B subunit beta

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of EIF2B2 protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EIF2B2 mRNA

PMID:34186270 PMID:36041667

NCBI chr 6:110,597,979...110,604,403
Ensembl chr 6:110,597,729...110,604,403

G

eukaryotic translation initiation factor 2B subunit delta

increases expression

ISO

bisphenol F results in increased expression of EIF2B4 protein

NCBI chr 6:30,903,148...30,908,803
Ensembl chr 6:30,903,219...30,908,800

G

eukaryotic translation initiation factor 2B subunit epsilon

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EIF2B5 mRNA

NCBI chr11:93,898,814...93,909,431
Ensembl chr11:93,898,814...93,908,800

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation
increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased phosphorylation of EIF2S1 protein
bisphenol F results in increased expression of EIF2S1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EIF2S1 mRNA
bisphenol F results in increased expression of EIF2S1 protein

PMID:33431410 PMID:34186270 PMID:36041667 PMID:38685157

NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649

G

eukaryotic translation initiation factor 2 subunit beta

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EIF2S2 mRNA
bisphenol F results in increased expression of EIF2S2 protein

PMID:34186270 PMID:36041667

NCBI chr 3:163,834,846...163,855,733
Ensembl chr 3:163,834,851...163,855,570

G

eukaryotic translation initiation factor 2 subunit gamma

increases expression

ISO

bisphenol F results in increased expression of EIF2S3X mRNA

NCBI chr X:62,910,292...62,933,936
Ensembl chr X:62,910,293...62,934,489

G

eukaryotic translation initiation factor 3, subunit A

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EIF3A mRNA

NCBI chr 1:269,888,730...269,925,785
Ensembl chr 1:269,888,615...269,919,025

G

eukaryotic translation initiation factor 3, subunit B

increases expression

ISO

bisphenol F results in increased expression of EIF3B protein

NCBI chr12:19,310,308...19,334,768
Ensembl chr12:19,310,311...19,334,939

G

eukaryotic translation initiation factor 3 subunit E

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of EIF3E mRNA
bisphenol F results in increased expression of EIF3E protein

PMID:34186270 PMID:36041667

NCBI chr 7:76,224,567...76,257,346
Ensembl chr 7:76,224,568...76,257,785

G

eukaryotic translation initiation factor 3, subunit H

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EIF3H mRNA
bisphenol F results in increased expression of EIF3H protein

PMID:34186270 PMID:36041667

NCBI chr 7:84,980,891...85,064,284
Ensembl chr 7:84,980,891...85,071,546

G

eukaryotic translation initiation factor 3, subunit J

multiple interactions

ISO
EXP

[bisphenol F co-treated with Tretinoin] results in increased expression of EIF3J1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EIF3J mRNA

PMID:30951980 PMID:36041667

NCBI chr 3:129,438,715...129,460,953
Ensembl chr 3:129,438,722...129,462,246

G

eukaryotic translation initiation factor 3, subunit K

increases expression
decreases expression

ISO

bisphenol F results in increased expression of EIF3K protein
bisphenol F results in decreased expression of EIF3K mRNA

PMID:34186270 PMID:38685157

NCBI chr 1:93,387,628...93,397,551
Ensembl chr 1:93,387,628...93,397,802

G

eukaryotic translation initiation factor 3, subunit L

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EIF3L mRNA
bisphenol F results in increased expression of EIF3L mRNA

PMID:28628672 PMID:38685157

NCBI chr 7:112,522,222...112,544,063
Ensembl chr 7:112,507,831...112,544,062

G

eukaryotic translation initiation factor 4A1

increases expression
multiple interactions

ISO
EXP

bisphenol F results in increased expression of EIF4A1 protein
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EIF4A1 mRNA

PMID:34186270 PMID:36041667

NCBI chr10:54,883,093...54,888,602
Ensembl chr10:54,883,093...54,888,602

G

eukaryotic translation initiation factor 4A2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EIF4A2 mRNA

NCBI chr11:91,268,730...91,276,738
Ensembl chr11:91,268,731...91,275,323

G

eukaryotic translation initiation factor 4A3

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of EIF4A3 mRNA
bisphenol F results in increased expression of EIF4A3 protein

PMID:34186270 PMID:36041667

NCBI chr10:105,047,567...105,057,561
Ensembl chr10:105,047,568...105,058,207

G

eukaryotic translation initiation factor 4E

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EIF4E mRNA

NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:229,739,897...229,774,105

G

eukaryotic translation initiation factor 4E binding protein 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EIF4EBP2 mRNA
bisphenol F results in increased expression of EIF4EBP2 mRNA

PMID:28628672 PMID:38685157

NCBI chr20:29,922,260...29,942,922
Ensembl chr20:29,922,260...29,942,922

G

eukaryotic translation initiation factor 4E nuclear import factor 1

multiple interactions

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EIF4ENIF1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of EIF4ENIF1 mRNA

PMID:28628672 PMID:36041667

NCBI chr14:82,280,566...82,328,559
Ensembl chr14:82,280,748...82,323,242

G

eukaryotic translation initiation factor 4 gamma 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EIF4G1 mRNA
bisphenol F results in increased expression of EIF4G1 mRNA
bisphenol F results in increased expression of EIF4G1 protein

PMID:28628672 PMID:34186270 PMID:38685157

NCBI chr11:93,726,322...93,746,387
Ensembl chr11:93,726,322...93,746,367

G

eukaryotic translation initiation factor 4, gamma 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EIF4G2 mRNA
bisphenol F results in increased expression of EIF4G2 mRNA
bisphenol F results in increased expression of EIF4G2 protein

PMID:28628672 PMID:34186270 PMID:38685157

NCBI chr 1:174,616,102...174,628,252
Ensembl chr 1:174,616,103...174,628,252

G

eukaryotic translation initiation factor 4H

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EIF4H mRNA
bisphenol F results in increased expression of EIF4H protein

PMID:28628672 PMID:34186270

NCBI chr12:27,719,527...27,736,350
Ensembl chr12:27,719,321...27,736,346

G

eukaryotic translation initiation factor 5

increases expression

ISO

bisphenol F results in increased expression of EIF5 protein

NCBI chr 6:136,410,333...136,418,827
Ensembl chr 6:136,407,440...136,418,821

G

eukaryotic translation initiation factor 6

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EIF6 mRNA
bisphenol F results in increased expression of EIF6 mRNA
bisphenol F results in increased expression of EIF6 protein

PMID:28628672 PMID:34186270 PMID:38685157

NCBI chr 3:164,785,162...164,791,410
Ensembl chr 3:164,785,163...164,791,525

G

elaC ribonuclease Z 1

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ELAC1 mRNA

NCBI chr18:69,596,475...69,617,206
Ensembl chr18:69,598,827...69,616,175

G

endosome-lysosome associated apoptosis and autophagy regulator family member 2

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ELAPOR2 mRNA

NCBI chr 4:25,565,298...25,760,684
Ensembl chr 4:25,568,122...25,760,684

G

ELAV like RNA binding protein 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ELAVL1 mRNA

NCBI chr12:7,441,699...7,482,625
Ensembl chr12:7,441,699...7,482,631

G

E74 like ETS transcription factor 1

increases expression

ISO

bisphenol F results in increased expression of ELF1 mRNA

NCBI chr15:61,354,026...61,395,762
Ensembl chr15:61,330,877...61,395,758

G

extracellular leucine-rich repeat and fibronectin type III domain containing 2

decreases expression

ISO

bisphenol F results in decreased expression of ELFN2 mRNA

NCBI chr 7:112,101,998...112,153,280
Ensembl chr 7:112,074,331...112,153,451

G

ETS transcription factor ELK3

increases expression

ISO

bisphenol F results in increased expression of ELK3 mRNA

NCBI chr 7:29,655,676...29,718,163
Ensembl chr 7:29,655,693...29,691,661

G

ETS transcription factor ELK4

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ELK4 mRNA
bisphenol F results in increased expression of ELK4 mRNA

PMID:36041667 PMID:38685157

NCBI chr13:46,004,145...46,027,206
Ensembl chr13:46,004,182...46,027,199

G

elongation factor for RNA polymerase II

decreases expression

ISO

bisphenol F results in decreased expression of ELL mRNA

NCBI chr16:18,877,751...18,925,449
Ensembl chr16:18,877,751...18,925,076

G

elongation factor for RNA polymerase II 3

decreases expression

ISO

bisphenol F results in decreased expression of ELL3 mRNA

NCBI chr 3:128,866,755...128,870,896
Ensembl chr 3:128,864,777...128,870,852

G

engulfment and cell motility 1

increases expression
affects expression
multiple interactions
decreases methylation

ISO

bisphenol F results in increased expression of ELMO1 mRNA
bisphenol F affects the expression of ELMO1 mRNA
[bisphenol F co-treated with Fulvestrant] results in decreased methylation of ELMO1 gene
bisphenol F results in decreased methylation of ELMO1 gene

PMID:30951980 PMID:31601247 PMID:38685157

NCBI chr17:48,982,188...49,518,525
Ensembl chr17:48,982,188...49,518,159

G

engulfment and cell motility 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ELMO2 mRNA
bisphenol F results in increased expression of ELMO2 protein

PMID:28628672 PMID:34186270

NCBI chr 3:174,442,965...174,716,723
Ensembl chr 3:174,442,965...174,480,459

G

ELMO domain containing 2

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of ELMOD2 mRNA
bisphenol F results in increased expression of ELMOD2 protein

PMID:34186270 PMID:36041667

NCBI chr19:41,690,713...41,710,194
Ensembl chr19:41,690,762...41,710,194
Ensembl chr18:41,690,762...41,710,194

G

elastin

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ELN mRNA
bisphenol F results in decreased expression of ELN mRNA

PMID:30951980 PMID:38685157

NCBI chr12:27,604,983...27,648,413
Ensembl chr12:27,604,680...27,648,413

G

elongin B

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ELOB mRNA
bisphenol F results in decreased expression of ELOB mRNA

PMID:36041667 PMID:38685157

NCBI chr10:13,353,413...13,358,484
Ensembl chr10:13,353,417...13,358,563

G

ELOVL fatty acid elongase 3

increases expression

ISO

bisphenol F results in increased expression of ELOVL3 mRNA

NCBI chr 1:254,938,731...254,942,559
Ensembl chr 1:254,938,731...254,942,559

G

ELOVL fatty acid elongase 5

increases expression

ISO

bisphenol F results in increased expression of ELOVL5 protein

NCBI chr 8:87,671,164...87,737,618
Ensembl chr 8:87,671,159...87,737,616

G

ELOVL fatty acid elongase 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ELOVL6 mRNA

NCBI chr 2:220,738,095...220,845,528
Ensembl chr 2:220,738,064...220,845,549

G

elongator acetyltransferase complex subunit 2

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ELP2 mRNA

NCBI chr18:16,160,686...16,196,307
Ensembl chr18:16,160,671...16,196,414

G

elongator acetyltransferase complex subunit 6

decreases expression

ISO

bisphenol F results in decreased expression of ELP6 mRNA

NCBI chr 8:119,158,380...119,173,483
Ensembl chr 8:119,158,396...119,174,244

G

embigin

increases expression

ISO

bisphenol F results in increased expression of EMB mRNA

NCBI chr 2:50,803,468...50,858,001
Ensembl chr 2:50,801,973...50,862,920

G

ER membrane protein complex subunit 1

increases expression

ISO

bisphenol F results in increased expression of EMC1 protein

NCBI chr 5:156,891,773...156,917,092
Ensembl chr 5:156,891,773...156,917,092

G

ER membrane protein complex subunit 10

increases expression

ISO

bisphenol F results in increased expression of EMC10 mRNA

NCBI chr 1:104,119,040...104,125,409
Ensembl chr 1:104,119,040...104,125,368

G

ER membrane protein complex subunit 7

increases expression

ISO

bisphenol F results in increased expression of EMC7 protein

NCBI chr 3:119,714,617...119,728,748
Ensembl chr 3:119,718,357...119,730,486

G

endomucin

increases expression

ISO

bisphenol F results in increased expression of EMCN mRNA

NCBI chr 2:228,564,445...228,644,370
Ensembl chr 2:228,564,430...228,645,155

G

emerin

increases expression

ISO

bisphenol F results in increased expression of EMD mRNA

NCBI chr X:157,190,438...157,193,479
Ensembl chr X:157,189,819...157,197,095

G

essential meiotic structure-specific endonuclease 1

decreases expression

ISO

bisphenol F results in decreased expression of EME1 mRNA

NCBI chr10:80,083,585...80,092,450
Ensembl chr10:80,083,585...80,092,301

G

EMG1 N1-specific pseudouridine methyltransferase

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EMG1 mRNA

NCBI chr 4:159,195,545...159,203,826
Ensembl chr 4:159,195,564...159,203,826

G

elastin microfibril interfacer 1

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of EMILIN1 mRNA
bisphenol F results in increased expression of EMILIN1 protein
bisphenol F results in increased expression of EMILIN1 mRNA

PMID:30951980 PMID:34186270

NCBI chr 6:31,175,919...31,183,657
Ensembl chr 6:31,175,919...31,183,657

G

elastin microfibril interfacer 3

affects expression

ISO

bisphenol F affects the expression of EMILIN3 mRNA

NCBI chr 3:169,978,488...169,984,718
Ensembl chr 3:169,978,672...169,984,488

G

EMAP like 2

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in decreased expression of EML2 mRNA
bisphenol F results in increased expression of EML2 protein

PMID:34186270 PMID:36041667

NCBI chr 1:87,955,924...87,987,366
Ensembl chr 1:87,955,606...87,987,366

G

EMAP like 4

increases expression

ISO

bisphenol F results in increased expression of EML4 protein

NCBI chr 6:16,972,054...17,087,365
Ensembl chr 6:16,972,075...17,087,439

G

EMAP like 5

decreases expression

ISO

bisphenol F results in decreased expression of EML5 mRNA

NCBI chr 6:123,775,269...123,905,585
Ensembl chr 6:123,776,368...123,905,538

G

EMAP like 6

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] results in decreased methylation of EML6 gene

NCBI chr14:107,651,893...108,006,792
Ensembl chr14:107,699,400...108,005,409

G

epithelial membrane protein 1

multiple interactions
increases expression

ISO

[bisphenol F co-treated with Tretinoin] results in decreased expression of EMP1 mRNA
bisphenol F results in increased expression of EMP1 mRNA

NCBI chr 4:169,931,537...169,964,366
Ensembl chr 4:169,931,440...169,964,365

G

epithelial membrane protein 2

increases expression

ISO

bisphenol F results in increased expression of EMP2 mRNA

NCBI chr10:5,866,869...5,901,533
Ensembl chr10:5,866,922...5,901,532

G

epithelial membrane protein 3

increases expression

ISO

bisphenol F results in increased expression of EMP3 mRNA

NCBI chr 1:105,525,086...105,528,370
Ensembl chr 1:105,525,088...105,528,265

G

EMSY transcriptional repressor, BRCA2 interacting

multiple interactions
decreases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of EMSY mRNA
bisphenol F results in decreased expression of EMSY mRNA

PMID:36041667 PMID:38685157

NCBI chr 1:162,295,167...162,364,742
Ensembl chr 1:162,295,169...162,364,707

G

empty spiracles homeobox 2

decreases expression

ISO

bisphenol F results in decreased expression of EMX2 mRNA

NCBI chr 1:268,612,663...268,619,671
Ensembl chr 1:268,612,663...268,619,671

G

engrailed homeobox 1

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EN1 mRNA
bisphenol F results in increased expression of EN1 mRNA

PMID:28628672 PMID:30951980

NCBI chr13:34,303,684...34,309,269
Ensembl chr13:34,303,702...34,309,269

G

ENAH, actin regulator

increases expression

ISO

bisphenol F results in increased expression of ENAH protein

NCBI chr13:96,149,437...96,269,841
Ensembl chr13:96,149,437...96,269,796

G

ectodermal-neural cortex 1

multiple interactions

EXP

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ENC1 mRNA

NCBI chr 2:30,285,274...30,297,194
Ensembl chr 2:30,283,736...30,315,721

G

endoglin

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ENG mRNA
bisphenol F results in decreased expression of ENG mRNA

PMID:30951980 PMID:38685157

NCBI chr 3:36,332,190...36,370,324
Ensembl chr 3:36,326,202...36,370,933

G

enkurin domain containing 1

decreases expression

ISO

bisphenol F results in decreased expression of ENKD1 mRNA

NCBI chr19:50,501,963...50,506,447
Ensembl chr19:50,501,963...50,506,942

G

enkurin, TRPC channel interacting protein

increases expression

ISO

bisphenol F results in increased expression of ENKUR mRNA

NCBI chr17:88,599,057...88,622,668
Ensembl chr17:88,599,057...88,622,668

G

enolase 1

multiple interactions
increases expression

EXP
ISO

[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ENO1 mRNA
bisphenol F results in increased expression of ENO1 protein

PMID:34186270 PMID:36041667

NCBI chr 5:166,002,867...166,014,252
Ensembl chr 3:77,946,261...77,986,003
Ensembl chr 5:77,946,261...77,986,003

G

enolase 2

decreases expression

ISO

bisphenol F results in decreased expression of ENO2 mRNA

NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220

G

enolase 3

increases expression
decreases expression

ISO

bisphenol F results in increased expression of ENO3 mRNA
bisphenol F results in decreased expression of ENO3 mRNA

PMID:30951980 PMID:38685157

NCBI chr10:55,868,880...55,876,099
Ensembl chr10:55,866,101...55,874,540

G

enolase 4

increases expression

ISO

bisphenol F results in increased expression of ENO4 mRNA

NCBI chr 1:268,073,318...268,113,494
Ensembl chr 1:268,082,522...268,106,300

G

enolase-phosphatase 1

decreases expression

ISO

bisphenol F results in decreased expression of ENOPH1 mRNA

NCBI chr14:9,835,626...9,862,051
Ensembl chr14:9,835,627...9,873,668

G

enolase superfamily member 1

increases expression

ISO

bisphenol F results in increased expression of ENOSF1 protein

G

ectonucleotide pyrophosphatase/phosphodiesterase 1

multiple interactions
increases expression

ISO
EXP

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ENPP1 mRNA
[bisphenol A co-treated with bisphenol F co-treated with bisphenol S] results in increased expression of ENPP1 mRNA
[bisphenol F co-treated with Tretinoin] results in decreased expression of ENPP1 mRNA
bisphenol F results in increased expression of ENPP1 mRNA

PMID:28628672 PMID:30951980 PMID:36041667

NCBI chr 1:22,518,051...22,583,044
Ensembl chr 1:22,518,069...22,583,044

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

multiple interactions
increases expression

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ENPP2 mRNA
bisphenol F results in increased expression of ENPP2 mRNA

PMID:28628672 PMID:30951980

NCBI chr 7:88,092,140...88,214,758
Ensembl chr 7:88,092,140...88,214,957

G

ectonucleotide pyrophosphatase/phosphodiesterase 3

increases expression

ISO

bisphenol F results in increased expression of ENPP3 mRNA

NCBI chr 1:22,382,717...22,454,324
Ensembl chr 1:22,382,964...22,454,314

G

ectonucleotide pyrophosphatase/phosphodiesterase 4

increases expression

ISO

bisphenol F results in increased expression of ENPP4 mRNA

NCBI chr 9:24,386,351...24,396,248
Ensembl chr 9:24,360,272...24,396,152

G

ectonucleotide pyrophosphatase/phosphodiesterase family member 5

increases expression

ISO

bisphenol F results in increased expression of ENPP5 mRNA

NCBI chr 9:24,407,574...24,415,029
Ensembl chr 9:24,408,218...24,414,867

G

ectonucleotide pyrophosphatase/phosphodiesterase 6

multiple interactions

ISO

[bisphenol F co-treated with Fulvestrant] affects the methylation of ENPP6 gene

NCBI chr16:51,898,557...52,026,789
Ensembl chr16:51,898,557...52,026,728

G

ectonucleoside triphosphate diphosphohydrolase 1

increases expression

ISO

bisphenol F results in increased expression of ENTPD1 mRNA

NCBI chr 1:249,374,810...249,502,310
Ensembl chr 1:249,374,836...249,502,317

G

ectonucleoside triphosphate diphosphohydrolase 5

increases expression

ISO

bisphenol F results in increased expression of ENTPD5 mRNA

NCBI chr 6:109,750,210...109,786,376
Ensembl chr 6:109,753,204...109,786,495

G

ectonucleoside triphosphate diphosphohydrolase 6

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of ENTPD6 mRNA

NCBI chr 3:160,036,055...160,058,580
Ensembl chr 3:160,036,121...160,059,451

G

ectonucleoside triphosphate diphosphohydrolase 7

increases expression

ISO

bisphenol F results in increased expression of ENTPD7 mRNA

NCBI chr 1:252,508,594...252,550,269
Ensembl chr 1:252,508,594...252,550,269

G

ectonucleoside triphosphate diphosphohydrolase 8

decreases expression

ISO

bisphenol F results in decreased expression of ENTPD8 mRNA

NCBI chr 3:28,283,392...28,295,686
Ensembl chr 3:28,285,777...28,293,686

G

endosomal transmembrane epsin interactor 3

decreases expression

ISO

bisphenol F results in decreased expression of ENTREP3 mRNA

NCBI chr 2:176,886,903...176,893,047
Ensembl chr 2:176,887,135...176,893,047

G

EGF domain specific O-linked N-acetylglucosamine transferase

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EOGT mRNA

NCBI chr 4:131,275,587...131,313,243
Ensembl chr 4:131,276,573...131,311,926

G

eomesodermin

affects expression

ISO

bisphenol F affects the expression of EOMES mRNA

NCBI chr 8:127,059,215...127,067,070
Ensembl chr 8:127,059,215...127,067,070

G

E1A binding protein p400

multiple interactions

ISO

[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of EP400 mRNA

NCBI chr12:51,551,665...51,658,635
Ensembl chr12:51,551,695...51,658,634

G

endothelial PAS domain protein 1

decreases expression
increases expression

ISO

bisphenol F results in decreased expression of EPAS1 mRNA
bisphenol F results in increased expression of EPAS1 mRNA

PMID:28591870 PMID:38685157

NCBI chr 6:13,543,252...13,626,147
Ensembl chr 6:13,544,389...13,624,729

G

erythrocyte membrane protein band 4.1-like 1

increases expression

ISO

bisphenol F results in increased expression of EPB41L1 protein